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Abstract
Atherothrombotic stenosis at or around the carotid bifurcation is associated with an increased risk of
major ipsilateral ischaemic stroke. This risk is further increased following a transient ischaemic
attack or a minor ischaemic stroke, but can be reduced, in certain patients, by carotid endarterectomy.
However, whether or not the operation is beneficial is determined by the balance between the risk of
stroke and death due to the operation itself and the risk of ipsilateral ischaemic stroke without
surgery. The patients most likely to gain from surgery are likely to be those at greatest risk of stroke
on medical treatment alone. At present, extrapolation of the overall results of recent randomised
controlled trials of endarterectomy directly to clinical practice assumes that we cannot identify high
and low risk patients at the outset. However, this is not necessarily the case. Although the analyses
of the recent trials of endarterectomy have been stratified by the degree of carotid stenosis (a
powerful predictor of stroke risk), there may be other clinical and angiographic characteristics which
also identify patients at high risk of stroke and other vascular outcomes. The cost-effectiveness of
carotid surgery, which is questioned by many, would be increased considerably if it was possible to
use this and other information to predict the risks and likely benefits for individual patients.
The overall aim of this thesis was to provide information, additional to the overall results of the
European Carotid Surgery Trial (ECST), which would improve the effectiveness of carotid
endarterectomy in the prevention of stroke in clinical practice. Five main areas were studied. Firstly,
I reviewed the published literature on the imaging and measurement of carotid stenosis, and
attempted to produce quality standards for future studies (Chapters 3 and 4). In addition, I
determined the equivalence, reproducibility and prognostic value of three different methods of
measurement of carotid stenosis on angiograms, and determined the reproducibility and pathological
correlation of the assessment of plaque surface morphology, on 1001 consecutive carotid angiograms
from the ECST (Chapters 5 - 7). Secondly, using data on patients randomised to no-surgery in the
ECST, I studied the relationship between the degree of carotid stenosis, plaque surface morphology,
and other clinical and angiographic characteristics, and the risk of ipsilateral carotid territory
ischaemic stroke on medical treatment (Chapters 8 and 9). This highlighted the importance of other
XI
factors in addition to the degree of carotid stenosis which are important in predicting the risk of
stroke on medical treatment in individual patients, such as plaque surface morphology and post¬
stenotic collapse of the distal internal carotid artery. Thirdly, I studied the potential of
endarterectomy to reduce the risk of stroke in the territory of the contralateral asymptomatic carotid
artery (Chapters 10 and 12). Fourthly, I examined the published risks of stroke and death due to
carotid endarterectomy by performing a systematic review of the literature (Chapters 11 and 12). I
defined the absolute risks of stroke and death due to surgery with narrow confidence intervals, and
studied the factors which determine published risks. I studied the relationship between various
clinical, angiographic and operative factors and the risk of stroke and death due to endarterectomy in
patients randomised to surgery in the ECST (Chapter 13), and assessed the potential generalisability
of the clinical and angiographic risk factors for operative stroke and death in systematic review of the
published literature (Chapter 14). Finally, I examined the potential benefits of selecting patients for
carotid endarterectomy on the basis of the balance between their predicted individual risks of stroke
on medical treatment and stroke and death due to surgery (Section Five). I reviewed the problems of
simply applying the overall results of clinical trials to all future patients similar to those included in a
trial (Chapter 15). I highlighted the artefactual nature of some of the analyses of the relationship
between relative treatment effect and baseline risk which were being performed by some
investigators using meta-analysis of overall trial results (Chapter 16). Using data on the ECST
patients with 0-69% carotid stenosis, I developed a simple prognostic score to identify patients with
a high risk of stroke on medical treatment and a low risk of stroke and death due to endarterectomy
(Chapter 17). Stratification of the ECST patients with 70-99% stenosis using the score, suggested
that endarterectomy is only beneficial in a relatively small proportion of patients with a recently
symptomatic severe carotid stenosis. The validity of the score, and other related prognostic models,




I carried out the research described in this thesis between October 1992 and May 1996, during my
period as a research fellow with Professor Charles Warlow in the Department of Clinical
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"unaccustomed attacks ofnumbness and anaesthesia are signs of impending apoplexy"
Hippocrates circa 400 BC1
1.1 Introduction
Hippocrates' observation that apoplexy, or major stroke, is sometimes preceded by less severe
attacks of neurological symptoms is probably the first record of what we now refer to as transient
ischaemic attacks (TIA). However, it should be stated at the outset that, irrespective of treatment,
only a relatively small minority of patients who suffer a TIA subsequently develop "apoplexy."
Indeed, it is our inability to identify - and then treat - just these patients which colours much of the
management ofminor cerebral and ocular ischaemia. The work detailed in this thesis is an attempt
to determine which individual patients with TIA or minor ischaemic stroke are likely to benefit
most from one particular treatment - carotid endarterectomy.
Transient ischaemic attack is a rather vague term and much effort has gone into trying to develop a
useful clinical definition.2 However, because TIAs are only a part of a spectrum of cerebral
ischaemia, ranging from asymptomatic cerebral infarction to major disabling or fatal whole
hemisphere strokes, such definitions have per force been arbitrary. Indeed, it is not entirely clear
that TIA is a useful enough term to require exact definition. In reality there is very little difference
between the prognosis and long term management of what is usually regarded as a TIA and that of
minor ischaemic strokes with symptoms or signs lasting up to 7 days, or indeed major non-
disabling strokes. However, if for no other reason than it is necessary in order to understand the
literature, some definition of TIA must be given. In essence, a TIA is defined as an attack offocal
cerebral dysfunction or monocular visual loss of vascular origin and rapid onset, which symptoms
resolve completely without any permanent neurological deficit, although abnormal neurological
signs may remain, and which usually lasts between 30 seconds to 30 minutes, but may last up to 24
3
hours. For many purposes, a term encompassing transient cerebral ischaemia, minor ischaemic
stroke, major non-disabling ischaemic stroke, transient monocular blindness (amaurosis fugax) and
retinal artery occlusion would be more useful. Later in this thesis these conditions will sometimes
be referred to collectively as non-disabling cerebrovascular ischaemia.
1.2 Aetiology
Aetiology will be considered only in as much as it is likely to influence management. In the
majority of cases, the precise aetiology of a non-disabling cerebrovascular ischaemic event is
uncertain. Approximately 20% of events are either clinically or radiologically attributable to
transient ischaemia or infarction in a small area of the deep cerebral white matter. Common sense,
and a small amount of evidence, suggests that these "lacunar" events are likely to be due to local
thrombosis caused by disease of the small deep perforating arteries. Accurate diagnosis is
important in that it may influence the decision whether or not to investigate or treat any possible
carotid or cardiac causes of stroke. Somewhere between 20% and 30% of the remaining events are
associated with a significant stenosis of the ipsilateral internal carotid artery. That such stenoses
are likely to be of aetiological importance is demonstrated by the fact that the risk of stroke is
almost abolished following successful carotid endarterectomy. However, the extent to which
stroke results from reduced blood flow across the stenosis or from thrombus formation and distal
embolism from the plaque surface is unknown. This is an important area for future research as
elucidation of the relative importance of these two mechanisms would have important implications
for treatment; in particular, the likely efficacy of anticoagulation and treatment of hypertension.
A proportion of non-disabling cerebrovascular ischaemic events are due to embolism from the heart
or aortic arch. Atrial fibrillation or recent myocardial infarction should certainly prompt
investigation of the heart, but investigation and management of possible embolism from aortic
atheroma has not been shown to be of any value. In addition, there are several rare, but treatable,
4
causes of TIA or minor stroke which should be considered if the clinical context is appropriate.
These include inflammatory arterial disease (e.g. giant cell arteritis), haematological disorders (e.g.
polycythaemia), specific prothrombotic states (e.g. deficiencies of proteins S or C, or anti-
thrombin III), and arterial dissections.
1.3 Clinical diagnosis
A detailed discussion of the diagnosis of non-disabling cerebrovascular ischaemia would not be
relevant to this thesis, but several points should be noted. Although, initial consideration might
suggest that the diagnosis should be relatively straight forward, there is a wide differential
diagnosis (table 1.1), and considerable inter-observer disagreement/' Disagreement increases
when observers are asked to decide whether a cerebral TIA occurred in the anterior or posterior
cerebral circulation. The differentiation is necessary in order to determine whether imaging of the
carotid circulation is indicated. It is important, therefore, that the diagnosis is made by a
neurologist or by a clinician with an interest in cerebrovascular disease. Incorrect diagnosis will
lead either to unnecessary investigation and treatment of non-vascular symptoms, or perhaps more
importantly, delay in diagnosis of serious non-vascular pathology such as cerebral tumour or partial
epilepsy. False positive diagnoses of non-disabling cerebrovascular ischaemia will also decrease
the efficacy and cost effectiveness of preventative treatments. For example, the absolute benefit
derived from carotid endarterectomy for carotid stenosis in a patient with unrelated neurological
symptoms, such as non-specific dizziness, will be much less than that for truly symptomatic
stenosis.4
There are a number of points to remember when considering a diagnosis of TIA. In general,
symptoms are usually of sudden onset and are usually negative. That is to say that they represent
loss of function e.g. weakness or numbness, rather than tingling or abnormal movement. In
addition, as stated in their definition, TIAs are focal events. Global symptoms such as light
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headedness or dizziness are rarely due to cerebral ischaemia. TIAs rarely, if ever, cause loss of
consciousness. Finally, the majority of patients with TIA have risk factors for vascular disease.
Transient focal neurology in a young patient with no risk factors for vascular disease is probably
not a TIA.
Table 1.1. Differential diagnosis of transient focal cerebral symptoms and transient monocular visual loss.
Transient focal cerebral symptoms
Migrainous aura
Focal epileptic seizures
intracranial space occupying lesion (eg. tumour, subdural
haematoma, arteriovenous malformation)















The risk of stroke following TIA varies depending on the population studied. The risk is highest in
community based studies with a high proportion of elderly patients, and lowest in those patients
who are referred to hospital, particularly those who are randomised in clinical trials.5 The risk of
stroke decreases steadily with time after the last TIA. On balance, the risk of major stroke in the
first year after a TIA is probably somewhere between 5% and 10%. About half of these strokes
will be disabling. In addition, these patients are at increased risk of other vascular pathologies.
Patients presenting with symptomatic cerebrovascular disease have an annual risk of myocardial
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infarction or non-stroke vascular death of 2-5% per year. Indeed, they are more likely to die as a
consequence of ischaemic heart disease than cerebrovascular disease. Fortunately, many of the
strategies aimed at preventing stroke also reduce the risk of cardiac death.
As outlined in Section 3 of this thesis, patients presenting with non-disabling cerebrovascular
disease can be stratified according to their likely risk of major ischaemic stroke on medical
treatment using baseline clinical variables. If we consider the risk of carotid territory ischaemic
stroke, the most important of these is the severity of any stenosis of the ipsilateral internal carotid
artery. Stroke risk increases with the degree of stenosis, and rises particularly sharply above 70%
stenosis (Chapter 8). The risk is approximately double that distal to an asymptomatic stenosis
(Chapter 10). However, several other variables are also independent predictors of stroke risk after
correction for the degree of stenosis of the ipsilateral symptomatic carotid artery (Chapter 17). In
particular, the risk of stroke in patients with retinal ischaemic events is only half that in patients
with cerebral ischaemic events.
1.5 Investigation
Detailed discussion of the investigation of non-disabling cerebrovascular ischaemic events is
beyond the scope of this thesis, and is reviewed elsewhere.6 However, Section 2 does consider the
imaging and measurement of carotid stenosis. The most appropriate imaging strategy is subject to
debate, disagreement centering on whether or not non-invasive methods are adequate or whether
conventional arterial angiography is still required.
1.6 Medical treatment
There are several ways in which the efficacy of a treatment can be assessed. However, given the
potential biases inherent in non-randomised comparisons,7 discussion of treatment will be based
only on data from randomised controlled trials. The treatments discussed below are used in the
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context of general risk factor management. Other interventions, such as the cessation of smoking,
weight loss, regular exercise, and the control of diabetes are also very important.
1.6.1 Economics
Economic considerations are becoming increasingly important in decisions about how best to treat
patients. Reviews concerning the treatment of individual patients with non-disabling
cerebrovascular ischaemia will inevitably be biased in the direction of the high risk preventative
strategy rather than the population approach.8 However, the high risk approach does need to be
considered in the context of the cost and burden of stroke in the population as a whole. Stroke is
the third most common cause of death in the developed world. It is the most important single cause
of disability in people living in their own home, and caring for stroke patients is estimated to
account for approximately 4.3% of the NHS budget, and 13% of occupied in-patient bed days.9 In
Scotland, over 8000 deaths due to stroke are registered each year.9 However, since only about
20% of first strokes are fatal, the number of strokes will be much greater. In Oxfordshire, the crude
annual incidence of first stroke in the community was approximately 2 per 1000.10 About 50% of
these were disabling. The incidence of disabling stroke is, therefore, likely to be at least 1 per 1000
even ifwe consider only first strokes.
How much of this burden could be prevented by a high risk secondary prevention strategy, such as
carotid endarterectomy? Only about 15% of patients who suffer an ischaemic stroke have a
previous TIA, and it is unlikely that more than 25% of disabling strokes are preceded by any kind
of non-disabling cerebrovascular ischaemic event. Since many patients who do suffer "warning"
events do not present to medical attention at the time, and the majority of preventative strategies
do not reduce the risk of disabling stroke by much more than 50% in relative terms, it is unlikely
that the strategy laid out in this thesis would prevent more than 5% of disabling strokes in the
population as a whole. However, although in population terms treatment of patients presenting
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with non-disabling cerebrovascular ischaemic events is not of major importance, treatment is still
very worthwhile from the point of view of the individual patient, and the high incidence of
cerebrovascular disease ensures that such patients represent a common clinical problem. Evidence
of the overall efficacy of each of the major therapeutic interventions is reviewed briefly.
1.6.2 Antiplatelet agents
Data from all randomised trials of antiplatelet therapy in the prevention of vascular events were
combined by the Antiplatelet Trialists' Collaboration."'12 Data were obtained for 257 randomised
trials involving a total of 1 18,958 patients. Antiplatelet treatment had no effect on non-vascular
death, but produced highly significant reductions in the odds of non-fatal stroke (25%), non-fatal
myocardial infarction (34%) and vascular death (17%). The antiplatelet agent used in the majority
of studies was aspirin. There were too few patients included in trials comparing the efficacy
different antiplatelet drugs to draw any useful conclusions. In keeping with the results of individual
trials comparing the efficacy of different doses of aspirin,13,14 the meta-analysis produced no
evidence that high-dose aspirin (500-1500mg) was any more effective than medium dose (160-
325mg) or low dose (75-150mg) aspirin. Low dose aspirin has the advantage of a lower incidence
of gastrointestinal side-effects.
1.6.3 Anticoagulants
Anticoagulation, usually with warfarin, is indicated when there is a definite source of cardiac
embolism e.g. rheumatic mitral valve disease, a prosthetic heart valve, recent myocardial infarction
or dilated cardiomyopathy. In addition, warfarin has been shown to be superior to aspirin in the
prevention of stroke in patients with non-rheumatic atrial fibrillation, although aspirin is better than
nothing.15 Patients with recurrent TIAs refractory to treatment with aspirin are sometimes
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anticoagulated, although the data from clinical trials are contradictory and further trials are
ongoing.
1.6.4 Treatment ofhypertension
Observational studies have demonstrated a close relationship between blood pressure and the risk
of stroke.16,17 Stroke risk increases by 2% for every ImmHg increase in usual diastolic blood
pressure. A meta-analysis of all available data,18 and several subsequent large randomised primary
prevention trials,19'20 showed that relatively small reductions in blood pressure, of the order of 5-
lOmHg in systolic pressure, reduce the risk of stroke by approximately 50%. Roughly the same
relationship appears to hold in patients who have already developed symptoms of vascular
disease. However, in contrast to primary prevention, there are relatively few data on the efficacy of
blood pressure lowering in the secondary prevention of stroke, although a large trial is ongoing.
Moreover, there is a danger that treatment of hypertension might be harmful in those patients with
symptomatic cerebrovascular ischaemia who have an haemodynamically significant carotid
stenosis or occlusion. Thus whilst moderate hypertension should be treated in patients with non-
disabling cerebrovascular ischaemia with carotid stenosis of less than 50%, the balance of risks and
benefits are unknown in patients with more severe stenosis. This issue is considered further in
chapter 9.
1.6.5 Lipid lowering drugs
In common with hypertension, the risk of ischaemic stroke in the general population increases with
plasma cholesterol.17 Randomised trials of lipid lowering agents following myocardial infarction
have demonstrated reductions in the risk of stroke in the treated group.22'2j However, although
lipid lowering drugs do appear to lead to regression of carotid atheroma, there are relatively few
data from clinical trials to support the use of these agents in the prevention of stroke in patients
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with symptomatic cerebrovascular disease. Nevertheless, it seems likely that patients with
cerebrovascular disease will benefit, partly as a consequence of a reduction in cardiac events. The
results of on-going randomised trials are awaited.
1.7 Surgical treatment
Knowledge of the relationship between atheromatous disease of the extracranial carotid and
vertebral arteries and the occurrence of ischaemic stroke goes back to the nineteenth century. In
1856, Virchow described carotid thrombosis in a patient with sudden onset ipsilateral visual loss in
whom the ophthalmic and retinal arteries were patent.24 In 1888, Penzoldt reported a patient who
developed sudden permanent loss of vision in the right eye and later sustained a left hemiplegia.25
At post-mortem she was found to have thrombotic occlusion of the right distal common carotid
artery and a large area of cerebral softening in the right cerebral hemisphere. In 1905, Chiari
performed a number of pathological studies which led him to suggest that emboli could break away
from ulcerated carotid plaques in the neck and cause cerebral infarction.26'27 This mechanism of
stroke was reemphasised fifty years later by Miller Fisher.28'29
Several operations were developed in the 1950s and 60s in which the aim of surgery was to restore
the flow of blood to the brain in patients with stenosis or occlusion of the extracranial carotid or
vertebral circulations/0 One of the main contributions leading up to this was the development of
cerebral arteriography by Egas Moniz in 1927,31 and the subsequent demonstration of stenosis and
occlusion of the carotid arteries in life.32,j3 The development of extracranial/intracranial (EC/IC)
bypass surgery and carotid endarterectomy are described below. Several other surgical techniques
have been tried, although unlike endarterectomy and EC/IC bypass they have not been tested in
randomised controlled trials. These include various bypass procedures for occlusion of the
proximal neck and aortic arch vessels,34 vertebral artery endarterectomy, reconstruction or
bypass,35 and various arterial transpositions involving anastomosis of the subclavian and vertebral
11
arteries into the common carotid artery.36 Further discussion of these procedures is beyond the
scope of this thesis.
1.7.1 Extracranial/Intracranial bypass surgery
Patients with complete occlusion of the internal carotid artery are not suitable for carotid
endarterectomy. Patients with symptomatic carotid occlusion have an annual risk of ipsilateral
ischaemic stroke of around 5%.37'38 Many of these strokes are likely to be caused by embolism
from the occluded carotid artery, but there is evidence that cerebral hypoperfusion is also
important.39,40 With developments in microsurgical techniques in the 1960s it became possible to
perform EC/IC bypass surgery in such patients in order to increase cerebral perfusion.41 The most
commonly performed procedure involved anastomosis of branches of the superficial temporal
artery to the middle cerebral artery. This operation became very popular for symptomatic carotid
occlusion in the 1970's and early 1980's. As a consequence of this, a large randomised controlled
trial was performed.42 Although EC/IC bypass does appear to be effective in increasing cerebral
perfusion in some patients,43 the trial reported no reduction in the risk of stroke. Since the trial
reported in 1985, the use of EC/IC bypass surgery has declined dramatically. However, recent
studies have suggested that it is possible to identify a subgroup of patients with carotid occlusion
who have severe cerebral hypoperfusion and a particularly high risk of ipsilateral ischaemic
stroke.44,45 It is now being suggested that a further randomised trial is justified in this subgroup.46
1.7.2 Carotid endarterectomy
Somewhere between 20% and 30% of patients presenting with non-disabling cerebrovascular
ischaemia have a stenosis at or around the bifurcation of the ipsilateral carotid artery. The stenotic
plaque can be removed by a surgical procedure known as carotid endarterectomy. The operation
was introduced in the 1950s and became popular in the 1970s and early 1980s, but it was not until
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1991 that it was shown to be of value in patients with a recently symptomatic severe carotid
stenosis of 70-99%.47'48 The technical details of the surgical procedure will not be discussed here,
but photographs of three important stages of the operation can be found at the end of this chapter.
More detail of the surgical techniques used in the ECST is given in Chapter 13.
1.7.2.1 History
As described in section 1.1.7, interest in carotid surgery developed in parallel with the realisation
that embolism from atherothrombotic plaque at the origin of the internal carotid artery was a
common mechanism of ischaemic stroke. However, the history of carotid artery surgery goes back
much further. The first operations on the carotid artery were ligation procedures for trauma or
haemorrhage. The first report was in Benjamin Bell's Surgery in 1793.49 However, most early
ligations resulted in the death of the patient. The first successful ligaton was performed by a British
naval surgeon, David Fleming, in 18037° This operation was performed for late carotid rupture
following neck trauma in an attempted suicide. The first successful ligation for carotid aneurysm
was performed five years later in London by Astley Cooper.51 By 1868 Pilz was able to collect
600 recorded cases of carotid ligation for cervical aneurysm or haemorrhage with an overall
mortality of 43%.52 In 1878, an American surgeon named John Wyeth reported a 41% mortality
in a collected study of 898 common carotid ligations, and contrasted this with a 4.5% mortality for
ligation of the external carotid artery.53
There were relatively few developments for the next seventy years. However, in 1946, a
Portuguese surgeon, Cid Dos Santos, introduced thromboendarterectomy for restoration of flow in
peripheral vessels.54 The first successful reconstruction of the carotid artery was performed by
Carrea, Molins and Murphy in Buenos Aires in 1951.55 However, this was not an endarterectomy.
Rather they performed an end-to-end anastomosis of the left external carotid artery and the distal
internal carotid artery in a man of 41 with a recently symptomatic severe carotid stenosis.
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There is debate about who performed the first true carotid endarterectomy. In 1954, Eastcott,
Pickering and Rob published a case report detailing a carotid resection performed in May 1954 on a
66 years old woman with recurrent left carotid TIAs and a severe stenosis on angiography.56 The
patient made an uneventful recovery and was relieved of her TIAs. However, in 1975, DeBakey
reported that he had performed a carotid endarterectomy on a 53 year old man in August 1953.57
However, it was the report by Eastcott and colleagues which provided the impetus for the further
development of carotid surgery. Over the next five years there were numerous other reports of the
operation being performed and several technical improvements were suggested.30 The operation
became extremely popular in the 1960's and 70's. By the early 1980's there were over 100,000
procedures per year in the USA alone.58 However, at this point in time there was no evidence from
randomised controlled trials that the operation was of any value. This prompted several eminent
clinicians to question the widespread use the operation in the early 1980's.59"62 This led to a fall in
the number of operations being performed and set the scene for a number of large randomised
controlled trials.
1.7.2.2 Randomised controlled trials of endarterectomyfor symptomatic carotid stenosis
There have been five RCTs of carotid endarterectomy for symptomatic carotid stenosis.47,48'63"65
These are detailed in table 1.2. The first two studies were relatively small and did not produce
statistically significant results.63'64 The larger VA Cooperative Symptomatic Carotid Stenosis Trial
(VA #309) reported a non-significant trend in favor of surgery,65 but it wasn't until 1991 that the
European Carotid Surgery Trial (ECST) and the North American Symptomatic Carotid
Endarterectomy Trial (NASCET) demonstrated a clear reduction in the overall risk of stroke in
operated patients with recently symptomatic severe (70-99%) carotid stenosis.47'48 The ECST also
demonstrated that surgery was harmful in patients with mild stenosis (0-29%), in whom the risk of
stroke on medical treatment was too low to offset the operative risks. Both trials continued to
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randomise patients with moderate (30-69%) stenosis. Although in all the trials of endarterectomy
for symptomatic stenosis, patients were only randomised after the stenosis had been demonstrated
on a carotid angiogram, as outlined below, comparison of the trial results is complicated by the fact
that there were differences in the way in which the degree of stenosis was measured on the
angiogram. For example, the NACSET method of measurement underestimates the degree of
stenosis compared to the ECST method. Stenoses reported to be 70-99% by the NASCET trialists
were equivalent to 82-99% by the ECST method, and stenoses reported to be 70-99% by the ECST
trialists were 50-99% by the NASCET method (see Chapter 5). Nevertheless, since the equivalence
of the different methods of measurement has been defined, it should be possible to transform
individual patient data in order to allow the meta-analyses to be correctly stratified by the degree of
stenosis of the symptomatic artery.
Table 1.2. Details of all known randomised controlled trials of carotid endarterectomy for recently
symptomatic carotid stenosis.
Study Ref Published Stenosis 1 Cases per treatment group
(%) Medical Surgical
Fields et al 63 1970 147 169 2
Shaw et al 64 1984 21 20
VA #309 65 1991 50-99 98 91
ECST (mild) 47 1991 0-29 155 219
ECST (severe) 47 1991 70-99 323 455
ECST (moderate) 66 1996 30-69 631 959
NASCET (severe) 48 1991 70-99 331 328
NASCET (moderate) 68 1998 30-69 1118 1108
1 different methods ofmeasurement used
2 169 had unilateral endarterectomy for stenosis, 56 had bilateral endarterectomy or surgery for occlusion
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In June 1996, the ECST collaborators reported the results for patients with moderate i.e. 30-69%
stenosis.66 The results were reported separately for patients with stenosis of 30-49% and 50-69%
by the ECST method of measurement. The operative risks of stroke and death were 8.0% and 7.9%
respectively. Log rank tests for all-cause mortality in both groups showed a non-significant trend
against endarterectomy: 1.29 (95% CI 0.88-1.90) in the 30-49% group and 1.18 (0.88-1.58) in the
50-69% group. For survival free of major stroke, surgery was significantly harmful during the early
years of follow-up (p<0.05 for 0 to 3.4 years in the 30-49% group and 0 to 2.3 years in the 50-69%
group). This reflects the fact that most of the hazard in the surgery patients occurs within the first
few days after the operation, whereas the hazard in the medical group accrues gradually over years
of follow-up. However, despite nearly 10,000 patient-years of follow-up in the moderate stenosis
patients, there was no evidence of any benefit from endarterectomy up to eight years after the
operation in either the 30-49% or the 50-69% stenosis groups.
The final results of the ECST were reported in 199 8.67 Stratification of the results by decile of
stenosis, rather than the predefined stenosis groups, suggested that endarterectomy was only
significantly beneficial in patients with 80-99% stenosis. Only a very small trend in favour of
surgery was seen in patients with 70-79% stenosis. The benefit in patients with 80-99% stenosis
appeared to be greater in men than in women, with clear benefit in women only evident in patients
with 90-99% stenosis. However, none of these analyses were predefined subgroup analyses and
caution was advised.
The final results of the NASCET trial were presented to the collaborators in February 1998 and
published later in the year.68 The paper concentrated on the efficacy of surgery in the "moderate"
stenosis patients (30-69% NASCET stenosis; approximately 50-82% stenosis by the ECST method
ofmeasurement). Within the moderate stenosis group, the results were further stratified into a 30-
49% stenosis group (50 - 70% stenosis by the ECST method) and a 50-69% stenosis group (70 -
82% stenosis by the ECST method). The primary outcome event was fatal or non-fatal stroke
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ipsilateral to the symptomatic stenosis at five years. Among patients with 30-49% stenosis there
was no clear benefit from surgery (primary outcome: surgery - 14.9% vs medical - 18.7%, P =
0.16). There was, however, significant benefit from endarterectomy in the 50-69% stenosis group
(surgery - 15.7% vs medical - 22.2%, P = 0.045). Benefit was greatest among men, patients with
stroke as the qualifying event, and patients with hemispheric (as opposed to ocular) symptoms.
1.7.2.3 Randomised controlled trials ofendarterectomyfor asymptomatic carotid stenosis
This thesis deals mainly with the secondary prevention of stroke, but Chapters 10 and 12 do
contain analysis relating to asymptomatic carotid stenosis. There have been seven RCTs of carotid
endarterectomy for asymptomatic carotid stenosis,69"75 one of which was discontinued,71 and one
of which is ongoing.7" The trials are summarised in table 1.3. The CASANOVA study 70 and a
small trial by Clagett et al 69 did not produce statistically significant results. The VA study
demonstrated a significant reduction in the risk of the combined outcome of stroke and TIA in the
endarterectomy group, but did not have the power to demonstrate a reduction in the risk of stroke
alone.72 In 1995, the Asymptomatic Carotid Artery Study (ACAS) 73 demonstrated a clearly
significant reduction in the risk of ipsilateral ischaemic stroke in patients with 60-99%
asymptomatic stenosis; a reduction in the five year actuarial risk of ipsilateral ischaemic stroke or
operative death from 11% to 5.1% (p<0.001). In other words, 17 operations are required to prevent
one stroke over the next five years. Unlike the ECST and NASCET trials, the ACAS trial included
the risks of stroke and death due to carotid angiography in the overall outcome. However, the
operative risk of stroke and death due to endarterectomy was much lower than in the RCTs of
endarterectomy for symptomatic stenosis. That surgery for asymptomatic stenosis is safer than
surgery for symptomatic stenosis is confirmed by a systematic review of the literature in Chapter
12. Both the mortality and the risk of stroke were approximately half that found in patients with
symptomatic stenosis.
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The Asymptomatic Carotid Surgery Trial (ACST) is a large European RCT which is still recruiting
and has now randomised in excess of 2000 patients.75 It is not expected to publish results before
2002. This trial will add considerably to the existing randomised data which was recently
summarised in a meta-analysis.76
Table 1.3. Details of published (and known unpublished) randomised controlled trials of carotid
endarterectomy for asymptomatic carotid stenosis.
Study Ref Published Stenosis 1 Cases per treatment group
(%) Medical Surgical
Clagett et al 69 1984 9 15 14
CASANOVA 70 1991 50-90% 111 122
MACE 71 1992 50-99% 35 36
VA #167 72 1993 50-99% 233 211
ACAS 73 1995 60-99% 834 828
AURC 74 1998 70-99% 109 128
ACST 75 na 50-99% 1000+ 1000+
1 different methods ofmeasurement used
Thus, as with surgery for symptomatic stenosis, there is evidence of overall benefit from
endarterectomy in patients with asymptomatic stenosis. However, the low risk of ipsilateral
ischaemic stroke distal to an asymptomatic stenosis means that the overall reduction in the absolute
risk of stroke following endarterectomy will always be small. If the operation is to be a cost-
effective approach to the primary prevention of stroke then it is essential to identify high risk
groups or individuals in whom the absolute benefit derived from surgery will be greater.
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1.7.3 Carotid angioplasty
Angioplasty, with or without stenting, has been suggested as a potentially less costly alternative to
endarterectomy in patients with carotid stenosis. However, the initial risks of the procedure and the
rate of restenosis have yet to be defined with narrow confidence limits. Some authors have stressed
the need for randomised controlled trials,77'78 whereas others have been rather negative about the
procedure despite the absence of any reliable data.79'80 Publication of the CAVATAS study has
now provided useful data on which to base the further evaluation of angioplasty.81 The main core
of CAVATAS was a randomised comparison of angioplasty and endarterectomy. A total of 560
patients were recruited (504 randomised between angioplasty and endarterectomy). The 30 day
risks of stroke and death were 10% in both treatment groups and there was no clear benefit for
either treatment on initial follow-up. Follow-up continues in order to define the restenosis rates. A
small (17 patients) single centre randomised trial of angioplasty and stenting versus endarterectomy
was stopped in 1998 due to an unacceptably high complication rate in the angioplasty group (five
out of seven patients had strokes following angioplasty).82 A second and larger trial, CAVATAS
2, in which angioplasty will be combined with routine stenting, is currently being considered for
funding. Plans are also underway for a similar large randomised trial of carotid angioplasty and
stenting vs endarterectomy in the USA (CREST).
19
1.8 References
1) Clarke E. Apoplexy in the Hippocratic writings. Bull Hist Med 1963; 37: 301-314.
2) WHO (World Health Organisation) (1978) Cerebrovascular disorders: A clinical and research
classfication. World Health Organisation, Offset Publication No. 43, Geneva.
3) Kraaijeveld CL, van Gijn J, Schouten HJA, Staal A. Interobserver agreement for the diagnosis
of transient ischaemic attacks. Stroke 1984; 4: 723-725.
4) The European Carotid Surgery Trialists Collaborative Group. Risk of stroke in the distribution
of an asymptomatic carotid artery. Lancet 1995; 345: 209-212.
5) Hankey GJ, Slattery J, Warlow CP. The prognosis of hospital referred transient ischaemic
attacks. J Neurol Neurosurg Psychiartry 1991; 54: 793-802.
6) Hankey GJ, Warlow CP. Transient Ischaemic Attacks of the Brain and Eye. WB Saunders,
London, 1994.
7) Sacks H, Chalmers TC, Smith H. Randomized versus historical controls for clinical trials. Am
J Med 1982; 72: 233.
8) Rose G. Sick individuals and sick populations. Int J Epidemiol 1985; 14: 32-38.
9) Working Group of the National Medical Advisory Committee. Epidemiology and causes of
stroke (chapter 3). In: The management ofpatients with stroke. Edinburgh: HMSO, 1993.
10) Bamford J, Sandercock P, Dennis M et al. A prospective Study of acute cerebrovascular
disease in the community: the Oxfordshire Community Stroke Project, 1981-1986. 1.
Methodology, demography and incident cases of first ever stroke. J Neurol Neurosurg Psychiat
1988;51:1373-1380
11) Antiplatelet Trialist' Collaboration. Secondary prevention of vascular disease by prolonged
antiplatelet treatment. Br Med J 1988; 296:320-331.
12) Antiplatelet Trialist1 Collaboration. Collaborative overview of randomised trials of antiplatelet
therapy-1: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy
in varios categories of patients. Br Med J 1994; 308:81-106.
13) Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 versus 283 mg a day)
in patients after a transient ischsemic attack or minor ischaemic stroke. N Engl J Med 1991;
325:1261-1266.
14) SALT Collaborative Group. Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as
secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338:1345-1349.
15) European Atrial Fibrillation Trial Study Group. Secondary prevention in nonrheumatic atrial
fibrillation transient ischaemic attack or minor stroke. Lancet 1993; 342: 213-220.
20
16) MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke and coronary heart disease.
Prolonged differences in blood pressure: prospective observational studies corrected for the
regression dilution bias. Lancet 1990; 355:765-774.
17) Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13000
strokes in 450,000 people in 45 prospective cohorts. Lancet 1995; 346: 1647-53.
18) Dahlof B, Lindholm LH, Hannsson L et al. Morbidity and mortality in the Swedish Trial in
Old Patient with Hypertension (STOP-Hypertension). Lancet 1991;338:1281-1285.
19) MRC Working Party. Medical Research Council trial of treatment of hypertension in older
adults: principal results. Br Med J 1992; 304:405-412.
20) SHEP Cooperative research Group. Prevention of stroke by antihypertensiondrug treatment in
older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the
Elderly Program (SHEP). JAMA 1991;265:3255-3264.
21) Collins R, Peto R, MacMahon S et al. Blood pressure, stroke and coronary heart disease. Part
2, short term reductions in blood pressure: overview of randomised drug trials in their
epidemiological context. Lancet 1990; 335:827-838.
22) Scandanavian Sinvastatin Survival Study Group. Randomised trial of cholesterol lowering in
4444 patients with coronary heart disease: the Scandanavian Simvastatin Survival Study. Lancet
1994; 344: 1383-1389.
23) Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard
CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart
disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333: 1301-1307.
24) Gurdjian ES. History of occlusive cerebrovascular disease, I: from Wepfer to Moniz. Arch
Neurol 1979;36:340-343.
25) Penzoldt F. Uber thrombose (autochtone oder embolische) der carotis. Dtsch Arch f Klin
Med 1891; 28: 80-93.
26) Fields WS, LemakNA. A History ofStroke. New York, NY: Oxford University Press; 1989.
27) Chiari H. Uber des verhalten des teilungswinkels der carotis communis bei der endarteritis
chronica deformans. Verh Dtsch Ges Pathol 1905; 9: 326-30.
28) Fisher M. Occlusion of the internal carotid arteiy. Arch Neurol Psychiatry 1951; 65: 346-77.
29) Fisher M. Occlusion of the carotid arteries. Arch Neurol Psychiatry 1954; 72: 187-204.
30) Thompson JE. The evolution of surgery for the treatment and prevention of stroke: the Willis
Lecture. Stroke 1996; 27: 1427-34.
21
31) Moniz E. L'encephalographic arterielle: son importance dans la localisation des tumeurs
cerebrales. Rev Neurol (Paris) 1927; 2: 72-90.
32) Moniz E, Lima A, de Lacerda R. Hemiplegies par thrombose de la carotide interne. Presse
Med 1937; 45:977-80.
33) Johnson HC, Walker AE. The angiographic diagnosis of spontaneous thrombosis of the
internal and common carotid arteries. JNeurosurg 1951; 8: 631-59.
34) Thompson JE. Surgery for Cerebrovascular Insufficiency (Stroke). Springfield, Illinois:
Charles C Thomas Publishing; 1968.
35) Berguer R. Advances in vertebral artery surgery. In: Veith FJ, ed. Current Critical Problems
in Vascular Surgery. St Louis, Mo. Quality Medical Publishing Inc: 1991; 404-408.
36) Edwards WH Jr, Tapper SS, Edwards WH Sr, Mulherin JL Jr, Martin RS, Jenkins JM.
Subclavian revascularisation: a quarter century experience. Ann Surg 1994; 219: 673-78.
37) Hankey GJ, Warlow CP. Prognosis of symptomatic carotid artery occlusion. Cerebrovasc Dis
1991; 1: 245-56.
38) Cote R, Barnett HJM, Taylor DW. Internal carotid occlusion: a prospective study. Stroke
1983; 14:898-901.
39) Bullock R, Mendelow AD, Bone I et al. Cerebral blood flow and C02 responsiveness as an
indicator of collatoral reserve capacity in patients with carotid artery disease. Br J Surg 1985; 72:
348-351.
40) Norrving B, Nilsson B, Risberg J. rCBF in patients with carotid occlusion. Resting and
hypercapnic flow related to collateral pattern. Stroke 1982; 13: 155-162.
41) Yasargil MG, Krayenbuhl HA, Jacobson JH. Microneurosurgical arterial reconstruction.
Surgery 1970; 67: 222-23.
42) EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the
risk of ischaemic stroke. N Engl J Med 1985; 313:1191-1200.
43) Powers WJ, Grubb RL, Raichle ME. Clinical results of extracranial-intracranial bypass surgery
in patients with hemodynamic cerebrovascular disease. J Neurosurg 1989; 70: 61-67.
44) Klijn CJM, Kappelle LJ, Tulleken CJF, van Gijn J. Symptomatic carotid artery occlusion: a
reappraisal of haemodynamic factors. Stroke 1997; 28: 2084-93.
45) Grubb RL, Derdeyn CP, Fritsch SM, Carpenter DA, YundtKD, Videen TO, Spitznagel EL,
Powers WJ. Importance of haemodynamic factors in the prognosis of symptomatic carotid
occlusion. JAMA 1998; 280: 1055-60.
22
46) Adams HP. Occlusion of the internal carotid artery: Reopening a closed door? JAMA 1998;
280: 1093-94.
47) European Carotid Surgery Trialists' Collaborative Group. MRC European Carotid Surgery
Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid
stenosis. Lancet 1991; 337: 1235-1243.
48) North American Symptomatic carotid Endarterectomy Trial Collaborators. Beneficial effect of
carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med
1991; 325: 445-453.
49) Wood JR. Early history of the operation of ligature of the primitive carotid artery. N Y J Med
1857; July: 1-59.
50) Keevil JJ. David Fleming and the operation for ligation of the carotid artery. Br J Surg 1949;
37: 92-95.
51) Cooper A. Account of the first successful operation performed on the common carotid artery
for aneurysm in the year 1808 with the post-mortem examination in the year 1821. Guy's Hosp
Rep 1836; 1:53-59.
52) Hamby WB. Intracranial aneurysms. Springfield, Illinois. Charles C Thomas Publishing;
1952.
53) Wyeth JA. Prize essay: essays upon the surgical anatomy and history of the common,
external and internal carotid arteries and the surgical anatomy of the innominate and subclavian
arteries. Appendix to Transactions ofthe AMA [Philadelphia, Pa]. 1878; 29: 1-245.
54) Dos Santos JC. From embolectomy to endarterectomy or the fall of a myth. J Cardiovasc
Surg 1976; 17: 113-128.
55) Carrea R, Mollins M, Murphy G. Surgical treatment of spontaneous thrombosis of the
internal carotid artery in the neck: carotid-carotideal anastomosis. Report of a case. Acta Neurol
Latin Am 1955; 1: 71-78.
56) Eastcott HHG, Pickering GW, Rob CG. Reconstruction of internal carotid artery in a patient
with intermittent attacks of hemiplegia. Lancet 1954; 2: 994-96.
57) DeBakey ME. Successful carotid endarterectomy for cerebrovascular insufficiency. JAMA
1975; 233: 1083-85.
58) Gillum RF. Epidemiology of carotid endarterectomy and cerebral arteriography in the United
States. Stroke 1995; 26: 1724-28.
59) WarlowCP. Carotid endarterectomy: Does it work? Strokel994; 15: 1068-76
23
60) Chambers BR, Norris J. The case against surgery for asymptomatic carotid stenosis. Stroke
1984; 15: 964-67.
61) Barnett HJM, Plum F, Walton JN. Carotid endarterectomy - an expression of concern.
Stroke 1984; 15: 941-43.
62) Jonas S. Can carotid endarterectomy be justified? No. Arch Neurol 1987; 44: 652-54.
63) Fields WS, Maslenikov V, Meyer JS, Hass WK, Remington RD, MacDonald M. Joint study
of extracranial arterial occlusion. V Progress report on prognosis following surgery or non-surgical
treatment for transient cerebral ischaemic attacks and cervical carotid artery lesions. JAMA 1970;
211: 1993-2003.
64) Shaw DA, Venables GS, Cartilidge NEF, Bates D, Dickinson PFI. Carotid endarterectomy in
patients with transient cerebral ischaemia. J Neurol Sci 1984; 64: 45-53.
65) Mayberg MR, Wilson E, Yatsu F et al. Carotid endarterectomy and prevention of cerebral
ischaemia in symptomatic carotid stenosis. JAMA 1991; 266: 3289-3294.
66) European Carotid Surgery Trialists' Collaborative Group. MRC European Carotid Surgery
Trial: results in patients with 30-69% stenosis. Lancet 1996; 347: 1591-1593
67) European Carotid Surgery Trialists' Collaborative Group. Randomised trial of endarterectomy
for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial
(ECST). Lancet 1998; 351: 1379-87
68) North American Symptomatic Carotid Endarterectomy Trialists' Collaborative Group. The
final results of the NASCET trial. N Engl J Med 1998; 339: 1415-25
69) Clagget GP, Youkey JR, Brigham RA et al. Asymptomatic cervical bruit and abnormal ocular
pneumoplesmography: A prospective study comparing two approaches to management. Surgery
1984; 96: 823-830.
70) Mayo Asymptomatic Carotid Endarterectomy Study Group. Effectiveness of carotid
endarterectomy for asymptomatic carotid stenosis. Stroke 1989; 20; 844-849.
71) The Casanova Study Group. Carotid surgery versus medical therapy in asymptomatic carotid
stenosis. Stroke 1991; 22: 1229-1235.
72) Hobson RW, Weiss DG, Fields WS et al. Efficacy of carotid endarterectomy for
asymptomatic carotid stenosis. N Engl J Med 1993; 328: 221-227.
73) Asymptomatic Carotid Atherosclerosis Study Group. Carotid endarterectomy for patients with
asymptomatic internal carotid artery stenosis. JAMA 1995; 273: 1421-1428.
74) Lagneau P. Stenoses carotidiennes asymptomatiques. J Mai Vase 1993; 18: 209-212
24
75) Halliday AW. The Asymptomatic Carotid Surgery Trial (ACST). Rationale and design. Eur J
Vase Surg 1994; 8: 703-710.
76) Benavente O, Moher D, Pham B. Carotid endarterectomy for asymptomatic carotid stenosis:
a meta-analysis. BMJ 1998; 317: 1477-80.
77) Thompson JE. Carotid angioplasty - a reserved position. Cardiovasc Surg 1997; 5: 459-60.
78) Brown MM. Balloon angioplasty for cerebrovascular disease. Neurol Res 1992; 14 (suppl):
159-63.
79) Naylor AR, London NJM, Bell PRF. Carotid endarterectomy versus carotid angioplasty.
Lancet 1997; 349:203-4.
80) Beebe HG, Archie JP, Baker WH, et al. Concern about the safety of carotid angioplasty.
Stroke 1996; 27: 197-198.
81) Brown MB for the CAVATAS Investigators. Results of the Carotid and Vertebral Artery
Transluminal Angioplasty Study (CAVATAS). Cerebrovasc Dis 1998; 8(suppl 4): 21.
82) Naylor AR, Bolia A, Abbott RJ, Pye IF, Smith J, Lennard N, Lloyd AJ, London NJ, Bell
PR. Randomised study of carotid angioplasty and stenting versus carotid endarterectomy: a
stopped trial. J Vase Surg 1998; 28: 326-34.
25
Carotid endarterectomy: the operative site showing the
exposed carotid bifurcation. The white sling is around
the internal carotid artery.
Carotid endarterectomy: carotid artery clamped with a shunt
in place and the atheromatous plaque about to be removed.
Carotid endarterectomy: operative site after closure of
the arteriotomy using a synthetic patch graft.
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This chapter outlines the design of the ECST in the context of the general principles of the
design of large randomised controlled trials in cerebrovascular disease. Important features of
the design of the ECST are described in detail, and analyses of ECST data are presented where
relevant. Analysis and presentation of trial results are also discussed, with particular reference
to subgroup analysis and the difficulty of applying the overall results of large clinical trials to
indvidual patients in clinic.
2.2 Introduction
Cerebrovascular disease is a major public health problem; over the next 10 years approximately
15 million people will suffer an acute stroke in Europe and the United States.1 There is a clear
need for more effective treatments both to prevent stroke and to treat the acute event. There has,
in response to this, been a substantial increase in interest in the design, methodology, and
analysis of randomised controlled trials in cerebrovascular disease in recent years.2,3 Trials
have changed clinical practice in the management of virtually all areas cerebrovasular disease.
Treatment of hypertension has been shown to be highly effective in the primary prevention of
stroke.4 Antiplatelet treatment,3 anticoagulation,6 and carotid endarterectomy 7,8 have each
been shown to be effective in the secondary prevention of stroke. Other important
developments include the effectiveness of nimodipine in the treatment of subarachnoid
haemorrhage,9 and aspirin and thrombolytic therapy in the treatment of cerebral infarction.10"12
There are ongoing trials of many other potentially promising treatments such as angioplasty for
symptomatic carotid stenosis13 and neuroprotective treatments for acute ischaemic stroke.3
The design of a particular trial is very dependent on the nature of the disease under study. For
example, stroke is mainly a disease of the elderly. Many patients are relatively frail, and some
may already have a degree of physical disability. Patients frequently have coexisting systemic
vascular pathology, and are more likely to suffer a myocardial infarction or die of ischaemic
heart disease during follow-up than they are to have a further stroke or die as a consequence of
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their cerebrovascular disease. Each of these considerations affects the design and analysis of
trials in cerebrovascular disease. For example, trials of secondary prevention of stroke often
assess the effect of the intervention on the overall risk of stroke, myocardial infarction and
vascular death rather than on the neurological outcome alone.
There are many ways in which cerebrovascular disease lends itself to clinical trials. Vascular
disease is common, and so there is no shortage of patients. Treatments usually aim to prevent
acute events or improve outcome following an acute event, and so trial design is usually
relatively simple. Measurement of outcome can require little more than the counting of specific
follow-up events. In contrast, trials in other areas of neurology, in which a poor outcome is not
manifest by an easily appreciated acute event, require measurement of disease progression in all
patients. Indeed, the choice of outcome measure is the main issue in trial design in many
neurological diseases. The use of objective outcome measures such as death or disabling stroke
also means that blinded outcome assessment may not always be necessary in trials in
cerebrovascular disease. By contrast, the subjective nature of the outcome measures necessary
in trials in other more variable and slowly progressive diseases, such as multiple sclerosis and
Parkinson's disease, means that blind outcome assessment is of great importance. This can, of
course, be very difficult to achieve, and many trials are undermined by ineffective blinding. It
is partly for these reasons that cerebrovascular disease has produced more than its fair share of
large, methodologically sound, and consequently influential clinical trials.
2.3 Ethics and uncertainty
The ethics of randomisation in clinical trials are dealt with in detail elsewhere,14 but some
points are worth emphasising here. It is often argued that when a clinician is uncertain about the
efficacy of a treatment in a particular patient, the only scientifically valid response, in theory at
least, is to randomise the patient in a well-organised clinical trial. The patient may not receive
the best treatment but at least the trial result will help improve the management of future
patients. The present patient loses nothing because the clinician does not know how best to treat
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him or her anyway. However, this may not be the case. In order to be entered into the trial,
patients must give informed consent. They must understand that their doctors do not know how
best to treat them and that they may well be randomised to no treatment. This uncertainty,
although scientifically valid, may well undermine the confidence of the patient in the doctor,
and thereby diminish the therapeutic effect of the doctor-patient relationship. However, if the
detrimental effect of uncertainty on trial patients was clinically important, then one might
expect the outcome of patients randomised into the control group of clinical trials to be worse
than those treated similarly outwith the trial. In fact, the opposite is usually found to be the
case. Patients within clinical trials do better than those without.13 Although, one can never
exclude the possibility that this may be due to differences in case-mix or subtle differences in
treatment, we can at least conclude that there is no clear evidence that participation in a
clinical trial has a detrimental effect on patients.
Clinical trials are set up to establish the efficacy of treatments, new or established, about which
there is still some uncertainty, at least in the minds of the trialists. However, simply because
there is no clear evidence from clinical trials as to whether a treatment is beneficial, ineffective
or harmful, does not mean that there is necessarily widespread uncertainty about the use of the
treatment in clinical practice. Individual clinicians may have formed a definite opinion about a
treatment on the basis of their own clinical experience or following recommendations by a
respected authority. In fact, somewhat paradoxically, the consistency with which individual
clinicians use a treatment is often inversely proportional to the amount of clinical trial evidence
about the treatment. Treatments for which efficacy has been defined accurately for various
indications tend to be used by most clinicians to a similar extent in similar patients. However,
there is often great variation in the use of unproven treatments, with many clinicians using the
treatment in all their patients and many others never using the treatment. For example, there is
very little evidence as to whether or not the use of a carotid arterial shunt to bypass the
clamped portion of the internal carotid artery during carotid endarterectomy is beneficial.16
However, as is shown in Chapter 13, of those surgeons participating in the ECST, 60% used a
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shunt in fewer than 20% of their patients whereas 25% used a shunt in 80% or more (figure
13.3). Thus for both groups of surgeons a clinical trial in which they used a shunt in only half
of their patients would be a significant departure from their normal practice. The situation was
even more polarized for intra-operative EEG monitoring (figure 13.3). If large numbers of
patients are required and a multicentre trial is envisaged, it will, therefore, be necessary, prior
to setting up the trial, to persuade colleagues that the treatment is of uncertain value and that a
trial is necessary.
The first step in demonstrating the need for a clinical trial is to highlight the lack of definitive
evidence about the efficacy of the treatment. This will usually require a systematic review of
previous randomised controlled trials and possibly also any non-randomised comparisons with
other treatments. With regard to carotid endarterectomy and the ECST, the need for a
randomised trial was outlined by an influential review by Charles Warlow detailing the
evidence from two small trials which had been performed at the time and reporting the results
of an early systematic review of the operative morbidity and mortality of endarterectomy.17
This, and other critical articles 18-20 published at about the same time, appeared to have a
measurable effect on the number of operations being performed in the United States at that time
(figure 2.1).
Having demonstrated a lack of definitive evidence, the second step is to illustrate the extent of
variation in the use of the treatment in everyday clinical practice. For example, with reference
to figure 13.3, the two groups of surgeons cannot both be right. The lack of consistency
between surgeons is strong evidence in support of the need for a trial. The argument is
particularly strong if the treatment in question is expensive or has a significant associated
morbidity or mortality. A similar lack of consistency is also frequently evident in studies of the
variation in use of treatments between different countries (table 2.1). There is no definite
evidence for or against the use of steroids, glycerol or haemodilution in acute stroke, yet there
is great variability between countries in the use of these drugs.
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Table 2.1. Variations between 36 different countries in the use of ancillary treatments for acute ischaemic
stroke. Data derived from the International Stroke Trial.21 For each treatment, the proportion of patients
treated in the country with the greatest usage is compared with the proportion treated in all other countries
combined.
Proportion of patients treated Proportion treated in all other countries
Treatment
Glycerol Italy (50% of 1473 patients) 3% of 14647 patients in 35 countries
Steroids Turkey (32% of 225 patients) 4% of 15895 patients in 35 countries
Haemodilution Austria (54% of206 patients) 3% of 15523 patients in 34 countries
Czech Republic (38% of 391 pts)
In practice, one of the most useful arguments to use in order to encourage colleagues to enter
patients into a trial is the "uncertainty principle". If the clinician is certain that a particular
treatment is indicated for a particular patient, then the patient should not be entered into a trial.
If the clinician is certain that the patient will not benefit from the treatment, then the patient
should not be entered into the trial. However, if the clinician is uncertain about the likely
efficacy of the treatment in a particular patient then the patient should be randomised in the
trial. Clinicians will differ in the type of patients about which they feel uncertain, their "grey
area" of uncertainty. As a consequence, if a sufficiently large number of clinicians enter
patients into the trial, a broad spectrum of patients are likely to be included. This is illustrated
in the ECST by the differences between individual clinicians in terms of the ranges of severity
of carotid stenosis recorded in the patients whom they randomised (figure 2.2). Some clinicians
were certain that patients with severe stenosis benefited from surgery and only randomised
those with mild stenosis, others were only willing to randomise those with severe stenosis,
whereas others randomised patients with all degrees of stenosis. The uncertainty principle is,
therefore, a solid ethical and practical basis for a trial.
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2.4 Trial design
One of the most frequent and damming criticisms of clinical trials is that the results cannot be
applied to everyday clinical practice. This section will concentrate on the design considerations
in the ECST, and in trials in cerebrovascular disease in general, which influence the
generalisability of the eventual results to clinical practice. The majority of trials in
cerebrovascular disease are performed in three areas: primary or secondary prevention of
stroke in particular patient groups; treatment of acute stroke; and rehabilitation following
stroke. Cross-over design trials or n-of-1 trials cannot be used in the first two areas and are
rarely used in the latter area. Thus, as with the ECST, the vast majority of trials in
cerebrovascular disease use the parallel group design.
2.4.1 Pragmatic versus explanatory trials
The effectiveness of a treatment is not the same as the usefulness of a treatment. For example, a
treatment for acute ischaemic stroke may be effective in that it reduces infarct size, but may not
be useful because it is too poorly tolerated by patients, too expensive or too complex to
administer. The same is true of surgical treatments. For example, extra-cranial to intracranial
bypass surgery in patients with carotid occlusion is effective because it produces measurable
improvements in cerebral blood flow,22 but it is not useful because it has no effect on the risk
of ischaemic stroke.23 An ineffective drug or operation is, on the other hand, always useless
(excluding the placebo response). It is frequently argued, therefore, that a pragmatic trial to
establish usefulness should always be preceded by an explanatory trial to establish efficacy. An
explanatory trial seeks to measure the specific effect of the treatment on the pathophysiology of
the disease. Such trials are often small, include only a tightly defined group of patients, ensure
that all patients receive their allotted treatment, and frequently have non-clinical measures of
outcome. Pragmatic trials seek to measure the usefulness of treatments in conditions which, as
far as possible, mimic normal clinical practice. Ideally they should include a broad spectrum of
patients with the disease in question, they should be analysed on an intention-to-treat basis and
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they should have a clinically important measure of outcome. As a consequence pragmatic trials
usually need to be much larger than explanatory trials in order to confirm or exclude a useful
treatment effect. They are, however, much more likely than explanatory trials to change clinical
practice.
2.4.2 Selection ofpatients
Patient entry criteria determine whether the results of the trial will be highly applicable to a
very tightly defined, and probably small, group of patients, or whether they will be widely
generalisable to a less stringently defined, and probably much larger, population of patients
with the condition. For example, a trial of carotid endarterectomy for asymptomatic stenosis
might include all patients with a certain degree of stenosis or it might be limited to the small
proportion of patients with an ulcerated carotid plaque and an asymptomatic cerebral infarction
in the territory of the stenosed artery. The advantage of a highly applicable result is that it can
be applied with a degree of confidence to an individual patient, assuming that they fit the trial
criteria. The disadvantage is that the result may not inform management of the majority of
patients with the condition who would not fit the trial criteria. The disadvantage of a widely
generalisable result is that it cannot be used with any confidence to predict the likely response
to treatment of an individual patient. All that can be said is that if the treatment is given to a
sufficiently large number of patients, on average it will have a given effect.
Large trials with broad entry criteria do have a number of important advantages. Firstly,
generally speaking the broader the entry criteria, the more likely it is that the trial will recruit
sufficient patients to produce a definitive result. This is partly because more patients will be
eligible, but also because the entry criteria will overlap with the grey area of uncertainty of a
higher proportion of clinicians resulting in a larger number of collaborators. Secondly, even if
the trialists are mainly interested in a specific group of patients, it often makes more sense in
practice to adopt broad entry criteria as this will probably result in the randomisation of a
greater number of patients with the specific characteristics of interest than if entry is
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specifically limited to such patients. The main reasons for this are that the trial will have access
to the patients of a larger number of collaborators and, of particular importance, clinicians will
be randomising patients regularly and will, therefore, be familiar with the randomisation
procedure and trial protocol. By contrast, if only a small proportion of patients are eligible,
clinicians will tend to forget about the trial and miss the rare patient who does actually fit the
criteria. A large trial with broad entry criteria may well have sufficient power to allow
analysis of the efficacy of treatment in predefined groups of interest. For example, the
International Stroke Trial,10 which examined the effect of antithrombotic treatment in acute
ischaemic stroke, had a time window of up to 48 hours between stroke onset and randomisation.
It recruited 19,436 patients, 3165 (16%) of whom were randomised within six hours. It was
therefore the largest trial of very early intervention after acute stroke and had sufficient power
to examine the effect of treatment given within six hours of onset.
2.4.3 Eligibility criteriafor the ECST
Eligibility was determined using the uncertainty principle. If the patient fulfilled the
eligibility criteria outlined below, and was willing to consider surgery, then only if the
neurologist or surgeon were "substantially uncertain" whether to recommend surgery could
the patient be entered into the trial. Any patient, irrespective of age, sex, or race, who, within
the six months prior to randomisation, had experienced any combination of TIA, amaurosis
fugax, retinal infarction, minor ischaemic stroke or non-disabling major ischaemic stroke
within the distribution of one or both internal carotid arteries, and who had a stenosing and/or
ulcerating lesion of the symptomatic artery(s) at its origin in the neck, was eligible for the trial.
2.4.4 Exclusion criteria for the ECST
Patients were excluded on the following grounds:
1) Patient preference
2) Poor general health
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3) Little if any carotid stenosis
4) Occlusion of internal carotid artery
5) Stenosis of the distal internal carotid artery which was more severe than that at the
bifurcation
6) A technically inoperable carotid lesion
7) Presenting symptoms thought to be due to pathology other than carotid atherosclerosis e.g.
patients with recent myocardial infarction, mitral stenosis, atrial fibrillation.
8) Vertebrobasilar events only
9) Previous carotid endarterectomy of the symptomatic artery.
2.4.5 Entry requirements
Trials often require certain investigations to be performed or protocols followed prior to entry.
Similar arguments to those regarding patient selection apply to trial entry requirements. Again a
balance has to be achieved between what might be possible in an ideal world and what can be
achieved in practice. For example, a trial of carotid endarterectomy for asymptomatic carotid
stenosis would not only accrue patients very slowly if it insisted on four vessel selective carotid
arterial angiography in all patients prior to randomisation, but since the degree of carotid
stenosis is now increasingly measured by non-invasive methods, any recommendations made on
the basis of results which were based on the findings at angiography would rapidly become
redundant. Moreover, if the trial is to have a chance of being completed in the first place one
cannot exclude too many patients. One hospital taking part in one particular multicentre acute
stroke trial screened 192 patients over a two year period, but was able to enter only one patient
into the trial.24 This is an extreme example, but trial entry rates following screening of 10-20%
are very common, particularly in explanatory trials.23'26 Lasaga's Law states that "As soon as a
clinical trial begins, the supply of patients becomes one tenth of that which it was thought to be
before the trial started." 26
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2.4.6 Investigations requiredprior to randomisation in the ECST
The data recorded on the randomisation form are detailed in Appendix 1. It was also
recommended that collaborators check the platelet count, erythrocyte sedimentation rate, urea,
syphilis serology, chest x-ray, and echocardiogram if indicated, but no systematic record of
these investigations was kept. Computed tomographic brain scans were recommended in all
patients. Prior to January 1991, copies of all abnormal scans were sent to the Trial Office.
Although the majority of patients underwent carotid ultrasound scanning as a screening test,
results were not requested. All patients were required to undergo angiography. The exact
method of angiography was not, however, specified because of the considerable variation in
practice between departments of radiology. Conventional or digitally selected arterial
angiograms were preferred, but arch arterial angiograms and intravenous digital subtraction
angiograms were accepted. Biplanar views of the origin of the symptomatic ICA, with as
good a view as possible of the intracranial circulation on that side, were requested.
Although not mandatory, views of the contralateral ICA were recommended. Copies of all
angiograms were sent to the Trial Office.
2.4.7 Ensuring comparability with other trials
It is often difficult for a single trial to recruit sufficient patients to confirm or exclude moderate
treatment effects on relatively low risk outcomes, such as are found in trials of primary
prevention and secondary prevention of stroke, or to test for possible heterogeneity of treatment
effect across specific subgroups of patients. In this situation the only practical way of
determining the efficacy of treatment with sufficiently narrow confidence limits is to perform a
meta-analysis of trials as part of a systematic review. However, attempts to combine the results
of independent trials are frequently hampered by major differences in the design of trials,
particularly in the measurement of outcome. It is important, therefore, if it seems likely that a
meta-analysis of all trials may be necessary in future, that some consideration be given to
maximizing the comparability of the trial design with those of previous or ongoing trials.
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Moreover, meta-analysis of individual patient data has a number of advantages over meta¬
analysis of overall trial results. There is, therefore, something to be said for attempting to
maintain a degree of comparability of definitions and database structures. Much of the design
of the ECST was adopted by subsequent trials such the NASCET8 and the Asymptomatic
Carotid Surgery Trial (ACST),27 and similar measures of outcome have been used.
2.4.8 Sample size
There are a number of points regarding sample size calculations which relate particularly to
cerebrovascular disease. Firstly, and most importantly, the treatment effects involved in the
treatment or prevention of stroke are often relatively small. For example, one would probably
not expect a neuroprotective agent to yield much more than a 20% relative reduction in early
mortality following acute stroke. A similar relative risk reduction might be expected in the risk
of recurrent stroke with an antiplatelet drug in a secondary prevention trial. Given that in
neither of these examples would the absolute risk of the trial outcome in the control group be
much more than 10%, the expected reduction in the absolute risk of the trial outcome with
treatment would only be about 2%. Table 2.2 gives details of the power to demonstrate such a
treatment effect which different sample sizes would have. To be reasonably sure of
documenting the true efficacy of treatment the trial would require at least 12,000 patients and
ideally 20,000 patients. Although large simple trials do have some limitations,28'29 the case in
favour of them is very strong.30 The fact that it is possible to recruit such numbers is illustrated
by the recent success of the International Stroke Trial and the Chinese Acute Stroke Trial.10'11
The lack of power inherent in small trials is compounded by the tendency for the outcome in
patients entered into clinical trials to be better, irrespective of treatment, than that in those
who are not entered.15 It is important not to over-estimate the expected untreated risk of a poor
outcome in the control group when calculating the sample size. Simply extrapolating from the
risks reported in observational studies is likely to be inappropriate. For example, the risk of
stroke in patients randomised in the UK-TIA Aspirin trial was lower than a comparable
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hospital referred series of patients with apparently similar disease and very much lower than in
a comparable community based series.31 As a consequence of this the trial was not able to
demonstrate a significant reduction in the risk of stroke with aspirin treatment.
Table 2.2 Effect of sample size on the reliability of the result of a trial of an hypothetical treatment for
acute stroke The treatment is assumed to reduce case-fatality from 10% to 8% i.e. a 20% relative risk
reduction. Adapted from Dorman and Sandercock.3
Total Patients p* Trial Power (%) Comments on Trial Size
200 0.99 1 Completely inadequate
400 0.98 2 Completely inadequate
800 0.96 4 Completely inadequate
1,600 0.90 10 Completely inadequate
3,200 0.75 25 Inadequate
6,400 0.43 57 Barely adequate
12,800 0.09 91 Probably adequate
20,000 0.01 99 Definitely adequate
* approximate probability of failing to achieve P<0.01 significance if true relative risk reduction is 20%.
Trials in patients with cerebrovascular disease not infrequently have a sizable number of drop¬
outs and cross-overs from treatment to no treatment or vice versa. This is at least partly because
they involve an elderly population of patients who tend to be more liable to develop side-effects
of treatment. Since the trial will be analysed on an intention-to-treat basis, significant numbers
of cross-overs and drop-outs will undermine the power of the trial to demonstrate a given
treatment effect. This should be taken into account in the initial sample size calculation.
Moreover, if long follow-up is required, as is the case in primary or secondary prevention
trials, sample size calculations must also take account of a relatively high mortality due to non-
stroke vascular death and non-vascular death. However, the trial entry criteria can, of course,
be defined in such a way as to minimise the sample size required. For example, it has been
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argued that minor strokes and very severe strokes should both be excluded from trials of
treatments for acute ischaemic stroke. The minor strokes are likely to recover completely with
or without treatment and the very severe strokes will probably die irrespective of treatment. If
one accepts these assumptions, both groups could be excluded from the trial without loss of
power since only the outcome in patients with strokes of intermediate severity is likely to be
influenced by the treatment.
2.4.9 Sample size in the ECST
There were several difficulties in performing a sample size calculation in 1981 when the ECST
began. Firstly, what evidence there was suggested that the risk of stroke on medical treatment,
and consequently the likely treatment effect derived from endarterectomy, would increase with
severity of stenosis. The sample size required to demonstrate a given effect would, therefore,
vary with the range of stenosis of the population under study. Secondly, there was considerable
variability in the reported operative risk of stroke and death due to endarterectomy. Thirdly, it
was clear that with the early hazard of surgery, the relative treatment effect (i.e. benefit vs
harm) would vary with length of follow-up. For example, irrespective of the degree of stenosis,
endarterectomy would very probably be harmful with only six months follow-up because an
appreciable stroke risk in the non-surgery group would only accrue with the passage of time.
The trial design did not, therefore, include a designated sample size at which the trial would
stop. A data monitoring committee was set up to review the results periodically in order to
review the efficacy and safety data and stop the trial if and when it was appropriate to do so.
The primary outcome measure was major stroke or surgical death. There was no stopping rule
based on a predetermined significance level.
2.4.10 Treatmen t allocation
The purpose of randomisation in a clinical trial is to ensure that neither the patients nor the
clinician can predict in advance which treatment the patient will receive. Randomisation does
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not necessarily ensure that the prognosis in the treatment and control groups will be equal at
baseline. Indeed, in a small trial this is very unlikely to be the case. There is an argument,
therefore, that randomisation should be stratified according to important prognostic variables or
that a balance should be achieved using minimisation. However, these methods are best suited
to large, preferably multi-centre, trials in which there is central computer randomisation.
There are a number of outcomes in cerebrovascular disease for which there are important
prognostic variables. For example, there are established models for predicting recovery after
acute stroke^2 or the risk of stroke following a transient ischaemic attack.33 Trials should
consider balancing treatment allocation for these variables. The effect of imbalance is
illustrated in table 2.3 which details an hypothetical trial of an intervention intended to reduce
the risk of stroke and death due to carotid endarterectomy. There is a non-significant imbalance
in five important prognostic variables in favour of the intervention group. Using the hazard
ratios obtained from the systematic review of risk factors for stroke and death due to
endarterectomy detailed in Chapter 13, the predicted risk of a poor outcome in the control
group is nearly twice that in the intervention group irrespective of any effect of the intervention
itself. This degree of prognostic imbalance will, not infrequently, result from simple
randomisation in small and medium sized trials.
Trials should, of course, detail the balance of prognostic variables across the treatment groups
when reporting results. It is important to bear in mind, however, the fact that if a prognostic
variable is particularly important, a relatively minor imbalance between the treatment groups
may have a major effect on the trial result, irrespective of whether or not the imbalance is of
statistical significance. Reports of trials which do not give any information on the
characteristics of the different treatment groups should be interpreted with caution. For
example, a recent small randomised trial of gastrostomy feeding versus nasogastric feeding
following acute stroke reported a significant reduction in mortality in the gastrostomy group
[12% (2/16) vs 57% (8/14), P=0.04, Fisher exact test].34 The result was impressive, albeit
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somewhat implausible, but would have been more convincing had the baseline data also been
reported.
Table 2.3 The baseline clinical characteristics of patients randomised to treatment vs control in an
hypothetical trial of an intervention to reduce the risk of stroke and death due to carotid endarterectomy.
The likely effect of each characteristic on the difference in operative risk between the intervention group
and the control group is calculated from the respective hazard ratios derived from the multiple regression
analysis presented in table 13.7.
Treatment Control P1 Effect on operative Imbalance in
o<NIIC O(NIIC risk (HR and 95% CI) relative risk
Baseline characteristic
Female sex 6 12 P = 0.11 1.41 (1.16- 1.70) + 12%
Ocular symptoms only 12 6 P = 0.11 0.46 (0.24-0.91) +35%
Peripheral arterial disease 1 4 P = 0.34 1.44 (1.17- 1.79) +7%
Systolic BP > 180mmHg 3 8 P = 0.16 1.93 (1.22 -3.04) +23%
Overall excess operative risk in the intervention group vs the control group: +77%
1 Fisher exact test
2.4.11 Randomisation and baseline characteristics in the ECST
Patients were randomised by a telephone call to the Clinical Trials Service Unit at the
Radcliffe Infirmary, Oxford. Randomisation was stratified by centre, but not by any clinical
characteristics or known prognostic factors. Patients were randomised to "immediate surgery"
in 60% of cases and "no immediate surgery" in 40% of cases. Clinicians were asked to
ensure that patients in both groups received the "best medical treatment", which usually
included aspirin, treatment of hypertension, and advice to stop smoking. The baseline clinical
characteristics of patients according to randomised treatment allocation are shown in table 2.4.
There were no statistically significant or clinically important differences between the groups.
Table 2.4. The baseline clinical characteristics of patients randomised in the ECST stratified according
to randomised treatment allocation.
Surgery (n= 1,807) Control (n=1211)
Demography
Male 1299 (72%) 869 (72%)
Mean (SD) age in years 62.5 (8.1) 62.3 (8.0)
lschaemic events
Any cerebral transient ischaemic attack 895 (50%) 595 (49%)
Any amaurosis fugax 452 (25%) 318 (26%)
Any minor stroke (symptoms <7 days) 408 (23%) 253 (21%)
Any major stroke 491 (27%) 340 (28%)
Any retinal infarction 113 (6%) 73 (6%)
Infarct on CT scan on symptomatic side 456 (25%) 295 (24%)
Residual neurological signs 535 (30%) 346 (29%)
Mean (SD) days from last symptoms 62.3 (53.4) 62.3 (52.7)
History
Hypertension* 839/1614 (52%) 504/1078 (47)
Mean (SD) systolic blood pressure (mm Hg) 151 (22.3) 150.2(21.3)
Mean (SD) diastolic blood pressure (mmHg) 86.2(11.4) 86.3 (10.8)
Ischaemic heart disease 443 (24%) 258 (21%)
Peripheral vascular disease 292(16%) 203 (17%)
Diabetes 208 (12%) 145 (12%)
Current cigarette smoking* 844/1604 (53%) 557/1077 (52)
Previous carotid endarterectomy* 29/1614 (2%) 23/1081(2%)
Laboratory data
Mean blood cholesterol (mmol/L)* 6.4(13.5) 6.4(13.8)
Mean (SD) packed-cell volume 43.3 (6.6) 43.8 (6.9)
Stenosis of symptomatic carotid artery
0-29% 240(13%) 179(15%)
30-49% 390 (22%) 261 (22%)
50-69% 582 (32%) 377 (31%)
70-99% 586 (32%) 389 (32%)
Occluded 9 (0.5%) 5 (0.4%)
Stenosis of contralateral carotid artery
0-29% 894 (53%) 569 (51%)
30-49% 379 (22%) 261 (23%)
50-69% 264 (16%) 176 (16%)
70-99% 107 (6%) 67 (6%)
Occluded 49 (3%) 49 (4%)
Missing (no views available) 114(6%) 89 (7%)
♦Variables not collected beyond January, 1992: for cholesterol n=1573 surgery, 1059 control; for packed-
cell volume n=1614, 1081.
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2.4.12 Blinding
The necessity for blinding depends to a certain extent on the design of the trial, particularly the
outcome measures used. There are two main reasons for blinding the trial clinicians. Firstly, in
order that clinicians are not biased in their assessment of clinical outcomes. Blinded outcome
assessment is vital in trials in which the outcome measure is subjective. The subjectivity of an
outcome measure is best judged by measuring its inter-observer reproducibility. For example,
inter-observer agreement in the diagnosis of transient ischaemic attacks or in the detection of
abnormal neurological signs is relatively poor.32'36 Thus a non-blind trial in which a transient
ischaemic attack was an outcome event or in which outcome was measured using some sort of
neurological impairment scale would be susceptible to bias. In the case of measurement of
neurological impairment and disability, the potential for biased assessment was clearly
demonstrated in a recent multiple sclerosis trial in which blind and non-blind outcome
assessment produced very different results/7
There is less potential for bias in assessment of outcome in trials in which the outcomes are
objective e.g. death or major stroke. Thus trials of carotid endarterectomy have not gone to
elaborate lengths to blind assessors to whether or not the patient had had the operation. Such
trials do, however, usually have a blinded audit committee which studies a report by the trial
clinician of any potential trial outcome event and decides how the event should be classified.
The second reason why blinding to treatment allocation is important is that the use of non-trial
treatments and interventions should not be influenced by a knowledge of whether or not the
patients received the trial treatment. Non-blind trials cannot, of course, exclude this possibility
and should, therefore, document all potentially important non-trial treatments given to patients
during follow-up and report these data with the trial.
2.4.13 Blinded audit and non-trial treatments in the ECST
The reporting of trial outcome events by collaborating clinicians was not blind to treatment
allocation. However, events were subject to an audit process which was blind to treatment
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allocation. If a trial outcome event occurred, then the collaborating clinician informed the trial
centre using a standard form. The form was assessed by Professor Warlow, or in the later years
of the trial by myself, and a non-blind summary of the clinical history, examination findings
and investigations relating to the event was produced. This usually required additional
information from the collaborating clinician, the hospital notes, the records of the family doctor
or death certificate and post-mortem report in the case of fatal outcomes. The non-blind
summary of the event was then sent to the collaborator for confirmation and signature. If the
non-blind summary was satisfactory, a blind summary was produced which was identical to the
non-blind summary in all respects other than in reference to treatment allocation. The blind
summary was then sent to an independent clinician for assessment as to whether it constituted a
valid trial outcome.
Table 2.5. The proportion of patients randomised to surgery vs no-surgery who were receiving relevant
non-trial drug treatments during follow-up in 1990.
Treatment Surgery (n=1202) No surgery (n=809) Significance
Aspirin 841 (70%) 558 (69%) ns
Dipyridamole 229(19%) 152 (19%) ns
Ticlopidine 43 (4%) 36 (4%) ns
Anticoagulation 72 (6%) 35 (4%) ns
Diuretic 281 (23%) 172 (21%) ns
Beta-blocker 293 (24%) 186(23%) ns
Calcium antagonist 240 (20%) 163 (20%) ns
Digoxin 60 (5%) 24 (3%) ns
Lipid lowering drugs 68 (6%) 49 (6%) ns
The use of non-trial treatments which it was considered might bias the occurrence of any of the
trial outcome events was monitored at each annual follow-up by the collaborating neurologist.
The proportions of patients in the surgery and the no-surgery groups who were receiving the
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recorded non-trial drug treatments during one of the routine analyses in 1990 are shown in
Table 2.5. Other potentially confounding treatments, such as coronary artery bypass grafting,
ECMC bypass surgery, non-trial carotid endarterectomy, and venesection, were also monitored.
In addition, other markers of possible differences in management which might lead to bias, such
as systolic and diastolic blood pressure and current smoking on follow-up, were monitored.
2.4.14 Follow-up
Insufficient follow-up is a potential shortcoming of clinical trials in cerebrovascular disease.
Long follow-up is likely to increase the cost of the trial and make complete follow-up more
difficult to achieve. However, it is quite possible for the effectiveness of treatments to change
with time. For example, recovery following acute stroke may continue for six months to two
years,38'j9 and so measurement of functional outcome at hospital discharge in an acute stroke
trial will give a very incomplete picture of the effect of treatment and may well be less sensitive
than assessment of outcome at six months. Similar considerations apply to secondary
prevention trials. There are several reasons to expect that the efficacy of endarterectomy will
change during follow-up. Firstly, given that the harm due to endarterectomy occurs early in the
surgery group, there would be a period of about one year after randomisation during which
surgery would be more harmful than no surgery. Thereafter the number of strokes in the no-
surgery group would continue to increase and would offset the surgical risk. Follow-up would
then be required for several more years before the reduction in risk of stroke with surgery
would begin to plateau. Secondly, there is a risk that the benefit of endarterectomy might last
for a few years and then diminish as a consequence of late restenosis of the operated artery.
Restenosis would be likely to increase the stroke risk in the surgery group, but this increase
might not occur until as late as five or ten years after randomisation. Without follow-up of at
least five years it would not be possible to determine whether endarterectomy prevented stroke
or simply delayed the occurrence by a few years.
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The problem of insufficient follow-up in endarterectomy trials is likely to be greater in trials in
asymptomatic patients than in symptomatic patients. As shown in Chapter 8, the risk of stroke
distal to a recently symptomatic stenosis falls fairly rapidly with time and reaches as low as 1-
2% per annum after two years. However, there is no similar evidence of a fall off in stroke risk
distal to an asymptomatic stenosis. Although endarterectomy for asymptomatic carotid stenosis
does reduce the risk of ipsilateral ischaemic stroke,40'4' the benefit after five years is small and
the procedure is regarded by many as being of little value.42 The benefit derived from the
operation is determined to a great extent by the risk of stroke without treatment. This is
relatively low after five years of follow-up, and only just offsets the risk of the operation itself.
However, a 50 year old man with a severe asymptomatic carotid stenosis may survive for 20 or
more years. The cumulative risk of stroke due to the carotid stenosis is likely to be considerable
over that length of time. The results of a trial performed in an elderly population with only a
few years follow-up may well underestimate the likely benefit of surgery in a patient such as
this. Clearly, 20 year follow-up is impractical, but trialists should consider the potential
problems which may result from too short a period of follow-up.
2.4.15 Follow-up in the ECST
Patients were reviewed by a collaborating physician, usually a neurologist, at four months and
one year after randomisation, and annually thereafter. Any patient not attending hospital
was followed up through their family or other doctor. Information collected at each follow-
up included details of any new strokes since last review, any previous strokes with persisting
symptoms, any myocardial infarcts, TIAs, angina or symptoms of peripheral vascular
disease, medications, smoking status, and blood pressure. The follow-up forms are detailed in
Appendix 2. All patients were followed up until death. Of the 3024 patients randomised in the
trial, complete follow-up was available on 2999 (99.4%). The mean length of follow-up was
6.1 years. The median follow-up was 5.2 years and the range was 1 to 13.8 years.
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2.4.16 Outcome measures
The choice of outcome measure is an important issue in trial design in cerebrovascular disease.
It has implications for the cost of the trial, the sample size required to obtain a clear result, and
the likelihood that the trial will influence clinical practice. Important considerations in choosing
an outcome measure include validity, reproducibility, sensitivity to change, clinical meaning,
and the burden it places on patients and clinicians taking part in the trial. Outcome measures
which have been used in trials in cerebrovascular disease include event rates, neurological
impairment, disability or handicap, quality of life, and various other indicators such as length of
hospital stay, proportion of patients returning home, and health-economic assessments of the
cost of illness. The most commonly used outcomes are discussed below.
Single events or "endpoints": Assessment of the relative frequency of particular events
across the treatment groups is probably the simplest method of measuring the efficacy of
treatment. The event could be death in a trial of a treatment for acute stroke or stroke in a trial
of a preventative treatment. In acute treatment trials with short follow-up it may be reasonable
simply to compare the proportion of events in each group. In trials of treatments aiming to
prevent stroke, in which long follow-up is required, the comparison of event rates should be
based on an actuarial analysis.
The use of single events as outcome measures has several advantages over the use of more
complex scales or surrogate outcome measures. Firstly, in the majority of cases the occurrence
of the event in question will be fairly obvious e.g. death or disabling stroke. In other words, the
outcome assessment will have good inter-observer agreement. The true efficacy of the
treatment will not, therefore, be blurred by variation between different observers in the
measurement of outcome. This does, of course, depend on the choice of event. For example, the
diagnosis of transient ischaemic attacks has relatively poor inter-observer agreement.35
Secondly, if an objective measure of outcome is used, such as death or disabling stroke, then
there is much less potential for bias in unblind or poorly blinded trials than if a more subjective
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measure, such as an impairment score or stroke scale were used. Thirdly, assessment of the
frequency of specific events will usually be cheaper and will place less of a burden on the
patient and clinician than measurement of more complex scores. Finally, the actual value of the
treatment can be more easily appreciated by future patients and clinicians if it is analysed as an
event rate than if it is expressed as a change in the mean value of a particular stroke scale.
Measurement of event rates does, however, have certain disadvantages. It takes no account of
the consequences of the event on the impairment, disability or handicap of the patient. A stroke,
for example, can range in severity from slight numbness in one hand to a complete hemiplegia
with dysphasia or neglect. It seems wrong that these two events should be given the same
weight in any analysis of the effectiveness of a treatment. In one of the carotid endarterectomy
trials, even stroke and transient ischaemic attack were lumped together as a single composite
outcome event.41 Not only .does this make it difficult for clinicians to assess the utility of the
treatment (Does it prevent major strokes or just transient ischaemic attacks?), but it assumes
that the relative proportion of strokes and transient events will be the same in each treatment
group. This is, however, by no means always likely to be the case. For example, in trials of
carotid endarterectomy the majority of outcome events in patients randomised to surgery occur
during or shortly after the operation. Since the procedure is usually carried out under general
anaesthesia, it is likely that many transient ischaemic attacks and minor strokes will be missed.
By contrast, outcome events in patients randomised to medical treatment occur gradually over
the next few years and a significant proportion of reported events are transient or minor. A
direct comparison of event rate in such trials may, therefore, to be biased in favour of surgery.
A further disadvantage of using the number of patients experiencing a particular event as an
outcome measure is the difficulty in dealing with multiple events in single patients. This can be
difficult to accommodate in standard survival analyses. However, it is quite possible for a
single patient to have several disabling strokes during follow-up. This is also a problem when
composite outcomes, such as stroke, myocardial infarction or vascular death, are used. A single
patient may suffer all of these events during follow-up. It is possible to look at the cumulative
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event rate in each treatment group rather than simply the number of patients suffering an event,
but further research is required in order to produce a consensus about the most appropriate
techniques to use.
Surrogate outcomes: Non-clinical surrogate outcomes can be used to measure the effect of
treatment e.g. infarct size on CT brain scan in an acute stroke trial, or cerebrovascular
reactivity in trials of treatment for carotid stenosis. They are looking for a biological effect. Is
the treatment doing anything at all? Surrogate outcome measures are important in explanatory
trials in order to determine whether or not a treatment is worth investigating further in large
pragmatic clinical trials. They do not, however, tell us anything about the clinical usefulness of
the treatment. However, one major advantage of surrogate outcome measures, such as infarct
size, is that the measurement which is used for the trial analysis can be made by a radiologist
who has not seen the patient and who is, therefore, more likely to be blind to treatment
allocation than a clinician who has to examine the patient in order to derive a score on a stroke
scale. Ideally, of course, measurements such as infarct size should be automated, thereby
precluding assessor bias altogether.
Impairment: Several stroke scales have been used as outcome measures in trials in
cerebrovascular disease. These are usually impairment scales which allot scores to various
neurological signs and then add them all up to produce an overall score. It is, of course, very
difficult for either patients or doctors to know exactly what a particular score represents, or
more importantly, whether a treatment which results in a given change in mean score is
worthwhile. It has been argued that a patient is more than the sum of their signs, and that
adding up arbitrary scores for speech, power, level of consciousness, eye signs, and reflex
changes is as meaningless as adding up the concentrations of blood urea, sodium, potassium
and glucose to make up an overall "metabolic score."43 This argument is difficult to oppose.
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One important disadvantage of many of the impairment scores used in stroke trials is their
tendency to concentrate mainly on motor signs. Subtle difficulties with speech or visuospatial
functioning may not contribute much to the stroke severity score even though they can be
extremely disabling for the patient. The true impact of such impairments is much more likely to
be registered by measurements of handicap or health-related quality of life. Moreover, the
assumption made by many that a detailed neurological score will necessarily be more sensitive
to any effect of treatment than a simple disability or handicap scale is by no means self-evident.
Complex scores tend to have greater inter-observer variability which will introduce background
noise into the analysis and reduce the power of the trial. More research is required into the
sensitivity to change of different types of outcome measure.
Disability, handicap and simple questions: There are several generic disability scales, such as
the Barthel scale,44 which have been used in stroke trials. These are based on the ability of the
patient to perform specific tasks and, as such, have more obvious meaning to doctors and
patients. Although the Barthel scale is similar to an impairment score in that it simply adds up
scores for different activities of daily living, the total score (ranging from 0 - 100) has been
shown to have a degree of validity in that it predicts the level of autonomy following stroke
rehabilitation. For example, a score of 20 or more immediately after a stroke or a score of 40 or
more at the time of transfer to a rehabilitation centre are highly predictive of a return to home
following rehabilitation.45 Moreover, the absolute score at a given time can be roughly equated
with a level of independence. A score of 60 corresponds to the level of function required to live
at home with moderate assistance, and a score of 85 corresponds to independence with minimal
assistance.46
However, even with scales such as the Barthel it is still difficult to know exactly what a change
of a given number of points actually means. Simple handicap scores overcome this difficulty to
some extent. The most widely used of these is the Rankin Scale which has five levels of
disability from no significant disability to totally bedridden.47 The score is analysed as a
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categorical variable and the meaning of both absolute scores and changes in score are relatively
easily understood by clinicians and patients. It has also been shown to have good inter-observer
reproducibility.47 The modified Rankin Scale was used in the ECST (table 2.6).
Table 2.6. The modified Rankin Scale used to assess disability/handicap due to strokes which occurred
during follow-up in the ECST.
Grade Description
0 No symptoms
1 Minor symptoms which do not interfere with lifestyle
2 Minor handicap. Symptoms which lead to some restriction in lifestyle but do
not interfere with the patient's ability to look after themselves.
3 Moderate handicap. Symptoms which significantly restrict lifestyle and
prevent a totally independent existence.
4 Moderately severe handicap. Symptoms which clearly prevent independent
existence although not needing constant care and attention.
5 Severe handicap. Totally dependent, requiring constant attention day and
night.
One common misconception regarding outcome scales is that the more complex a scale is i.e.
the greater the number of possible scores, the more discriminating it will be. In other words, a
scale which divides patients into a large number of groups has much greater statistical power to
detect a difference between treatment groups than a scale which divides patient into just a few
groups. In actual fact, the increase in "statistical power" with increasing numbers of
subdivisions is very much a case of diminishing returns (table 2.7). The logical extension of
this observation is to limit outcome assessment to a series of simple questions, such as "Have





Table 2.7 The reduction in variance (i.e. "the statistical power") of a measurement according to the
number of subdivisions of the measurement. The example assumes that the quantity being measured has
true integer values ofO to 100. Adapted from Richard Peto (personal communication).
Number of possible Approximate variance Reduction in variance achieved
values ofmeasurement by measurement
1 (0-100 i.e. not measured) 900 (i.e. sd = 30) 0%
2 (0-50,50-100) 225 (i.e. sd = 15) 75%
3 (0-33 etc) 100 89%
5 (0-20 etc) 36 96%
10 (0-10 etc) 9 99%
100 (0-1 etc) 0 100%
One of the main advantages of disability scales, handicap scales and simple questions is that
they can often be completed by the patient themselves or administered by non-clinical
assistants. Both options are cheaper than medical assessment and are often particularly
appropriate in large multicentre trials. Self-assessment by patients has the advantage that it
eliminates the potential for external assessor bias, although it does not avoid bias due to
placebo effects experienced by patients. Postal or telephone follow-up using very simple scales
is easily standardised and relatively inexpensive.
Quality of life and the importance of the patient's point of view: It can be argued that the
most important overall measure of the effect which a treatment has on a patient is the effect on
overall health-related quality of life. If we consider an hypothetical new antiplatelet drug
intended for use in the secondary prevention of ischaemic stroke. The drug produces a modest,
but worthwhile, 25% relative reduction in the risk of recurrent stroke over the next few years,
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and appears to be marginally more effective than aspirin. However, it causes significant
malaise, nausea or diarrhoea in 15% of patients, and more mild symptoms in over 30%. How
should the benefit of a reduced risk of stroke be balanced against the distress caused by the side
effects of the drug? Side effects are rarely incorporated into the overall trial result, and are
usually simply listed separately. The decision as to whether the benefits of treatment justify the
side-effects is therefore left for doctors reading the paper to decide for themselves. However,
since the concerns of doctors and patients may not coincide this may be inappropriate.
Measuring outcome using an overall measure of health-related quality of life would at least
record the patients perspective as to whether or not the treatment was worse than the disease
itself. Measures of health-related quality of life which have been studied in stroke patients
include the Short Form-36 49'50 and the EuroQol.50'31
2.4.17 Outcome measures used in the ECST
The outcome measures used in the ECST were, of course, chosen in the early 1980's when
there was little or no interest in the concept of health-related quality of life. However, it is
probably reasonable to assume that the occurrence of a disabling stroke is usually associated
with a reduction in health-related quality of life. If one is dealing with a treatment, such as
endarterectomy, which other than operative stroke has a low risk of long term on-going side
effects, it is probably reasonable to extrapolate from a reduction in the overall incidence of
stroke to an improvement in health-related quality of life. This is quite different from a drug
treatment, for example, which might reduce the incidence of stroke, but also cause on-going
side effects which could negate any improvement in health-related quality of life consequent
upon the reduction in stroke incidence.
No attempt was made to measure the effect of endarterectomy on surrogate outcomes such as
cerebrovascular reserve or incidence of new infarcts on folow-up CT brain scans. The ECST
was intended to be a pragmatic trial, and aimed to assess the effect of endarterectomy on
clinically important outcomes. The main purpose of carotid endarterectomy was considered to
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be the prevention of stroke. Whatever other outcomes were measured, it was clearly necessary
to assess the effect of the operation on the incidence of stroke. From an explanatory viewpoint
the incidence of ipsilateral carotid-territory ischaemic stroke would be the most appropriate
measure because these were the specific events which the operation aimed to prevent. From a
pragmatic viewpoint the incidence of any stroke would be most appropriate because we wanted
to know what effect the operation had on the total burden of stroke in this group of patients.
Given that the operation is associated with a 1-2% mortality, it was also necessary to assess
the effect of the operation on fatal stroke, the main cause of death due to endarterectomy, and
on all cause mortality.
It was clearly necessary to have some measure of the severity of strokes which occurred on
follow-up, both to quantify the efficacy of endarterectomy and to ensure that there was no
systematic difference in the severity of strokes which occurred at endarterectomy compared
with those occurring on medical treatment. For the reasons discussed earlier it was felt that this
was best measured using a simple handicap scale rather than a complex impairment or
disability scale. The Rankin scale47 was chosen (table 2.6). Although the occurrence of
transient ischaemic attacks and minor strokes with symptoms lasting less than seven days were
recorded at each follow-up visit, only strokes with symptoms lasting seven days or longer were
audited as possible outcome events. The definitions of the main trial outcome events are given
below:
Stroke was defined as a clinical syndrome characterised by rapidly developing
symptoms and/or signs of focal and at times global (applied to patients in deep coma
and those with subarachnoid haemorrhage), loss of cerebral function lasting longer than
24 h or leading to death, with no apparent cause other than that of vascular origin.
Major stroke was a stroke, as defined above, with symptoms lasting longer than 7 days.
Disabling stroke was a stroke that after 6 months was associated with disability
recorded on the modified Rankin scale of 3,4, or 5. If the patient died of a cause other
than stroke within the 6 months after the stroke, or if there had been a further stroke in
that period, we used an intelligent clinical estimate of the likely future disability from
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the original stroke. After a disabling stroke, a patient was classified as permanently
disabled, hence only one such event was possible in each patient.
Fatal stroke was that deemed by the clinical audit committee to have caused the death
of the patient, either directly by the brain damage or indirectly by some non-neurological
complication, at any stage after the stroke.
Surgical events were all strokes lasting longer than 7 days and all deaths occurring
within 30 days of trial surgery (in surgery or control patients).
Ipsilateral major ischaemic stroke was any major stroke in the distribution of the
symptomatic (at the time of randomisation) carotid artery, or of uncertain vascular
distribution, and which was not definitely haemorrhagic in origin, and which was not a
surgical event.
Haemorrhagic major stroke was any major stroke classified by computed tomography,
magnetic resonance imaging, lumbar puncture, or necropsy as definitely due to primary
intracerebral or subarachnoid haemorrhage.
Other major stroke was any major stroke that was not a surgical event or an ipsilateral
major ischaemic stroke (i.e. strokes that were haemorrhagic, in the vertebrobasilar
distribution, or in the distribution of the contralateral carotid artery).
Non-stroke vascular death was any death that was due to vascular disease but not
stroke, and which did not occur within 30 days of trial surgery. This category included
sudden deaths and those due to the complications of cardiac disease and ruptured aortic
aneurysm.
Non-vascular death was any death definitely due to non-vascular causes such as cancer.
Unknown cause ofdeath was all deaths not otherwise classified.
2.4.18 Limiting the complications of treatment
Treatments used in cerebrovascular disease often have an associated risk of serious
complications e.g. thrombolysis in acute ischaemic stroke or anticoagulation in the prevention
of stroke. Whilst it is always desirable to reduce this risk as much as possible, clinical trials
often go to such lengths that the eventual result may no longer be generalisable to normal
clinical practice. For example, some trials of carotid endarterectomy allowed only surgeons
who could demonstrate very low operative complication rates to participate in the trial, and had
mechanisms in place to prevent a surgeon entering further patients if his or her complication
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rate in the patients operated in the trial exceeded a certain figure.8,40 The benefit derived from
endarterectomy in these trials might well exceed that which would be obtained in everyday
clinical practice. Similarly, trials of anticoagulants, such as warfarin, often insist on very
frequent 1NR testing and probably partly as a consequence of this have relatively few
haemorrhagic complications.52 The risks of treatment with warfarin may be much greater in
clinical practice when such tight control is not always possible. The underlying issue is, of
course, whether a trial should attempt to determine the efficacy of a treatment when used in the
context of best possible practice or in the context of everyday clinical practice. Trialists may
not agree about which option is most valid (this is to some extent a transatlantic controversy) ,
but the issue should certainly be borne in mind when designing a trial protocol.
2.4.19 Surgicalpolicy in the ECST
Prior to collaboration in the trial, surgeons were requested, where possible, to give figures for
their operative risk of stroke and death based on their last 50 carotid endarterectomies.
However, no surgeon was refused the right to participate in the trial as a consequence of these
data. Moreover, no surgeon was excluded from the trial on the basis of his or her operative risk
of stroke and death during the trial. The variation in operative risk between surgeons in the
trial is analysed in Chapter 13.
Surgery was performed by designated collaborators in the trialandnotbyjuniorcolleagues.lt
was recommended that surgery be performed as soon as possible after randomisation,
although it was recommended that operation was delayed for about four weeks after a
stroke. Any strokes occurring after randomisation but prior to surgery were included in the
surgery group for subsequent analysis. It was requested that no other elective surgical
procedures, including contralateral endarterectomy, should be performed under the same
anaesthetic. No recommendations were made regarding the type of anaesthetic which was used
or the nature of any intraoperative monitoring. However, the surgeon was requested to provide
these and the other details of the operation listed on the surgery form in Appendix 2.
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2.5 Multicentre trials
Multicentre trials are often required in order to determine the efficacy of treatments in
cerebrovascular disease. In fact, the vast majority of trials which have had a major impact on
clinical practice in cerebrovascular disease over the last 10 years have been multicentre trials.
This is simply a reflection of the fact that very large numbers of patients are required in order to
demonstrate moderate but important treatment effects, particularly if the absolute risk of a poor
outcome is low.30 Multicentre trials allow large numbers of patients to be randomised over a
relatively short period of time. This produces a quick result before people lose interest in the
treatment. As has been discussed elsewhere,53 multicentre trials also have other advantages:
1) They lead to wide dissemination of results and have the credibility to change clinical
practice.
2) They allow inclusion of a broader range of patients than would be likely from a single
centre.
3) They benefit from a pooling of skills and expertise from different centres in many
countries.
In addition, they foster national and international collaboration and often lead to further
collaborative studies and trials.
The nuts and bolts of performing a multicentre trial in cerebrovascular disease have been
discussed in detail by experienced trialists.53'54 Briefly, the most important advice is to keep
the trial as simple as it is possible to make it. This includes basic design, randomisation
procedure, collection of baseline data, and follow-up. Entry criteria should be broad and simple.
Few if any extra investigations should be required prior to randomisation. Randomisation
should be performed by telephone to a central office, and as much baseline information as is
required should be collected over the phone at the time of randomisation. Care must be taken to
collect only data which will be required to answer the main trial questions and to perform
planned subgroup analyses. Forms should be kept to a minimum and should rarely be longer
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than a single page. Baseline data and clinical assessments should be simple to obtain. Simple
data are usually the most reproducible, and reproducibility of assessments across different
centres and different countries is vital in a multicentre trial. Ideally, entering the patient into
the trial and following them up should involve no more work than would be done as part of
normal clinical practice outwith the trial. Follow-up should, therefore, be performed when
patients would usually be seen anyway or, if possible, by telephone or questionnaire from the
trial center. Collaborating clinicians are inevitably busy and the trial will not be their highest
priority. "Randomize and forget" trials are most likely to recruit patients. Finally, and of great
importance in obtaining funding, the simpler the trial is, the less expensive it is likely to be.
2.6 Analysis of data and presentation of results
There are several issues relating to the analysis of trial data and reporting of results which are
important in trials in cerebrovascular disease and particularly relevant to the ECST.
2.6.1 Intention to treat analysis: The primary analysis in any phase III randomised
controlled trial should be an intention-to-treat analysis. This is important in cerebrovascular
disease in which there is often a high rate of non-compliance with the randomised treatment
allocation. It may be reasonable to perform an efficacy analysis, but the results should be
interpreted with caution and a bias cannot be excluded. The potential for bias is illustrated by
examining the outcome in patients who were randomised to surgical treatment in the ECST, but
who were not operated and "crossed-over" to medical treatment (figure 2.3). The risk of
vascular death was considerably greater in this group than in those patients who were
randomised to medical treatment alone. In other words, the cross-over patients were a
particularly poor prognostic group. This is perhaps to be expected when one considers the
reasons why the patients might not have been operated e.g. the surgeon or anesthetist
considered them to be too high an operative risk; the patient declined the operation. The
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reasons given in the ECST are listed in table 2.8. In an efficacy analysis this group would be
removed from the surgery group and added to the medical treatment group. In other words, a
group of patients with a high risk of a poor outcome would be removed from the treatment
group and added to the control group, leading to a considerable bias.
Table 2.8. Reasons for non-compliance with allocated treatment in the 62 (3.4%) of the 1807 patients
randomised to surgery who had not had an endarterectomy within one year of randomisation
Reason for non-compliance Number of cases
Patient refused surgery 26
Surgeon refused to operate 15
Occluded artery 4
Persisting symptoms 6
Stroke or death prior to surgery 5
Other 6
Total 62
Of particular interest is the fact that the baseline clinical and angiographic characteristics of the
patients who crossed-over from surgical treatment to medical treatment were identical to those
who did not (table 2.9). In other words, the difference in prognosis was not explicable on the
basis of measurable differences between the patients. This illustrates several important points.
Firstly, subtle clinical considerations, which are difficult to measure, can be of considerable
prognostic importance. Secondly, that prognostic models, such as those detailed later in this
thesis, are not likely to be powerful enough to correct for important differences in case-mix.
Thirdly, that if bias is to be avoided, measurement of the efficacy of treatment requires a
randomised controlled trial with an intention-to-treat analysis.
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Table 2.9. The baseline clinical and angiographic characteristics of patients randomised to surgical
treatment who did not undergo carotid endarterectomy compared with the other patients randomised in the
ECST.
Baseline characteristic Surgery to no-surgery cross-overs Other cases








Mean (SD) diastolic blood pressure (mmHg)
























2.6.2 Subgroup analysis: Subgroup analysis is not intrinsically bad. Although it is
frequently criticized, it can be essential to the proper understanding of a trial result. Problems
arise with subgroup analysis when trial data are stratified according to several different baseline
characteristics without any clear pre-hoc hypothesis. If enough analyses are performed, one will
almost invariably find a subgroup of patients in whom the treatment effect is significantly
different from the remainder. For example, in the ISIS 2 trial,55 the effect of aspirin on
mortality following acute myocardial infarction varied according to birth sign: relative odds
reduction with aspirin for patients born under Gemini and Libra was -9% (sd=13, 2P = ns)
versus 28% (sd=5, 2P < 0.00001) for those born under other birth signs. However, this is a
very artificial subgroup analysis. Gemini and Libra are not even adjacent birth signs on the
Zodiac. The trialists simply added together the two birth signs in which there was least
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evidence of efficacy. The ECST data contain a much more convincing analysis: the effect of
carotid endarterectomy on the risk of ipsilateral ischaemic stroke in patients with recently
symptomatic 70-99% carotid stenosis according to month of birth. The relative reduction in the
odds of stroke with surgery was -20% (sd=30, 2P = ns) for those born in January to April
versus 70% (sd=10, 2P = 0.000004) for those born in May to December!
It is not usually difficult to then produce a seemingly plausible hypothesis to explain why the
finding was, in fact, exactly what might have been expected. If it is stated how many other
analyses were done in order to produce the one significant result, then it is possible to adjust
the level of significance for multiple comparisons. However, this information may not always
be given. Likewise, one suspects that subgroup analyses which were genuinely post-hoc may
sometimes be presented as if they had been pre-hoc hypotheses. It is for these reasons that
subgroup analyses are generally viewed with caution.
There are several instances when subgroup analyses have produced misleading results in trials
in cerebrovascular disease. For example, the results of one influential trial of aspirin in
threatened stroke suggested that aspirin was effective in the secondary prevention of stroke in
men, but not in women."6 Many theories were produced to explain why this was exactly what
would be expected, and for a period of time women were not given aspirin. However,
subsequent trials and a definitive meta-analysis have demonstrated that the benefit of aspirin in
women is equal to that in men.5
2.6.3 Generalising the trial result to individualpatients: It is often difficult, given the
very heterogeneous populations of individuals who tend to be included in large trials in
cerebrovascular disease, to know to what extent an overall trial result can be applied with
confidence to the decision whether or not to treat an individual patient. The absolute benefit a
patient will derive from a treatment will, of course, vary depending on the absolute risk of a
poor outcome without treatment, but the relative treatment effect is generally assumed to be
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qualitatively, if not quantitatively, constant. Thus the overall relative risk reduction is assumed
to be generalisable to all future patients who fit the trial entry criteria. However, this may not
always be the case. Heterogeneity of relative treatment effect is especially likely when, as is
often the case in cerebrovascular disease, a treatment has an appreciable risk of serious harm. It
is quite conceivable that a treatment might be beneficial in some patients and harmful in others,
the overall trial result merely reflecting the balance between these two groups. For example,
carotid endarterectomy reduces the overall risk of ischaemic stroke in patients with a recently
symptomatic stenosis of the internal carotid artery, but has a 5-7% operative risk of stroke or
death (Section 4). Although it now widely recommended that all such patients should be
considered for surgery, in neither of the major trials did more than 25% of patients randomised
to medical treatment actually have a stroke on follow-up. In other words, the remaining 75% of
patients who remained stroke free could not possibly have benefited from surgery had they been
randomised to endarterectomy. Indeed, given the risk of stroke or death due to the operation,
they would, as a group, undoubtedly have been harmed.
Application of the overall results of clinical trials to all patients is predicated on the assumption
that we cannot identify in advance those patients who will do badly without treatment, and
who should therefore be treated, and those patients who will do well without treatment, and
who should not therefore be subjected to the risks of treatment. However, this negative
approach may not be justified. Whilst, we can seldom predict outcome with 100% accuracy,
there are validated prognostic models in several branches of medicine which can reliably
stratify patients according to their likely level of risk of various clinical outcomes. Stratification
of the results of clinical trials using such models can provide an insight into the potential
unreliability of overall trial results. This was illustrated in a meta-analysis of individual patient
data from trials of coronary artery bypass grafting versus medical treatment in patients with
ischaemic heart disease.57 Bypass grafting had an associated 30 day operative case-fatality of
3.2%, but nevertheless resulted in a reduced overall case fatality compared with medical
treatment on follow-up. However, after stratification of patients according to baseline risk of
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death on medical treatment using an independently derived prognostic model, it was evident
that grafting was probably harmful in low risk patients, but was highly beneficial in high risk
patients. The overall trial result was not telling the whole story. Bypass grafting was of no
obvious value in one group of patients, but was highly beneficial in another, and most
importantly, these groups could be defined.
The approach suggested is most applicable to treatments which are associated with a risk of
serious harm, but should also be considered for low risk but expensive treatments. If clinicians
were able to treat only those patients who actually needed treatment and avoid unnecessary
treatment of patients who were destined to do well without treatment, the financial savings
could be considerable. In general, the relative efficacy of a safe treatment would seem less
likely to vary qualitatively than that of a risky treatment. However, the efficacy of treatment
might, for example, depend on the extent to which a disease has already progressed or the
specific pathophysiology of the disease in a particular patient. While multiple subgroup
analyses are undesirable and potentially misleading, we should be cautious about assuming that
overall trial results can necessarily be applied to all patients.
One of the main aims of the work reported in this thesis was to explore the extent to which
there is identifiable heterogeneity of relative treatment effect for carotid endarterectomy in
patients with symptomatic carotid stenosis. Variation in treatment effect with predicted
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2.8 Legends to figures
Figure 2.1. The number of carotid endarterectomies performed each year in the United States
between 1970 and 1996 (data approximated from several independent sources). Various factors
which may have influenced the rates are marked.
Figure 2.2. Examples from the ECST of the range of stenoses of symptomatic patients
randomised by specific collaborators i.e. their grey areas of uncertainty.
Figure 2.3 Survival free of vascular death in patients randomised to no-surgery in the ECST






















Imaging and measurement of carotid stenosis
72
Chapter 3.
Imaging and measurement of stenosis of the internal carotid artery: a critical
appraisal of the design and analysis of published studies
3.1 Summary
3.2 Background









The first part of this chapter details the reasons why measurement of the degree of carotid
stenosis is important in clinical practice, and discusses the currently important clinical issues
relating to this. The second part of the chapter is a systematic review of published studies of
the imaging and measurement of carotid stenosis. The review assesses the methodological
quality of the studies and suggests standards for future studies.
3.2 Background
Measurement of the degree of stenosis of the internal carotid artery has generated great interest
in the last few years,1"10 but why is this seemingly arcane topic so important? The
preliminary results of ECST and NASCET showed that the degree of linear narrowing of the
diseased portion of the proximal internal carotid artery on an angiogram was a major predictor
of ipsilateral ischaemic stroke in patients presenting with TIA or non-disabling ischaemic
stroke.11'12 This confirmed the results of previous cohort studies.13'14 Consequently, the degree
of stenosis determines, to at least some extent, whether or not a patient is likely to benefit from
carotid endarterectomy. Other factors are also important, but management frequently hinges
on the single measurement of stenosis. However, the ECST and NASCET used different
methods to measure the degree of stenosis on the trial angiograms. Since the results of both
trials were stratified by degree of stenosis, this created difficulty in comparing the results of the
two trials and confusion in the application of the trial results to clinical practice.
How is stenosis measured on an angiogram?
It was not evident to either the ECST or the NASCET trials until 1991 that they had been
measuring the degree of carotid stenosis by different methods. Both trials measured the degree
of linear stenosis at the point around the bifurcation where it appeared to be most severe. This
could be the distal common carotid artery (CCA), the carotid bulb, or the proximal internal
carotid artery (ICA). Both trials used the same measurement principle. Stenosis was measured
as a ratio of the lumen diameter at the point of maximum stenosis, the minimum residual
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lumen [MRL], and a measurement (D) which correlated with the original lumen diameter at
the point of the MRL i.e % stenosis = 100 x (1 - MRL/D). There are, in fact, three different
methods of making such a measurement, each ofwhich corrects for variation in the size of
normal artery lumen in a different way (figure 3.1). The three methods may, therefore, produce
different measurements for the same stenosis.
The ECST method: The ECST method measures D as a visual estimate of the original lumen
diameter at the site of maximum stenosis i.e. not necessarily at the widest point of the carotid
bulb. Some clinicians find this estimate extremely difficult, arguing that one cannot measure
what one cannot see. Proponents of the ECST method point to the fact that it measures the
actual vessel stenosis.
The NASCET method: The NASCET method does not rely on an estimation of the original
lumen, but measures D as the lumen diameter at a more distal undiseased portion of the ICA.
If the stenosis is maximum in the distal ICA, the ECST and NASCET methods will produce
similar results. However, in the majority of cases, the maximum stenosis is in the larger
diameter carotid bulb, in which case the NASCET method will tend to underestimate stenosis
compared to the ECST method. Moreover, because the bulb is on average about twice the
diameter of the distal ICA, the NASCET method often produces negative values for mild to
moderate stenoses of the bulb. The NASCET method can also be undermined by the variable
degree of collapse of the ICA which occurs distal to a tight stenosis.15
The common carotid method: The common carotid method uses the lumen diameter of the
common carotid artery as the denominator. The common carotid diameter correlates with
that of the internal carotid bulb,16 and is usually constant throughout its length, the vessel
seldom being so narrowed by atheroma that a normal portion cannot be found.
Why not measure the absolute residual lumen diameter?
The degree of carotid stenosis does not, of course, necessarily have to be measured as a ratio. It
has been suggested that an absolute measurement of the MRL, corrected for magnification,
should be used.15 However, such correction is technically difficult, and in any event the
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diameter of the undiseased carotid artery varies considerably from one individual to another
and between males and females.16 The absolute lumen diameter of a severe stenosis in a large
man may be greater than the lumen diameter of a mild stenosis in a small woman. The
results of ECST indicate that they would not benefit equally from carotid endarterectomy. To
be of any clinical use, a measurement of stenosis must take into account the original size of the
artery.
Why not measure the area stenosis?
It has also been suggested that a measure of the area stenosis, or the reduction in cross-sectional
diameter of the diseased artery, might be a better method.17 This would have a number of
theoretical advantages. Firstly, it would circumvent the problem of non-circular stenoses. In the
majority of stenoses, the cross-section of the residual lumen is approximately circular. This
means, of course, that the linear diameter is closely related to the area, and that the linear
diameter of the residual lumen will be the approximately the same from whichever direction it is
viewed. However, some stenoses are elliptical or slit. In these cases, the degree of linear
stenosis will vary considerably depending on which angiographic views are available, and any
single measurement will not correlate particularly well with the area stenosis. Secondly, it tends
to be assumed that area stenosis is likely to be a better predictor of stroke risk than linear
stenosis. It is argued that linear stenosis is probably a surrogate for area stenosis, and that since
it does not always correlate well with area stenosis, it is likely to be a less powerful predictor.
However, although this may be true, it still remains to be proved. The practical situation at the
moment is that the only information we have about who benefits from endarterectomy comes
from trials in which the results were stratified by linear stenosis. It is possible to get accurate
measures of area stenosis using modern non-invasive imaging techniques, but a large cohort
study is required in order to compare the prognostic values of linear and area stenosis
measurements.
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Does it matter which method ofmeasurement oflinear stenosis is used?
Measurement of carotid stenosis is clearly important in the management of patients with TIA or
minor stroke, but does it really matter which method is used? Trials of carotid endarterectomy
in patients with symptomatic carotid stenosis have produced much needed data on which
patients benefit from the procedure, and in which patients it is likely to be harmful.
However, application of the results of these trials to clinical practice has been partly
undermined by argument and confusion about how carotid stenosis should be measured.1"10
Although the interim analyses of both the European and North American trials reported surgery
to be beneficial in patients with greater than 70% stenosis, the results of these trials are not
directly comparable. As is demonstrated in Chapter 5, the use of different methods of
measurement of stenosis leads to quite different results. Definition of the equivalence of the
different methods of measurement of stenosis is of some help, but ideally a single standard
method of measurement should be adopted by all. The criteria for selection of a standard
method ofmeasurement of ICA stenosis must include the ability of the measurement to predict
risk of ipsilateral ischaemic stroke and the reproducibility of measurement.
Progression to non-invasive imaging
Conventional arterial angiography has significant associated morbidity and mortality,18'19
whereas non-invasive methods of imaging, such as duplex ultrasound scanning, spiral CT
scanning and magnetic resonance angiography, appear to be safe. The morbidity and
mortality associated with arterial angiography were probably underestimated in early
retrospective studies.20"22 A review of the prospective studies of the complications of
angiography in patients with cerebrovascular disease, revealed a risk of neurological
complications lasting less than 7 days, of 30 per 1000, of permanent neurological sequelae
of 10 per 1000, and an overall mortality of 1 per 1000.18 A recent prospective study of
selective arterial angiography in cerebrovascular disease revealed a permanent neurological
complication rate of 2.5%, rising to 8% in patients with severe stenosis, and a mortality due to
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fatal stroke of 1%.19 Moreover, arterial angiography is also costly and time-consuming, often
requiring admission to hosptial.23 Although, factors such as plaque surface morphology,
intracranial abnormalities, and disease of the external carotid circulation are probably best
visualised using angiography, and may influence the effectiveness of endarterectomy, it is
unclear whether or not any advantage of arterial angiography in these respects will outweigh
the reported risks. Furthermore, a combination of non-invasive techniques, such as duplex
ultrasound and magnetic resonance angiography may well provide equivalent information.
Why is angiographic stenosis the gold standard?
The results of ECST and NASCET are based on measurements of stenosis on angiograms. It
would be unethical to repeat these trials using non-invasive methods of imaging and so,
whether we like it or not, the only direct data we have about the association between the
degree of symptomatic carotid stenosis and the risks and benefits of carotid endarterectomy
are based on angiography. Angiography has many shortcomings, and some non-invasive
methods may have important advantages, but they must still be validated against angiography.
Although it is interesting to assess how closely various imaging techniques agree with
absolute measurements made on pathological specimens,2'24 it is of little clinical relevance.
The exact relationship between the degree of stenosis measured by the non-invasive technique
and that measured by angiography, preferably using an agreed standard method, must be
accurately defined. For example, if magnetic resonance angiography overestimates stenosis
compared to conventional arterial angiography, we need to know the size of this bias and the
manner in which it varies with the degree of stenosis. However, before we can validate non¬
invasive methods of imaging and measurement of carotid stenosis, we must first determine the
properties ofmeasurements of stenosis made on conventional angiograms.
3.3 Review of published studies
3.3.1 Introduction
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There are several hundred published studies of imaging and measurement of carotid stenosis.
However, many studies have been undermined by poor design and inappropriate analysis and
presentation of data. It is at least partly as a consequence of this that there is still no consensus
about how best to image the carotid artery. If non-invasive methods of imaging are to be
properly validated, and the findings of different studies compared, then a consistent
approach to study design and analysis must be adopted. The importance of many aspects of
study methodology, such as the need for independent blinded observers when studying the
reproducibility of a method of measurement, is self evident. However, there are a number of
errors in methodology which have been made consistently in the published literature, and
which undermine the value of otherwise useful studies.
The review described below aimed to assess the design, analysis and reporting of a random
sample of published studies of imaging and measurement of carotid stenosis using eight simple
criteria. In order to assess whether the quality of studies increased following publication of the
initial results of ECST and NASCET, and the consequent realisation of the importance of
accurate measurement of the degree of carotid stenosis, papers published in two specific periods
were studied: 1970-90 (prior to ECST and NASCET); and 1993-97 (some years after ECST
and NASCET).
3.3.2 Methods
Inclusion criteria: I aimed to review papers which reported original data derived from imaging
the carotid circulation in human subjects; the primary aim of which was either to determine the
properties of the measurement of carotid stenosis using one imaging modality or to compare
measurements of stenosis using two or more different imaging modalities. The review was
confined to studies published in English language journals.
Search strategy: Papers were identified using the following means:
1) Papers already known to the author from previous studies of the literature.
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2) A single observer (PMR) identified potential papers using CD ROM (Cambridge Medline
1970-97). The search strategy was based on combinations of the following terms: carotid;
stenosis; angiography; duplex; Doppler; ultrasound; ultrasonography; magnetic resonance
imaging; magnetic resonance angiography.
3) The reference lists of all papers known to the authors and of papers identified from the
literature were searched.
Selection of studies for review: Given the very large number of published studies, it was not
possible to review all those identified in the literature search. Therefore, of the studies which
fulfilled the inclusion criteria, twenty were randomly selected from each of the two publication
periods. The selection was performed using the random number generating function in SPSS
(version 7.0).
Methodological criteria: Each paper was assessed by two reviewers (PMR and STP). The
number of patients studied was recorded and nine methodological criteria were used to assess
the quality of the papers (see below). Each of the criteria are considered in detail in the
discussion. If the two reviewers disagreed in their assessment of a paper, they re-assessed the
paper together until a consensus was reached. The exact graphical or statistical methods used
to measure the reproducibility of measurement of stenosis or the comparability of different
methods ofmeasurement were also recorded. These are reported in the next chapter.
The criteria used to assess the selected studies are as follows:
1) Prospective rather than retrospective study design.
2) Patient selection based on a consecutive series or a random sample.
3) Adequate detail of study population reported (details of the age, sex, clinical presentation
and indications for investigation in the patients studied).
4) Adequate detail of imaging techniques reported (sufficient for the study to be repeated).
5) Inclusion of all investigations i.e. patients with poor quality imaging not excluded.
6) Blinded assessment of images.
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7) Adequate detail of derivation of measurement of stenosis from images/data reported in
paper (sufficient for the study to be repeated).
8) Adequate data reported on the reproducibility ofmeasurements of stenosis reported (data on
either intra-observer agreement or inter-observer agreement accepted).
9) Study powered according to a sample size calculation
3.3.3 Results
The electronic literature search identified 486 publications which concerned carotid imaging.
Exclusion of studies which did not fit our inclusion criteria left 132 studies. A further 13
studies which were already known to the author, and which fulfilled the inclusion criteria, were
not identified by the search. A search of the reference lists of these 145 studies revealed a
further 17 studies which fulfilled the inclusion criteria. Of the resulting sample of 162 studies,
93 were published prior to 1991 and 69 were published between 1993 and 1997. Twenty
studies from each period were randomly selected for detailed review (1970-91 23-44 and 1993-
97 45-64).
Table 3.1. Forty randomly selected studies of imaging of carotid stenosis assessed according to nine simple
methodological criteria.
Number of studies fulfilling criteria
1970-90 studies 1993-97 studies
Methodological Criteria
1) Prospective design 4 (20%)
2) Patient selection: consecutive series or random sample 8 (40%)
3) Adequate detail of study population reported in paper 3 (15%)
4) Adequate detail of imaging techniques reported in paper 19 (95%)
5) Inclusion of all investigations i.e. patients with poor quality imaging 7 (35%)
not excluded.
6) Blinded assessment of images 11 (55%)
7) Adequate detail ofmethod of derivation of measurement 12 (60%)








8) Data reported on the reproducibility ofmeasurement of stenosis 6 (30%) 9 (45%)
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9) Study powered according to a sample size calculation 0 (0%) 0 (0%)
The methodological assessments of the two cohorts of studies are shown in table 3.1. There
were many methodological deficiencies in both cohorts, with relatively little evidence of
improvement with time. The only major improvements in the 1993-97 cohort were in the
description of the study population and the method of measurement of stenosis used for the
particular techniques studied. There was great variation between individual studies in the
number of criteria which were satisfied (table 3.2). Seven studies satisfied seven or more
critera, whereas ten studies satisfied two or less. Each of the methodological criteria are
considered in detail in the discussion.
Table 3.2. Forty randomly selected studies of imaging of carotid stenosis, published during two time periods,
stratified according to the number of methodological criteria which they satisfied.
Number of studies fulfilling criteria
1970-90 studies 1993-97 studies





The sample sizes in many studies were small (table 3.3). The 1993-97 studies tended to be
considerably smaller than the earlier studies. Excluding the largest single studies in the two
cohorts which tend to skew the data (500 patients40 and 400 patients63), the mean sample size
was 96 (SD=23) in the 1970-90 studies and 56 (SD=18) in the 1993-97 studies (ANOVA,
P0.0001). Ten of the early studies had sample sizes of 100 or more compared to only two of
the more recent studies.
82
Table 3.3. Forty randomly selected studies of imaging of carotid stenosis, published during two time periods,
stratified according to the number of patients studied.
Number of studies
1970-90 studies 1993-97 studies






200-499 . 1 1
500+ 1 0
3.3.4 Discussion
It is clearly important that effective investigations should be encouraged and ineffective
investigations abandoned. The only way in which this will be achieved is by the performance,
publication and dissemination of high quality and adequately powered clinical studies and
systematic reviews. However, the design and reporting of the majority of studies reviewed here
did not reach a sufficient standard. Although there is no gold standard with which to assess the
quality of a study, and the choice of assessments could be criticised, the nine criteria could not
really be said to be unreasonable. The fact that 7 (18%) studies satisfied nearly all the criteria
suggests that they were not unrealistic. Each of the methodological criteria which were used in
this study are justified below.
Study design (1) and selection of patients (2)
Studies should concentrate on patient populations which are comparable to patients seen in
ordinary clinical practice. The answer to an important question is of little value if asked of the
"wrong" patients. For example, a study of the reproducibility of measurement of stenosis on
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angiograms from a group of patients, the majority of whom had a carotid stenosis of less
than 30% by the ECST method (less than zero by the NASCET method),26 will tell us very
little about measurement in patients with moderate and severe stenosis, the group in whom
variability might effect clinical decision making. Similarly, a study of intravenous digital
subtraction angiography in predominantly young fit patients will give much better results than
an identical study in an older more relevant population with widespread vascular disease,
because the causes of inadequate visualisation of the stenosis using intravenous angiography
such as movement artefact, cardiac failure and poor respiratory function, increase in frequency
with age and concurrent disease. The population studied is of particular importance in studies
of the complications of imaging procedures. Studies of the complications of conventional
selective arterial angiography which concentrated on an elderly population with symptomatic
cerebrovascular disease found much higher morbidity and mortality than studies in less
selected populations.18'19
Patients studied should be consecutive or random samples. Selection bias can undermine the
generalisability of study results. For example, several of the 1970-90 studies compared arterial
angiography with intravenous digital subtraction angiography. However, most of these were
retrospective and confined to a small proportion of patients who, presumably for specific
reasons, had been imaged by both techniques.25'30'33'36,37'40'41 In units which routinely
perform intravenous angiography, arterial angiography is more likely to be performed in
patients in whom intravenous angiography has not been completely adequate. Results from
studies of such highly selected patients are unlikely to be generalisable. Only four of the 1970-
90 studies were prospective, and only four of the retrospective studies selected patients in a
consecutive or random fashion. This was somewhat improved in the later cohort, but there were
still several retrospective studies with potentially biased selection of cases.
3) Was the study population adequately described?
It is essential that papers describe the study population. A study is of little value, no matter
how well it is performed, if the published paper does not give sufficient information to
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allow other investigators to replicate the work or other clinicians to apply the results to their
own clinical practice. However, few of the 1970-90 studies reported any clinical data on the
patients whose carotid arteries were imaged. The age, sex, clinical presentation and
indications for investigation in the patients studied should be the minimum required. This was
the one area in which the 1993-97 studies were much improved.
4) Were sufficient details of the imaging technique provided?
Clearly, any study of an imaging technique should give sufficient technical detail for others
to be able to repeat it. This is, in fact, the one area where virtually all studies excelled.
Indeed, there is often a striking contrast between the amount of technical detail and the lack of
any other methodological information. Overall, in the 40 studies reviewed, the median number
of lines of text detailing the imaging technique was 20 (range 5 - 60) compared with a median
of only 3 lines (range 1 - 20) describing the selection of cases and their clinical details!
5) Were all investigations included?
In general, poor quality investigations should not be excluded from studies of imaging or
measurement of stenosis. If a patient has been exposed to the risks of an investigation and the
result has been used to inform a clinical decision, it should be good enough to include in a
study. Many of the 1970-90 studies which compared the accuracy and reproducibility of
measurement of stenosis using intravenous angiography with that using arterial angiography
excluded intravenous investigations which were considered inadequate.30,34,40'41,44
Consequently, intravenous angiography compared well with conventional angiography. The
results of these studies contrast with two studies which included all investigations, in which
adequate views of both carotid bifurcations were seen in only 26% 35 and 42% 36 of patients
imaged with intravenous angiography. Similarly, some studies of the reproducibility of
measurement of stenosis on angiograms have been confined to angiograms selected on the
OA OO
basis of quality. ' ' Exclusion of poor quality investigations undermines the relevance of
these studies to clinical practice.
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6) Was the assessment of images blind to other information?
The need for blinding of observers to any information which might bias their measurements is
self-evident. For example, in studies of the inter-observer reproducibility ofmeasurement of the
degree of carotid stenosis using a particular technique, each observer should be independent and
blind to the findings of the other. Similarly, in studies comparing measurements made using
different techniques, the observer should be blind to any information which might lead to
recognition of the fact that two investigations are from the same patient. Despite the importance
of blinding, in nearly half the studies reviewed it was neither implicit nor stated that observers
were blinded.
7) Was the method of measurement of stenosis described?
Although it is only in recent years that the disparities between measurements made by the
different methods have been realised, it is still very surprising that eight of the 1970-90
studies did not define how stenosis had been measured on the angiograms.30"32'35'36'41'42'44 Of
those studies which did give details, there was an even split between the "ECST method"
25,28.29,34,40 an(j ^ "NASCET method".27'33,37'39'43 An exact definition of how the degree of is
derived is particularly important in studies of non-invasive methods of imaging. Perhaps not
surprisingly given the increased awareness of the disparities between the different methods of
measurement, only two of the 1993-97 studies failed to give an adequate description of the
method used.53'61 Of the remaining 1993-97 studies, ten used only the NASCET method,46,49"
51,54-56,58,59,63 ^our usecj Qn|y method,45'47'48'64 and four used both methods.52'57'60'62
8) Were data on the reproducibility of measurements reported?
Inter-observer agreement in the interpretation of radiological investigations may be little greater
than that expected by chance alone.65"67 Reproducibility of measurements of stenosis on
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angiograms of the coronary or peripheral arterial circulations can be very poor.68'69 There is no
reason to assume that measurements of carotid stenosis by any technique will be less prone to
observer variability. Any study which involves measurement of stenosis should give some
information about the reproducibility of the measurements made. Measurements are only
likely to have clinical utility if they are reproducible. However, fewer than half of the studies
reported any reproducibility data.
9) Sample size
Clinical trials often require very large sample sizes in order to measure the effectiveness of
treatments with sufficient precision to influence clinical practice.70 The same principles should
be applied to the validation of new methods of imaging. However, it is difficult to perform
randomised controlled trials comparing different imaging methods. Trials would have to be
vast in order to produce a reliable estimate of the effect of a method on eventual patient
outcome.71 In practice, it is reasonable for imaging studies to compare a new technique with
an established gold-standard in the same group of patients and then extrapolate the results in
order to estimate the likely outcome if the old technique were to be replaced by the new
technique. However, although such studies will need much smaller sample sizes than
randomised controlled trials looking at patient outcome, they still need to have the power to
define the differences between the different techniques with clinically useful precision.
The sample size required will depend on the exact nature of the question being assessed. The
simplest question, and the one which generally requires the smallest sample size, is assessment
of the sensitivity and specificity of one test to detect a threshold defined using a gold standard
e.g. 70% stenosis or complete occlusion as defined on conventional angiography. However,
even this requires a large sample size to have clinically useful precision. For example, if we
suppose that a population of 600 patients has a 20% prevalence of 70-99% carotid stenosis on
conventional angiography (i.e. 120 cases), and that carotid ultrasound correctly identifies 108
of these. The sensitivity of carotid ultrasound in the detection of severe stenosis in this
particular study is 90%, but the lower 95% confidence interval of this estimate is only 75%. In
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other words, even though the sample size was larger than any of the 40 studies reviewed here,
and was 10 times larger than many of them, the study still doesn't have the power to exclude
clinically unacceptable false negative rates.
None of the 40 studies reviewed were powered according to pre-specified sample size
calculation. However, some of the small sample sizes in the 1970-90 studies are understandable.
Many of these studies were performed very early in the evolution of non-invasive methods and
the results were not intended to be applied directly to clinical practice. Moreover, the
importance of accurate measurement of stenosis had not been clearly demonstrated. The
situation was quite different, however, at the time of 1993-97 studies. Most of the imaging
techniques studied were already used routinely and now required proper validation. This was
implicit in many of the studies, several of which made clinical recommendations on the basis of
their results. However, the sample sizes were completely inadequate in virtually all of the 1993-
97 studies. Indeed, on average the later studies were much smaller than the earlier studies. A
continuing profusion of small studies, many of which have inadequate methodology, is likely to
confuse rather than inform clinical practice.
Meta-analyses of imaging studies
One way in which to extract some useful information from a group of small studies is to
combine the results in order to increase precision.72 The techniques are now in place to allow
useful meta-analysis of diagnostic studies.73"76 However, this is only possible if the design of
studies and the analysis and presentation of data are of a sufficient and reasonably uniform
standard. Our results suggest that this is not currently the case for published studies of imaging
and measurement of carotid stenosis.
Conclusions
If the results of clinical trials of carotid endarterectomy are to be applied to clinical practice
using non-invasive imaging, then new techniques must be properly validated against
angiography. Review of previous research in this area shows that study methodology and
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reporting of results are often poor. Chapter 4 examines the statistical analysis of the data
presented in the 40 papers reviewed here and comes to the same conclusion. It will only be
possible to apply the results of studies to clinical practice if the design, analysis, and reporting
are of good quality. The quality standards set out in this Chapter for study design, and those set
out in the next chapter for analysis and presentation of data, are a reasonable basis on which to
proceed.
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3.5 Legend to Figure
Figure 3.1. A schematic representation of the bifurcation of the carotid artery in the neck. The
hatched area represents an atherosclerotic plaque. The three commonly used methods of




Measurement of the degree of stenosis of the internal carotid artery:






4.5.1 Analysis ofpercent stenosis as a categorical variable






This chapter reviews the issues relating to the statistical analysis and presentation of data in
studies of imaging and measurement of carotid stenosis. The techniques used in the 40 studies
reviewed in Chapter 3 are examined, and the advantages and disadvantages of these and other
techniques are discussed.
4.2 Introduction
As discussed in Chapter 3, none of the non-invasive techniques of imaging of symptomatic
carotid stenosis have been shown in clinical trials to differentiate between patients who
benefit from endarterectomy and patients who do not, and so it is necessary to validate them
against conventional angiography. Unfortunately, although there are several hundred published
studies of non-invasive imaging of carotid stenosis,1 many published studies have been
undermined by poor design. Partly as a consequence of this, there is still no consensus about
how best to image the carotid artery. If non-invasive methods of imaging are to be properly
validated, and the findings of different studies compared, then a consistent approach to
study design and analysis must be adopted. The previous chapter assessed the design and
reporting of a random sample of 40 published studies of imaging and measurement of carotid
stenosis. In this chapter, the statistical analysis and presentation of data in the same 40 studies
will be assessed.
From a clinical point of view, two of the most important questions about a non-invasive method
of imaging of carotid stenosis are how reproducibility the measurements of stenosis are, and
how measurements made using the technique compare with those made using arterial
angiography or other non-invasive techniques. The reproducibility of assessments in many areas
of medicine is often surprisingly poor.2"5 This is certainly true of the interpretation of some
radiological investigations.6"8 Measurement of the degree of narrowing of vessels using
techniques of arterial imaging is no exception. The reproducibility of measurements of stenosis
on angiograms of the coronary or peripheral arterial circulations can be very poor.9'10
Measurement of carotid stenosis using any imaging technique is likely to have at least some
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inter-observer and intra-observer variability. The clinical utility of the technique is critically
dependent on the reproducibility of its measurements. A technique which produces very
different results in the hands of different operators, or at different times with the same operator,
will be virtually useless. It is important that the reproducibility of any imaging technique which
is to be used in clinical practice is well documented. This requires that the analysis and
presentation of the reproducibility data is as rigorous as possible.
The comparison of the measurements made using one of the non-invasive methods ofmeasuring
carotid stenosis with those made using arterial angiography or another non-invasive technique is
also important. Given that both techniques will have less than perfect reproducibility, it is likely
that agreement between the two will be less than the inter-observer reproducibility of either
technique alone. Indeed, agreement can sometimes be poor.11"13 It is essential, therefore, that
analysis and presentation of data comparing measurements of carotid stenosis made using
different techniques is as clinically useful as possible.
As discussed in Chapter 3, studies of imaging and measurement of carotid stenosis will often
need to be very large in order to assess the utility of a particular technique with precision.14,15
Although many of the published studies make clinical recommendations, the vast majority are
too small to allow the clinical utility of the particular technique to be properly assessed.
Definitive recommendations would ideally require large and expensive multi-centre studies.
However, systematic reviews of data from smaller studies could also be very useful. If the
results of a series of well conducted independent studies were consistent then even if no single
study was definitive it would be reasonable to allow the results to influence clinical practice.16"18
However, comparison of the results of similar studies is rarely possible because of a lack of
consistency in the methods of analysis and presentation of data. This chapter considers the
advantages and disadvantages of the different methods of analysis and presentation of data on
the reproducibility of measurement of carotid stenosis using the technique and the comparison
ofmeasurements made using one technique with those made using another.
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4.3 Methods
The methods and results of the literature search and the selection of the random sample of 40
studies for review was described in Chapter 3. The same studies are reassessed here from the
point of view of the statistical analyses used and the presentation of data. One of the main
analyses in all 40 studies was either an assessment of the reproducibility of measurement of
stenosis using a single imaging technique or the comparison of measurements made using two
or more independent techniques. The statistical methods used to make these assessments were
recorded for each study by one observer (PMR). Where individual studies used more than one
method of analysis, all methods were recorded. In common with Chapter 3, the studies were
divided into those published during 1970 - 1990 and those published during 1993 - 1997.
4.4 Results
The statistical techniques used in the 40 studies could be separated into ten categories. The
frequencies of each type of analysis is given in table 4.1. There were no major differences in
the techniques used in the 1970-1990 studies and the 1993-97 studies.
Table 4.1. The techniques of statistical analysis and presentation of data in 40 randomly selected studies
of imaging and measurement of carotid stenosis.
Number of studies fulfilling criteria
1970-90 studies 1993-97 studies
Analyses used to assess the reproducibility of measurement of
stenosis or comparability of different methods of measurement:
Categorical analyses
1) Simple cross-tabulation with % agreement 11 (55%) 14(70%)
2) Simple cross-tabulation with Kappa statistic 3 (15%) 6 (30%)
3) Simple cross-tabulation with sensitivity/specificity 13 (65%) 12(60%)
4) Receiver operating curve of sensitivity vs specificity 0 (0%) 2(10%)
Continuous variable analyses
1) Scatterplot 12 (60%) 8 (40%)
2) Correlation coefficient 8 (40%) 10 (50%)
3) Intra-class correlation coefficient 1 (5%) 0 (0%)
4) Regression equations 2(10%) 1 (5%)
5) Tables and figures of absolute differences 2 (10%) 3 (15%)
6) Bland and Altman plots 0 (0%) 1 (5%)
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4.5 Discussion
The advantages and disadvantages of each of the ten different methods analysis and
presentation of data are discussed below. Each approach will be illustrated using measurements
of the degree of carotid stenosis made by two independent observers on 1001 carotid
angiograms using the ECST method ofmeasurement
The techniques of analysis used can be divided into two broad categories; those in which the
degree of stenosis is a continuous variable and those in which it is a categorical variable.
Although percent carotid stenosis is bound by zero and 100 and is usually rounded to the nearest
percentage point, it is essentially a continuous variable. However, certain analyses divided the
measurements up into categories, and treat the degree of stenosis as a categorical variable.
These techniques will be discussed first.
4.5.1 Analysis of percent stenosis as a categorical variable
The categorical methods of assessment require that percentage stenosis is divided into a
number of categories, such as 0-29%, 30-69%, 70-99% and occlusion as used in the ECST and
NASCET trials. Once the measurements are categorised it is possible to create cross-
tabulations and determine the extent to which the different observers or techniques agree in the
allocation ofmeasurements into the chosen categories (table 4.2).
1) Percent agreement: Agreement between observers can be expressed simply as a percentage
agreement (with confidence limits) i.e. the percentage of cases in which both observers allocate
the measurement into the same category. In the example shown in table 4.2, this occurred in
80% of cases. However, since a certain level of agreement would be expected by chance alone,
a simple percent agreement can give a misleadingly good impression of the level of agreement.
2) The kappa statistic: Agreement can be corrected for that which would be expected by
chance alone using the kappa statistic.19 This statistic represents the extent to which agreement
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in the allocation of measurements into the particular categories is greater than that expected by
chance alone. A kappa value of 0 indicates chance agreement, a value of-1 indicates complete
disagreement and a value of 1 indicates perfect agreement. Intermediate kappa values are
generally classified as follows: 0-0.2 very poor, 0.2-0.4 poor, 0.4-0.6 moderate-, 0.6-0.8 good\
0.8-1.0 excellent. Thus in the example given in table 4.2, although the overall percentage
agreement between observers was 80%, the kappa value was only 0.66.
Table 4.2. Comparison of the allocation of stenoses into mild (0-29%), moderate (30-69%) and severe
(70-99%) groups by two observers using the ECST method of measuring stenosis. Data from study
described in Chapter 5.
Observer A
0-29% 30-69% 70-99% Total
Observer B
0-29% 94 51 0 145
30-69% 40 398 73 511
70-99% 0 39 306 345
Total 134 488 379 1001
Agreement = 80%
Kappa (95% CI) = 0.66 (95% CI = 0.62 - 0.70)
3) Sensitivity and specificity: Studies comparing measurements made by one technique with
those made using another technique often report the sensitivity and specificity of one method
for the identification of a certain degree of stenosis by the other method. In other words, one
technique (e.g. Doppler ultrasonography) is regarded as the technique under test and the other
technique (e.g. conventional selective arterial angiography) is regarded as the gold standard.
This can be useful for answering a specific clinical question, such as how sensitive is Doppler
scanning at differentiating between tight stenosis and complete occlusion, or how good is a
trainee radiologist at deciding whether a stenosis is greater or less than 70% using the
measurement of an experienced radiologist as a gold standard? For example, with reference to
the latter question, table 4.3 shows that Observer B has a sensitivity 81% (306/376) and
specificity of 94% (583/622) with respect to Observer A. This is useful information, but is
relatively limited.
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Table 4.3. Comparison of agreement between two observers in the categorisation of stenoses as 70-99%




0-69% 583 73 656
70-99% 39 306 345
Total 622 379 1001
Agreement = 88%
Kappa (95% CI) = 0.76 (95% CI = 0.72 - 0.80)
4) Receiver operating curves
A receiver operating curve is simply a plot of sensitivity vs specificity (or 1-specificity by
tradition). It is based on the sensitivity and specificity of prediction of measurements made by
one observer by measurements made by the other. As described above, calculations of
sensitivity and specificity are usually based on a two way categorisation of the measurements of
both the observers or techniques e.g. 0-69% stenosis vs 79-99% stenosis as in table 4.3. In a
receiver operating curve, the reference measurement (i.e. the measurement which is being
predicted) is divided into two categories in exactly the same way. However, test measurement
(i.e. the measurement which is doing the predicting) is subdivided more finely. The most
commonly used approach is to rank the test measurements and then divide them into ten equal
groups (deciles). The sensitivity and specificity of prediction of the reference measurement are
then calculated for cut-off points at above and below each decile split of the test variable. The
resulting values are then plotted as illustrated in figure 4.1. Figure 4.1 is based on the prediction
of 70-99% stenosis as defined by Observer A using the measurements made by Observer B. In
this example, the cut-off points for the measurements made by Observer B were based on 10%
stenosis bands (0-9% vs 10-99%, 0-19% vs 20-99% and so on) rather than on ten equal groups
of ranked measurements. These cut-off points are shown as the percentages on the figure. As
expected when the cut-off point for the measurements of Observer B are low (eg, 20% or 30%)
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the sensitivity of prediction of 70-99% stenosis by Observer A is almost 100%, but the
specificity is low. However, as the cut-off point increases such that the specificity becomes
reasonable, the sensitivity begins to fall. As shown above using the data from table 4.3, the
sensitivity and specificity for the clinically important cut-off point of 70% are 81% and 94%
respectively.
The advantage of the ROC curve is that it illustrates the relationship of sensitivity and
specificity of prediction at different cut-off points. This allows clinicians to chose the cut-off
point which would be most useful for a specific clinical situation. For example, assume that
figure 4.1 was based on the prediction of 70-99% stenosis at angiography by a non-invasive
method of measurement. If we wanted to set a threshold for selection of patients for
angiography using the non-invasive method of imaging as a screening test, then we might want
to set the cut-off point lower than 70% - say 50% - in order to limit the false negative results.
The sensitivity of prediction at the 50% cut-off point is 98% rather than 81% with the cut-off
point is at 70%. The ROC curve also allows the overall predictive values of different
techniques to be compared. The predictive power is represented by the area between the
diagonal of no agreement (figure 4.1) and the curve.
Disadvantages ofanalyses as a categorical variable
There are several drawbacks to the two-by-two cross-tabulation approach. Firstly, different
studies seldom choose the same categories. For example, 11 of the 1970-90 studies
categorised measurements of stenosis in order to compare different observers or
techniques, but only three of these studies chose comparable categories. The situation was
little better among the 14 of the 1993-1996 studies which adopted this approach. Lack of
common of categories means that the agreements reported in different studies cannot be
compared. Indeed, the apparent level of agreement can vary quite considerably. Table 4.3,
shows the same data which was presented in table 4.2, but with different categories of stenosis -
the mild and moderate categories have been collapsed into a single group. This simple change
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increases the percentage disagreement from 20% to 12% and produces a statistically significant
increase in the kappa value.
A second major criticism of the cross-tabulation based statistics, such as kappa, is that they
assign reproducibility a single value. This ignores the fact that the reproducibility of
measurement of carotid stenosis varies considerably with the severity of stenosis.
Reproducibility ofmeasurement of stenosis on angiograms is relatively poor with minor degrees
of stenosis, but improves considerably as the degree of stenosis increases (see below). Not only
is it, therefore, over-simplistic to attempt to describe reproducibility with a single value, but it
follows that, even when measurements of stenosis are split into identical categories, the results
obtained using the kappa statistic will vary depending upon the distribution of the stenoses
studied within those categories. This makes results from different studies extremely difficult to
compare.
The ROC curve approach avoids some of the disadvantages described above. By using different
cut-off points it gives some information on the way in which agreement (or prediction of one
variable by the other) varies with degree of stenosis. However, the problem of comparability
between studies which chose different cut-off points remains.
4.5.2 Analysis of percent stenosis as a continuous variable
These methods of assessment of reproducibility treat percent stenosis as a continuous variable.
This avoids the problem of lack of comparability of categories, and has a number of other
advantages.
1) Scatterplots: The most obvious method of analysis is simply to plot the measurements of
one observer against those of the other (figure 4.2). This gives a visual impression of range of
disagreements which can be expected at different degrees of stenosis. The overall extent of
agreement is not quantified, but as discussed above, it is not necessarily helpful to assign
agreement a single value. One disadvantage of scatterplots is that they tend to underestimate the
105
extent of agreement. This is because each point on a scatterplot can be represented by only a
single dot even though there might be several measurements which coincide with that point. For
example, in figure 4.2 there is a single dot at the point where both observers measure 50%
stenosis. However, there were in fact 15 angiograms on which both observers measured 50%
stenosis - on the scatterplot these 15 dots appear as one. This can be avoided if each point is
represented by an integer equal to the number of measurements which were represented at that
point.
2) Correlation coefficient: Some studies attempt further statistical analyses of scatterplots.
One of the most frequently used measures of reproducibility in this situation is the correlation
coefficient between the measurements of two observers or two techniques. This was used in 5
studies in the 1970-1990 cohort and 10 studies in the 1993-1997 cohort. However, the use of
correlation as a measure of agreement is only valid if there is no overall bias between the
observers. If there is a consistent bias, then one could find perfect correlation in the presence of
zero agreement. For example, if one observer always overestimated stenosis by 10% compared
with the other observer, the correlation coefficient between their measurements would be 1, but
they would never agree. In statistical terms, correlation and agreement are entirely different
concepts and the use of correlation coefficients to measure agreement should be discouraged.
Moreover, even in the absence of bias, a correlation coefficient is very difficult to interpret. For
example, the correlation between the measurements of stenosis by two observers using the
ECST method shown in figure 4.2 is very high (r = 0.90, PO.OOOOl), despite the fact that the
two observers disagreed by over 5% in 599 (60%) of cases, and by greater than 10% in 296
(30%) cases. A correlation coefficient conveys little practically useful information, and the
significance level relating to the correlation coefficient is even less helpful.
4) The intraclass correlation coefficient: The intraclass correlation coefficient was originally
used in genetics to judge sib-ship correlations. However, it is now most often used to describe
the proportion of variance of an observation which is due to between subject variability in the
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"true" scores of a measuring instrument.20 The correlation can be estimated from a study
involving a number of observers making measurements on a number of patients. It has some of
the disadvantages of the kappa statistic in that it attempts to describe the level of agreement with
a single numerical value. As described above this is an oversimplification given that the
reproducibility ofmeasurement of stenosis varies with the degree of stenosis.
5) Regression equations or curvefitting
Regression can be used to analyse any consistent overall relationship or bias between
measurements of one observer or technique and those of another. However, it gives no
information about the variance or spread of the measurements. Nevertheless, information about
any consistent bias between observers or techniques can be useful. For example, in figure 4.2,
it can be seen that the relationship between the measurements ofObservers A and B is not quite
unity. The regression equation is: Observer B measurement = 0.89 (Observer A measurement)
+ 5%. The 95% confidence limits of the regression coefficient can be calculated: 0.87 - 0.91 in
the case of figure 4.2. However, care must be taken in interpreting this relationship. It doesn't
necessarily follow that, as might be assumed from figure 4.2, that Observer B tends to
overestimate mild stenoses and underestimate severe stenoses. Much of this apparent bias is in
fact artefact due to regression to the mean and boundary effects. These artefacts are discussed in
more detail later.
6) Absolute differences: Of more practical clinical value is an appreciation of the range of
absolute differences between measurements made by two observers or two techniques. For
example, how often do the measurements differ by more than 10% stenosis? This can be
gleaned from a simple scatterplot, but is easier to appreciate if it is presented in the form of a
table or a figure such as figure 4.3. From figure 4.3 it can be seen that the median difference
between the observers was somewhere between 5% and 9% stenosis, but that a significant
proportion ofmeasurements differed by more than 20% stenosis.
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Presentation of the data as in figure 4.3 is useful, but it hides other important information.
Agreement between two observers or two techniques is made up of two separate elements; the
background imprecision of measurement of each of the observers or techniques and the bias
between the observers or techniques. In figure 4.3, these two elements are combined to give the
absolute difference between the observers or techniques. The separate contributions of
imprecision and bias to the overall disagreement can be seen in figure 4.4. This shows the
direction as well as the size of the absolute differences between the measurements of observers
A and B. It can be seen that, on average, Observer A tends to overestimate the degree of
stenosis compared with Observer B - the most frequent difference is a 5-9% stenosis
overestimation by Observer A. It is important to determine the extent to which the level of
disagreement between two observers or techniques is due to imprecision or bias. For example, it
would be very useful to know that a particular non-invasive technique of imaging overestimated
stenosis by 10%, on average, compared with conventional angiography. A correction could
then be applied. When comparing different imaging techniques bias is at least as important as
imprecision. However, when considering the inter-observer disagreement between two
observers, the imprecision between the two observers is likely to be more generalisable to other
observers than their bias. The bias will be specific to those particular individuals. Studies
should, therefore, present data in a way which allows the reader to distinguish between
imprecision and bias.
7) Bland andAltman plots: One disadvantage of the presentation of data in figure 4.4 is that
it is not possible to judge whether or not the disagreement between the two observers or
techniques varies with the severity of stenosis. The ability of a technique to distinguish between
a 60% stenosis and an 80% stenosis will have greater clinical implications than its ability to
distinguish between 10% stenosis and 30% stenosis. Bland and Altman have suggested that the
most informative presentation of data comparing measurements of a continuous variables by
two observers or two techniques is as a plot of the difference between the measurements against
the mean of the measurements (figure 4.5). The mean of the two measurements is used in order
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to avoid the artefact which occurs when the difference between two measurements is plotted
against the value of one of the individual measurements. The artefact is illustrated in figure 4.6.
It appears that Observer A tends to underestimate the degree of stenosis compared with
Observer B when the stenosis is mild, but overestimate the stenosis when it is severe.
Consequently, there is a highly statistically significant correlation (r = 0.26, PO.OOl, regression
equation: y = 0.12x - 4.7). However, the apparent correlation is simply an artefact due to a
combination of two properties of measurement of percent stenosis. The first property is the
tendency for measurements to regress to the mean on repeated measurement. If Observer A
measures a stenosis particularly low, on average Observer B is likely to measure it as more
severe, and if Observer A measures the degree of stenosis to be particularly high, on average
Observer B is likely to measure it as less severe. The difference between the measurements
plotted against either of the individual measurements will inevitably lead to the artefactual
relationship illustrated in figure 4.6. This is not due to a bias between the observers, but is
simply the inevitable consequence of a measurement which has a degree of observer variability.
The second property of percent stenosis which leads to the artefactual relationship is the fact
that it is bounded by zero and 100%. This leads to artefact due to boundary effects. For
example, ifObserver A measures a stenosis as 0% then, by the ECST method at least, Observer
B can only measure then stenosis as equal or greater. The opposite tendency will occur is
Observer A measures the stenosis to be 100%. Both the regression to the mean artefact and the
boundary artefact are avoided if the difference between the two measurements is plotted
against the mean measurement (Bland and Altman plot). This is a reasonable approach for
assessment of the intra-observer or inter-observer reproducibility of a measurement of stenosis
in which the measurements of both observers should be given equal weight. However, it is not
necessarily appropriate when one technique of measurement is being compared with that of a
"gold-standard" technique e.g. a non-invasive method of imaging versus arterial angiography.
The statistical problems specific to this situation are complex.
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8) Plots of imprecision and bias versus degree ofstenosis: Comparison of measurements of
stenosis made by different imaging techniques is different in certain respects from comparison
of measurements of stenosis made by two observers using the same imaging technique. When
comparing two different techniques, the most important property of the measurements is the
bias between them. By how much do measurements made using one method differ from those
using the other? Agreement between methods is most often measured by categorising stenosis
and measuring agreement in allocation of stenoses into the categories or by calculating the
correlation coefficient between the measurements of the two methods. These approaches have
the same disadvantages as they have for measuring reproducibility, but most importantly they
tell us nothing about the bias between the techniques.
If we are to validate non-invasive methods of imaging against angiography we need to
know how the bias between the techniques varies with severity of stenosis. In order to assess
bias, the analysis of observer agreement for continuous variables suggested by Altman and
Bland '7 can be adapted to give a more easily appreciable measure of imprecision and bias at
different degrees of stenosis (figure 4.7). Stenoses are allocated into a particular decile using
the mean of the measurements by the two observers. Bias is then simply the difference
between the mean measurements of the two observers within that decile. Imprecision is related
to the difference between the measurements of the two observers or techniques divided by
the square root of two i.e. the perpendicular distances of points in figure 4.2 from the
diagonal which represents perfect agreement. Imprecision within each decile is best represented
by the standard deviation of the distribution of this distance for all the points allocated to that
decile. Figure 4.7 illustrates the results of the above analysis applied to measurements of
stenosis measured by two observers on 1001 angiograms (see Chapter 5). The bias between
these observers was relatively small. The imprecision, which is a guide to the likely
disagreement between two similar observers in the absence of any bias, decreases as stenosis
increases. For moderate stenoses two observers will frequently differ in their measurements of
stenosis by about 10% on average.
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4.6 Conclusions
If the results of clinical trials of carotid endarterectomy are to be applied to clinical practice
using non-invasive imaging then the reproducibility of the new techniques should be assessed
and results should be properly validated against angiography. Review of previous research in
this area shows that analysis and presentation of data are usually inadequate. There are several
disadvantages of treating stenosis as a categorical variable. The most useful approach is to
present the data graphically and to consider both the imprecision of measurement of stenosis
and the bias between measurements. This approach is used in Chapter 6 in order to compare the
reproducibility of measurement of stenosis on carotid angiograms using the ECST, NASCET
and CC methods of measurement.
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4.8 Figures
Figure 4.1. The receiver operating curve for the prediction of a 70-99% stenosis as measured by
Observer A by the measurements of Observer B. The levels of stenosis used as the cut-off
points for the calculation of the sensitivities and specificities of prediction are given for each
point (see Chapters 5 and 6 for explanation of data).
Figure 4.2. A scatterplot of measurements of the degree of stenosis by one observer against
those of another observer. Both observers used the ECST method ofmeasurement (see Chapters
5 and 6 for explanation of data).
Figure 4.3. The absolute difference between the measurements of carotid stenosis made by two
observers on 1001 angiograms using the ECST method of measurement (see Chapters 5 and 6
for explanation of data).
Figure 4.4. The absolute difference between the measurements of carotid stenosis made by two
observers on 1001 angiograms using the ECST method of measurement. Data are given as in
figure 4.3 except that the direction of the difference is also shown (see Chapters 5 and 6 for
explanation of data).
Figure 4.5. A Bland and Altman plot of the measurements of carotid stenosis made by two
observers on 1001 angiograms using the ECST method of measurement (see Chapters 5 and 6
for explanation of data).
Figure 4.6 A plot of the difference between the measurements of carotid stenosis made by two
observers on 1001 angiograms using the ECST method of measurement against the
measurements of one of the observers (see Chapters 5 and 6 for explanation of data).
Figure 4.7. The imprecision and bias of two observers measuring carotid stenosis by the ECST
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The equivalence of three different methods of measurement










Background and Purpose: There is confusion about how carotid stenosis should be measured on
angiograms. If the results of research based on different methods of measurement of stenosis are to
be compared, and the results of clinical trials properly applied to routine clinical practice,
measurements made by the different methods must first be formally compared.
Methods. The methods of measurement of stenosis used in the ECST, in the NASCET, and a
method based on measurement of the common carotid artery lumen diameter (CC), were compared.
Carotid stenosis was measured by two independent observers, using the three different methods of
measurement, on the angiographic view of the symptomatic carotid stenosis showing the most
severe disease in 1001 patients from the ECST.
Results: The ECST and CC methods disagreed with the NASCET method in the classification of
stenosis as mild (0-29%), moderate (30-69%) or severe (70-99%) in 51% of measurements. The
ECST and CC methods yielded twice as many severe stenoses as the NASCET method, and less
than a third the number of mild stenoses. The ECST and CC methods disagreed in 15% of
measurements. The relationships between measurements made by each method to the others were
approximately linear, allowing a simple equation to be derived in order to convert from one to the
others.
Conclusions: There were major and clinically important disparities between measurements of
stenosis using different methods of measurement on the same angiograms. However, it is possible




The study detailed in this chapter was performed in 1993 when the problem of how carotid stenosis
should be measured was highly topical in stroke.'"3 This followed the publication of the
preliminary results of the ECST4 and NASCET.5 Both trials indicated that the degree of stenosis,
expressed as a percentage reduction in the linear diameter, was a major factor in determining
whether a patient is likely to benefit from endarterectomy. Indeed, patient management still
frequently hinges on this single measurement. However, as described in Chapter 3, the two trials
measured stenosis differently. Both measured the lumen diameter at the point of maximum stenosis
[Dmin], but they differed in their choice of denominator. The ECST used the estimated normal
lumen diameter at the site of the lesion, based on a visual impression of where the normal arterial
wall was before development of the stenosis. The NASCET used the diameter of a visible portion
of disease-free ICA, distal to the stenosis, or classified the stenosis as 95% if the distal ICA had
collapsed.3 A third method of measurement of stenosis, using the diameter of the visible disease-
free distal common carotid artery [CCA] had also been advocated.6
As detailed in Chapter 3, there had been no consensus in the literature about which method should
be used. Use of more than one method had confused clinical practice and undermined the
generalisability of the results of research. Given the lack of agreement about which method is the
most appropriate, it was important to define the extent to which measurements made by each of the
methods actually differ. A preliminary collaborative study between the ECST and NASCET groups
suggested that the ECST and NASCET methods produced significantly different results.7 The
CCA method had not been systematically studied. If there were major differences between the three
methods, the relationship between the measurements must be defined, such that measurements
made using one method can be converted to the other two. The aim of this study was to compare
the results of the three methods on the same angiograms measured by the same observers.
123
5.3 Methods
One thousand and one consecutively selected carotid angiograms from patients randomised to "no
surgery" in the ECST were studied. No angiograms were excluded. The sample included
angiograms performed at approximately 100 centres in 14 European countries. They comprised 789
selective arterial angiograms, of which 307 were digitally subtracted, 174 aortic arch angiograms,
of which 92 were digitally subtracted, 29 intravenous digital subtraction angiograms, and 9
angiograms in which the technique was not clear. The mean age of patients studied was 62.1 years
(sd = 7.8), and 71% were male. Two independent observers (PMR and RJG) measured the degree
of stenosis of the symptomatic carotid artery by each of the three methods detailed in Chapter 3. In
patients with bilateral symptoms, the most stenosed artery was measured. Measurements were
made using a jeweller's eyepiece graduated in tenths of millimetres on the single angiographic view
which showed the tightest stenosis. The same measurement of Dmin was used for each of the
methods. Both observers were blind to measurements of the other and the clinical details. No marks
indicating the points ofmeasurement were placed on the angiogram films by either observer.
5.4 Results
In total, the two observers made 2002 stenosis measurements using each of the three methods. The
number of stenoses classified as mild (0-29%), moderate (30-69%) and severe (70-99%) by each of
the three methods are shown in table 5.1. The proportions within these groups were similar using
the ECST and CC methods, but the NASCET method classified three times as many stenoses as
mild compared with the ECST method, and the ECST and CC methods classified more than twice
as many stenoses as severe compared with the NASCET method. On 94 angiograms (9%), Dmin
was proximal or distal to the bulb. However, exclusion of these angiograms altered the results very
little, and they have therefore been included in all analyses.
124
Table 5.1. The number of stenoses categorised as mild, moderate or severe by the three methods of
measurement. 2002 measurements by two observers on 1001 angiograms.
Method Degree of linear stenosis (%)
0-29 30-69 70-99 Total
ECST 278 (14%) 1002(50%) 722 (36%) 2002
NASCET 896(45%) 776(39%) 330(16%) 2002
CC 294(15%) 953 (48%) 755 (37%) 2002
Comparisons between each of the methods in the categorisation of angiograms into the mild,
moderate and severe stenosis groups are shown in tables 5.2 to 5.4. The ECST and NASCET
methods disagreed on the classification of stenoses into the three categories in 51% of
measurements; in 1009 (99.6%) of the 1013 occasions where the two methods disagreed, the
NASCET method underestimated the category of stenosis compared with the ECST method (table
5.2).
Table 5.2 Comparison of the categorisation of stenoses as mild, moderate and severe by the ECST
and NASCET methods ofmeasurement. 2002 measurements by two observers on 1001 angiograms.
Stenosis (%) by the ECST method
0-29 30-69 70 -99
Stenosis (%) by the NASCET method
0-29 276 615 5
30-69 2 385 389
70-90 0 2 328
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The NASCET and CC methods disagreed on the category of stenosis on 1025 (51%) measurements
(table 5.3), with relative underestimation by the NASCET method on 1024 (99.9%).
Table 5.3 Comparison of the categorisation of stenoses as mild, moderate and severe by the CC
and NASCET methods ofmeasurement. 2002 measurements by two observers on 1001 angiograms.
Stenosis (%) by the CC method
0-29 30-69 70-99
Stenosis (%) by the NASCET method
0-29 294 598 4
30-69 0 354 422
70-90 0 1 329
The CC method and the ECST method disagreed on the category of stenosis on 305 (15%)
measurements, with no significant bias in either direction (table 5.4).
Table 5.4 Comparison of the categorisation of stenoses as mild, moderate and severe by the ECST
and NASCET methods ofmeasurement. 2002 measurements by two observers on 1001 angiograms.
Stenosis (%) by the CC method
0-29 30-69 70 -99
Stenosis (%) by the ECST method
0-29 200 78 0
30-69 94 825 83
70-90 0 50 672
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The relationships between measurements made by each of the methods are shown in figures 5.1 to
5.3. The mean of the measurements made by the two observers was used in order to minimise error
due to observer variability. In each case, there was some spread of measurements, particularly with
mild stenosis, but the relationships were approximately linear (at least in the clinically important
range of 50-99% ECST stenosis). The plot of ECST vs CC measurements approximated to a line
with a slope of 1.00 and an intercept on the CCA axis of 0%. The lines fitting the plots of ECST vs
NASCET and CC vs NASCET are identical, with a slope of 0.6 and an intercept on the ECST and
CC axes at +40%. The following equation describes the relationship between measurements made
by the NASCET method and those made by either the ECST or CC methods:
Using this equation, measurements made by one method can be converted to those expected by the
other methods. The equation can then be internally validated by assessing the agreement between
the predicted measurements and the actual measurements in categorisation of stenosis into mild,
moderate or severe groups (table 5.5). For example, agreement between the ECST and NASCET
methods increased from 49% to 83% when NASCET measurements were transposed to an ECST
scale.
Table 5.5. The initial agreement in the categorisation of stenosis as mild, moderate or severe
between each of the three methods, and the agreement following conversion of measurements using
the equations described above.
Comparison Initial agreement (%) Agreement after conversion (%)
ECST or CC % stenosis = 0.6(NASCET % stenosis) + 40%
NASCET vs ECST 49 83
CC vs ESCT 85 85
NASCET vs CC 49 87
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The differences between the results of the methods ofmeasurement were accounted for by the use
of different denominators. The mean and the 95% confidence intervals of the ratio of each
denominator to the others are given in Table 5.6. The ECST denominator was, on average, the same
as the CCA lumen, although the 95% range of the proportion was from 0.71 to 1.41. The
distribution of the ECST denominator:CCA ratio was similar for both observers (figure 5.4). The
ICA:CCA ratio varied with the severity of stenosis, remaining constant up to 70% ECST stenosis
(NASCET 50%), then falling steadily as stenosis increased further (figure 5.5).
Table 5.6 . The ratios and the 95% rangeof the ratios of each of the denominators of the three
methods ofmeasuring stenosis to the others.
Comparison Mean ratio 95% range
ECST denonimator vs CCA lumen 1.00 (0.71-1.41)
ECST denominator vs ICA lumen 1.68 (1.1 1 - 2.55)
CCA lumen vs ICA lumen 1.68 (1.15 - 2.44)
5.5 Discussion
The first aim of this study was to determine the frequency with which the three methods of
measuring stenosis placed the same patient into different categories of stenosis severity. The
differences between the ECST and NASCET methods were considerable. Moreover, these
differences were of major clinical importance. Both the ECST and NASCET trials demonstrated
that surgery is beneficial in patients with severe stenosis (70-99%). However, the ECST result
appears to apply to twice as many patients as the NASCET result (table 5.1). Conversely, the
128
NASCET method ofmeasurement, categorises three times as many patients as the ECST method as
having mild (0-29%) stenosis.
The second aim of the study was to define the equivalence of measurements made by the three
methods. The disparities between the ECST and NASCET methods can be illustrated using the
conversion equation. ECST stenoses of 30% and 70% are around -17% and 50% respectively by
the NACSET method. A NASCET stenosis of 70% is equivalent to an ECST measurement of
82%. Indeed, it is likely that this difference in the definition of "severe" stenosis accounted for
many of the differences between the preliminary ECST and NASCET results. Re-analysis of the
ECST results, confined to patients with 82-99% stenosis i.e. a severe stenosis by the NASCET
method of measurement, produces almost identical results to those reported from the NASCET
severe stenosis group.2
The approximately linear relationships between measurements made by each of the three methods
allows simple conversion equations to be derived. These conversions are not exact, since there is a
spread of measurements about the line to which they are fitted, but the internal validation suggests
that they work reasonably well. Moreover, the spread of measurements decreases as the clinical
importance of accurate measurement increases i.e. at moderate and severe stenosis. The
disagreement in categorisation of stenosis between the ECST and NASCET methods is decreased
three fold after converting the NASCET measurements. Conversion from the NASCET method to
the CC methods works equally well. That an error of categorisation remains in about 15% of
stenoses must be interpreted in the light of the 16-20% inter-observer variability of each of the
methods in allocating stenoses to these same categories (see Chapter 6). Even if the conversion
equations were perfect, observer variation in the individual measurements would limit the
agreement following conversion to below 90%. Ideally, if the results of studies based on different
measurements of stenosis are to be compared, the angiograms should be remeasured using the same
method. However, this is often not practical, and conversion equations will be required.
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The close approximation of the ECST and CC methods indicates that the ECST denominator is, on
average, the same as the CCA lumen. Two previous angiogram studies reported a mean ratio of the
bulb lumen to the CCA lumen of 1.19.6,8 However, both studies found that the ratio of 1.19 was
very variable, with a standard deviation of 0.09 in one 6 and 0.19 in the other.8 In other words the
ratio varied from less than 1.0 to over 1.4. These studies were confined to normal angiograms and,
of particular importance, measured the diameter of the bulb at its widest point. The ECST method
of measurement of stenosis uses the lumen diameter at the point of maximum stenosis, which is not
infrequently outwith the bulb. Moreover, even when the maximum stenosis is within the bulb it
seldom coincides exactly with the widest point. The ratio of the ECST denominator to the CCA
lumen diameter will clearly vary with the site of the stenosis and will usually be less than 1.2. This
study demonstrated that the ratio of the ECST denominator to the CCA lumen, in over a thousand
bifurcations, varied from 0.7 to 1.4, and that the average ratio was 1.00, both observers producing
similar distributions.
Collapse of the ICA distal to tight stenoses has been noted previously.9 By the NASCET method,
any stenosis distal to which the ICA is collapsed, is classified as 95%.10 Despite attempts to define
criteria for determining exactly when the ICA should be regarded as "collapsed",3 the judgement
must remain somewhat subjective, and is likely to have observer variability. This study
demonstrates a steady reduction of the ICA lumen, compared to the CCA lumen, beginning at about
70% ECST stenosis (50% NASCET stenosis). Moreover, collapse of the ICA is marked in some
patients but not in others, such that groups of patients with the same ECST or CC stenoses might
have varying NASCET stenoses. This inconsistency of measurement of severe stenoses is a
problem for the NASCET method. Given the difficulty some observers have with estimation of the
normal bulb lumen in the ECST method, the CC method would appear to have the fewest
drawbacks. The CCA is usually well visualised on angiography, without overlapping vessels, and is
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rarely severely affected by atheroma. Most importantly, it is the most reproducible of the three
methods.
This study has demonstrated major differences between the results of three methods of
measurement of carotid stenosis on the same angiograms. These differences have important
implications for clinical practice. However, the relationships between measurements made by the
three methods are approximately linear, and conversions can be made using the equation given.
These data provide the basis for informed debate about which method of measurement of stenosis
should be adopted as the standard. The choice of a standard method should depend on ability to
predict ipsilateral ischaemic stroke and reproducibility. These characteristics are studied in Chapter
6.
5.6 References
1) Alexandrov AV, Bladin CF, Maggisano R, Norris JW. Measuring carotid stenosis. Time for a
reappraisal. Stroke 1993; 24: 1292-1296.
2) Barnett HJM, Warlow CP. Carotid endarterectomy and the measurement of stenosis. Stroke
1993; 24:1281-1284.
3) Fox AJ. How to measure carotid stenosis. Radiology 1993; 186: 316-318.
4) European Carotid Surgery Trialists' Collaborative Group. MRC European Carotid Surgery Trial:
interim results for symptomatic patients with severe (70-99%) or with mild (0- 29%) carotid
stenosis. Lancet 1991; 337: 1235-1243.
5) North American Symptomatic carotid Endarterectomy Trial Collaborators. Beneficial effect of
carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med
1991; 325: 445-453.
6) Williams MA, Nicoliades AN. Predicting the normal dimensions of the internal and external
carotid arteries from the diameter of the common carotid. Eur J Vase Surg 1987; 1: 91- 96.
7) Rothwell PM, Warlow CP. The European Carotid Surgery Trial (ECST). In: Surgery for Stroke
(Greenhalgh RM, Hollier LH eds). London, WB Saunders 1993.
131
8) Schneidau A, Harrison MJG, Hurst C. Predicting the normal dimensions of the internal carotid
artery. Eur J Vase Surg 1988; 2: 273-275.
9) Brown PM, Johnston KW. The difficulty of quantifying the severity of carotid stenosis. Surgery
1982; 92: 468-473.
10) North American Symptomatic Carotid Endarterectomy Trial (NASCET) Steering Committee.
North American Symptomatic Carotid Endarterectomy Trial: methods, patient characteristics, and
progress. Stroke 1991; 22: 711-720.
5.7 Legends to figures
Figure 5.1. The relationship between the mean measurements of carotid stenosis of two observers
on 1001 angiograms for the ECST method vs the NASCET method. Each point represents
measurements from one or more angiograms.
Figure 5.2. The relationship between the mean measurements of carotid stenosis of two observers
on 1001 angiograms of the ECST method vs the CC). Each point represents measurements from
one or more angiograms.
Figure 5.3. The relationship between the mean measurements of carotid stenosis of two observers
on 1001 angiograms for the NASCET method vs the CC. Each point represents measurements from
one or more angiograms.
Figure 5.4. The number of bifurcations measured by two observers (PMR + RJG) classified
according to the ratio of the ECST denominator measurement to the common carotid artery lumen
measurement.
Figure 5.5. The mean ratio, by decile of European Carotid Surgery Trial (ECST) stenosis, of the
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Figure 5.3
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The prognostic value and reproducibility of different methods











Background and purpose: The use of three methods of measuring carotid stenosis producing
different values on the same angiograms has caused confusion and reduced the generalisability of
the results of research. If the results of future studies are to be properly applied to clinical
practice, and if non-invasive methods of imaging are to be properly validated against angiography,
a single standard method of measurement of stenosis on angiograms must be adopted. This
standard method should be selected on the basis of ability to predict risk of ipsilateral carotid
distribution ischaemic stroke and reproducibility.
Methods: The methods of measurement of carotid stenosis used in the ECST and NASCET, and a
method based on the measurement of the common carotid lumen diameter (CC) were studied.
Their ability to predict ipsilateral carotid distribution ischaemic stroke was assessed in 1001
consecutively selected patients randomised to medical treatment in the ECST. Carotid stenosis
was measured by two independent observers, using each of the three methods, on the angiographic
view showing the most severe stenosis of the symptomatic carotid bifurcation. The inter- observer
agreement was determined, and 50 angiograms were remeasured in order to determine the intra-
observer agreement.
Results: There was little difference in the ability of the three methods to predict ipsilateral carotid
distribution ischaemic stroke. The CC method was consistently the most reproducible of the three
methods, particularly in the clinically important range of 50%-90% stenosis.
Conclusion: The CC method of measurement should be adopted as the standard method of
measuring the degree of carotid stenosis on angiograms.
6.2 Introduction
The ECST and NASCET showed that the degree of stenosis of the origin of internal carotid artery
is a major predictor of the risk of ipsilateral ischaemic stroke, and consequently, of the potential
benefit from carotid endarterectomy, in patients presenting with a recent TIA or minor ischaemic
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stroke.1'2 The three different methods of measuring stenosis on an angiogram have been
described in Chapters 3 and 5. As shown in Chapter 5, the NASCET method produces very
different results from the ECST or CC methods. Although, it is possible to convert measurements
made by each method to those of the others using linear equations, if the results of future
research and clinical trials are to be properly applied to clinical practice, then a single standard
method should be adopted by all. This would increase the generalisability of research findings and
would facilitate the validation of non-invasive methods of imaging which will inevitably replace
conventional angiography with its attendant risks and costs.
How should a standard method be selected? The ability of each of the methods to predict the risk
of ipsilateral ischaemic stroke is probably the most important criterion. Which method is best able
to separate patients at high and low risk of stroke? The three methods are unlikely to vary
significantly in this respect, but this remains to be proven. Therefore, the first aim of this study
was to measure the ability of each of the methods to predict the risk of ipsilateral carotid
distribution ischaemic stroke.
The reproducibility of measurements made by each of the methods may differ. Reproducibility of
measurements of angiographic vessel stenosis can be exceedingly poor.3'4 Poor reproducibility of
measurement of carotid stenosis would undermine selection of patients for endarterectomy and
reduce the overall efficacy of the procedure. If the prognostic value of stenosis measured by each
of the methods is similar, the most reproducible method would be the logical choice as a standard.
Therefore, the second aim of the study was to determine the inter-observer and intra-observer
variability ofmeasurement of stenosis by each of the three methods on the same angiograms.
6.3 Methods
The details of the 1001 consecutively selected ECST carotid angiograms studied are reported in
Chapter 5. No angiograms were excluded. Briefly, they comprised 789 selective arterial
angiograms, of which 307 were digitally subtracted, 174 aortic arch angiograms, of which 92 were
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digitally subtracted, 29 intravenous digital subtraction angiograms, and 9 angiograms in which the
technique was not clear. The mean age of patients studied was 62.1 years (sd = 7.8), and 71%
were male.
Two independent observers (PMR and RJG) measured the degree of stenosis of the symptomatic
carotid artery by each of the three methods. In patients with bilateral symptoms, the most
stenosed artery was measured. Measurements were made using a jeweller's eyepiece graduated in
tenths of millimetres on the single angiographic view which showed the tightest stenosis. The
same measurement of the minimum residual lumen diameter was used for each of the methods.
Both observers were blind to measurements of the other and the clinical details. No marks
indicating the points of measurement were placed on the angiogram films by either observer. In
order to examine intra-observer variation, each observer repeated the measurement of 50
randomly selected angiograms.six months after the first reading.
6.4 Statistical Analysis
Prognostic value: The outcome used to assess the prognostic value of the methods of
measurement of stenosis was carotid distribution ischaemic stroke lasting longer than seven days
ipsilateral to the measured stenosis. The prognostic value of measurements made by each of the
three methods was represented as the area under the receiver operating curve derived from the
predictive properties of the mean measurement of the two observers. For each method, the 1001
mean measurements were ranked according to degree of stenosis and divided into deciles. The
sensitivity and specificity of the three methods were defined between each decile using Kaplan
Meier estimates of three year risk of ipsilateral carotid territory ischaemic stroke.
Reproducibility: As discussed in Chapter 4, no single statistic is ideal for summarizing
reproducibility of measurement of a continuous variable such as carotid stenosis. In order to
determine the relationship between reproducibility and degree of stenosis, I used the method of
Altman and Bland.9 No variance stabilizing transformation appears to be obviously applicable
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and hence the imprecision in measurement is analysed within each decile of stenosis, a procedure
which gives readily understandable results and can be represented graphically. As described in
Chapter 4, stenoses are allocated into a particular decile using the mean of the measurements by
the two observers. Imprecision in measurement within each decile is represented by the standard
deviation of the perpendicular distances of all points from the diagonal representing perfect
agreement. In order to compare the precision of the three methods, the results of the NASCET
method of measurement were transformed onto the ECST scale using the equation described in
Chapter 5. In other words, all three methods were compared in the same range i.e. 0% to 100%
stenosis. In order to calculate the bias between observers, the mean of each pair of measurements
was again used to allocate the stenosis into a particular decile. The bias within a decile was taken
as the mean of the differences between the two measurements for all stenoses allocated to the
decile.
Data are also presented in the more traditional form as the percentage agreement and the Kappa
statistic for agreement between the observers in the categorisation of stenosis as mild (0-29%),
moderate (30-69%) or severe (70-99%). Intra-observer agreement was calculated by combining
the measurements of both observers and comparing the first measurements with the second
measurements.
6.5 Results
Prediction of Ipsilateral Ischaemic Stroke: The analysis was based on 122 ipsilateral ischaemic
strokes. The receiver operating curves representing the predictive power of each of the three
methods of measurement were almost identical (figure 6.1), indicating no difference between the
predictive powers of the methods.
Reproducibility: For each of the methods, the measurements of one observer are plotted against
those of the other in figures 6.2 to 6.4. The spread of measurements provides a visual measure of
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the extent of disagreement. Subjectively, the spread is least with the CC method and most with the
ECST method. Bland and Altman plots are also given for each of the methods of measurement
(figures 6.5 to 6.7) and give the same impression. The results of the NASCET method of
measurement are shown in their usual untransformed manner in figure 6.7.
Imprecision of measurement was much larger than the bias for each of the methods (figures 6.8
and 6.9). Imprecision fell steadily as stenosis increased. For stenoses greater than 80%, the
imprecision of each of the methods was identical (figure 6.8). For stenoses less than 40%, the
ECST method was most precise, and in the range of 50-90%, the CC method was most precise.
Table 6.1. Comparison of the allocation of stenoses into mild (0-29%), moderate (30-69%) and severe (70-
99%) groups by both observers for each of the three methods ofmeasuring stenosis. Measurements using the
NASCET method are transformed onto an ECST scale.
Observer A
ECST method CC method NASCET method
0-29 30-69 70-99 0-29 30-69 70-99 0-29 30-69 70-99
Observer B
0-29% 94 51 0 113 46 0 97 47 0
30-69% 40 398 73 22 395 68 40 397 56
70-99% 0 39 306 0 25 332 0 36 328
Agreement 80% 84% 82%
Kappa (95% CI) 0.66 (0.62- 0.70) 0.76 (0.72- 0.80) 0.72 (0.68-0.76)
The Kappa statistic (standard error) for inter-observer agreement in the categorisation of stenoses
as mild, moderate, or severe was 0.76 [0.02] for the common carotid method, 0.72 [0.02] for the
NASCET method, and 0.66 [0.02] for the ECST method. The difference between the ECST and
NASCET methods was not significant. The CC method was significantly better than the ECST
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method, but not the NASCET method. As expected, the same trend was reflected in the %
disagreement in the allocation of stenoses into the same categories (table 6.1) and the number of
occasions on which the two observers agreed to within less than 1% stenosis [CC method: 204
(20.4%). NASCET method: 186 (18.6%). ECST method: 160 (16.0%)].
Table 6.2 shows that the CC method produced the highest level of agreement between observers
to within 5% stenosis, and the lowest level of disagreement by greater than 10% stenosis. The
bias between the two observers was relatively small (figure 6.9). For each method, one observer
consistently overestimated stenosis with respect to the other by between one and five percent.
Bias was greater for mild stenoses and fell as stenosis increased. There was no overall difference
between each of the three methods in terms of the bias between the two observers.
Table 6.2. The measurements of stenosis made by the two observers for each of the methods of




0-5% 402 440 459
6-10% 303 300 297
> 10 296 261 245
Total 1001 1001 1001
Intra-observer agreement was greater than inter-observer agreement. For both observers combined
the Kappa value for intra-observer agreement in the categorisation of stenoses as mild, moderate,
or severe was 0.84 for the CC method, 0.78 for the NASCET method, and 0.68 for the ECST
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method. The differences were not statistically significant, but the trend was similar to that for
inter-observer agreement.
6.6 Discussion
That each of the three methods were of very similar prognostic value was expected and is
consistent with the very similar results in the ECST and NASCET trials when identical ranges of
stenosis were compared. The discussion will therefore concentrate on the reproducibility of the
methods. However, it should be borne in mind that factors other than the degree of stenosis, such
as plaque surface morphology or stenosis of the external carotid artery, may also be of prognostic
value and an index combining a number of factors may eventually prove to be most appropriate
(see Chapters 8 and 17).
Considering the importance of the degree of carotid stenosis in the management of patients with
cerebrovascular disease, at the time when this study was performed there has been remarkably
little published research on the reproducibility of its measurement on angiograms. Chikos et al10
examined the observer variability of measurement of stenosis using the ECST method on carotid
angiograms of 100 consecutive patients. The clinical details and the indications for angiography
were unclear, and 36 angiograms were excluded because they did not reach an unspecified quality
standard. Moreover, the majority of angiograms measured had only mild stenosis, and so the
results are of little relevance to present day clinical practice. Brown and Johnston" looked at the
observer variability of quantitative measurement of stenosis on selected high quality selective
arterial angiograms, but did not actually quantify the variability. Murie and McKay12 found inter-
observer and intra-observer agreements of 74% and 83% respectively for categorisation of
stenosis measured using the NASCET method on 100 randomly selected angiograms into six
categories (0%, <25%, 25-49%, 50-75%, 75-99% and occlusion). At the time that this study was
performed, the reproducibility of the ECST and NASCET methods of measurement of stenosis
had not been compared, and the reproducibility of the CC method had never been studied.
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Judging by the overall percentage agreement and kappa statistics for inter-observer and intra-
observer agreement in allocation of stenoses into the mild, moderate and severe categories, the CC
method was the most reproducible. However, such single figure assessments of overall agreement
obscure any variation in agreement with the degree of stenosis, and cannot determine which
method has the highest level of agreement in the clinically important range of 50-90% ECST
stenosis, where significant variability might influence the surgery versus no-surgery decision.
More information can be gained from the plots of one observer against another (figures 6.2 to
6.4). For each of the three methods the spread of measurements decreased with increasing
stenosis. This is seen more easily in the Bland and Altman plots (figures 6.5 to 6.7) and is best
quantified in the plot of imprecision by decile of stenosis (figure 6.8). The bias between observers
in the measurement of stenosis was relatively small and contributed little to the overall
disagreement (figure 6.9). However, this result refers to the two observers in this study and cannot
be generalised. Bias between other observers may be greater. The imprecision between observers
is more generalisable, and can be regarded as a measure of the disagreement expected between
two observers who had no overall bias with respect to each other. It is therefore an approximate
measure of the least disagreement likely between two observers. The imprecision was high. For
stenoses of 40-50% (ECST), the imprecision between observers was approximately 10% for each
of the methods. Disagreement will often be greater because imprecision is defined as the standard
deviation of the overall range of imprecision within each decile. Measurements by two observers
often differed by over 20% for mild or moderate stenoses. Disagreement between observers in the
range of 50-90% (ECST) is likely to be of greatest clinical importance. Within this range the
imprecision was consistently least for the CC method.
This study has shown that each of the three methods of measuring stenosis predicts the risk of
stroke equally well, but that the CC method is the most reproducible measure of the degree of
stenosis on angiograms. The CC method is also likely to be the most easily measured by non¬
invasive imaging techniques. Given the significant risk of complications of carotid
angiography,13'14 the transition to non- invasive imaging to select patients for endarterectomy
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seems inevitable. The common carotid artery is more easily visualised using carotid duplex
ultrasound techniques than the internal carotid artery distal to the bulb, and use of the common
carotid method would avoid the difficulty in visualising the bulb diameter in the presence of a
calcified plaque. The lack of turbulent flow in the common carotid artery compared to areas distal
to the bifurcation and stenosis is likely to result in better visualisation on magnetic resonance
angiography. Finally, the common carotid artery is rarely so affected by disease to such an extent
that its normal diameter cannot be measured at some point along its course.
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6.8 Legends to Figures
Figure 6.1. The receiver operating curves for the power of each of the three methods of
measuring stenosis to predict the Kaplan Meier risk of ipsilateral carotid distribution ischaemic
stroke at three years: ECST method (dashed line); NASCET method (dotted line); CC method
(solid line).
Figure 6.2 The measurements of two observers of 1001 stenoses plotted against each other for the
ECST method ofmeasurement. Each point may represent measurements of one or more stenoses.
Figure 6.3 The measurements of two observers of 1001 stenoses plotted against each other for the
CC method ofmeasurement. Each point may represent measurements of one or more stenoses.
Figure 6.4 The measurements of two observers of 1001 stenoses plotted against each other for the
NASCET method of measurement. Each point may represent measurements of one or more
stenoses. NASCET measurements were transformed to the ECST scale.
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Figure 6.5 A Bland and Altman plot of measurements of two observers of 1001 stenoses for the
ECST method ofmeasurement. Each point may represent measurements of one or more stenoses.
Figure 6.6 A Bland and Altman plot of the measurements of two observers of 1001 stenoses for
the CC method ofmeasurement. Each point may represent measurements of one or more stenoses.
Figure 6.7 A Bland and Altman plot of the measurements of two observers of 1001 stenoses for
the NASCET method of measurement. Each point may represent measurements of one or more
stenoses.
Figure 6.8. The imprecision between two observers in the measurement of carotid stenosis by the
ECST (dashed line), NASCET (dotted line) and CC (solid line) methods by decile of stenosis.
NASCET measurements were transformed to the ECST scale.
Figure 6.9. The bias between two observers in the measurement of carotid stenosis by the ECST
(dashed line), NASCET (dotted line) and CC (solid line) methods by decile of stenosis. NASCET
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Chapter 7
The effect of angiographic technique and image quality on the reproducibility of









Background: There is a longstanding debate as to which technique of angiography is the most
appropriate method of imaging the carotid circulation in patients with cerebrovascular disease.
Progress towards the routine use of non-invasive methods of imaging for the selection of
patients for carotid endarterectomy requires that new techniques are validated against an
angiographic gold-standard. However, before this can be done properly, it is necessary to
determine the measurement characteristics of the different angiographic techniques.
Methods: This chapter reports a study of the reproducibility of measurement of carotid
stenosis and the assessment of plaque surface morphology according to angiographic
technique, method of image acquisition and image quality.
Results: Inter-observer agreement (Kappa statistic, 95% CI) for categorisation of carotid
stenosis as 0-29%, 30-69% Or 70-99% was good (0.68, 0.63-0.73) on 789 conventional or
digitally subtracted selective angiograms, good (0.64 ,0.54-0.75) on 174 conventional and
digitally subtracted aortic arch injection angiograms, but was poor (0.29 ,0.02-0.80) on 29
intravenous digital subtraction angiograms. Inter-observer agreement did not vary with the
method of image acquisition of arterial angiograms, but was dependent on the quality of
visualisation of the stenosis: kappa = 0.73 (0.67 - 0.79) for good quality angiograms vs 0.54
(0.44-0.64) forpoor quality angiograms.
Inter-observer agreement for assessment of plaque surface morphology was moderate
(Kappa 0.4 to 0.6) and did not vary with type of angiography or method of image aquisition.
However, plaque surface irregularity was reported most frequently on selective angiograms and
on those angiograms on which the quality of visualisation of the stenosis was good.
Conclusion: The reproducibility of measurement of carotid stenosis and the assessment of
plaque surface morphology vary depending on the type of angiography and the quality of
visualisation of the stenosis. This should be taken into account when validating non-invasive
methods of imaging the carotid bifurcation.
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7.2 Introduction
As discussed in previous chapters, there has been much interest in how best to image and
measure carotid stenosis following the results of ECST and NASCET. Although, there have
been several advances in non-invasive imaging of the carotid arteries,'"3 angiography with its
attendant risks of stroke and death4'5 is still required by most neurologists and vascular
surgeons prior to endarterectomy. There is a longstanding debate as to which technique of
angiography is the most appropriate method of imaging the carotid circulation in patients with
cerebrovascular disease.6"8 Conventional or digitally subtracted selective angiography
produces high quality images, but may be associated with a high risk of stroke.4'5 Aortic arch
angiography is prone to vessel overlap and difficulty in obtaining the true lateral views of the
posterior wall of the bulb, and although intravenous digital subtraction angiography probably
has the lowest morbidity,9 the image quality is variable and it is also undermined by vessel
overlap.
Progress towards the routine use of non-invasive methods of imaging for the selection of
patients for carotid endarterectomy requires that new techniques are validated against an
angiographic gold-standard; not because angiography is the ideal, but because the only
information available about which patients benefit from carotid endarterectomy is based on
measurement of stenosis and assessment of plaque surface morphology on angiograms.
However, before non-invasive methods of imaging can be properly validated it is necessary to
determine the measurement characteristics of the different angiographic techniques. This study
compares the reproducibility ofmeasurement of carotid stenosis and the assessment of plaque
surface morphology using the different techniques of angiography.
7.3 Methods
The sample of 1001 consecutively selected carotid angiograms from patients randomised to "no
surgery" in the ECST has been described in Chapters 5 and 6. They comprised 789 selective
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arterial angiograms, of which 307 were digitally subtracted; 174 aortic arch angiograms, of
which 92 were digitally subtracted; 29 intravenous digital subtraction angiograms; and 9
angiograms in which the technique was not clear. This study is confined to the 992
angiograms in which the technique was clear. Two independent observers (PMR & RJG)
measured the degree of carotid stenosis and assessed the plaque surface morphology.
Stenosis was measured by the ECST method on the same single view which showed the
most severe stenosis. This "optimal" view was chosen by PMR. Plaques were categorised as
"smooth" or "irregular" using the definitions suggested by the NASCET trialists.10 " More
details of this assessment are given in Chapter 8. Each observer was blind to measurements of
the other and the clinical details. One observer (RJG) categorised the visualisation of the
stenosis on each angiogram as "good", "adequate" or "poor". This judgement was based on the
sharpness of the image, contrast visualisation and the presence or absence of vessel overlap.
Statistical analysis: As discussed in Chapter 4, no single statistic adequately defines the
reproducibility of measurement of a continuous variable such as percent stenosis. Ideally,
imprecision and bias should be presented graphically. However, in this study the number of
aortic arch angiograms and intravenous digital subtraction angiograms were not sufficient to
allow this approach. Instead, unweighted Kappa statistics10 were used in order to measure
agreement in the categorisation of stenoses as mild (0-29%), moderate (30-69%) and severe
(70-99%), and the categorisation of plaque surface morphology as smooth or irregular.
7.4 Results
Optimal View
The lateral view was chosen as the view which showed the most severe stenosis for 76% of
selective angiograms but only 8% of arch angiograms and 21% of intravenous angiograms
(table 7.1).
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Table 7.1. The view selected to show the most severe stenosis of the symptomatic carotid artery
according to the technique of angiography and the method of image acquisition.
Optimal View
Angiogram Lateral Oblique Anterior Total
Technique of Angiography
Selective 597(76%) 79(10%) 113(14%) 789
Arch injection 13 (8%) 137(79%) 24(14%) 174
Intravenous 6(21%) 21(72%) 2(7%) 29
Method of Image Acquisition 1
Conventional 361 (64%) 110(20%) 93(17%) 564
Digital subtraction 247(62%) 107(27%) 45(11%) 399
1
arterial angiograms only
The degree of stenosis was measurable on two different views in 478 cases. There was no
differences in mean stenosis between lateral and oblique views or oblique and anterior views,
but in the 372 cases in which a lateral and anterior view of the same stenosis were measured,
the mean degree of stenosis was 5.0% (95% CI, 1.4-8.6) greater on the lateral view (table 7.2).
Table 7.2. In cases where two different views of the same stenosis were available, note was
made of the view which was considered to show the most severe stenosis and the mean %
stenosis was calculated for each view.
Combination of Views View showing most severe stenosis Mean % Stenosis (95% CI)
Lateral vs Anterior (n = 372)
Lateral 297
Anterior 75
Lateral vs Oblique (n = 83)
Lateral 53
Oblique 30









Difference between means = 5.0% (95% CI, 1.4-8.6)
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Reproducibility ofmeasurement ofstenosis
Reproducibility of categorisation of stenoses as 0-29%, 30-69% and 70-99% was similar for
selective injection and aortic arch injection angiograms (table 7.3), and the absolute
differences between observers in the measurements of stenosis were similar (table 7.4).
Although the number of intravenous injection angiograms was small, the reproducibility of
categorisation of stenosis was significantly lower than that obtained with other the techniques
(table 7.3), and the absolute differences between observers tended to be greater (table 7.4).
Table 7.3. Comparison of the allocation of stenoses into 0-29%, 30-69% and 70-99% stenosis groups
(ECST method) by both observers for each of the different angiographic techniques.
Observer A
Selective injection Aortic arch injection Intravenous injection
0-29 30-69 70-99 0-29 30-69 70-99 0-29 30-69 70-99
Observer B
0-29% 79 41 1 11 7 0 1 3 0
30-69% 31 315 54 8 72 12 1 8 4
70-99% 0 26 242 0 9 55 0 4 8
Agreement 81% 79% 58%
Kappa (95% CI) 0.68 (0.63 - 0.73) 0.64 (0.54 - 0.75) 0.29 (-0.02 - 0.59)
Table 7.4. Classification of cases (%) according to the difference between the measurements of %
stenosis of the two observers and the technique of angiography, the method of image acquisition, and
the quality of visualisation of the stenosis.
Type of angiography Digital image acquisition* Visualisation of stenosis
Difference Selective Arch Venous No Yes Good Adequate Poor
0% 125(16) 30(17) 2 (7) 90(16) 64(16) 77(17) 50(14) 30(16)
1-9% 439 (56) 90 (52) 14 (48) 302 (54) 227 (57) 270 (60) 176 (52) 91 (48)
10-19% 175 (22) 41 (24) 8 (28) 134 (24) 82 (21) 87(19) 89 (26) 48 (25)
>19 40 (5) 13 (8) 5(17) 38 (7) 25 (6) 19 (4) 27 (8) 22(12)




Reproducibility of categorisation of stenosis was unrelated to the method of image acquisition,
but did fall significantly as the quality of visualisation of the stenosis decreased (table 7.5).
Table 7.5. Agreement between two observers in the categorisation of severity of stenosis as 0-
29%, 30-69%, and 70-99% according to the technique of angiography, the method of image
acquisition, and the quality of visualisation of the stenosis.
Cases Agreements (%) Kappa (95% CI)
Technique of Angiography
Selective injection
Conventional 482 385 (80) 0.67 (0.61-0.73)
Digital subtraction 307 252 (82) 0.70 (0.63-0.77)
Total 789 636 (81) 0.68 (0.63-0.73)
Aortic arch injection
Conventional 82 64(78) 0.63 (0.51-0.75)
Digital Subtraction 92 74 (80) 0.65 (0.54-0.77)
Total 174 138 (80) 0.64 (0.54-0.75)
Intravenous injection 29 17(59) 0.29 (-0.02-0.8)
Method of Image Acquisition 1
Conventional 564 450 (80) 0.66 (0.60-0.72)
Digital subtraction 399 323 (82) 0.69 (0.63-0.75)
Quality of Visualisation of Stenosis
Good 453 379 (83.7)2 0.73 (0.67-0.79)
Adequate 348 273 (78.4) 0.64 (0.56-0.72)
Poor 191 139(72.8) 0.54 (0.44-0.64)
1 arterial angiograms only
2 X2 for trend = 10.4, P=0.001
Assessment ofplaque surface morphology
Both observers agreed on the categorisation of plaque surface morphology as smooth or
irregular in 798 (80.4%) cases (kappa = 0.55, 95% CI = 0.52 - 0.58). Reproducibility did not
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vary with quality of visualisation of stenosis, type of angiography or method of image
acquisition (table 7.6).
Table 7.6. Kappa statistics for inter-observer agreement in the assessment of plaque surface
morphology (smooth or irregular) according to the technique of angiography, method of
image acquisition and quality of visualisation of the stenosis.
Cases Agreements (%) Kappa (95% CI)
Technique of Angiography
Selective injection
Conventional 482 381 (79) 0.55 (0.48-0.62)
Digital subtraction 307 252 (82) 0.56 (0.47-0.65)
Total 789 633 (80) 0.56(0.51-0.61)
Aortic arch injection
Conventional 82 67(82) 0.59 (0.44-0.74)
Digital subtraction 92 62 (67) 0.48 (0.33-0.62)
Total 174 129 (75) 0.54 (0.43-0.64)
Intravenous injection 29 19 (66) 0.43 (0.14-0.71)
Method of Image Acquisition
Conventional 564 448 (79) 0.56 (0.50-0.62)
Digital subtraction 399 314(79) 0.55 (0.48-0.64)
Quality of Visualisation of Stenosis
Good 453 371 (82) 0.58 (0.51-0.67)
Adequate 348 274 (79) 0.56 (0.47-0.65)
Poor 191 136(72) 0.50 (0.40-0.62)
The proportion of stenoses classified by both observers as irregular increased with the quality
of the image, and was greater in selective injection angiograms than aortic arch injection
angiograms or intravenous angiograms (table 7.7).
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Table 7.7. Classification of cases where both observers agreed on the appearance of the plaque
surface according to the quality of visualisation of the stenosis, the technique of angiography,
and the method of image acquisition.
Cases (%)
Plaque Surface Morphology: Smooth Irregular Total





82 (30) 192 (70)








190 (30) 443 (70)
59 (46) 70 (54)




Method of Image Acquisition
Conventional
Digitally subtracted
134 (30) 314 (70)3
116 (37) 198 (63)
448
314
1 X2 for trend = 4.1, P=0.04
2 X2 for heterogeneity = 13, P=0.001
3 X2 for heterogeneity = 3.1, P=0.08
7.5 Discussion
In general, the reproducibility ofmeasurement of arterial stenosis on angiograms is poor.11"13
The reproducibility of measurement of carotid stenosis on angiograms is somewhat better than
that reported for coronary or peripheral arterial angiograms, but as shown in Chapter 6 and
previous studies,1'14"17 is still no more than moderate. Most studies investigating the
reproducibility of measurement of carotid stenosis on angiograms report results for selective
and arch arterial angiograms combined1'15'16 or arterial and intravenous angiograms
combined.17 No study has compared the reproducibility of the individual angiographic
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techniques. This study did not compare the different techniques in the same patients, but does
nevertheless allow some conclusions to be drawn.
Measurement of stenosis was no more reproducible on selective injection angiograms than on
arch angiograms. However, the availability of measurable lateral views of the bifurcation in
the majority of patients with selective angiography may well be an advantage over arch
injections angiograms. In those angiograms in which two measurable views of the
bifurcation were available, the lateral view was most frequently considered to show the most
severe linear stenosis. This probably reflects the tendency for carotid plaques to form on the
posterior wall of the bulb. However, the difference in mean stenosis between lateral and
anterior views was only of the order of 5%, and would be unlikely to have a major effect on the
decision as to which patients should be referred for endarterectomy.
The reproducibility of measurement of stenosis on intravenous angiograms was poor.
Although the sample of intravenous angiograms was relatively small, and the possibility that
there may have been a bias in the selection of patients for the different angiographic techniques
cannot be excluded, the poor results with intravenous angiography are in marked contrast to
the majority of previous studies comparing the accuracy of measurement of stenosis using
intravenous angiography with arterial angiography.18"22 However, all of these studies excluded
intravenous angiograms which were flawed by inadequate vessel definition, movement
artifact, or vessel overlap. In other words, the investigations in which arterial angiography
would have been superior were specifically excluded. One study in which no investigations
were excluded reported inadequate visualisation of the carotid stenosis in 74% of cases.23
The poor inter-observer agreement of the measurement of stenosis on intravenous angiograms
casts doubt on the usefulness of intravenous angiography in selecting patients for carotid
endarterectomy and its use for the validation of non-invasive methods of imaging.
As in previous studies,24"26 the reproducibility of assessment of plaque surface morphology
was only moderate (kappa = 0.4-0.6), and did not vary with angiographic technique. Despite
this lack of reproducibility, angiographic plaque surface morphology has been shown to be a
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powerful independent risk factor for stroke on medical treatment in both ECST (Chapter 8) and
NASCET.27 The assessment of plaque surface morphology by non-invasive methods of
imaging must therefore be validated against angiography. The tendency for irregularity to be
identified more frequently on selective injection angiograms than on aortic arch injection or
intravenous angiograms is difficult to interpret in the absence of a gold standard. The
difference may be due to chance variation in the characteristics of the stenoses imaged or the
possibility that ulceration might be more easily visible on lateral views of the bifurcation.
In summary, there are no major differences in the reproducibility of either the measurement of
carotid stenosis or the assessment of plaque surface morphology between selective injection
and arch injection arterial angiograms. Reproducibility of measurement of stenosis was less
good on intravenous angiograms. Selective injection angiography produced more measurable
lateral views of the bifurcation than arch injection angiography and might have improved the
visualisation of plaque surface irregularity. Reproducibility of measurement of stenosis was
unrelated to the method of image acquisition. Angiograms in which the quality of visualisation
of the stenosis was good were associated with more reproducible measurement of the degree of
stenosis and a greater frequency of plaque surface ulceration than angiograms with adequate or
poor visualisation; not surprisingly, bad images cannot be measured accurately. Non-invasive
methods of imaging of the carotid bifurcation would be best validated against intra-arterial
rather than intravenous angiograms, but the differences between arch and selective injection
intra-arterial angiograms are unlikely to be ofmajor importance.
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The risk of stroke on medical treatment
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Chapter 8
The relationship between the risk of ipsilateral ischaemic stroke on medical
treatment and severity of carotid stenosis and plaque surface morphology:










Background: Carotid territory ischaemic stroke is associated with significant atherosclerotic
narrowing at the origin of the ipsilateral internal carotid artery in 20-30% of cases. The risk of
stroke increases with the degree of stenosis, and is reduced following endarterectomy, but the
mechanism by which carotid atheroma causes stroke is still unclear
Aims: To determine the relationship between plaque surface morphology, severity of carotid
stenosis and the risk of ipsilateral ischaemic stroke on medical treatment.
Methods: Severity of carotid stenosis and plaque surface morphology were assessed on the
angiographic views of the recently symptomatic carotid stenosis in 3007 ECST patients. The
findings were related to baseline clinical characteristics, the pathological characteristics of
plaques which were subsequently examined at endarterectomy, and the risks of carotid territory
ipsilateral ischaemic stroke on follow-up.
Results: The early risk of ipsilateral ischaemic stroke on medical treatment is closely related to
the degree of carotid stenosis. However, the risk of stroke falls rapidly with time and is no longer
related to the degree of stenosis two years after presentation. Angiographic plaque surface
irregularity and plaque surface thrombus at endarterectomy are common and increase in
frequency as the degree of stenosis increases (both P<0.0001). Angiographic plaque surface
irregularity is associated with plaque surface thrombus formation after correction for stenosis
(hazard ratio = 1.32, 95% CI=T.16-1.44, P=0.0006), and is an independent predictor of ipsilateral
ischaemic stroke on medical treatment (hazard ratio = 1.80, 1.14-2.83, P=0.01), but not of the
"background" stroke risk following endarterectomy.
Conclusions: Angiographic plaque irregularity is associated with surface thrombus formation,
and an increased risk of ipsilateral ischaemic stroke on medical treatment at all degrees of
stenosis. The increase in stroke risk with severity of stenosis may at least partly be accounted
for by the parallel increase in plaque surface irregularity and thrombus formation. These
observations support the hypothesis that thromboembolism is an important pathological
mechanism of ischaemic stroke in patients with recently symptomatic carotid stenosis.
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8.2 Introduction
Cerebral infarction in the territory of the carotid arteries accounts for most strokes in Western
countries.1'2 Significant atherosclerotic narrowing of the origin of the internal carotid artery
ipsilateral to the infarct is found in 20-30% of those who are investigated,3'5 compared with 5-
10% of the age-matched general population.6'7 That carotid atheroma may cause stroke was
suggested at the beginning of the century,8 and was proven by the observation that
endarterectomy of severe atherothrombotic stenosis reduces the risks of both asymptomatic
cerebral microemboli,9 and ipsilateral carotid territory ischaemic stroke.10'11 However, although
the risk of stroke increases with the severity of stenosis,10'12 the mechanism by which carotid
atherosclerosis causes stroke is still controversial.1"1 Cerebral infarction may result from the
reduction in cerebral perfusion pressure which occurs distal to a tight carotid stenosis or
occlusion.14"17 However, analogy with coronary atherosclerosis would suggest that plaque
instability, rupture, local thrombus formation and distal embolisation may also be important.
Stable angina is associated with uncomplicated plaques with a smooth fibrous surface and little
adherent thrombus, whereas unstable angina and myocardial infarction are almost invariably
associated with an irregular, fissured, or ruptured plaque with local thrombus formation.18'19
That ischaemic stroke may have a similar pathogenesis is suggested by the observation of
embolic material in the retinal circulation of patients with transient ischaemic attacks,20'21 the
high frequency of cerebral microemboli distal to symptomatic carotid stenosis,22,23 and the fall in
frequency of microemboli and plaque surface thrombus with time after a symptomatic ischaemic
event.9'24'25
A better understanding of the pathogenesis of ischaemic stroke associated with symptomatic
carotid stenosis would influence treatment strategies and help identify patients at particularly
high risk of stroke. Chapter 9 examines the relationship between blood pressure and
haemodynamic compromise due to carotid stenosis and the risk of ischaemic stroke on medical
treatment. This chapter aims to determine the relationship between plaque surface morphology,
severity of carotid stenosis and the risk of cerebral infarction. The angiographic characteristics of
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3007 recently symptomatic carotid plaques, 1671 of which were subsequently examined at
endarterectomy, were studied in patients randomised in the ECST. The reproducibility of
assessment of angiographic plaque morphology was determined, and plaque surface irregularity
was related to baseline clinical characteristics and to the macroscopic appearance of the plaque at
endarterectomy. Baseline severity of carotid stenosis and angiographic plaque surface
morphology were related to the subsequent risk of ischaemic stroke on medical treatment, and the
"background" risk of stroke following carotid endarterectomy.
8.3 Methods
The present study was confined to the 3007 (99.4%) of the 3024 ECST patients in whom a
randomisation angiogram was available in the trial office. In the majority of cases, only one
carotid artery was symptomatic, but in the 197 patients who had had ischaemic symptoms in the
territories of both carotid arteries, the stenosis which was most recently symptomatic was studied.
The degree of stenosis at the origin of both internal carotid arteries was measured on the
angiogram by two independent observers using the ECST method (PMR and CPW).
Plaque surface morphology was assessed by one observer (PMR). Surface morphology was
classified as smooth or irregular (figure 8.1). This was a subjective judgement, and was not
based on any standardised criteria. However, this categorisation has been shown by others to be
reproducible and to be predictive of ischaemic stroke distal to severe carotid stenosis.26'27 As
detailed in Chapter 7, plaque surface morphology was assessed by a second independent observer
(RG) on 1001 angiograms in order to assess inter-observer reproducibility. Each observer re¬
assessed a random sample of 50 angiograms at least one month later in order to calculate intra-
observer reproducibility. All assessors were blind to the clinical details and to the assessments of
the others.
At carotid endarterectomy the surgeon was asked to record whether or not the surface of the
plaque was ulcerated, and whether or not there was any adherent thrombus. These assessments
were not based on any standardised criteria and the surgeon was not blind to the pre-
176
randomisation angiogram. Follow-up was performed at a hospital clinic by the randomising
neurologist at 4 and 12 months after randomisation, and annually thereafter. For the purpose of
this study, the analysis of the risk of ischaemic stroke is restricted to first strokes lasting longer
than seven days i.e. "major" ischaemic strokes . Where no CT brain scan was available or where
the scan was performed more than 30 days after the stroke, the stroke was categorised as
ischaemic. Further definitions of outcome events are given in Chapter 2.
Statistical analysis: All analyses of the risk of ischaemic stroke ipsilateral to the symptomatic
carotid artery were performed using Kaplan Meier survival analysis and censoring for non-stroke
death. Survival analyses, multiple logistic regression analyses, and Cox's proportional hazards
modelling were performed using SPSS for Windows version 7.0.
8.4 Results
Of the 3007 patients studied, 1268 received medical treatment alone and 1739 patients were
randomised to surgery and underwent carotid endarterectomy. For the purposes of this study, 60
patients who were randomised to surgery but not operated were included in the medical treatment
group. This might, in theory, have introduced a small bias into comparisons of stroke risk, but
exclusion of these cases did not alter our findings. The median time from last ischaemic
symptoms referable to the symptomatic artery and randomisation was 47 days (interquartile
range = 21-91 days). Mean follow-up was 6.4 years (range = 1-13). In patients randomised to
surgery, the median time to endarterectomy was 14 days (interquartile range = 6-30). Patient
characteristics, the trial results and the morbidity and mortality of surgery are reported elsewhere
in this thesis.
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Carotid stenosis and stroke risk
The Kaplan Meier risks of carotid territory ischaemic stroke ipsilateral to the symptomatic
carotid artery on medical treatment alone were 7.9% (95% CI 6.4-9.4) at two years and 12.4%
(10.4-14.4) at five years. The same risks in patients who underwent carotid endarterectomy,
excluding strokes occurring within 30 days of the operation (operative strokes), were 2.3% (1.6-
3.0) and 4.2% (3.1-5.3) respectively.
The risk of carotid territory ischaemic stroke in the no-surgery group was closely related to the
degree of carotid stenosis for the first two years after trial entry (figure 8.2). During the first two
years the risk increased sharply with the degree of stenosis, whereas the "background" stroke
risk following endarterectomy in the surgery group (excluding operative strokes) was unrelated to
the degree of stenosis. However, the risk of ipsilateral carotid territory ischaemic stroke on
medical treatment fell rapidly with time from randomisation (figure 8.3), whereas the
"background" risk of stroke following endarterectomy, and the risks of acute myocardial
infarction and non-stroke vascular death, remained relatively constant (figure 8.4). By three
years after randomisation the risk of carotid territory ischaemic stroke in the no-surgery group
was very low, and did not appear to be related to the baseline measurement of carotid stenosis.
However, because the majority of strokes in the no-surgery group occurred within the first two
years after randomisation, the degree of stenosis of the symptomatic artery was highly predictive
of the overall risk of ipsilateral carotid territory ischaemic stroke in the no-surgery group after
correction for age, sex and the other baseline clinical and angiographic characteristics listed in
table 8.1.
Plaque surface morphology
Reproducibility: Two independent observers agreed on the categorisation of 1001 consecutive
stenoses as smooth or irregular in 81% of cases (Kappa = 0.56, 95% CI=0.53-0.59). Intra-
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observer agreement on a random sample of 50 angiograms was good: Observer 1 - kappa = 0.73
(0.3 - 0.9); Observer B - kappa = 0.65 (0.3-0.8).
Table 8.1. The predictive value of the degree of symptomatic carotid stenosis and the surface morphology
of the stenosis for first carotid territory ischaemic stroke ipsilateral to the symptomatic stenosis. The terms
are derived from a Cox proportional hazards model which included all the baseline clinical and
angiographic variables listed at the foot of the table.
Wald statistic' P Hazard Ratio (95% CI)
Patients randomised to medical treatment only
Plaque surface irregularity 6.5 .01 1.80 (1.14 -2.83)
Degree of carotid stenosis:2
Cubic term 28.9 0.0000 1.34
(Square term 28.4 0.0000 1.30)
(Linear term 26.4 0.0000 1.25)
Patients randomised to surgery
Plaque surface irregularity 2.27 0.13 1.39 (0.91 -2.12)
Degree of carotid stenosis (linear term) 1.1 0.29 1.06 (0.95 - 1.17)
Additional variables included in model: age, sex, cerebral events vs ocular events, residual neurological
signs after seven days, diabetes, any ischaemic event within last two months, number of events within last
three months, previous myocardial infarction, systolic blood pressure, diastolic blood pressure, peripheral
vascular disease, angina without previous myocardial infarction, ECG signs of left ventricular hypertrophy,
cerebral infarction on symptomatic side on CT brain scan, occlusion of the contralateral internal carotid
artery and post-stenotic collapse of the internal carotid artery
'
Degrees of freedom for all variables =1
2 Cubic term used in the model shown. Parameters given for squared and linear terms are those obtained
when the term was substituted for the cubic term. For the purpose of illustration the hazard ratios and
confidence intervals given in the table refer to the increase in risk for 80% stenosis vs 70% stenosis.
Clinical characteristics: A total of 1897 (63.1%) symptomatic stenoses had surface irregularity
visible on the angiogram. There were small, but statistically significant, differences in mean age
and mean cholesterol concentration between patients with smooth and irregular plaques, but no
difference in sex, blood pressure, or the prevalences of diabetes or smoking. Patients with
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irregular plaques were more likely than those with smooth plaques to have had a previous
myocardial infarction, but not a history of angina (table 8.2). There was a small excess of patients
with irregular plaques taking aspirin at baseline, but there was no difference during follow-up in
the ECST.
Table 8.2. Clinical characteristics at randomisation of patients with irregular carotid plaques vs smooth
plaques on angiograms of the 3007 symptomatic carotid arteries.
Plaque surface morphology
Irregular Smooth P
Cases 1897 (63%) 1110(37%)
Male sex 1383 (73%) 778 (70%) ns
Mean (sd) age (years) 62.9 (8.0) 61.6(8.4) <0.001
Mean (sd) ICA stenosis (%) 61.8(19.3) 52.7(21.9) <0.0001
Mean (sd) systolic BP (mmHg) 150.9 (23.6) 149.6 (22.5) ns
Mean (sd) diastolic BP (mmHg) 86.2(11.6) 85.8(12.4) ns
Mean (sd) cholesterol (mmol/L)1 6.4 (1.4) 6.3 (1.4) 0.007
Diabetes 226 (12%) 123 (11%) ns
Current cigarette smoking2 877 (46%) 522 (47%) ns
Previous anginaJ 217(11%) 121 (11%) ns
Previous myocardial infarction 251 (13%) 111 (10%) 0.005
Medication:
Aspirin 1107 (58%) 586 (53%) 0.003
Other antiplatelet 189(10%) 105 (10%) ns
Warfarin 133 (7%) 87 (8%) ns
Lipid lowering drug 55 (3%) 45 (4%) ns
1
data available in 2631 (88%) cases.
2
data available in 2688 (89%) cases
3
Angina without previous myocardial infarction
Pathological correlation: Data on the macroscopic appearance of the carotid plaque from the
symptomatic carotid artery at endarterectomy were available in 1671 (96.1%) of the 1739 patients
randomised to surgery. Macroscopic ulceration was reported in 1132 (68%) cases and thrombus
adherent to the plaque surface was reported in 493 (30%) cases. Macroscopic ulceration was
about twice as frequent in those cases where the plaque surface morphology was classified as
irregular at angiography compared to those classified as smooth (779/1066 vs 353/605, odds
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ratio = 1.94, 95% CI = 1.57 - 2.39, PO.OOOl). Surface thrombus was also more frequent in those
cases where the plaque surface morphology was classified as irregular at angiography (345/1066
vs 148/605, odds ratio = 1.74, 95% CI = 1.39 - 2.17, PO.OOOl). Plaque ulceration and
macroscopic plaque surface thrombus formation visible at endarterectomy were closely related
[449/1 178 (38%) vs 44/561 (7.8%), OR=7.24, 95% CI=5.2-10.1, PO.OOOl].
Relationship with severity of stenosis: Both the proportion of stenoses with surface irregularity
at angiography (X2 for trend = 123, PO.OOOl) and the proportion reported to have adherent
surface thrombus at operation (X2 for trend = 57, PO.OOOl) increased with the degree of stenosis
of the symptomatic artery (figure 8.5). However, angiographic irregularity remained a significant
predictor of surface thrombus formation after correction for confounding by the degree of
stenosis of the symptomatic artery in a multiple logistic regression analysis (hazard ratio = 1.32 ,
95% CI = 1.16-1.44, P=0.0006).
Risk of stroke: In the no-surgery group, the risk of ischaemic stroke in the territory of arteries
with stenoses which appeared irregular at angiography was greater than that distal to smooth
stenoses (fig 8.6). This difference remained after correction for the degree of stenosis of the
symptomatic artery, and the other baseline clinical and angiographic characteristics listed in table
8.1, using a Cox proportional hazards model (risk ratio = 1.80, 95% CI = 1.14- 2.83, P=0.01).
By contrast, in patients treated surgically, angiographic plaque surface irregularity was unrelated
to the risk of ipsilateral carotid territory ischaemic stroke on follow-up (table 8.1). In particular
there was no association with the background risk of ipsilateral ischaemic strokes occurring
more than 30 days after surgery (risk ratio = 1.04, 0.82- 1.30, P=0.77).
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8.5 Discussion
Since many patients with carotid stenosis now routinely undergo endarterectomy, the natural
history of carotid atherosclerosis is no longer amenable to study. Previous studies of the
angiographic appearance of "symptomatic" carotid atherosclerosis have been relatively small and
have produced contradictory results.3"5'26"31 This is the largest cohort of patients with carotid
stenosis imaged and measured by angiography ever reported. Moreover, carotid endarterectomy
was allocated at random, and the surgery and no-surgery groups were therefore likely to be identi¬
cal in all respects other than initial surgical treatment. It was possible, therefore, to compare the
association of severity of carotid stenosis and plaque surface morphology with the risk of
ipsilateral ischaemic stroke in patients on medical treatment alone with that following
endarterectomy and draw conclusions about causality without bias or confounding. The inclusion
of the 60 patients randomised to surgery who were not operated in the no-surgery group did not
appear to compromise this.
Carotid stenosis and stroke risk
The reproducibility of the measurement of carotid stenosis using the ECST method and its
equivalence with other methods were reported in Section 2. In order to reduce imprecision in
measurement of stenosis in this study, we used the mean of two measurements by independent
observers. The two year risk of carotid territory ischaemic stroke increased sharply with the
degree of stenosis (fig 8.2). The risk of stroke in patients with over 80% stenosis was nearly ten
times higher than the risk in patients with less than 40% stenosis. However, stroke risk fell very
rapidly with time. By three years, the risk was low and was no longer clearly related to the initial
measurement of stenosis (fig 8.3). Thus, in patients presenting with TIA or non-disabling
ischaemic stroke, the majority of carotid territory ischaemic strokes attributable to symptomatic
carotid stenoses occur in the first two years after the occurrence of symptoms.
In order to estimate the proportion of strokes which occurred as a direct consequence of the
stenosis, the stroke risk in patients on medical treatment alone was compared with the
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"background" risk of stroke following carotid endarterectomy (excluding strokes which occurred
within 30 days of endarterectomy) i.e. with the risk attributable to strokes not directly related to
carotid disease, such as lacunar and cardioembolic strokes. Although it is possible that carotid
stenosis may still have an indirect role in the pathogenesis of such strokes, and that the observed
"background" risk of stroke in the surgery group might therefore be an underestimate, a number
of useful conclusions can still be drawn. Firstly, in the short term at least, symptomatic stenoses
of less than 50% cause few strokes. Secondly, accepting the possibility of some underestimation
of the "background" stroke risk following surgery, the number of ischaemic strokes occurring
during the first two years of follow- up after endarterectomy for more severe stenoses was still re¬
markably small. Carotid atheroma must, therefore, play an important part in the pathogenesis of
the vast majority of ischaemic strokes on medical treatment occurring distal to a recently symp¬
tomatic carotid stenosis ofmore than about 50%.
Plaque characteristics and stroke risk
Although assessment of plaque surface morphology on angiograms is subjective, previous studies
have not determined its reproducibility.3"5'26"31 Since there is no evidence that frankly ulcerated
plaques are any more likely to lead to thrombus formation than irregular plaques, the
angiographic appearance of stenoses was classified as simply smooth or irregular. The inter-
observer reliability was moderate and the intra-observer reliability was good. Moreover, the
assessment appeared to have pathological validity. Plaques classified as irregular on the
angiogram were significantly more likely than smooth plaques to have macroscopic surface
ulceration and thrombus formation at operation. Operative assessment of plaques was not blind to
the angiogram, but these results do accord with previous studies.26"31
Plaque surface irregularity visible at angiography has been shown to be associated with an
increased risk of ischaemic stroke in patients with 70-99% symptomatic stenosis measured using
the NASCET method.27 The ECST data show that the association between surface irregularity
and an increased risk of stroke holds for all degrees of stenosis, and that the effect is independent
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of other clinical and angiographic factors. The data also show that plaque surface morphology
does not predict "background" stroke risk following carotid endarterectomy, indicating that the
association with ischaemic stroke in the no-surgery group was likely to be causal. Indeed, given
that assessment of surface irregularity on angiograms is relatively crude, the true association
between plaque surface morphology and ischaemic stroke risk may well be much stronger. If so,
the close association between the prevalence of surface irregularity and the degree of stenosis,
would tend to result in an overestimation of the importance of stenosis, which can be measured
more accurately, in any analyses predicting the risk of stroke on medical treatment.
The analyses of the macroscopic appearance of endarterectomy specimens suggest that the effect
of plaque irregularity on stroke risk may be mediated by surface thrombus formation, presumably
resulting in local thrombotic occlusion or distal embolism. This is supported by the observation
that cerebral microemboli are more frequent distal to carotid plaques which are subsequently
found to have surface thrombus at endarterectomy.32 Moreover, the presence of thrombus at
endarterectomy and the number of cerebral emboli detected by transcranial Doppler scanning fall
with time from last clinical symptoms.9'24'25 Temporary plaque instability and thrombus
formation would therefore account for the rapid fall in risk of carotid territory ischaemic stroke
with time from trial entry in the no-surgery patients. The absence of a similar trend in the risk of
acute myocardial infarction or non-stroke vascular death is consistent with the high early stroke
risk being due to local rather than systemic factors.
Conclusions
The analyses reported in this chapter have shown that the vast majority of ischaemic strokes in
the territory of a recently symptomatic severe carotid stenosis occur as a consequence of the
stenosis. In other words, the carotid plaque is intimately involved in the pathogenesis of
ischaemic stroke. Angiographic plaque surface morphology, however, was closely related to the
risk of ipsilateral ischaemic stroke on medical treatment. The association was independent of the
degree of stenosis and was abolished by endarterectomy. It can be concluded that, in common
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with the pathogenesis of acute coronary syndromes,18'19 local thrombus formation due to an
unstable carotid atherosclerotic plaque is likely to be an important mechanism of ischaemic
stroke in the territory of a recently symptomatic carotid artery. The increase in stroke risk with
the degree of stenosis is, at least partly, accounted for by the parallel increase in plaque surface
irregularity and thrombus formation.
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8.7 Legends to figures
Figure 8.1. Examples of two angiographic views of the carotid bifurcation which were classified
as irregular (figure A) and two views which were classified as smooth (figure B).
Figure 8.2. The two year Kaplan Meier estimates of risk of ipsilateral carotid territoiy ischaemic
stroke by degree of stenosis of the symptomatic carotid artery in the no-surgeiy group and the
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"background" risk in the surgery group (excluding strokes occurring within 30 days of
endarterectomy).
Figure 8.3. The annual risk of ipsilateral carotid territory ischaemic stroke in the no-surgery
group according to the degree of symptomatic stenosis for the first six years after trial entry.
Figure 8.4 The annual risk of "background" ipsilateral carotid territory ischaemic stroke
following endarterectomy in the surgery group (excluding strokes occurring within 30 days of
endarterectomy), and the annual risks of non-stroke vascular death (NSVD) and acute myocardial
infarction (MI) in both treatment groups combined.
Figure 8.5. The prevalence of plaque surface irregularity on angiograms of 3007 symptomatic
carotid stenoses and the prevalence of macroscopic thrombus adherent to the plaque surface on
1671 symptomatic carotid stenoses at endarterectomy by degree of stenosis.
Figure 8.6. The three year Kaplan Meier risk of ischaemic stroke in the territory of the sympto¬
matic carotid artery according to the degree of carotid stenosis and the angiographic appearance
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Chapter 9
The relationship between the risk of ipsiiateral ischaemic stroke on medical
treatment, blood pressure and risk factors for reduced cerebral perfusion:











Background: The risk of carotid territory ischaemic stroke is increased in patients with
atheromatous narrowing of the internal carotid artery. Some patients with severe stenosis or
occlusion have reduced perfusion in the ipsilateral cerebral hemisphere. However, it is unclear to
what extent such haemodynamic insufficiency is associated with an increased risk of ischaemic
stroke.
Aims: To determine the effect of clinical and angiographic characteristics likely to be associated
with reduced cerebral perfusion on the risk of ipsilateral ischaemic stroke on medical treatment
in patients with recently symptomatic carotid stenosis.
Methods: Clinical and angiographic characteristics of 3007 patients in the European Carotid
Surgery Trial were studied. The risk of carotid territory ischaemic stroke on medical treatment
was analysed in relation to blood pressure at randomisation and during follow-up, and in relation
to several angiographic indices which are likely to be associated with reduced cerebral perfusion:
length of the ipsilateral carotid stenosis, post-stenotic collapse of the ipsilateral internal carotid
artery, stenosis of the ipsilateral external carotid artery, and stenosis of the contralateral carotid
artery.
Results: The risk of ipsilateral ischaemic stroke on medical treatment was not increased in
association with any of the clinical or angiographic characteristics likely to be associated with
haemodynamic insufficiency. Rather, post-stenotic collapse of the ipsilateral internal carotid
artery was associated with a significantly reduced risk of ischaemic stroke. The relationship
between both baseline and usual blood pressure and the risk of ipsilateral ischaemic stroke on
medical treatment was flat in patients with 0-49% carotid stenosis and patients with 50-99%
stenosis.
Conclusions-. There was no evidence that characteristics likely to be associated with reduced
cerebral perfusion were associated with an increased risk of ipsilateral ischaemic stroke in
patients with recently symptomatic carotid stenosis. However, the positive correlation usually
seen between blood pressure and stroke risk was absent.
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9.2 Introduction
Stenosis of the origin of the internal carotid artery is a common cause of carotid territory
ischaemic stroke.1'2 The risk of stroke increases with the severity of carotid stenosis, and is
reduced considerably after carotid endarterectomy.3'4 However, the mechanism by which carotid
atherosclerosis causes stroke is still controversial.5 There is increasing evidence to suggest that
plaque surface irregularity, local thrombus formation and distal embolism are important,6"12 and
this is supported by data presented in chapter 8. Angiographic plaque surface irregularity is an
important independent predictor of the risk of carotid territory ipsilateral ischaemic stroke on
medical treatment at all degrees of stenosis, and the frequency of plaque irregularity and
macroscopic surface thrombus formation increases with increasing severity of stenosis. However,
although this might account, at least in part, for the increase in the risk of ischaemic stroke with
degree of stenosis, haemodynamic compromise might also be important.13"27
There is a wealth of evidence that a proportion of patients who have a recently symptomatic
severe carotid stenosis or occlusion have diminished perfusion of the ipsilateral cerebral
hemisphere and absence of increased perfusion in response to raised levels of carbon dioxide.13"27
This has been shown using transcranial Doppler ultrasound,13"16 SPECT,17"19 133Xe radionuclide
CT,20"22 dynamic susceptibility contrast mri,23'24 and pet.18'25"27 ft has also been shown, using
magnetic resonance spectroscopy, that such patients have metabolic changes in the affected
hemisphere which are consistent with chronic ischaemia in the absence of any evidence of
cerebral infarction.28"31 Both the perfusion deficit and the metabolic changes are reversed
00 0^ 00 0/1
follow ing carotid endarterectomy and extracranial-intracranial bypass grafting. ' '
It is possible, therefore, that a proportion of ischaemic strokes which occur distal to a severe
carotid stenosis might occur as a direct result of reduced perfusion, or that reduced perfusion
might decrease the capacity of the cerebral circulation to resist infarction in the presence of
cerebral emboli. However, despite the evidence of cerebral hypoperfusion and ischaemic
metabolic changes distal to severe carotid stenosis, there is relatively little evidence to suggest
that these changes are useful in identifying patients at particularly high risk of stroke. Although
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one recent PET study showed that reduced cerebral perfusion is associated with an increased risk
of stroke on medical treatment in patients with unilateral carotid occlusion,27 no such link has
yet been demonstrated in patients with non-occlusive carotid disease. Moreover, even in patients
with symptomatic carotid occlusion intracranial-extracranial bypass grafting does not reduce the
risk of stroke despite the fact that it improves cerebral pefusion.35
A better understanding of the contribution of haemodynamic insufficiency to the pathogenesis of
ischaemic stroke distal to significant carotid stenosis would have important clinical implications.
For example, although treatment of hypertension is highly beneficial in the primary prevention of
stroke,36 and may be of overall benefit in patients with symptomatic cerebrovascular disease,37
there are no good data on the effect of blood pressure reduction in the subgroup of patients with
significant carotid stenosis. If haemodynamic insufficiency is an important factor in the
pathogenesis of ischaemic stroke distal to severe carotid stenosis, then treatment of hypertension
might increase this risk in certain patients. The analyses presented in this chapter are intended to
help determine whether or not haemodynamic compromise is likely to be a major factor in the
pathogenesis of stroke in patients with recently symptomatic carotid stenosis. The risk of carotid
territory ischaemic stroke on medical treatment was analysed in relation to blood pressure at
randomisation and during follow-up, and in relation to several angiographic indices which are
likely to be associated with reduced cerebral perfusion: length of the ipsilateral carotid stenosis;
post-stenotic collapse of the ipsilateral internal carotid artery, stenosis of the ipsilateral external
carotid artery, and stenosis of the contralateral carotid artery.
9.3 Methods
The carotid angiograms and clinical characteristics of patients randomised in the ECST were
studied. Carotid angiograms were performed on all patients prior to randomisation, and were
sent to the trial centre. Details of the angiographic techniques used were given in Chapter 7. The
present study was confined to the 3007 patients in whom a randomisation angiogram was
199
available in the trial centre. The following assessments were made on all angiograms for the
purpose of this study:
1) The degree of carotid stenosis: The degree of stenosis of both internal carotid arteries was
measured by two independent observers (PMR and CPW) using the ECST method. Details of the
reproducibility of this measurement and the equivalence with other methods were given in
Section 2. The mean of the two measurements was used in all analyses.
2) Poststenotic collapse of the internal carotid artery. In some patients with a tight carotid
stenosis, the normal internal carotid artery distal to the stenosis is narrowed or collapsed on the
angiogram.38"40 This is generally assumed to indicate a particularly low post-stenotic
intraluminal pressure. Such an appearance was the main characteristic used to define "near
occlusions" in the NASCET trial.40 In the present study, post-stenotic collapse was defined
using the ratio of the diameter of a representative section of the distal internal carotid artery
(ICA) to that of a disease free portion of the common carotid artery (CCA). As detailed in
Chapter 5, the mean ratio in the ECST patients remained constant up to 69% stenosis, and then
fell significantly as stenosis increased further. In keeping with this, it has been shown that
arterial stenoses of less than 50% do not usually cause any reduction in flow or pressure distal to
the lesion.I3,15'17'19'38'41 For the purpose of this study, patients with 0-49% stenosis were used in
order to define the normal range of the ICA:CCA ratio. Post-stenotic collapse was defined as an
ICA:CCA ratio of more than two standard deviations below the overall mean ratio in patients
with 0-49% stenosis.
3) Stenosis or occlusion ofthe ipsilateral external carotid artery: The degree of stenosis of the
external carotid artery ipsilateral to the symptomatic carotid stenosis was measured using a
method which was analogous to the ECST method of measuring the degree of stenosis of the
internal carotid artery i.e. the denominator was the estimated normal lumen diameter at the site
of maximum stenosis.
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4) Stenosis or occlusion of the contralateral carotid artery: The degree of stenosis of the
internal carotid artery contralateral to the symptomatic stenosis was measured using the ECST
method.
5) Length of the haemodynamically significant portion of the stenosis: The length of an arterial
stenosis has been shown to have a measurable haemodynamic effect.38'41'42 The effect is greatest
when the degree of stenosis of the vessel is severe.41 For the purpose of this study, the
haemodynamically significant portion of the stenosis was defined as the length of that portion of
the stenosis where the lumen was narrowed by more than 50%. This was recorded as a ratio with
the diameter of a disease-free portion of the CCA.
6) Plaque surface morphology. Carotid plaque surface morphology was classified as smooth or
irregular as detailed in Chapter 8
Blood pressure
Single measurements of systolic blood pressure (SBP) and diastolic blood pressure (DBP) were
recorded at the pre-randomisation clinic visit. Mean arterial pressure was calculated in the
standard way {DBP + (SBP - DBP)/3}. Blood pressure was measured again at each follow-up
visit (four months after randomisation and annually thereafter). Usual diastolic and systolic
blood pressures were calculated in patients randomised to no-surgery in order to correct partially
for the regression dilution bias that occurs when the risk of stroke is related to a single
measurement of blood pressure.43'44 Usual pressures were defined as the mean value derived
from all measurements taken at baseline and during the first two years follow-up (i.e. four
measurements in total). In patients who had a stroke on follow-up, measurements taken after the
stroke were not included.
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Outcome events: For the purpose of this study, the analysis of the risk of ischaemic stroke was
restricted to first strokes lasting longer than seven days i.e. "major" ischaemic strokes . Where no
CT brain scan was available or where the scan was performed more than 30 days after the stroke,
the stroke was categorised as ischaemic.
Statistical analysis: All actuarial risks of ischaemic stroke ipsilateral to the symptomatic
carotid artery were performed using Kaplan Meier survival analysis and censoring for non-stroke
death. Survival analyses, multiple logistic regression analyses, and Cox's proportional hazards
modelling were performed using SPSS for Windows version 7.0.
9.4 Results
Of the 3007 patients studied, 1268 received medical treatment alone and 1739 patients were
randomised to surgery and underwent carotid endarterectomy. For the purposes of this study, 60
patients who were randomised to surgery but not operated were included in the medical treatment
group. The median time from last ischaemic symptoms referable to the symptomatic artery and
randomisation was 47 days (interquartile range = 21-91 days). Mean follow-up was 6.4 years
(range = 1-13).
Poststenotic collapse ofthe internal carotid artery
Measurements of the ICA and CCA lumen diameters were made in 2901 (96.5%) cases. In the
1039 patients with less that 50% symptomatic stenosis, the lumen diameter of the internal carotid
artery distal to the symptomatic stenosis remained constant in comparison with the diameter of
the common carotid artery. The mean ratio was 0.61 (standard deviation = 0.08, 95% range =
0.42 - 0.87, median = 0.62). The lower limit of normal was therefore defined as an ICA/CCA
ratio of 0.42.
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The mean (SD) ICA/CCA ratio fell as the degree of stenosis exceeded 50% [50-59%, n=193,
0.61 (0.09); 60-69%, n=198, 0.60 (0.10); 70-79%, n=182, 0.59 (0.10); 80-89%, n=174, 0.56
(0.12); 90-99%, n=51, 0.44 (0.18)]. The ratio was below 0.42 in 149 (8%) of patients with
greater than 50% stenosis, and 102 (18%) of patients with 80-99% stenosis. The proportion of
cases with post-stenotic collapse is presented by decile of stenosis in figure 9.1.
The baseline clinical and imaging characteristics of patients with and without post-stenotic
collapse are given in table 9.1. An ICA/CCA ratio of less than 0.42 was associated with male
sex, a lower usual diastolic blood pressure, and the presence of infarction in the territory of the
symptomatic artery on the randomisation CT brain scan. These associations remained significant
after correction for confounding by the degree of carotid stenosis in a multiple regression
analysis. In contrast, the apparent association between post-stenotic collapse and presentation
with an ocular ischaemic event was no longer significant after correction for degree of carotid
stenosis. Presentation with ocular events was strongly correlated with the severity of stenosis.
Post-stenotic collapse was associated with a reduced risk of ipsilateral carotid territory ischaemic
stroke on medical treatment (figure 9.2). When the analysis was confined to patients with 80-99%
stenosis, the same trend was seen but it did not reach statistical significance; the crude stroke
risk in patients with post-stenotic collapse was 8% (4/47) compared with 18% (30/169) in
patients with no collapse (Fisher exact test, P = 0.09). The difference remained non-significant in
an actuarial analysis (log rank = 2.2, df = 1 , P = 0.12). However, post-stenotic collapse was a
significant predictor of a reduced risk of stroke in the medical group as a whole in a Cox
proportional hazards analysis taking into account all baseline clinical and imaging characteristics
including severity of stenosis: hazard ratio = 0.40, 95% CI = 0.17-0.94, P = 0.03 (see Chapter
17).
Patients with post-stenotic collapse of the internal carotid artery who were randomised to surgery
had a significantly lower risk of operative stroke within 30 days of endarterectomy: 2/110
(1.8%) versus 116/1642 (7.1%); Fisher exact test, P = 0.03; odds ratio = 0.24, 95% CI = 0.06 -
0.99.
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Table 9.1 Clinical and angiographic characteristics of patients with collapse of the post-stenotic internal
carotid artery compared those with no collapse.
Appearance of the internal carotid artery distal to the stenosis
Characteristic Collapsed Not collapsed P
Cases 174 2727
Mean (sd) age (years) 61.7 (8) 62.5 (8) 0.2
Male sex 148 (85%) 1947(71%) <0.0001
Diabetes 19 319 0.8
Angina 30 459 0.9
Previous myocardial infarction 15 331 0.8
Peripheral vascular disease 35 436 0.2
Residual neurological signs 56 792 0.4
Mean (sd) diastolic blood pressure (mmHg) 86.7 (12) 86.0 (12) 0.5
Mean (sd) systolic blood pressure (mmHg) 151.6(21) 150.3 (23) 0.5
Mean (sd) usual diastolic blood pressure (mmHg) 80.8 (20) 83.7 (17) 0.02
Mean (sd) usual systolic blood pressure (mmHg) 143.9 (37) 148.2 (32) 0.07
Events prior to randomisation:
Cerebral transient ischaemic attack 84 1340 0.9
Ocular ischaemic event 69 (40%) 668 (25%) <0.0001
Minor ischaemic stroke 38 600 0.9
Major non-disabling stroke 54 748 0.3
Event(s) within two months of randomisation 111 1601 0.2
Imaging prior to randomisation:
Cerebral infarction in the symptomatic
carotid territory on CT brain scan 59 (34%) 115(25%) 0.006
Median degree of symptomatic carotid stenosis 83% 55% 0.0001
Plaque surface irregularity on symptomatic side 122 1772 0.2
Median degree of contralateral carotid stenosis 29% 29% 0.4
Occlusion of the contralateral carotid artery 5 89 0.8
Stroke risk in patients with other angiographic riskfactorsfor reduced cerebralperfusion
There was no relationship between the risk of carotid territory ischaemic stroke on medical
treatment the other angiographic indices thought to be associated with reduced cerebral perfusion
i.e. length of the ipsilateral carotid stenosis; stenosis or occlusion of the ipsilateral external
carotid artery, and stenosis or occlusion of the contralateral carotid artery (table 9.2). The
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analysis in table 9.2 is corrected for the degree of ipsilateral carotid stenosis because the severity
of ipsilateral external carotid stenosis and the severity of contralateral carotid stenosis were both
related to the degree of symptomatic stenosis (figure 9.1).
Table 9.2. A Cox's proportional hazards model predicting first carotid territory ischaemic stroke
ipsilateral to the symptomatic stenosis in no-surgery patients correcting for age, sex and degree of
ipsilateral carotid stenosis.
Angiographic characteristics Hazard ratio (95% CI) Significance
Length of symptomatic stenosis 1 0.90 (0.74-1.08) ns
50-100% stenosis of ipsilateral external carotid artery 0.90 (0.50-1.61) ns
50-100% stenosis of contralateral internal carotid artery 1.11 (0.73-1.68) ns
1
as a ratio of the lumen diameter of a disease-free portion of the ipsilateral common carotid artery
Stroke risk and bloodpressure
There was no relationship between the degree of symptomatic carotid stenosis and baseline blood
pressure (figure 9.3). Table 9.3 shows the mean arterial blood pressure at baseline and the usual
mean arterial pressure on follow-up in patients randomised to medical treatment. There are no
significant differences between patients who suffered an ipsilateral ischaemic stroke on follow-up
and those patients who did not. There were also no differences in baseline or usual systolic or
diastolic pressures.
Neither baseline diastolic blood pressure nor baseline systolic blood pressure were significant
predictors of the risk of carotid territory ischaemic stroke distal to the symptomatic stenosis on
medical treatment in a Cox proportional hazards analysis taking into account all baseline clinical
and imaging characteristics (see Chapter 17): hazard ratio for baseline diastolic blood pressure
(per 10 mmHg) = 1.10, 95% CI = 0.8 - 1.3, P = 0.61; hazard ratio for baseline systolic blood
pressure (per 10 mmHg) = 1.05, 95% CI = 0.9 - 1.2, P = 0.82.
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Table 9.3. Mean arterial pressure at randomisation and averaged over subsequent follow-up visits in
patients randomised to medical treatment who suffered an ischaemic stroke in the territory of the
symptomatic artery during follow-up compared with those who did not. The data are stratified by the degree
of stenosis of the symptomatic artery. None of the differences reach statistical significance.
Ipsilateral ischaemic stroke on follow-up
Mean arterial pressure (mmHg) Yes No
0-99% stenosis
Cases 136 1098
Mean (SD) baseline pressure 108.0(12.1) 107.6 613.2)
Mean (SD) usual pressure 109.1 (9.2) 108.1 (9.9)
50-99% stenosis
Cases 103 636
Mean (SD) baseline pressure 107.9(12.7) 107.4 02.9)
Mean (SD) usual pressure 108.8 (8.9) 108.5 (9.8)
The risk of carotid territory ischaemic stroke distal to the symptomatic stenosis is stratified
according to blood pressure in tables 9.4 - 9.6. Patients are divided into those with 0-49%
symptomatic stenosis and those with 50-99% stenosis. Data are presented for baseline and usual
diastolic pressure (table 9.4), baseline and usual systolic pressure (table 9.5) and baseline and
usual mean arterial pressure (table 9.6). It was decided to categorise the blood pressures in these
tables into standard bands rather than into equal groups (e.g. quartiles) in order to facilitate
comparison with other studies. None of the analyses show a clear association between blood
pressure and stroke risk, and there are no clear differences in the nature of the relationships
between patients with 0-49% symptomatic stenosis and patients with 50-99% symptomatic
stenosis.
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Table 9.4. The five year actuarial risk of carotid territory ipsilateral ischaemic stroke on medical treatment
by baseline diastolic blood pressure and usual diastolic blood pressure in patients with 0-49% symptomatic
carotid stenosis and patients with 50-99% symptomatic carotid stenosis. For each comparison heterogeneity
of risk is tested using the log rank test.
Cases 5 yr risk of log rank test
stroke (95% CI) P
Symptomatic carotid stenosis = 0-49%
Baseline diastolic bloodpressure:
Usual diastolic bloodpressure:
Symptomatic carotid stenosis = 50-99%
Baseline diastolic bloodpressure:
Usual diastolic bloodpressure:
<80 61 3.5 (0-8) 0.75
80-89 165 6.8 (3-11)
90-99 142 9.0 (4 - 14)
>100 74 5.1 (0-10)
<80 84 7.1 (1-13) 0.81
80-89 231 5.2 (3-9)
90-99 101 9.3 (2-15)
>100 26 13.6 (0-25)
= 50-99
<80 105 14.1 (7-21) 0.89
80-89 297 15.4 (11-20)
90-99 256 14.4 (10-19)
>100 108 18.5 (11-27)
<80 146 11.3 (5-17) 0.63
80-89 390 16.0 (12-20)
90-99 191 16.6 (11-23)
>100 39 14.1 (2-25)
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Table 9.5. The five year actuarial risk of carotid territory ipsilateral ischaemic stroke on medical treatment
by baseline systolic blood pressure and usual systolic blood pressure in patients with 0-49% symptomatic
carotid stenosis and patients with 50-99% symptomatic carotid stenosis. For each comparison heterogeneity
of risk is tested using the log rank test.
Cases 5 yr risk of log rank test
stroke (95% CI) P
Symptomatic carotid stenosis = 0-49%
Baseline systolic bloodpressure:
<130 49 2.2 (0-7) 0.33
130-149 159 6.7 (3-11)
150-169 144 9.1 (4-14)
>170 90 7.5 (2-13)
Usual systolic bloodpressure:
<130 50 6.4 (0-13) 0.41
130-149 169 4.7 (1 - 10)
150-169 171 9.0 (4-13)
>170 52 6.0 (0 - 14)
Symptomatic carotid stenosis = 50-99%
Baseline systolic bloodpressure:
<130 65 18.8 (8-30) 0.58
130-149 291 14.7 (10-19)
150-169 248 14.4 (9-19)
>170 162 16.8 (11-23)
Usual systolic bloodpressure:
<130 54 29.0 (13-45) 0.15
130-149 289 14.1 (10-18)
150-169 307 16.0 (12-20)
>170 116 11.0 (5-17)
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Table 9.6. The five year actuarial risk of carotid territory ipsilateral ischaemic stroke on medical treatment
by mean arterial blood pressure at baseline and usual mean arterial pressure in patients with 0-49%
symptomatic carotid stenosis and patients with 50-99% symptomatic carotid stenosis. For each comparison
heterogeneity of risk is tested using the log rank test.
Cases 5 yr risk of log rank test
stroke (95% CI) P
Symptomatic carotid stenosis = 0-49%
Baseline mean arterial pressure:
Usual mean arterial pressure:
Symptomatic carotid stenosis = 50-99%
Baseline mean arterial pressure:
Usual mean arterial pressure:
<100 108 3.1 (0-7) 0.08
100-109 142 6.5 (2-11)
110-119 111 12.1 (5-19)
>120 81 5.0 (0-10)
<100 100 6.7 (2-11) 0.40
100-109 182 5.0 (2-8)
110-119 114 9.6 (3 - 15)
>120 46 7.4 (0-17)
= 50-99
<100 177 16.8 (11-27) 0.46
100-109 258 12.8 (8-17)
110-119 202 16.4 (10-24)
>120 129 18.0 (11-25)
<100 146 16.3 (9-23) 0.89
100-109 311 15.6 (11-20)
110-119 228 15.5 (10-21)
>120 81 10.6 (4-17)
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9.5 Discussion
The analyses presented above do not provide strong evidence for or against the potential
importance of haemodynamic compromise in the pathogenesis of ischaemic stroke distal to a
symptomatic carotid stenosis. The findings are somewhat conflicting. On the one hand, the
baseline angiographic characteristics which were thought likely to be associated with reduced
cerebral perfusion were not associated with an increased risk of stroke. Indeed, although
associated with an increased frequency of cerebral infarction on the baseline CT brain scan, post¬
stenotic collapse of the internal carotid artery was associated with a significantly reduced risk of
stroke on medical treatment. On the other hand, the positive correlation between blood pressure
and stroke risk, which is seen in the primary prevention setting43 and in the generality of patients
with TIA or minor ischaemic stroke,44 was not evident in patients with carotid stenosis. The
significance of each these observations is discussed below.
Stroke risk in patients with angiographic riskfactorsfor reduced cerebral perfusion
Blood flow through an artery begins to be compromised when linear stenosis exceeds 50%.13'15'17"
i9,38,4i p[owever? although patients with severe carotid stenosis often have reduced perfusion
reserve in the ipsilateral cerebral hemisphere, and greater than 50% stenosis is necessary for this
to occur, it is rarely sufficient on its own.13"27 The majority of patients with haemodynamic
insufficiency also have evidence of reduced collateral flow, usually with at least 50% stenosis of
the contralateral internal carotid artery and evidence of collateral flow through the external
carotid artery.20'25 Greater than 50% stenosis or occlusion of the ipsilateral external carotid artery
or the contralateral internal carotid artery would therefore be expected to exacerbate any
haemodynamic insufficiency by reducing collateral flow. However, these characteristics were
not associated with an increased risk of ipsilateral ischaemic stroke in the no-surgery group in
ECST patients with 50-99% symptomatic stenosis. Similarly, the length of an arterial stenosis
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has been shown to have a measurable haemodynamic effect.38'41'42 The effect is greatest when
the degree of stenosis of the vessel is greater than 50%.41 However, the length of the
haemodynamically significant portion of the symptomatic carotid stenosis was not associated
with the risk of stroke on medical treatment. These observations suggest that few patients with
significant symptomatic carotid stenosis have such severe reductions in cerebral perfusion that
they are at risk of developing cerebral infarction as a consequence of reduced flow.
The role of reduced cerebral perfusion in the pathogenesis of stroke distal to symptomatic carotid
stenosis is also brought into question by the significantly reduced risk of stroke on medical
treatment in patients with post-stenotic collapse of the internal carotid artery. Collapse of the
internal carotid artery distal to a tight stenosis presumably occurs as a consequence of very low
intraluminal pressure. It is likely, therefore, to be a good index of poor perfusion pressure in the
distal internal carotid artery and the middle cerebral artery. Any collateral circulation via the
circle of Willis or the ophthalmic circulation would be expected to increase the back pressure
down the internal carotid artery as well as the distal perfusion pressure. If reduced perfusion was
a major cause of ischaemic stroke in patients with severe carotid stenosis, it would be surprising
to find that post-stenotic collapse of the internal carotid artery was associated with a reduction in
risk of ipsilateral ischaemic stroke on medical treatment alone. These observations suggest that
although haemodynamic compromise is relatively common in patients with significant carotid
stenosis, and may have a permissive role in the development of symptomatic cerebral ischaemia,
it is not a major precipitant of ischaemic stroke. This accords with the finding that although
extracranial to intracranial arterial bypass surgery improves cerebral perfusion,33'34 it does not
prevent stroke.35 Moreover, since, on average, carotid stenosis, and consequently haemodynamic
compromise, mostly increases with time,45'46 the rapid fall in stroke risk on medical treatment
with time from presenting symptoms demonstrated in Chapter 8 (see fig 8.2) would be difficult
to explain if cerebral hypoperfusion was an important pathophysiological mechanism.
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Stroke risk and bloodpressure
Observational studies have demonstrated a close relationship between blood pressure and the risk
of stroke.43,44 Stroke risk increases by 2% for every ImmHg increase in usual diastolic blood
pressure. A meta-analysis of all available data36 showed that relatively small reductions in blood
pressure, of the order of 5-10mHg in systolic pressure, reduce the risk of stroke by approximately
50%. Roughly the same relationship appears to hold in patients who have already developed
symptoms of vascular disease.37,44 However, in contrast to primary prevention, there is relatively
little data on the efficacy of blood pressure lowering in the secondary prevention of stroke.3' If
cerebral hypoperfusion was an important pathophysiological mechanism of stroke, there would
be a danger that treatment of hypertension might be harmful in those patients with symptomatic
cerebrovascular ischaemia who have an haemodynamically significant carotid stenosis.
The positive correlation between blood pressure and stroke risk on medical treatment, which is
seen in the primary prevention setting43 and in the generality of patients with TIA or minor
ischaemic stroke,44 was not evident in ECST patients with carotid stenosis. This could be
interpreted as evidence that hypertension is not a major cause of stroke in patients with
significant carotid disease, and that treatment of hypertension might be unhelpful or even harmful
as far as the risk of ischaemic stroke is concerned. However, there are a number of provisos.
Firstly, the lack of a positive correlation between blood pressure and stroke risk may simply be
due to insufficient numbers of patients and outcome events. The analyses presented above have
relatively little power in patients with particularly high or particularly low blood pressure.
Secondly, there is no obvious difference in the relationship between blood pressure and stroke in
patients with 0-49% stenosis and those with 50-99% stenosis. If haemodynamic compromise was
responsible for the loss of the positive correlation then it would only be expected in patients with
50-99% stenosis. Thirdly, the analysis was confined to ipsilateral ischaemic stroke. The previous
large observational study in the secondary prevention setting looked at any ischaemic stroke on
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follow-up. It is possible that the relationship in this study would also have been flat if the analysis
had been confined to stroke in the territory of the previous symptoms. More data will be required
in order to solve this problem.
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9.7 Figures
Figure 9.1. The proportion of cases with post-stenotic collapse of the symptomatic internal
carotid artery, greater than 70% stenosis of the contralateral carotid artery, and greater than 50%
stenosis of the external carotid artery, by the degree of symptomatic carotid stenosis.
Figure 9.2 The five year actuarial risk of ipsilateral carotid territory ischaemic stroke by
degree of symptomatic carotid stenosis. Patients with collapse of the post-stenotic internal carotid
artery are grouped separately.
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Background: A proportion of patients with symptomatic carotid stenosis also have a significant
stenosis at or around the origin of the contralateral carotid artery. In the majority of cases, this
stenosis is asymptomatic. Although it is not routine practice to perform endarterectomy on the
asymptomatic side, it has often been suggested that the risk of stroke in the territory of the
contralateral asymptomatic stenosis may be greater than that in truly asymptomatic patients. This
chapter details the risk of stroke in the distribution of the asymptomatic carotid artery contralateral
to the symptomatic carotid stenosis in 2295 patients randomised in the ECST.
Results: During a mean follow-up of 4.5 years (analyses performed in 1995), there were 69 carotid
territory strokes, nine of which were fatal, giving three year Kaplan-Meier risks of stroke and fatal
stroke of 2.1% (95% CI, 1.5-2.8) and 0.3% (95% CI, 0.06-0.56) respectively. The risk in the 127
patients with severe (70-99%) carotid stenosis was 5.7% (95% CI, 1.5-9.8).
Conclusions: Given this low risk of stroke, it is unlikely that carotid endarterectomy on the
asymptomatic side would be of much benefit in absolute terms. There is no evidence that the risk
of stroke contralateral to a symptomatic stenosis is greater than that in truly asymptomatic patients.
10.2 Introduction
Certain patients with a recent carotid distribution transient ischaemic attack or non-disabling
ischaemic stroke, and a severe stenosis of the relevant carotid artery, benefit from carotid
endarterectomy.1'2 Although endarterectomy for asymptomatic carotid stenosis is also of some
benefit, the reduction in risk of stroke following surgery is much smaller in absolute terms.3"7 With
a prevalence of greater than 50% carotid stenosis in 5-10% of the general population over 65 years
of age,8'9 and in 20-30% of patients attending hospital with ischaemic heart disease or peripheral
vascular disease,10'11 and the availability of cheap, reliable and safe non-invasive screening
techniques, a policy of surgery for asymptomatic stenosis has major public health implications.
222
There is still a degree of uncertainty about the overall risk of stroke distal to an asymptomatic
carotid stenosis. The ACAS trial was relatively small and did not have the power to define the
overall risk of ipsilateral ischaemic stroke on medical treatment with great precision.4 Previous
natural history studies of the risk of stroke distal to an asymptomatic carotid stenosis have also
been relatively small and have not been able to define stroke risks with narrow confidence intervals
for different degrees of carotid stenosis.12'14"19 In the ACAS trial, the risk of stroke in the medical
group appeared to be approximately equal in patients with 60-79% stenosis and patients with 80-
99% stenosis.4 This could be due either to chance and small numbers or alternatively it might be
an artefact due to measurement of the degree of stenosis using carotid ultrasound rather than
arterial angiography in patients randomised to medical treatment in ACAS. However, further data
are clearly required in order to settle the issue. There are, therefore, still a number of important
outstanding issues relating to the natural history of asymptomatic carotid stenosis:
1) What is the overall risk stroke distal to an asymptomatic stenosis, and how does this risk vary
with degree ofstenosis?
2) What is the risk ofdisabling stroke?
3) Is the overall risk of stroke distal to an asymptomatic stenosis higher in patients with a
contralateral recently symptomatic stenosis?
4) What are the risk factors for ipsilateral ischaemic stroke distal to as asymptomatic stenosis
and can we identify a subgroup ofpatients with a high risk ofstroke?
The ECST patients who had only unilateral symptoms represent a cohort of patients with an
asymptomatic carotid artery imaged using arterial angiography. They were followed up regularly
by a neurologist, and all strokes and related disability were recorded. Although, the number of
patients with severe asymptomatic stenosis was relatively small, the ECST data still provide an
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opportunity to study the risk of stroke in the distribution of an asymptomatic carotid artery in
patients receiving standard medical therapy and to attempt to answer some of the questions listed
above.
10.3 Patients and methods
The analyses of stroke risk presented in the first part of this chapter are confined to the 2695
patients randomised in the ECST prior to January 1992, so that they are consistent with the ECST
paper published in the Lancet in 1995.20 Two hundred and five patients were excluded because of
a history of TIAs or strokes in the distribution of both carotid arteries. A further 15 patients,
randomised to surgery, who had undergone bilateral endarterectomy shortly after randomisation,
and 180 patients with an absent or inadequate angiographic view of the asymptomatic carotid
artery, were also excluded, leaving 2295 patients eligible for the study. At least two years of
follow-up data were available in 2252 patients (98.1%). The main outcome studied was first stroke,
haemorrhage or infarct, in the distribution of the asymptomatic carotid artery, which was fatal or
lasted more than seven days. Disabling stroke was defined as a stroke which resulted in a Rankin
score of three or more six months after the stroke.21 For comparison the risk of stroke, defined in
the same way, in the distribution of the symptomatic carotid artery was analysed in the same 2295
patients. Life-table methods and logrank tests were used for formal analyses of time from
randomisation to first stroke, censoring for non-stroke death. Patients who underwent carotid
endarterectomy on the asymptomatic side during follow-up were not censored.
Risk factors for stroke: In order to maximise the power of the analysis to detect possible risk
factors for stroke distal to an asymptomatic stenosis, the full ECST analysis dataset of 3007
patients with full follow-up was used. Univariate analyses were performed using all the baseline
clinical and angiographic characteristics. Cox's proportional hazards modeling was used to define
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independent clinical and angiographic risk factors for stroke. Ischaemic stroke lasting longer than
seven days in the territory of the asymptomatic stenosis was the outcome event for all the risk
factor modeling.
10.4 Results
Baseline data: Mean duration of follow-up was 4.5 years (range: 2 - 11.4 years) in the 2295
patients on which the analysis of overall stroke risk is based. The baseline clinical data by degree
of stenosis of the asymptomatic carotid artery are given in table 10.1. The prevalence of ischaemic
heart disease and peripheral vascular disease and mean systolic blood pressure increased with the
degree of asymptomatic stenosis, but there were no other significant differences between patients
with mild (0-29%), moderate (30-69%) or severe (70-99%) asymptomatic stenosis. Four hundred
and eighty patients had a stenosis of less than 10%.
Table 10.1. The baseline characteristics of the 2295 patients studied grouped according to the
degree of stenosis of the asymptomatic carotid artery.
Baseline variable Degree of asymptomatic stenosis (%)
0-29 30-69 70-99 Occlusion
Patients 1270 843 127 55
Mean age (yr) 61.5 62.9 64.4 64.2
Male (%) 71.2 69.7 70.9 72.7
Previous angina and/or 19.2 27.0 33.1 27.3 1
myocardial infarction (%)
Peripheral vascular disease (%) 13.2 20.0 23.6 38.2 2
Diabetic (%) 10.6 10.5 14.2 10.9
Mean systolic BP (mmHg) 149 152 157 150 3
Mean diastolic BP (mmHg) 86 87 87 86
Mean cholesterol (mmol/1) 6.4 6.5 6.5 6.3
Current cigarette smokers (%) 53 52 50 56
Mean obesity index (kg/m^) 25.1 25.4 25.8 25.3
1 Chi square for linear trend = 21.4, P« 0.001
2 Chi square for linear trend = 38.2, P« 0.001
3
Regression analysis for trend, P = 0.014
225
Risk ofstroke. Five strokes in the distribution of the asymptomatic artery occurred within 30 days
of carotid endarterectomy performed on the symptomatic artery, and of 37 patients who underwent
endarterectomy on the asymptomatic side at some stage during follow-up, seven had a stroke in the
distribution of the operated artery within 30 days of surgery (table 10.2). The reason for
endarterectomy on the asymptomatic side was development of TIA or stroke in 19 cases (stenosis:
4 mild; 7 moderate; 8 severe), but in 11 cases endarterectomy was performed specifically for
asymptomatic stenosis (stenosis: 2 moderate; 9 severe), and in seven cases (stenosis: 2 moderate; 5
severe) the reason for surgery was unknown. All these surgical strokes are included in the analysis
of stroke risk. Overall, 69 patients suffered a first stroke lasting longer than seven days in the
distribution of the asymptomatic carotid artery during follow-up, giving an overall Kaplan-Meier
estimate of stroke risk at three years of 2.1% (95% CI, 1.5 - 2.8). The stroke risk was almost
identical in patients with mild and moderate stenosis (table 10.2, fig 10.1), but the three year risk
increased to 9.8% (95% CI, 0.6-21) in patients with 80-89% stenosis, and to 14.4% (95% CI, 5 -
38) in patients with 90-99% stenosis (fig 10.2). However, neither these risks, nor the 5.7% risk in
patients with 70-99% stenosis as a whole, were statistically significantly greater than the stroke risk
in the remainder of the group. The 30 day case fatality due to stroke was 13%, giving a Kaplan-
Meier three year risk of fatal stroke of 0.3% (95% CI, 0.06-0.56). A Rankin disability score was
available in 50 (83%) of the 60 non-fatal strokes (table 10.2). Of these, 14 (28%) were disabling
(Rankin > 2) at six months. If the strokes in which disability was unknown are regarded as having
been disabling, then the Kaplan Meier three year risk of a disabling or fatal stroke was 1.0% (95%
CI, 0.3-1.8). The risk of stroke on the asymptomatic side did not differ significantly with treatment
allocated for the symptomatic stenosis [surgery: 40/1390 (2.9%) vs no surgery: 29/905 (3.2%)].
Figure 10.3 shows the Kaplan-Meier curves derived from analysis of follow-up of the 2295 patients
for: (1) survival free from stroke in the distribution of a severe asymptomatic carotid stenosis; (2)
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survival free from stroke in the distribution of a severe symptomatic stenosis, in patients
randomised to surgery, excluding all strokes and deaths within 30 days of endarterectomy; (3)
survival free from stroke in the distribution of a severe symptomatic stenosis in patients
randomised to medical treatment. The Kaplan- Meier three year risk of carotid distribution stroke
ipsilateral to a severe asymptomatic stenosis (5.7%, 95% CI = 1.5 - 9.8) was significantly less than
the same risk ipsilateral to a severe symptomatic stenosis with medical treatment (17.1%, 95% CI =
13.3 - 20.1), and non-significantly greater than the risk ipsilateral to a severe symptomatic stenosis
following successful endarterectomy (3.1%, 95% CI = 1.4 - 4.4).
Table 10.2. Details of number, Kaplan-Meier [K-M] three year risk estimates, aetiology, CT scan
appearance, and related disability of all strokes lasting more than seven days in the distribution of
the asymptomatic carotid artery recorded during follow-up.
0-29
Degree of asymptomatic stenosis (%)
30-69 70-99 Occlusion Total
Patients 1270 843 127 55 2295
Strokes 28 26 13 2 69
K-M 3 year risk 1.8% 2.1% 5.7% 3.7% 2.1%
(95% CI) (1-3) (1-3) (1-10) (0-9) (1-3)
CT scan appearance:
Infarction 17 15 8 0 40
Haemorrhage 2 1 0 0 3
No CT available 9 10 5 2 26
Strokes following CEA:
Symptomatic side surgery 3 0 2 0 5
Asymptomatic side surgery 1 2 4 0 7
Status at 6 months post-stroke:
Rankin 0-2 16 15 4 1 36
Rankin > 2 5 4 4 1 14
Not known 5 3 2 0 10
Dead 2 4 3 0 9
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Risk factors for stroke: The larger cohort of 2810 patients used for risk factor modeling had a
mean follow-up of 6 years. The univariate analysis of baseline risk factors is shown in table 10.3.
Again there was no link between randomisation to endarterectomy on the symptomatic side and
stroke on the asymptomatic side. The only significant predictors of asymptomatic territory
ischaemic stroke were the nature of the presenting symptoms on the symptomatic side (ocular
events only vs cerebral events), infarction visible on the CT brain scan in the territory of the
asymptomatic artery, the degree of asymptomatic stenosis and the mean diastolic blood pressure.
Each of these variables remained significant in the Cox proportional hazards model (table 10.4).
Age also became a significant predictor of stroke when added to the above variables in the
multivariate model.
Table 10.3. The relationship between baseline clinical and angiographic variables and risk of
ipsilateral ischaemic stroke in the distribution of the asymptomatic carotid artery in 2810 patients
with an asymptomatic stenosis in the ECST.
Ipsilateral ischaemic stroke
Risk factor Yes No P1
Cases 157 2653
Randomised treatment (endarterectomy 95 (61%) 1595 (60%) 0.9
on symptomatic side)
Age (mean/sd) 63.6 (7.7) 62.4(8.1) 0.07
Male sex 114 (73%) 1902 (72%) 0.8
Diabetes 22 (14%) 300(11%) 0.3
Ocular events only 13 (8%) 392 (15%) 0.02
Peripheral vascular disease 25 (16%) 423 (16%) 0.99
Angina 29(18%) 442(17%) 0.5
Previous myocardial infarction 21 (13%) 315 (12%) 0.6
Irregular asymptomatic stenosis 67 (50%) 948 (45%) 0.3
Infarction visible on CT brain scan in
territory of asymptomatic artery 21 (13%) 165 (6%) <0.001
Mean (SD) asymptomatic stenosis 47.5 (26.1) 41.8 (37.9) 0.06
Median (range) asymptomatic stenosis 48.0 (0-100) 37.5 (0-100) 0.02'
Mean (SD) systolic blood pressure 152(20) 150(23) 0.3
Mean (SD) diastolic blood pressure 88(11) 86(12) 0.03
1 Chi squared test for categorical variables and ANOVA for comparison ofmeans.
2 Mann Whitney test
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Table 10.4. The significant variables in a Cox's proportional hazards model for risk of ipsilateral
ischaemic stroke in the distribution of the asymptomatic carotid artery in 2810 patients with an
asymptomatic stenosis in the ECST. All variables listed in table 10.3 were entered into the model.
Risk factor Wald Hazard ratio (95% CI) P
Age (per 10 years) 7.9 1.06(1.01 - 1.12) 0.005
Ocular events only 7.3 0.45 (0.23-0.74) 0.006
Infarction visible on CT brain scan in 13.2 2.38 (1.42-3.80) 0.0003
territory of asymptomatic artery
Asymptomatic stenosis (per 10%) 4.2 1.06(1.01 - 1.12) 0.04
Diastolic blood pressure (per lOmmHg) 4.0 1.13 (1.01 - 1.30) 0.04
10.5 Discussion
In patients with symptomatic carotid stenosis, the degree of stenosis appears to be one of the most
important predictors of stroke risk in the territory of the symptomatic artery. In contrast to ACAS,
the asymptomatic side data from the ECST suggest that the degree of carotid stenosis is also an
important predictor of stroke risk on medical treatment on the asymptomatic side. Although the
number of patients with severe asymptomatic stenosis were relatively small, all stenoses were
imaged using angiography, allowing the degree of stenosis to be measured accurately and
reproducibly. Ultrasound imaging was used in the majority of previous studies.12'14"19
The overall 2.1% three year risk of stroke in the distribution of the asymptomatic artery is low, but
is unlikely to be an underestimate. Follow-up was carried out regularly by experienced
neurologists, and was complete in over 98% of cases. All strokes were counted, including those
caused by surgery on the symptomatic or asymptomatic arteiy. The patients studied had all already
suffered symptoms referable to one carotid stenosis, had a high frequency of diabetes, ischaemic
heart disease and peripheral vascular disease, and over half were cigarette smokers. However, it is
possible that endarterectomy performed on the asymptomatic artery, albeit in only a few patients,
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might have prevented a small number of strokes. Also strokes with symptoms lasting for less than
seven days were not counted.
The low risk of stroke in this study is in keeping with ultrasound-based studies of risk of stroke in
the distribution of asymptomatic carotid arteries in truly asymptomatic patients. Chambers and
Norris followed up patients with asymptomatic stenosis for a mean of two years, and reported six
strokes in 113 patients with 75-100% stenosis.17 Hennerici et al followed up 235 patients with
greater than 50% asymptomatic stenosis for a mean of 32 months and reported seven strokes.12
Bogousslavsky et al followed-up 38 patients with 90-99% asymptomatic stenosis for a mean of four
years and reported three ischaemic strokes.14 There is no evidence from the ECST, therefore, that
the overall risk of stroke distal to an asymptomatic stenosis is higher in patients with a contralateral
recently symptomatic stenosis than in truly asymptomatic patients.
Each year 5-20% of patients with a previously asymptomatic carotid stenosis are said to suffer
"neurological events" or "cerebral ischaemic events." 15>17-22'23 The VA trial of carotid
endarterectomy for asymptomatic stenosis reported a significant reduction in "cerebral ischaemic
events" in the treated group, although there was no significant effect on the risk of stroke or death.6
In all these studies, the vast majority of "neurological events" or "cerebral ischaemic events." were
TIAs. Although it can be argued from a pathophysiological point of view that the distinction
between TLA and stroke is arbitrary, an outcome which gives equal weight to transient events
which cause no lasting disability, and major strokes causing death or lifelong dependency, is too
broad to have any real clinical meaning.
The burden of disability resulting from stroke in the distribution of an asymptomatic carotid
stenosis has not been measured with precision. Although less heterogeneous than "cerebral
ischaemic events", there is still considerable variation in the severity of stroke, ranging from minor
sensory disturbance to devastating permanent hemiparesis with aphasia or neglect. It is therefore
necessary to at least categorise strokes as non-disabling, disabling, or fatal. The case fatality of
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stroke in this study was 13%. In over 70% of the non-fatal strokes where a Rankin score was
available, there was no significant disability six months after the stroke.
The risks of stroke in patients with 80-90% and 90-99% stenosis were based on small numbers of
patients with very few outcome events, and the confidence intervals were therefore extremely wide.
The overall risk in patients with 70- 99% stenosis was lower, but was based on a larger number of
patients and therefore has greater validity. However, these data do suggest that the shape of
relationship between the degree of asymptomatic stenosis and stroke risk is similar to that reported
in ECST and NASCET for the risk of stroke in the territory of a symptomatic stenosis.
What might be gained from endarterectomy for 70-99% stenosis on the contralateral asymptomatic
side in patients with symptomatic carotid stenosis? The risk of stroke distal to a 70-99%
asymptomatic stenosis is somewhat greater than the background risk of ipsilateral carotid
distribution stroke following successful endarterectomy on the symptomatic side (fig 10.3) -
probably largely due to lacunar and cardio-embolic strokes. However, surgical mortality and
morbidity would have to be veiy low for surgery to be beneficial. Indeed, even the stringent 3%
limit on risk of stroke and death recommended by the American Heart Association for surgeons
operating on asymptomatic stenoses might well nullify any benefit.3 Moreover, even with
complication-free surgery, the cost effectiveness of the procedure must be in doubt: possibly about
five strokes prevented over five years following successful endarterectomy in 127 patients with
severe asymptomatic stenosis (fig 10.3).
For endarterectomy on the asymptomatic side to be cost-effective, it would be necessary to identify
a subgroup of individuals with a higher than average risk of ischaemic stroke in the territory of the
asymptomatic arteiy. There were some significant risk factors in the ECST, but the prevalence of
the potentially important risk factors was low. For example, the most powerful risk factor was
infarction visible on the CT brain scan in the territory of the asymptomatic artery. However, this
was only present in 7% of patients overall and only 13% of those who had strokes. Similarly,
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ocular versus cerebral symptoms on the contralateral side were predictive of a low risk subgroup in
whom endarterectomy on the asymptomatic side would be unlikely to be beneficial. However, this
would discount only about 14% of patients overall. The effects of other significant risk factors,
such as age and diastolic blood pressure were rather small. Therefore, even if the model detailed in
table 10.4 was validated in an independent dataset, it would be unlikely to be of major help to
clinicians.
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10.7 Legends to figures
Figure 10.1. Actuarial analysis of survival free from stroke lasting longer than seven days in the
distribution of an asymptomatic artery, in patients grouped according to the degree of
asymptomatic stenosis at entry.
Figure 10.2. Kaplan-Meier three year estimates and 95% confidence intervals of risk of stroke
lasting longer than seven days in the distribution of an asymptomatic artery by degree of
asymptomatic carotid stenosis. The number above the error bar indicates the number of patients in
each stenosis group.
Figure 10.3. Actuarial analysis of survival free from stroke in the distribution of a severe (70-99%)
carotid stenosis in: (1) patients with asymptomatic stenosis counting all carotid territory strokes
ipsilateral to the asymptomatic stenosis; (2) patients with symptomatic stenosis randomised to
carotid endarterectomy, excluding all surgery-related strokes and deaths i.e. this is the background
ipsilateral stroke risk after successful surgery; (3) patients with symptomatic stenosis randomised to






































































A systematic review of the risks of stroke and death due to endarterectomy










Background and Purpose: Carotid endarterectomy reduces the risk of carotid territory
ischaemic stroke ipsilateral to a recently symptomatic severe carotid stenosis. However, the
benefit is limited by the risks of stroke and death associated with the operation. Although
reported surgical risks vary enormously, there has been no systematic review of the published
literature.
Methods: A systematic review of mortality and the risk of stroke and death due to
endarterectomy for symptomatic carotid stenosis in studies published between 1980 and 1994.
Results: Fifty one studies fulfilled the inclusion criteria. Overall mortality was 1.62%
(95% CI = 1.3-1.9) and the risk of stroke and death was 5.64% (4.4-6.9). However, there was
significant heterogeneity of risk of stroke and death (P<0.001). The risk varied systematically
with the methods and the authorship of the study. The risk of stroke and death was highest in
studies in which patients were assessed by a neurologist following surgery (7.7%, 5.0-10.2)
and lowest in studies with a single author affiliated to a department of surgery (2.3%, 1.8-
2.7). After correcting for study methodology there was no temporal trend in the risk of stroke
and/or death between 1980 and 1995.
Conclusions: The reported risks of endarterectomy for symptomatic carotid stenosis show
significantly greater variability than would be expected by chance. However, much of this
variability can be accounted for by differences in methodology and authorship. The 5.6%
overall risk of stroke and death is consistent with present guidelines.
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11.2 Introduction
As discussed already, carotid endarterectomy reduces the risk of carotid territory ischaemic
stroke ipsilateral to a recently symptomatic severe (70-99%) carotid stenosis.1,2 The
operation is one of the most frequently performed in Western countries,3 and rates continue to
rise.4'5 The benefit of endarterectomy is, however, limited by the morbidity and mortality of
the procedure, particularly the risks of stroke and death. However, these risks vary
enormously in different reports,6 and reviews often fail to differentiate between the higher
risks in symptomatic than in asymptomatic patients.7'8 Recommended maximum
complication rates for endarterectomy for symptomatic stenosis have been published,9'10 but
these were based on non-systematic review of a small number of selected reports. Non-
systematic reviews tend to be selective and may be biased by the opinions of the authors
whereas systematic reviews have clearly defined methods and should, in theory at least, be
a more accurate reflection of the true state of the literature."
So, what are the risks of stroke and death due to endarterectomy for symptomatic carotid
stenosis? Is the apparent heterogeneity of reported risks greater than would be expected by
chance alone? If so, can it be explained by differences in study methodology? Curiously,
there has been no systematic review of the morbidity and mortality of carotid endarterectomy
for symptomatic stenosis. This chapter details a systematic review of all studies published
since 1980 which reported the risks of stroke and death following carotid endarterectomy for
symptomatic carotid stenosis. In combination with a previous overview,12 temporal trends in
reported risk over the last 30 years are also examined.
11.3 Methods
The systematic review was confined to studies published since 1980 in order to reflect
present day surgical practice. All published studies reporting the morbidity and mortality of
carotid endarterectomy were searched for. Studies were identified (PMR) from CD-ROM
(Cambridge Medline, 1980-1995) using the search terms "carotid endarterectomy" and
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"carotid surgery". The Cochrane Collaboration Stroke Database,lj and the reference lists of
all papers identified electronically were also searched. However, hand searching of journals
was not performed and unpublished data were not sought. Studies were included in the
overview if they reported the risks of stroke and death within 30 days of carotid
endarterectomy in patients with symptoms referable to the operated carotid artery (i.e.
amaurosis fugax, transient cerebral ischaemic attack, retinal infarction or completed stroke).
Papers in which risks for patients operated for symptomatic stenosis were not reported
separately from patients operated for non-hemispheric symptoms or asymptomatic stenosis
were excluded. Mortality and stroke risk were defined per operation. The 95% confidence
intervals of the overall risks of death and stroke and/or death were calculated allowing for
extra-binomial variation.14 Standard methods of calculating confidence intervals produce
artificially narrow intervals when there is heterogeneity of risk between different studies.
Studies were divided into the following groups: those in which postoperative assessment was
performed by a neurologist/general physician; those in which one or more authors were
affiliated to a department of neurology/medicine, but in which it was not explicitly stated
who assessed outcome; those with multiple authors all of whom were affiliated to a
department of surgery; single author studies with affiliation to a department of surgery.
Studies were also stratified according to whether they were performed prospectively or
retrospectively. These factors were analysed, along with year of publication, in an unweighted
multiple regression analysis of the operative risk of stroke and/or death.
The studies identified in this review were combined with those studies published prior to
1980 in a previous review.12 Overall mortality and the risk of stroke and death were analysed
in five year periods.
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11.4 Results
A total of 126 studies reporting the complications of carotid endarterectomy were
identified. Only 51 studies 2,15 64 fulfilled the inclusion criteria. Sixty nine studies were
excluded because they did not report operative risks in patients with symptomatic stenosis
alone, and a further six studies were excluded because they reported only percentage risks
without giving the number of operations, strokes or deaths on which these were based. The
overall mortality estimate was based on 17105 operations. One study reported only deaths and
so the overall estimate of stroke and death was based on 15956 operations.
Overall mortality due to surgery for symptomatic stenosis (figure 11.1) was 1.62% (95% CI
1.3-1.9). Two studies did not give the cause of death.17,48 Among the remainder, the overall
risk of fatal stroke was 0.86% (95% CI 0.70 - 1.02) and the overall risk of non-stroke death
was 0.70% (95% CI 0.56 - 0.84). The risk of stroke and/or death due to endarterectomy for
symptomatic stenosis (figure 11.1) was 5.64% (95% CI 4.4 - 6.9). There was, however,
significant heterogeneity (X2 = 203, df=49, P<0.001) in the reported risk of stroke and/or
death (figure 11.2).
Study methodology and authorship
Nine reports (2605 operations) stated that a neurologist or physician performed the
postoperative assessment. (^.24,27,28,30,5 >,52,64) Eleyen reports (20,3.,32,34,35,37,42,49,59,60,63)
included a neurologist or physician among the authors, but did not state who assessed outcome
(3217 operations). There were five single author reports (1849 operations) with affiliation to
departments of surgery. (16,18,29-44,50) remajning 26 reports had multiple authors all of whom
were affiliated to departments of surgery (8375 operations). In 19 of the 51 reports (6591
operations), (2-16.i7,20,22-28,30,35,43,51,52,55,59,64) was c]ear from the methods that the study had
been performed prospectively.
The risk of stroke and death varied according to the category of report (table 11.1). The risk
was higher in those studies in which one or more authors were affiliated to a department of
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neurology than in studies where all authors were affiliated to departments of surgery (figure
11.3). Moreover, the risk was highest in the subset of studies in which patients were assessed
by a neurologist in the post-operative period and lowest in those studies in which a single
surgeon reported their own results (figure 11.4, table 11.1). There was no significant difference
in overall risk between prospective and retrospective studies, although there was a trend
towards a higher risk in the former (table 11.1).
Table 11.1. Mortality and risk of stroke and/or death according to study methodology and
authorship.




Stroke and/or death (%)
(95% CI)
Prospective 19 1.9(1.3-2.6) 5.6 (3.9-7.3)
Retrospective 32 1.5(1.2-1.8) 5.1 (4.3-5.8)
Neurologist assessor 9 1.4 (0.2-2.7) 7.7 (5.0-10.2)
Neurologist author 11 1.8(1.2-2.5) 6.4 (4.6-8.1)
Multiple surgeon authors 26 1.7(1.4-1.9) 5.5 (4.8-6.1)
Single surgeon author 5 0.7 (0.4-1.0) 2.3 (1.8-2.7)
A multiple regression analysis revealed that after correcting for year of publication much of
the apparent heterogeneity of the operative risk of stroke and/or death was related to
differences in study methodology (table 11.2). Compared with studies with multiple surgeon
authors, studies with assessment by a neurologist or physician and studies with a neurologist
or physician as an author reported significantly higher risks. Studies with a single surgeon as
the author reported significantly lower risks.
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Table 11.2. An unweighted multiple regression analysis of the effect of study methodology on
the reported operative risk of stroke and death.
Study characteristic Parameter SE P Odds ratio (95% CI)
estimate
















compared with studies with multiple authors all of whom were affiliated to a department of surgery.
Time trends in operative risk
Mortality and risk of stroke and death due to carotid endarterectomy for symptomatic stenosis
were reported in 11 studies published prior to 1980 in a previous overview.12 Three studies
published in the 1960s reported high operative risks, but since 1970 reported operative
mortality and risk of stroke and death have, on average, been significantly lower (figure 11.5).
There has been no change in operative mortality over the 15 year period covered by the
present overview. However, there has been a significant increase in the reported operative risk
of stroke and death: 1980-84, 4.34% (95% CI 2.26-6.42); 1985-1989, 5.28% (4.40-6.16);
1990-94, 6.08 (5.30-6.86), although when corrected for differences in study methodology and
authorship in a multiple regression analysis, year of publication was not independently
associated with risk of stroke and death (table 11.2).
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11.5 Discussion
This study is the first systematic review of the mortality and the risk of stroke due to carotid
endarterectomy for symptomatic carotid stenosis. However, electronic searches invariably
miss some published studies,65 and so it is unlikely that the review is definitive. Inclusion of
studies is unlikely, however, to have been consistently biased with respect to the reported
mortality or morbidity. Indeed, bias between studies resulting from differences in study
methodology is likely to have been far greater than any exclusion bias. Similarly, although
60% of the papers reporting the complications of carotid endarterectomy identified from the
literature search did not fulfil the inclusion criteria, selection should not have introduced bias.
The majority of studies were excluded simply because the risks of endarterectomy were
reported for combined populations of symptomatic and asymptomatic studies. Since the risks
of surgery for asymptomatic stenosis are consistently .lower than for symptomatic stenosis
(see Chapter 12), combined risks would have been difficult to interpret.
The reported risks of stroke and death were very statistically heterogeneous. Of course,
differences between studies may reflect differences in case-mix or surgical experience, but the
above analysis suggests that differences in study methodology accounted for much of the
heterogeneity. Studies in which postoperative assessment was performed by a neurologist
reported risks of stroke and death which were, on average, over three times higher than those
reported in studies by single surgeons. There are several possible explanations for the disparity.
Briefly, the first possibility is scientific fraud. A few surgeons might have dishonestly reported
low morbidity. Secondly, and more likely, is publication bias. Surgeons with particularly
high operative stroke risks might be less likely to publish their results. Thirdly, and
perhaps most likely, is diagnostic bias; surgeons might simply be less able to diagnose minor
or unusual strokes than neurologists. Finally, surgeons might be more likely to undertake a
study in the first place if they thought that their record was good, whereas neurologists might
be more interested if they thought that the operative risks were high. Which, if any, of these
biases account for the results is unclear. However, the findings do support the recommendation
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that audit of the morbidity and mortality rates for carotid endarterectomy should be
independently validated.10 Surprisingly, there was little difference between the risks in
prospective as opposed to retrospective studies, although the distinction was somewhat
blurred in many reports.
In view of the apparent biases introduced by different study methodologies and the marked
heterogeneity of the reported risks of stroke and death it is difficult to know how the 5.6%
overall risk of stroke and/or death should be interpreted. It is comparable with the risks
reported in the recent large trials of endarterectomy for symptomatic stenosis,1'2 and with the
American Heart Association guidelines.10 Moreover, despite the overall statistical
heterogeneity, only two of the 51 studies reviewed reported statistically significantly lower
risks of stroke and/or death.29'44 Both were reported by single surgeons, and in both, the
risks of non-fatal stroke were little more than double the risks of death. As a general rule, case
fatality for first stroke is usually about 10-20%.66 In keeping with this the ratios of non¬
fatal operative stroke to operative mortality in NASCET2 and ECST1 were 6 and 8
respectively. Studies which reported much lower ratios may well have missed a proportion of
non-fatal strokes.
How should individual surgeons compare their own complication rates with the overall rates
reported here, or the recommended maximum acceptable complication rates published
elsewhere?9'10 The wide confidence intervals around the complication rates in the relatively
small numbers of cases which comprise the recent experience of most surgeons makes
meaningful comparison very difficult. For example, a surgeon or trainee with a true 2%
operative risk of stroke and/or death has to perform over 150 operations before the upper
95% confidence interval of his risk falls below the 5.64% overall risk in this review. Similarly,
a surgeon with a 10% risk has also to perform at least 150 procedures before his risk can be
said to be significantly greater than the norm. This results in a "catch-22" situation, whereby a
surgeon is unlikely to be sure whether or not he is sufficiently competent to routinely perform
carotid endarterectomy for symptomatic carotid stenosis unless or until he has already
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performed 150 procedures. There is, of course, no way around this problem, and surgeons,
auditors and patients simply have to cope with the uncertainty.
The reported risk of stroke and death due to surgery for symptomatic carotid stenosis has
increased since 1980, but this appears to be accounted for by temporal trends in study
methodology. When study methodology was taken into account in the multiple logistic
regression analysis, year of publication was no longer independently associated with risk of
stroke and death. Moreover, temporal trends are difficult to interpret anyway given the changes
in the frequency with which the operation has been performed over the past 20 years, and
likely changes in the characteristics of patients undergoing surgery following the results
of recent clinical trials.1'2 However, some general conclusions can be drawn. For example,
the increasing use in recent years of intensive peri-operative monitoring does not seem to
have had a marked effect on reported operative risk. The utility of this approach cannot, of
course, be properly assessed without randomised clinical trials, but it appears that any benefit
is unlikely to be large.
In conclusion, the reported mortality and risk of stroke and/or death due to endarterectomy for
symptomatic carotid stenosis are heterogeneous. Much of the variability is, however, due to
differences in study methodology. In particular, outcome assessment by a neurologist was
associated with a higher risk of stroke and death than outcome assessment by surgeons, and
studies with single surgeon authors were associated with a lower risk of stroke and death
than studies in which the authorship comprised two or more surgeons. The overall risks of
death and stroke and/or death were in line with current recommendations for surgery for
symptomatic carotid stenosis. It was not possible to assess other factors, such as surgical
experience or large vs small hospitals etc.
248
11.6 References
1) European Carotid Surgery Trialists'Collaborative Group. MRC European Carotid Surgery
Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%)
carotid stenosis. Lancet 1991; 337: 1235-1243.
2) North American Symptomatic carotid Endarterectomy Trial Collaborators. Beneficial
effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N
Engl J Med 1991; 325: 445-453.
3) Pokras R, Dyken ML. Dramatic changes in the performance of endarterectomy for
diseases of the extracranial arteries of the head. Stroke 1988; 19: 1289-1290.
4) Murie JA, Morris PJ. Carotid endarterectomy in Great Britain and Ireland: trends and
current practice. Br J Surg 1991; 78: 397-400.
5) John TG, Naylor AR, Howlett J, Gillespie I, Jenkins A, Ruckley CV. An audit of trends and
current practice of carotid endarterectomy in Edinburgh (1975-1990). J R Coll Surg Edinb
1993; 38: 138-141.
6) Till JS, Toole JF, Howard VJ, Ford CS, Williams D. Declining morbidity and mortality of
carotid endarterectomy. Stroke 1987; 18: 823-829.
7) Owens ML, Wilson SE. Prevention of neurologic complications of carotid endarterectomy.
Arch Surg 1982; 117: 551-554.
8) Tippet TM, Sisco AB, CHapleau CE. Carotid endarterectomy: Review of 150 consecutive
cases in two small community hopitals. J Neurosurg 1985; 63: 387-389.
9) Beebe HG, Clagett GP, DeWeese JA, Moore WS, Robertson JT, Sandok B, Wolf PA.
Assessing risk associated with carotid endarterectomy: A statement for health professionals
by an ad hoc committee on carotid surgery standards of the Stroke Council, American
Heart Association. Stroke 1989; 20: 314-315.
10) Ad Hoc Committee, American Heart Association. Guidelines for carotid endarterectomy.
Stroke 1995; 26: 188-201.
11) Mulrow CD. The medical review article: state of the science. Ann Intern Med 1987; 106:
485-488.
12) Warlow CP. Carotid endarterectomy: Does it work? Stroke 1984; 15: 1068-1076.
13) Cochrane Database of Systematic Reviews. BMJ Publishing, London, 1995.
14) McCullagh P, Nelder JA. Generalised linear models. Chapman and Hall, London, 1979.
15) Owens ML, Atkinson JB, Wilson SE. Recurrent transient ischaemic attacks after
carotid endarterectomy. Arch Surg 1980; 115: 482-486.
16) Whittmore AD. Carotid endarterectomy: an alternative approach. Arch Surg 1980; 115:
940-942.
249
17) Whitney DG, Kahn EM, Estes JW, Jones CE. Carotid artery surgery without a temporary
indwelling shunt: 1917 consecutive procedures. Arch Surg 1980; 115: 1393-1398.
18) Carmichael JD. carotid surgery in the community hospital: 367 consecutive operations.
Arch Surg 1980; 115:937-939.
19) White JS, Sirinek KR, Root D, Rogers W. Morbidity and mortality of carotid
endarterectomy. Arch Surg 1981; 116: 409-412.20) Eriksson S-E, Link H, Aim A, Radberg C,
Kostulas V. Results from 88 consecutive prophylactic carotid endarterectomies in cerebral
infarction and transient ischaemic attacks. Acta Neurol Scand 1981; 63: 209-219.
21) Carson SN, Demling RH, Esquivel CO. Aspirin failure in symptomatic atherosclerotic
carotid artery disease. Surgery 1981; 90: 1084-1091.
22) Parkin PJ, Kendall BE, Marshall J, McDonald WI. Amaurosis fugax: some aspects of
management. J Neurol Neurosurg Psych 1982; 45: 1-6.
23) Hertzer NR, Beven EG, Modic MT, O'Hara PJ, Vogt DP, Weinstein MA. Early patency
of the carotid artery after endarterectomy: digital subtraction angiography after two hundred
sixty-two operations. Surgery 1982; 92: 1049-1056.
24) UK-TLA Study Group. Variation in the use of angiography and carotid endarterectomy
by neurologists in the UK-TIA Aspirin Trial. Brit Med J 1983;286:514-517.
25) Takolander RJ, Bergentz SE, Ericsson BF. Carotid artery surgery in patients with minor
stroke. Br J Surg 1983; 70: 13-16.
26) Thompson JE. Carotid endarterectomy, 1982 - the state of the art. Br J Surg 1983; 70: 371-
376.
27) Wishnant JP, Sandok BA, Sundt TM. Carotid endarterectomy for unilateral carotid system
transient cerebral ischaemia. Mayo Clin Proc 1983; 58: 171-175.
28) Muuronen A. Outcome of surgical treatment of 110 patients with transient ischaemic
attack. Stroke 1984; 15: 959-964.
29) Haffner CD. Minimising the risks of carotid endarterectomy. J Vase Surg 1984; 1: 392-
397.
30) Shaw DA, Venables GS, Cartlidge NEF, Bates D, Dickinson PH. Carotid endarterectomy
in patients with transient cerebral ischaemia. J Neurol Sci 1984; 64: 45-53.
31) Brott T, Thalinger K. The practice of carotid endarterectomy in a large metropolitan area.
Stroke 1984; 15: 950-955.
32) Browse NL, Ross-Russell R. Carotid endarterectomy and the Javid sunt: the early results
of 215 consecutive operations for transient ischaemic attacks. Br J Surg 1984; 17: 53-57.
33) Fode NC, Sundt TM, Robertson JT, Peerless SJ, Shields CB. Multicentre retrospective
review of results and complications of carotid endarterectomy in 1981. Stroke 1986; 17: 370-
376.
250
34) Toronto Cerebrovascular Study Group. Risks of carotid endarterectomy. Stroke 1986; 17:
848-852.
35) Sacquegna T, D'Addato M, Baldrati, Cortelli P, Lamieri C, Merlo Pich E, Vitacchiano G,
Pedrini L. Long-term prognosis after carotid endarterectomy. Eur Neurol 1986; 25: 36-39.
36) Hertzer NR, Flanagan RA, O'Hara PJ, Beven EG. Surgical vs non-operative treatment of
symptomatic carotid stenosis. Ann Surg 1986; 204: 154-162.
37) Kempczinski RF, Brott TG, Labutta RJ. The influence of surgical specialty and
caseload on the results of carotid endarterectomy. J Vase Surg 1986; 3: 911-916.
38) Bernstein EF, Dilley RB. Late results after carotid endarterectomy for amaurosis fugax. J
Vase Surg 1987; 6: 333-340.
39) Sise MJ, Sedwitz MM, Rowley WR, Shackford SR. Prospective analysis of carotid
endarterectomy and silent cerebral infarction in 97 patients. Stroke 1989; 20: 329-332.
40) Friedmann P, Garb JL, Berman J, Sullivan C, Celoria G, Rhee SW. Carotid
endarterectomy. Clinical results in a community-based teaching hospital. Stroke 1988; 19:
1323-1327.
41) Peters RA, Hanson TL, Fontenelle LJ. The influence of resident surgical training on
outcome of carotid endarterectomy in a teaching hospital. Surg Gynaecol Obst 1988; 166: 487-
490.
42) AbuRahma AF, Robinson P. Indications and complications of carotid endarterectomy as
performed by four different surgical specialty groups. J Cardiovasc Surg 1988; 29: 277-282.
43) Gumerlock MK, Neuwelt EA. Carotid endarterectomy: to shunt or not to shunt? Stroke
1988; 19: 1485-1490.
44) Nunn DB. Carotid endarterectomy in patients with territorial transient ischemic attacks. J
Vase Surg 1988; 8: 447-452.
45) Rosenthal D, Zeichner WD, Lamis PA, Stanton PE. Neurological deficit after carotid
endarterectomy: Pathogenesis and management. Surgery 1983; 94: 776-780.
46) Zuccarelo M, Yeh H, Tew JM. Morbidity and mortality of carotid endarterectomy
under local anaesthesia: a retrospective study. Neurosurgery 1988; 23: 445-450.
47) Kirshner DL, O'Brien MS, Ricotta JJ. Risk factors in a community experience with carotid
endarterectomy. J Vase Surg 1989; 10: 178-186.
48) Healy DA, Clowes AW, Zierler RE, Nicholls SC, Bergelin RO, Primozich JF, Strandness
DE. Immediate and long-term results of carotid endarterectomy. Stroke 1989; 20: 1138-1142.
49) Maini BS, Mullins TF, Catlin J, O'Mara P. Carotid endarterectomy: A ten year analysis of
outcome and cost of treatment. J Vase Surg 1990; 12: 732-740.
50) Hoyne RF. Review of 272 consecutive carotid endarterectomies in a smaller community.
Surg, Gynaecol, Obst 1990; 170: 522-526.
251
51) Mayburg MR, Wilson SE, Yatsu F et al for the Veterans Affairs Cooperative Studies
Program 309 Trialists Group. Carotid endarterectomy and prevention of cerebral ischemia in
symptomatic carotid stenosis. JAMA 1991; 266: 3289-3294.
52) Burns RJ, Willoughby JO. South Australian carotid endarterectomy study. Med J Aust
1991; 154: 650-653.
53) Allcutt DA, Chakraborty M, Sengupta RP. Neurosurgical experience with carotid
endarterectomy: a 12 year study. Br J Neurosurg 1991; 5: 257-264.
54) Mattos MA, Hodgson KJ, Londrey GL, Barkmeier LD, Ramsey DE, Garfield M, Sumner
DS. Carotid endarterectomy: operative risks, recurrent stenosis, and long-term stroke rates in a
modern series. J Cardiovasc Surg 1992; 33: 387-400.
55) Earnshaw JJ, Hayward JK, Horrocks M, Baird RN. The importance of vascular surgical
audit to surgeons, patients and purchasers. Eur J Vase Surg 1992; 6: 540-544.
56) Maxwell JG, Covington DL, Churchill MP, Rutherford EJ, Clancy TV, Tackett AD.
Results of staged bilateral carotid endarterectomy. Arch Surg 1992; 127: 793-799.
57) Perler BA, Burdick JF, Williams GM. Does contrlateral internal carotid artery occlusion
increase the risk of carotid endarterectomy? J Vase Surg 1992; 16: 347-353.
58) Vigo J. Carotid endarterectomy in Puerto Rico. Bol Asoc Med P Rico 1992; 84: 128-131.
59) Kadwa AM, Robbs JV. Carotid endarterectomy in Durban - the first 10 years. S Afr Med
J 1993; 83: 248-252.
60) Goldstein LB, McCrory C, Landsman PB, Samsa GP, Ancukiewicz M, Oddone EZ,
Matchar DB. Multicentre review of preoperative risk factors for carotid endarterectomy in
patients with ipsilateral symptoms. Stroke 1994; 25: 1116-1121.
61) Niak DK, Shirer WC, Stephenson CB, Meech PR. Carotid endarterectomy at Wellington
Hospital. NZ Med J 1994; 107: 334-335.
62) Musser DJ, Nicholas GG, Reed JF. Death and adverse cardiac events after carotid
endarterectomy. J Vase Surg 1994; 19: 615-622.
63) Kawaguchi S, Sakaki T, Tsunoda S, Morimoto T, Hoshida T, Hirmaatsu K, Iwanaga H,
Nikaido Y. Strategies to improve the outcome of carotid endarterectomy. Neurol Med Chir
(Tokyo) 1994; 34: 86-90.
64) The European Carotid Surgery Trialists Collaborative Group. The morbidity and
mortality of carotid endarterectomy in the European Carotid Surgery Trial. Cerebrovasc Dis
1995; 5: 226.
65) Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews.
In Systematic Reviews (Chalmers I, Altman DG, eds). BMJ, London, 1995.
252
66) Bamford J, Sandercock P, Dennis M, Burns J, Warlow C. A prospective study of acute
cerebrovascular disease in the community: the Oxfordshire Community Stroke Project -
1981-1986. J Neurol Neurosurg Psychiat 1990; 53: 16-22.
11.7 Legends to figures
Figure 11.1 Mortality and the risks of stroke and death due to carotid endarterectomy for
symptomatic carotid stenosis in 51 studies published since 1980. The risks in each study are
represented by a square (observed risk) and a line (95% confidence interval of the observed
risk), and are reported per operation rather than per patient. The variance of the observed risk
is inversely proportional to the size of the square. The overall risk is represented by a
diamond.
Figure 11.2 The risks of stroke and death (95% CI) due to carotid endarterectomy for
symptomatic carotid stenosis in 51 studies published between 1980 and 1994.
Figure 11.3 The risks of stroke and death (95% CI) due to carotid endarterectomy for
symptomatic carotid stenosis in studies with an author affiliated to a department of neurology
(dark bars) and studies in which all authors were affiliated to departments of surgery (light
bars).
Figure 11.4 The risks of stroke and death (95% CI) due to carotid endarterectomy for
symptomatic carotid stenosis in studies in which it was explicit that outcome was assessed by
a neurologist (denoted by * ) and studies with a single author with affiliation to a department
of surgery (denoted by #).
Figure 11.5 Mortality and risk of stroke and death due to endarterectomy for symptomatic
carotid stenosis during five year periods from 1965 to 1994. Pre-1980 data were derived from
a previous review.12 The error bars represent the 95% confidence intervals of the risk
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Chapter 12
A systematic comparison of the risks of stroke and death due to endarterectomy










Background and purpose-. There is some evidence that carotid endarterectomy reduces
the risk of ipsilateral carotid territory ischaemic stroke in patients with severe asymptomatic
carotid stenosis. However, the benefit of endarterectomy is dependent on a low risk of stroke
and/or death due to surgery. Whether or not the low operative risks reported in recent
clinical trials and cited in recent guidelines are widely generalisable to clinical practice is
unclear. Is endarterectomy for asymptomatic carotid stenosis really safer than surgery for
recently symptomatic stenosis?
Methods-. A systematic review comparing the risks of stroke and death due to carotid
endarterectomy, performed by the same surgeons or in the same institutions, for symptomatic
and asymptomatic stenosis in studies published between 1980 and 1994.
Results'. Twenty five studies fulfilled the inclusion criteria. Mortality within 30 days of
endarterectomy was 1.31% for asymptomatic stenosis and 1.81% for symptomatic stenosis
(odds ratio = 0.69, 0.49-0.99). The risks of fatal stroke were 0.47% and 0.91%
respectively (odds ratio = 0.57, 0.34-0.98). The overall risk of stroke and death was 3.35%
for asymptomatic and 5.18% for symptomatic stenosis (odds ratio = 0.61, 0.51 - 0.74).
Conclusions: Mortality and the risk of stroke and death due to carotid endarterectomy are
significantly lower for asymptomatic stenosis than for symptomatic stenosis. These findings
are consistent across virtually all studies and are likely to be widely generalisable.
12.2 Introduction
Carotid endarterectomy reduces the risk of carotid territory ischaemic stroke ipsilateral to
a recently symptomatic severe (70-99%) carotid stenosis.1'2 There is now evidence that
individuals with asymptomatic carotid stenosis might also benefit from surgery.3
However, the risk of ischaemic stroke in the territory of an asymptomatic carotid stenosis on
medical treatment has consistently been found to be low,4'5 and is less than half that
260
associated with a symptomatic carotid stenosis of similar severity.5 The benefit of
endarterectomy for asymptomatic carotid stenosis is, therefore, critically dependent on the
morbidity and mortality of surgery. The 50% reduction in stroke risk in patients randomised
to endarterectomy in the ACAS study6 was the result of very low surgical morbidity and
mortality. The risk of stroke and death within 30 days of endarterectomy, excluding the risk
of angiography, was 1.5% (95% CI = 0.8-2.7). In the VA study,7 which did not demonstrate
a definite reduction in stroke risk following surgery for asymptomatic stenosis, the risk of
stroke and death associated with surgery was 4.3% (95% CI = 1.8-7.9). The VA result is not
significantly different from the risks in the trials of surgery for symptomatic stenosis.1'2
Are the low risks of stroke and death in the ACAS study and in those studies of surgery for
asymptomatic stenosis referenced in recent guidelines,8 generalisable? Is the risk of stroke
and death due to surgery for asymptomatic stenosis genuinely less than that for symptomatic
stenosis? In order to answer these questions, a systematic review of published studies
reporting the morbidity and mortality of carotid endarterectomy for symptomatic and
asymptomatic stenosis was performed. To ensure that any differences in risk could not be
attributed to differences in surgical skill the analysis was restricted to studies which
reported the results of surgery for symptomatic and asymptomatic stenosis performed by
the same surgeons or in the same institutions.
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15.3 Methods
The review was confined to studies published since 1980 in order to reflect present day
surgical practice. As detailed in Chapter 11, the studies were identified from CD-ROM
(Cambridge Medline) using the search strategies: carotid endarterectomy; carotid surgery.
The Cochrane Collaboration Stroke Database9 and the reference lists of all papers
identified electronically were also searched. Papers were included if they fulfilled the
following criteria: 1) The numbers of strokes and deaths occurring within 30 days of
carotid endarterectomy (or similar time period) performed for symptomatic and
asymptomatic stenosis were reported separately; 2) The number of operations were clearly
defined in each group; 3) Symptomatic patients were defined as having suffered a carotid
distribution transient ischaemic attack or completed stroke ipsilateral to the stenosis; 4)
Endarterectomy for symptomatic and asymptomatic patients was performed by the same
surgeons or in the same institutions.
Mortality and the risk of stroke and/or death were defined per operation. The confidence
intervals of the absolute risks of death, fatal stroke, and stroke and/or death were
calculated using an extra-binomial method in order to take into account any heterogeneity of
risk amongst the individual studies.10 The overall odds ratios for death, fatal stroke and
stroke and/or death due to endarterectomy for asymptomatic versus symptomatic stenosis
were calculated using the Mantel-Haenszel method.
12.4 Results
Twenty five studies11"35 fulfilled the criteria for inclusion in the review. All studies reported
the total number of strokes and deaths, but three studies did not give the number of deaths
separately.14'31'35 There were no deaths in one study.19 Thus, the overview ofmortality odds
ratios was based on 21 studies including 2521 operations for asymptomatic stenosis and
9529 operations for symptomatic stenosis (figure 12.1), and the overview of stroke and
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death was based 25 studies including 3139 operations for asymptomatic stenosis and
11917 operations for symptomatic stenosis (figure 12.1).
There were 33 deaths (1.31%, 95% CI = 0.80-1.78) attributed to endarterectomy for
asymptomatic stenosis and 172 deaths (1.81%, 1.46-2.13) attributed to surgery for
symptomatic stenosis (odds ratio = 0.69, 0.49-0.99). The relative odds of death following
surgery for asymptomatic vs symptomatic stenosis showed no statistically significant
heterogeneity between studies (X2 = 12.6, df=20, P=0.90). Two studies gave no
information on the causes of death."'24 Among the remainder, the risk of non stroke
death was 0.81% (0.48-2.25) following surgery for asymptomatic stenosis and 0.80% (0.60-
0.99) following surgery for symptomatic stenosis. The risk of fatal stroke was 0.47% (0.20-
0.79) for asymptomatic stenosis and 0.91% (0.51-1.14) for symptomatic stenosis (odds ratio
= 0.57,0.38-0.98).
In no single study was the risk of stroke and death due to endarterectomy for asymptomatic
stenosis statistically significantly lower than the risk for symptomatic stenosis. However,
there was a trend towards a lower risk for asymptomatic stenosis in 24 of the 25 studies. The
overall risks of stroke and death were 3.35% (2.38-4.31) for asymptomatic stenosis and 5.18
(4.30-6.06) for symptomatic stenosis (odds ratio = 0.61, 0.51 - 0.74, figure 12.1). There was
no significant heterogeneity between studies in the relative odds of stroke and death
following surgery for asymptomatic vs symptomatic stenosis (X2 = 13.6, df=24,
P=0.96).
12.5 Discussion
Although no single study demonstrated a statistically significant difference, the overall
mortality and risk of stroke and/or death due to carotid endarterectomy for asymptomatic
stenosis were significantly lower than for symptomatic stenosis in this systematic review.
Indeed, this observation was remarkably consistent across almost all the studies suggesting
that the finding is generalisable. The absolute estimates of risk are susceptible to publication
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bias and might, therefore, be underestimates. However, the relative odds of complications
following surgery for asymptomatic versus symptomatic stenosis are unlikely to be biased
because the comparisons were made within studies. The operations on both groups were
performed by the same surgeons or in the same institutions.
The risks of non-stroke death attributed to endarterectomy were almost identical for
symptomatic and asymptomatic stenosis. The 40% difference in the overall odds of stroke
and death was, therefore, accounted for by the significantly lower risks of fatal and non¬
fatal stroke associated with surgery for asymptomatic stenosis.
Why is surgery safer for asymptomatic stenosis? Symptomatic patients have by definition
already suffered a stroke or transient ischaemic attack in the distribution of the artery which
is to be operated, and the same factors which caused the presenting symptoms, such as
intra-luminal thrombosis or poor collateral circulation, might also predispose to stroke at
operation. Additionally, clinical characteristics, such as age, sex or the proportion with
coexisting cardiac disease, may differ between symptomatic and asymptomatic patients.
Only one of the 25 studies reviewed compared the characteristics of the two groups of
patients.18 There were no differences. Similarly, the reported baseline characteristics of
the patients randomised to surgery in the ACAS and VA asymptomatic trials3'8 are almost
identical to those in the ECST and NASCET symptomatic studies.1'2 As far as one can tell,
symptomatic and asymptomatic patients appear to have similar clinical characteristics.
The 3.35% overall risk of stroke and death due to endarterectomy for asymptomatic stenosis
is similar to the 4.3% risk in the VA trial,8 and is in keeping with the 3% limit set by the
American Heart Association.37 It is, however, statistically significantly greater than the
1.5% risk in the ACAS trial.3 This difference is difficult to explain, and casts some doubt
on the generalisability of the ACAS trial results to more routine surgical practice.
In conclusion, the mortality and risk of stroke and death due to carotid endarterectomy
performed by the same surgeons or in the same institutions is approximately 40% lower for
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asymptomatic stenosis than for symptomatic stenosis. This finding is very consistent and is
likely to be widely generalisable.
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12.7 Figure
Figure 12.1. The odds of death and the odds of stroke and death associated with carotid
endarterectomy for asymptomatic versus symptomatic carotid stenosis within 25 studies
identified from the published literature. The number of deaths, strokes and operations are
given and odds ratios of less than one indicate a lower risk for asymptomatic stenosis. For
each study, the square represents the odds ratio and the line represents the 95% confidence
interval of the odds ratio. The size of the square is inversely proportional to the variance of





























































































































































































Morbidity and case fatality due to carotid endarterectomy in the ECST: absolute










Background andpurpose: Chapter 11 demonstrated how the published risks of stroke and death
due to carotid endarterectomy vary with study authorship. Given the difficulty in interpreting the
published literature, it is useful to study the risks of stroke and death in cohorts of patients which
were established prospectively and in which the decision to analyse and report the results was not
data-dependent. The ECST surgery patients represent a large cohort of patients with symptomatic
carotid stenosis in which the complications of carotid endarterectomy were assessed by a
neurologist as well as a surgeon. These data are likely to provide as accurate an estimate as
possible of the true morbidity and mortality of carotid endarterectomy, at least as it was performed
by experienced surgeons in Europe in the 1980s and 90s. In addition, analysis of the individual
patient data allows non-randomised examination of the interactions between the operative risk of
stroke and death and different clinical and angiographic characteristics, different operative and
anaesthetic techniques, and different surgeons.
Methods: The risk of stroke lasting longer than seven days and death within 30 days of
endarterectomy was analysed in ECST surgery patients in relation to baseline clinical and
angiographic characteristics, operative and anaesthetic techniques and individual surgeons.
Results: Among the 1729 patients who were randomised to surgery and underwent carotid
endarterectomy within one year of randomisation, there were 18 deaths within 30 days of
surgery (1.0%, 95% CI = 0.6-1.6) and 105 non-fatal strokes lasting longer than seven days
(6.1%, 95% CI = 5.0 - 7.3). The risk of death or stroke lasting longer than seven days was 7.1%
(95% CI = 5.9-8.4). Several clinical and angiographic characteristics appeared to predict the
operative risk of stroke and death in univariate analyses, but there were only four independent risk
factors in a multiple regression analysis. Presentation with ocular ischaemic events only (as
opposed to cerebral events or both) was associated with a low operative risk, whereas female sex,
systolic hypertension and peripheral vascular disease were each associated with a high operative
risk. These risk factors remained significant after correction for operative and anaesthetic
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technique. There was considerable variation in the use of intra-operative shunting, patching, and
EEG monitoring. However, none of these factors appeared to be independent predictors of
operative stroke and death. The only operative technique which appeared to predict operative risk
was use of anticoagulants during surgery. Anticoagulants were associated with a reduction in
operative risk. Overall, there was little evidence of important heterogeneity of operative risk
among individual surgeons.
Conclusions: The operative risks of stroke and death in the ECST were comparable with those in
NASCET and in other similar published studies. The risk appeared to be related to a number of
baseline clinical characteristics of the patients but, for the most part, was unrelated to surgical
techniques or the identity of the individual surgeons.
13.2 Introduction
Chapters 11 and 12 examined the published risks of stroke and death due to carotid
endarterectomy. However, as was suggested by the variation in reported risks with study
authorship in Chapter 11, there is likely to be a degree of publication bias. One would expect
there to be a tendency for surgeons or institutions with a high operative risk to be less inclined to
publish their data than those with low risks. It is useful, therefore, to look at the absolute risks of
stroke and death in cohorts of patients which were established prospectively and in which the
decision to analyse and report the results was not data-dependent. The ECST surgery patients
represent such a cohort. In fact, they are the largest published cohort of patients with symptomatic
carotid stenosis in which the complications of carotid endarterectomy were assessed by a
neurologist as well as a surgeon. The ECST data are, therefore, likely to provide as accurate an
estimate as possible of the true morbidity and mortality of carotid endarterectomy, at least as it
was performed by experienced surgeons in Europe in the 1980s and 90s.
In addition to providing accurate estimates of the absolute risks of the procedure, analysis of the
ECST data has another advantage when compared with the published data examined in the
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previous two chapters. Having access to the individual patient data allows more complex analyses
of the interactions between different variables and the operative risks. It is possible to get some
insight into the extent to which these risks are dependent on the characteristics of the patient, the
surgical or anaesthetic technique, and the individual surgeon. Although all commentators stress
the need for continuing audit of operative performance if the benefits of endarterectomy
demonstrated in recent trials are to be translated into clinical practice,1"3 it is unclear to what
extent the operative risks of a particular surgeon, or a particular institution, are a reflection of
case-mix, surgical or anaesthetic technique, or operative skill. Some of the analyses presented in
this chapter cast a certain amount of light on this issue.
13.3 Methods
Surgery data recorded in the ECST
The methods of the ECST have been discussed in previous chapters. Briefly, patients were
randomised if they had suffered a carotid distribution transient ischaemic attack, minor ischaemic
stroke, non-disabling major ischaemic stroke, or a retinal infarction within the previous six
months, and if, after a carotid angiogram, the neurologist and surgeon were uncertain whether
to recommend carotid endarterectomy. Patients were randomised to "immediate surgery" (60%)
or to "avoid immediate surgery" (40%). At randomisation, certain baseline clinical data were
recorded and sent to the main trial centre along with the pre-randomisation carotid angiogram
and a pre-randomisation computed tomographic (CT) brain scan, if abnormal. The degree of
stenosis at the origin of both internal carotid arteries was measured by two observers (PMR and
CPW) on the angiogram by the ECST method.
It was strongly recommended that the surgeon performing the endarterectomy was the
collaborating surgeon and not a trainee or assistant. The surgeon recorded details of the operation
and of any adverse events which occurred prior to hospital discharge. Patients were reviewed by
a neurologist four months after the operation. The main operative outcomes studied were death,
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non-fatal stroke lasting longer than seven days, and non-fatal myocardial infarction. Clinical
details of outcomes, including CT scan and necropsy reports where available, were sent to the
main trial centre for classification by a neurologist and then by a blinded clinical audit
committee. Details of any reoperation or post-operative arterial imaging were also requested.
The local neurologist recorded the actual or expected disability on the Rankin scale4 six
months after each stroke. Myocardial infarction was defined on the basis of a suggestive
clinical history with either electrocardiographic changes or increased cardiac enzyme
concentrations. Other routinely recorded outcomes included local haematoma requiring surgical
drainage, deep venous thrombosis, pulmonary embolus, transient ischaemic attack and stroke
lasting less than seven days, nerve palsy and wound infection.
Analysis
Only events occurring within 30 days of surgery are included in the analyses presented here. Four
patients had a stroke in the territory of the symptomatic carotid artery after randomisation but
prior to surgery, and were not, therefore, operated. They are excluded from the analyses in this
chapter, although they would, of course, be included in any intention-to-treat analysis of the
overall effect of endarterectomy on the risk of stroke.
Severity of operative strokes: Analyses of the efficacy of endarterectomy are usually based
simply on the effect of the operation on the absolute number of strokes which occur on medical
treatment only vs surgical treatment. However, this assumes that the strokes in the two groups are
of similar severity. In order to determine whether or not this is the case, the range of disability due
to strokes occurring within 30 days of surgery was compared with that due to first stroke on
follow-up in the no-surgery group.
The effect of clinical and angiographic characteristics on operative risk: The operative risk of
stroke and death was stratified according to the presence or absence of each of the clinical and
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angiographic characteristics which were recorded at randomisation (tables 13.4 and 13.6). These
factors were then entered into a forward stepwise multiple logistic regression analysis (SPSS for
Windows, version 7.0) predicting the operative risk of stroke and death. Variables were entered at
a significance level of P=0.05 and removed at a level ofP=0.1.
The effect of surgical and anaesthetic technique on operative risk: The operating surgeon
recorded information on use of: local vs general anaesthetic; intra-operative carotid artery shunt;
carotid patch graft; intra-operative anticoagulation; and intra-operative EEG monitoring. The
association between the use of each of these techniques and the operative risk of stroke and death
was examined. The associations were then corrected for any differences in case-mix using the
prognostic model derived from analysis of the clinical and angiographic characteristics discussed
above. It was assumed that there would be interactions between the use of the various different
surgical techniques. For example, patients operated under local anaesthetic would be less likely to
have had EEG monitoring than those operated under general anaesthetic. A further multiple
logistic regression analysis was therefore performed to correct the apparent associations between
each of the surgical techniques and the risk of operative stroke and death for use of other
techniques.
Heterogeneity of operative risk of stroke and death attributable to individual surgeons: The
extent to which the operative risks of individual surgeons are related to surgical skill and
experience is very difficult to assess. Heterogeneity of operative risks of stroke and death could
be tested across all surgeons in the trial using either a parametric approach (e.g. analysis of
variance) or a non-parametric approach (e.g. chi squared test for heterogeneity). However, since
147 surgeons had operated in the trial, the majority operating on only a very small number of
patients, the requirement of these tests for 146 degrees of freedom would make it difficult to
detect genuinely important heterogeneity among the relatively small number of surgeons who had
performed a significant number of operations in the trial. Moreover, a standard test for
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heterogeneity, such as a chi-squared test, cannot be used because the numbers of expected
adverse events for each surgeon are so low. With an overall rate of stroke and death of 7.1%,
only two of the surgeons would have an expected number of adverse events of greater than 5.
Similarly, an analysis of variance or a regression analysis would be difficult to interpret when
there are more surgeons than there are operative strokes and deaths. However, rather than tiying
to test for overall heterogeneity of risk, it is possible to look for outliers i.e. individual surgeons
whose operative risks appear to be higher or lower than the groups' as a whole. A graphical
approach to testing for heterogeneity of operative risk of stroke and death was therefore used. The
scatter of the risks of individual surgeons was related to various confidence intervals for the
overall risk of stroke and death as a function of the number of operations performed.
Interactions between the effects of case-mix, operative technique and surgeon-. Each of these
potential determinants of operative risk are likely to be related. For example, certain surgeons are
likely to use particular surgical techniques more than others and certain operative or anaesthetic
techniques are likely to be used more commonly in patients with particular clinical characteristics.
The presence of such interactions was assessed and the relationships between the various factors
and operative risk was again assessed using multiple logistic regression analysis in order to try to
identify which factors were independently related to the outcome.
13.4 Results
Information on a total of 1791 (99%) of the ECST patients who were randomised to carotid
endarterectomy was available for analysis. Sixty two (3%) of these did not undergo surgery. Of
the 1202 patients randomised to medical treatment, 116 eventually underwent carotid
endarterectomy during the next year. However, this paper is confined to the 1729 patients who
were randomised to surgery and underwent carotid endarterectomy within one year of
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randomisation. The mean time from last ipsilateral carotid territory cerebrovascular symptoms
to surgery was 85 days [95% range = 10 - 240]. The median delay between randomisation and
surgery was 23 days [95% Range = 1 - 100], Details of the post-operative assessment by the
surgeon and the one month assessment by the study neurologist were available in all cases.
Table 13.1. Case fatality and risk ofmajor stroke within 30 days of carotid endarterectomy.
The data refer to 1729 cases receiving trial surgery.
Complication Cases Risk (95% CI)
Fatal
Stroke 11 0.6% (0.3-1.1)
Myocardial infarction 5 0.3% (0.1-0.7)
Other 2 0.1% (0 -0.3)
Total 17 1.0% (0.6-1.6)
Non-fatal Stroke lasting > 7 days 105 6.1% (5.0-7.3)
Death or stroke lasting > 7 days 122 7.1% (5.9-8.4)
The risk ofmajor stroke or death due to surgery
There were 18 deaths within 30 days of surgery (1.0%, 95% CI 0.6-1.6). All but two of these
occurred within five days of the operation. Eleven deaths were due to stroke (table 13.1). There
were 105 non-fatal strokes lasting longer than seven days within 30 days of surgery (6.1%, 95%
CI = 5.0 - 7.3). The risk of death or stroke lasting longer than seven days was 7.1% (95% CI 5.9-
8.4). A CT brain scan was performed within four weeks of the stroke in 66 (54%) cases. The scan
was normal or showed an infarct in 64 cases and showed an intracerebral haemorrhage in two
cases. Of the 54 cases without a CT scan within four weeks, three had an infarct at autopsy and
five were shown on Doppler or angiography to have occluded the operated artery shortly after
surgery. The stroke was in the territory of the operated artery in 105 (91%) cases, in the
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territory of the contralateral carotid artery in 7 (6%) cases and in the vertebrobasilar territory in 4
(3%) cases. All but 6 occured within 7 days of surgery (figure 13.1).
Other complications ofsurgery
There were 34 (2.0%, 95% CI 1.4-2.7) transient ischaemic attacks and strokes lasting less than 7
days (table 13.2). The combined risk of any stroke or TLA was 8.7% (95% CI 7.4-10.1). In
addition to 4 deaths due to myocardial infarction, there were 4 non-fatal myocardial infarctions
and 4 episodes of unstable angina. The most common minor complications were peripheral
nerve palsy and neck haematoma requiring reoperation (table 13.2).
Table 13.2. Operative complications in 1729 patients within 30 days of carotid endarterectomy.
Complication Cases Risk (95% CI)
Stroke lasting < 7 days or TIA 34 2.0% (1.4-2.7)
Myocardial infarction 4 0.2% (0.1-0.6)
Unstable angina 4 0.2% (0.1-0.6)
Peripheral nerve palsy 111 6.4% (5.3-7.7)
Neck haematoma requiring reoperation 53 3.1% (2.3-4.0)
Wound infection 4 0.2% (0.1-0.6)
Deep venous thrombosis or pulmonary embolism 2 0.1% (0 -0.5)
Severity ofoperative strokes
Neither the case fatality nor the disability due to stroke occurring within 30 days of surgery
differed from that due to first strokes during follow-up in the no-surgery group (table 13.3).
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Table 13.3. Comparison of disability due to strokes within 30 days of carotid endarterectomy with that




Surgery No surgery P
Fatal 11 (10%) 26 (14%) ns
Disabilty after 6 months
in survivors1
Rankin 0-2 64 (55%) 104 (56%) ns
Rankin 2-6 41 (35% 56 (30%) ns
Total 116(100%) 186(100%) -
1 disability not known in six endarterectomy cases
The effect of clinical and angiographic characteristics on operative risk
The operative risk of major stroke and death is stratified according to clinical characteristics in
table 13.4. The characteristics which were associated with a higher than expected risk of stroke
and death were female sex, systolic blood pressure > 180 mmHg at baseline assessment, cerebral
transient ischaemic attack and peripheral vascular disease. Patients with ocular symptoms only
(amaurosis fugax or retinal artery occlusion) had a lower than expected stroke risk. Age,
diabetes mellitus, and the presence of infarction in the territory of the symptomatic artery on the
randomisation CT brain scan were not related to stroke risk.
The operative risk of major stroke and death is stratified according to angiographic characteristics
in tables 13.5 and 13.6. The only characteristics which were associated with statistically
significant heterogeneity of operative risk of stroke and death were the degree of stenosis of the
operated artery (x2 = 24.7, df=9, P=0.003 across the ten deciles of stenosis, table 13.5, figure 13.2)
and disease (stenosis close to the origin of at least 20%) of the ipsilateral external carotid artery
(odds ratio = 1.61, 95% CI = 1.05 - 2.47, table 13.6). Two operative strokes occurred among the
11 cases in which no pre-randomisation angiogram was available, and one stroke occurred among
the seven patients who were found to have an occluded artery at operation. These cases were
excluded from the analysis in table 13.5.
278
Table 13.4. Clinical characteristics of patients who died or suffered a non-fatal stroke lasting longer than
seven days within 30 days of carotid endarterectomy.
Stroke or death within 30 days of surgery
Variables No Yes Risk Odds ratio (95% CI)
Sex Female 429 51 10.6% 1.97(1.4-2.9)
Male 1178 71 5.7%
Age <50 120 9 7.0% 1.01 (0.5-2.0)
50-60 466 30 6.0% 0.82 (0.5-1.3)
60-70 743 60 7.5% 1.16 (0.8-1.7)
>70 280 21 7.0% 1.01 (0.6-1.6)
Systolic BP < 120 144 5 3.4% 0.44 (0.2-1.1)
(mmHg) 120-160 1096 76 6.5% 0.77 (0.5-1.1)
160-180 253 25 9.0% 1.38 (0.9-2.2)
> 180 114 16 12.3% 2.13 (1.2-3.7)
Presenting Ocular event 299 9 2.9% 0.35 (0.2-0.7)
Symptoms Stroke 756 53 6.6% 0.87 (0.6-1.3)
Cerebral TIA 552 60 9.7% 1.85 (1.3-2.7)
Time since 0-1 274 19 6.5% 0.87 (0.5-1.5)
last symptoms 1-3 679 52 6.9% 0.98 (0.7-1.4)
(months)1 >3 618 51 7.6% 1.11 (0.8-1.6)
Number of events 0-3 972 67 6.5% 0.79 (0.5-1.1)
in last 3 months2 3-5 428 35 7.6% 1.10 (0.7-1.7)
>6 199 20 9.1% 1.38 (0.8-2.3)
Peripheral vascular Yes 249 35 12.3% 2.19 (1.5-3.3)
disease No 1358 87 6.0%
Diabetes mellitus Yes 178 15 7.8% 1.13 (0.6-2.0)
No 683 54 7.3%
Angina Yes 281 24 7.9% 1.16 (0.7-1.8)
No 1326 98 6.9%
Previous myocardial Yes 200 19 8.7% 1.30 (0.8-2.2)
infarction No 1407 103 6.8%
Myocardial infarction Yes 43 5 10.4% 1.55 (0.6-4.0)
during previous year No 1564 117 7.0%
Infarct on CT Yes 398 33 8.3% 1.12 (0.7-1.7)
brain scan3 No 1165 86 7.4%
1
not known in 36 cases 2 not known in 9 cases 3 not known in 47 cases
The relationship between the degree of stenosis of the internal carotid artery and the operative risk
was non-linear. In particular, it appeared to be lower in patients with very severe stenosis (80-
99%) than in patients with less severe disease (4.6% vs 7.6%, OR = 0.59, 95% CI = 0.34- 1.01).
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Table 13.5. The risk of stroke and death within 30 days of endarterectomy in patients randomised to
surgery in the ECST by decile of stenosis of the symptomatic carotid artery. Data are based 120 events
among 1711 patients - one operative stroke occurred among the 9 cases in which no pre-randomisation
angiogram was available, and one stroke occurred among the 9 patients who were found to have an occluded
artery at operation. These cases and events were excluded from the table.
Stenosis (%): 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-9?
Cases 6 68 148 191 180 329 215 227 246 101
Strokes 0 6 2 13 18 22 22 21 12 4
Risk (%) 0 8.8 1.4 6.8 10.0 6.7 10.2 9.3 4.9 4.0
X2 for heterogeneity = 24.7, df=9, P=0.003
There was a trend towards -higher than expected risk of stroke and death associated with
occlusion of the contralateral carotid artery, but no obvious relationships with angiographic plaque
surface irregularity or stenosis (at least 20%) of the ipsilateral carotid siphon (table 13.6).
Table 13.6. Angiographic characteristics of patients who died or suffered a non-fatal stroke lasting longer
than seven days within 30 days of carotid endarterectomy.
Stroke or Death within 30 days ofSurgery
Variables No Yes Risk OR (95% CI)
Contralateral 0-29% 797 58 6.8% 0.91 (0.62-1.33)
carotid 30 - 69% 572 44 7.1% 1.01 (0.69-1.50)
stenosis1 70 - 99% 84 6 6.7% 0.93 (0.40-2.10)
occlusion 42 6 12.5% 1.92 (0.80-4.62)
Ipsilateral external Yes 278 31 10.0% 1.61 (1.05-2.47)
carotid stenosis2 No 1284 89 6.5%
Ipsilateral carotid Yes 978 82 7.7% 1.34 (0.65-1.94)
plaque irregularity3 No 639 40 5.9%
Ipsilateral carotid Yes 172 15 8.0% 1.31 (0.74-2.34)
siphon stenosis4 No 1114 74 6.2%
1
not known in 120 cases; 2 not known in 47 cases; 3 not known in 18 cases; 4 not known in 354 cases
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The results of a stepwise multiple logistic regression analysis based on all the clinical and
angiographic characteristics listed in tables 13.4-13.6 are given in table 13.7. Four
characteristics were independent risk factors for stroke lasting longer than seven days or death
within 30 days of endarterectomy. Presentation with ocular ischaemic events only (as opposed to
cerebral events or both) was associated with a low operative risk, whereas female sex, systolic
hypertension and peripheral vascular disease were each associated with a high operative risk.
Table 13.7. A multiple regression analysis of the operative risk of stroke and death in the 1729 patients
who underwent carotid endarterectomy in the ECST in relation to the potential clinical and angiographic
risk factors.
Risk Factor " Hazard Ratio (95% CI) P
Ocular vs cerebral symptoms 0.46 (0.24 - 0.91) 0.02
Female sex 1.41 (1.16 - 1.70) 0.0005
Systolic hypertension (> 180mmHg) 1.93 (1.22 - 3.04) 0.005
Peripheral vascular disease 1.44 (1.17 - 1.79) 0.0007
The effect of surgical and anaesthetic technique on operative risk
The relationships between the surgical and anaesthetic techniques recorded in the ECST and the
risks of operative stroke and death are given in table 13.8. In these non-randomised comparisons,
the operative risks were significantly higher in those patients who were not anticoagulated during
surgery and those patients in whom a shunt was used. There were non-significant trends towards
lower risks associated with use of local anaesthetic and EEG monitoring, and a trend towards a
higher risk associated with use of patch grafting.
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Table 13.8. The operative risk of stroke and death due to endarterectomy in ECST surgery patients according
to the use of various surgical and anaesthetic techniques. Statistical significance is tested using a chi-squared
test unless stated otherwise.
Stroke or Death within 30 days of Surgery


















































0.68 (0.45 - 1.01) 0.06
1
not known in 10 cases 2 not known in 14 cases 3 not known in 18 cases 4 Fisher exact test (two tailed)
There were however significant differences in the clinical and angiographic characteristics
between patients in whom the various techniques were used (table 13.9). Although the statistical
significance of the comparisons in table 13.9 have not been corrected for multiple comparisons,
some of the significant results are likely to reflect genuine policies. For example, the higher than
expected proportion of patients aged over 75 years undergoing the operation under local
anaesthetic and the lower than expected usage of EEG monitoring during local anaesthesia would
be expected. Some of the other apparent interactions between operative techniques and baseline
characteristics may well be due to chance. However, this is not important, since they will
influence the operative risk associated with use of the technique irrespective of whether they are
the result of chance or a definite policy.
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Table13.9.Comparisonofthroportionfca esundergoingsu gerywi hparticularoperativetechniquw dpa tic larcli ic lch ract risticw thp oportionf thewholesurgerygr uphohadt atc ar ct ristic.St tis icalcompa i onseperformedus gX2t trFi he 'sx cttwh repp opriate. TechniqueAllcasesProportionfcasesundergoingsurgeryw thparticulartechniquewh vtclinicalcharacteristic LocalanaestheticAnticoagulationP tchgr ftC otiduntEEGm i oring Age>75years Femalesex Oculareventso ly Peripheralvascular disease SystolicBP>180mmHg Carotidstenosis>80%94(5.4%) 481(27.8%) 251(14.4%) 284(16.3%)7(12.1%)P=0.02 12(20.7%)P=0.23 5(8.6%)P=0.20 2(3.4%)P=0.007 226(13.0%)3(5.2%P=0. 7 347(20.0%)5(8.6P=0.0387(5.4%)P=0 83 437(27.3%)P=0.30 225(14.1%)P=0.15 252(15.8%)P=0.0329(6.1%)P=0 46 130(27.1%)P=0.77 55(12.8%)P=0.03 86(18.0%)P=0.26 205(12.8%)P=0.4663(13 2 )P=0 90 327(20.5%)P=0.0899 .7 )P= 65
38(6.1%)P=0 37 191(30.4%)P=0.05) 86(13.7%)P=0.51 109(17.4%)P=0.38
18(2.8%)P=0.0003 179(28.0%)P=0.8 83(13.0%)P=0.19 95(14.9%)P=0.21
89(14.2%)P=0.27(13 1 )P=0.89 140(22.3%)P=0.07133(38. %)P= .49
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Given the apparent differences between patients who underwent surgery with the different
techniques, it was necessary to attempt to correct the associations with operative risk for case-mix.
This was done by including the six baseline characteristics detailed in table 13.9 in a multiple
logistic regression analysis along with each surgical or anaesthetic technique. Both the crude and
corrected associations between each of the techniques and the operative risk of stroke and death
are shown in table 13.10.
Table 13.10. The uncorrected hazard ratio for operative risk of stroke and death due to endarterectomy
according to the use of various surgical and anaesthetic techniques and the same hazard ratio corrected for
differences in the baseline characteristics listed in table 13.7.
Stroke or Death within 30 days of surgery
Uncorrected Corrected
Technique Hazard ratio (95% CI) P Hazard ratio (95% CI) P
Local anaesthetic 0.22 (0.03 - 1.60) 0.12 0.27 (0.04- 1.97) 0.20
Anticoagulation 0.41 (0.24-0.71) 0.001 0.43 (0.26-0.73) 0.002
Carotid shunt 1.52 (1.05-2.20) 0.02 1.39 (0.96-2.03) 0.08
Patch graft 1.31 (0.88- 1.95) 0.18 1.20 (0.81 - 1.80) 0.36
EEG monitoring 0.68 (0.45- 1.01) 0.06 0.66 (0.44- 1.00) 0.05
Each of the associations were weaker when corrected for case-mix apart from the decreased risk
associated with EEG monitoring. The increased operative risk associated with the use of carotid
shunting was no longer significant when corrected for case-mix, but the decreased risk associated
with intra-operative anticoagulation remained highly significant.
The surgical and anaesthetic techniques were not, of course, used independently. If one technique
was employed this would affect the likelihood of some of the other techniques being used. The
interactions between the use of the different techniques are shown in table 13.11.
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Table 13.11. The number and observed/expected ratio of cases undergoing surgery with a particular
operative technique who were also subject to the other techniques. Statistical comparisons are performed
using a X2 test or Fisher's exact test where appropriate.
Number and observed/expected cases undergoing surgery with both techniques
Technique Anticoagulation Patch graft Carotid shunt EEG monitoring
Local anaesthetic 58, 1.07, P=0.02 16, 0.98, P=0.99 7, 0.33, PO.OOl 6, 0.28, T3AO OO
Anticoagulation 462, 1.05, PO.OOl 591, 1.02, P=0.01 603, 1.02, IIo oo G/l
Patch graft - 266, 1.54 PO.OOl 167,0.94, P=0.3
Carotid shunt -- 121,0.52, PO.OOl
Some of the interactions detailed in table 13.11 were major. For example, patients who had an
intraoperative shunt were 54% more likely to have a patch graft and 48% less likely to have EEG
monitoring than those who were not shunted. The apparent associations between each of the
techniques and operative risk should, therefore, be corrected for interactions due to differential use
of other techniques. Table 13.12 shows the results of a multiple logistic regression analysis in
which the associations were corrected for the use of other techniques as well as clinical case-mix.
Table 13.12. The associations between the use of the various anaesthetic and surgical techniques and the
operative risk of stroke and death corrected for clinical case-mix and use of the other techniques.
Technique Hazard ratio (95% CI) P
Local anaesthetic 0.29 (0.04 - 0.47) 0.22
Anticoagulation 0.43 (0.25 - 0.74) 0.002
Patch graft 1.22 (0.80- 1.87) 0.35
Carotid shunt 1.25 (0.83 - 1.88) 0.22
EEG monitoring 0.72 (0.47 -1.11) 0.14
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The apparent associations between the operative risk of stroke and death and the use of EEG
monitoring and carotid shunting which were detailed in table 13.10 were no longer present when
corrected for interactions with the use of other techniques. However, the decreased operative risk
associated with intra-operative use of anticoagulants remained.
Finally, with regard to surgical and anaesthetic techniques, it is interesting to look at the variation
in usage of these techniques by different surgeons. Figure 13.3 shows the number of surgeons
who used local anaesthetic in a proportion of their patients and the numbers who used intra¬
operative anticoagulants. This analysis was restricted to the 54 surgeons who had 10 or more
patients in the trial in order that the proportions for each surgeon would be sufficiently meaningful
to interpret (10 out of 10 is more informative than one out of one). Only four of the 54 surgeons
operated under local anaesthetic and none of these used it in more than 40% of their patients.
Intraoperative anticoagulation was used in all patients by 38 (70%) surgeons and in at least 70%
of patients by all but two surgeons. There was much less consistency in the use of the other
techniques (figure 13.4). Many surgeons did not use EEG monitoring, shunting and patching in
any of their patients whilst others used these techniques in all of their patients. Relatively few
surgeons used the techniques selectively in only a proportion of patients. The fact that the use of
techniques across the group of surgeons was very non-uniform could, of course, have an effect on
the apparent relationship between use of a particular technique and operative risk. Heterogeneity
of operative risk of stroke and death attributable to individual surgeons is discussed below.
Heterogeneity ofoperative risk ofstroke and death attributable to individual surgeons
A total of 147 surgeons operated in the trial. However, 22 operated on only one patient, and 93
operated on fewer than 10 patients. In contrast, the two most active surgeons operated on 75 and
90 patients, and the 10 most active surgeons (7% of all trial surgeons) operated on 523 (30%)
patients. The detailed distribution is given in table 13.13.
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Table 13.13. The number of cases operated on within the trial by each of the ECST surgeons
Number of cases: 1 2 3 4 5 5-9 10-19 20-30 40-60 60-100
Surgeons: 22 10 13 10 9 29 30 15 7 2
As discussed in the analysis section of the methods, heterogeneity of operative risk between
surgeons is best assessed using a simple graphical approach. Firstly, if one considers the 71
surgeons who had no operative strokes or deaths at all, it is possible to examine whether or not
any of these surgeons had an operative risk which was significantly lower than that of the rest of
the group. Figure 13.5 shows the upper 95% confidence interval of the operative risk of a
surgeon who had no operative events according to the number of operations he performed. It is
evident that the surgeon would have to perform at least 50 operations before the upper confidence
interval of his or her risk fell below the overall operative risk of stroke and death of 7.1%. Figure
13.6 shows the number of operations performed by those surgeons who had no operative events.
Over half had performed three operations or less and only nine had operated on over ten patients,
the maximum number being 24. Thus none of these cases had an operative risk which would be
outwith the expected range of risks assuming a true risk of 7%.
Secondly, if one considers the surgeons who did have at least one operative stroke or death, a
similar approach is possible. Figure 13.7 shows the operative risks of each of these surgeons and
the number of patients on which each of the risks were based. There was only one surgeon,
Surgeon X, for whom the operative risk was outwith the upper 90% confidence interval of a 7%
risk. Indeed, this surgeon's risk was outwith the 99% confidence limit. However, with the
exception of this surgeon, there was remarkably little heterogeneity apparent among the risks of
the other surgeons. No other surgeon had a risk which was outwith the 90% confidence intervals
of a 7% risk. Given that there were 76 surgeons who had at least one adverse event, one might
reasonably expect to find approximately four (5%) of them to have risks above the 90%
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confidence limit of the overall risk by chance alone. This analysis demonstrates, therefore, that
there was remarkably little heterogeneity of operative risk by surgeon.
Surgeon X
Given that Surgeon X was such an obvious outlier in figure 13.7, it is reasonable to look at his or
her risk more closely. Surgeon X operated on 50 patients and had 11 operative strokes or deaths.
The 22% operative risk was significantly greater than that in the rest of the group (11/50 vs
111/1679, OR = 4.0, 95% CI = 2.0-8.0, X2 = 17.5, dfr=l, P=0.00003). The probability of such a
difference occurring by chance is 1 in 33,333. Although the observation is data derived, even if
this probability is divided by the number of surgeons who took part in ECST (i.e. 33,333/147), it
is still low at 1 in 227 (or P <0.005). The high operative risk recorded by SurgeonX may well be
real rather than the result of chance. However, it does not necessarily follow that SurgeonXwas a
poor surgeon. As detailed above, operative risk also depends on clinical case-mix and operative
and anaesthetic techniques. Correction of the odds ratio for operative stroke and death associated
with Surgeon X for the baseline characteristics defined in table 13.7, and for the operative and
anaesthetic techniques listed in table 13.8, reduces the association to well within the range of
chance (odds ratio = 1.9, 95% CI = 0.6 - 5.2, P=0.2).
13.5 Discussion
Operative morbidity andmortality in the ECST
The morbidity and mortality data for trial surgery in the ECST are likely to be reliable. Patients
were assessed by both a study surgeon and a study neurologist. Post-operative assessment by the
surgeon was available in all cases and assessment by the neurologist in over 99% of cases. The
1% mortality due to endarterectomy for symptomatic carotid stenosis in the ECST is lower that
found in the systematic review of the published literature reported in Chapter 11, but the 7%
risk of stroke and death is greater than that estimated from the literature. Interestingly, however,
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the risk of stroke and death is similar to the risk reported in those studies in which outcome was
assessed by neurologists (see Chapter 11).
Although, the overall risk of stroke and death due to endarterectomy in ECST is greater than
that reported in NASCET, this difference disappears when the same range of stenosis is compared
i.e. 80-99% ECST stenosis vs 70-99% NASCET stenosis.5 The NASCET risk of 5.8%
(19/328, 95% CI = 3.5 - 8.9) is, in fact, slightly higher than the ECST (80-99% stenosis) risk of
4.6% (95% CI = 2.7 - 7.4). However, this difference is not statistically significant and is partly
accounted for by the fact that the ECST risk is restricted to strokes lasting longer than 7 days. In
practical terms, therefore, the risks of stroke and death due to endarterectomy appear to be
similar in the two studies. The ECST and NASCET risks are not, of course, generalisable to
all surgeons, but they are likely to be reasonable estimates of best practice.
The proportion of strokes within 30 days of endarterectomy which were disabling or fatal
(Rankin >2) was almost identical to the proportion in patients on medical treatment only (45%
vs 44% respectively). This is an important observation which has not been made previously.
Although an outcome based on disability-free survival is likely to be the most appropriate
measure of the benefit of carotid endarterectomy, these findings suggest that simple comparisons
of the numbers of strokes in the two treatment groups are unlikely to be biased for or against
endarterectomy with regard to disability.
Most reviews of the complications of carotid endarterectomy concentrate on the risks of
stroke and death. These are the major outcomes of interest, but a significant amount of the total
morbidity following endarterectomy is due to causes other than stroke. Excluding the pre¬
operative anxiety and the discomfort following the operation, there was a 3% risk of wound
haematoma requiring re-operation, a 6.5% risk of cranial nerve palsy and small, but
nevertheless important, risks of non-fatal myocardial infarction, unstable angina, deep venous
thrombosis and pulmonary embolism. These risks are comparable to those reported in NASCET.6
Similar risks of cranial nerve injury have been reported previously.7,8 In contrast to these
studies, the ECST did not systematically collect data on which cranial nerve was injured or
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whether recovery was complete. In previous studies the facial, hypoglossal and recurrent
laryngeal nerves are most commonly damaged, and recovery is complete within one year in
approximately 90% of patients.7'8 It is difficult to estimate the disability which is associated
with cranial nerve injury but in some cases it might easily be equivalent to the disability caused by
a minor stroke.
The effect of clinical and angiographic characteristics on operative risk
The apparent effects of the various clinical and angiographic characteristics on the operative risk
in ECST are difficult to interpret in isolation. Each of the relationships between risk factor and
outcome is a subgroup analysis. Two problems stem from this. Firstly, it is impossible to exclude
the possibility of confounding. Is it really female sex which increases operative risk or is there
some other factor which is associated with female sex? A randomised trial of the effect of
female sex is, of course, impossible. Biological gender is fixed and we are unable to allocate it
randomly to a population of patients. It is impossible, therefore, ever to be certain that an analysis
of the effect of gender on operative risk is unconfounded. In other words, risk factor analysis, and
prognostic modelling in general, tells us only about association and not about causation.
However, this is not necessarily a problem. The clinician does not need to know exactly what it is
about being female that increases the operative risk. Rather, he or she simply needs to know
whether the association with an increased risk is robust and generalisable. This brings us to the
second problem. That is the problem of chance associations. Some of the associations in tables
13.4 to 13.6 are likely to be due to chance. The best way to check the validity of these associations
is to look at whether they have been observed previously in independent datasets and to look
prospectively at other similar datasets. Chapter 14 describes a systematic review of the published
literature on the effect of the various clinical and angiographic risk factors on the operative risk of
endarterectomy. The validity of the observations made in this chapter on the ESCT data are,
therefore, discussed in more detail in Chapter 14.
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The effect of surgical and anaesthetic technique on operative risk
There are insufficient data from randomised controlled trials to indicate whether the routine use of
particular surgical techniques (e.g. shunting or patching) or particular anaesthetic/monitoring
techniques (e.g. local anaesthetic or EEG recording) has a significant effect on the operative risk
of stroke and death.9"11 More trials are necessary. However, in the meantime, some information
can be gleaned from non-randomised comparisons such as those in the ECST. These subgroup
analyses are, of course, confounded in the same way as those described above. However, some
correction for known potential confounders, such as clinical and angiographic characteristics, can
be made using multiple regression analysis. Such analyses produce data which are helpful in as
much as they generate hypotheses which help to define the areas in which future trials are likely to
be most helpful.
The data on the usage of the various techniques by different surgeons (figures 13.3 and 13.4)
illustrate one further difficulty with interpretation of the relationship between the techniques and
operative risk. That is the problem of confounding by surgeon. Although, there appears to be little
overall heterogeneity of operative risk among the ECST surgeons, some of the techniques looked
at in the ECST, such as operation under local anaesthetic or operation without anticoagulation,
were used by only a small number of surgeons. It is impossible to be certain, therefore, that the
low operative risk (albeit non-significant) seen with local anaesthetic, for example, is not due to
particularly good surgical skills in the few surgeons who operated under local. However,
techniques such as shunting and patching were used by a much larger proportion of surgeons and
so it is less likely that there might be a chance bias.
There were trends (statistically significant in 2 cases and approaching significance in the other 3
cases) suggesting associations between each of the five surgical or anaesthetic techniques studied
and operative risk of stroke and death (table 13.8). However, there were two obvious causes of
confounding. Firstly, there were differences between the patients in which the different techniques
were used (table 13.9) e.g. patients receiving EEG monitoring were less likely to be over 75
years of age. Secondly, there were significant interactions between the use of the different
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techniques in individual patients (table 13.11) e.g. patients in whom an intra-operative shunt was
used were more likely to be patched and less likely to have EEG monitoring. Correction for case-
mix (table 13.10) and correction for interactions between the techniques (table 13.12) reduced the
size and statistical significance of each of the apparent associations with operative outcome. In
particular, the increased operative risk associated with shunting was no longer evident and the
reduced risk associated with EEG monitoring became non-significant. The hazard ratio suggested
a reduction in operative risk associated with the use of local anaesthetic, but this was non¬
significant. Only intra-operative use of anticoagulants remained significantly associated with
operative outcome with a doubling in the risk of stroke and death in those patients who were not
anticoagulated.
The vast majority of ECST surgeons used intra-operative anticoagulation as a matter of routine.
There is no good evidence from randomised trials that it is effective, but the data presented above
suggest that it might well be. Moreover, there appears to be such uniformity of opinion among
surgeons about the need for routine anticoagulation that a trial would be very unlikely to be viable.
However, although the limitations of non-randomised comparisons must be borne in mind, the
ECST data provide no evidence in support of the effectiveness of the other interventions studied.
Heterogeneity ofoperative risk ofstroke and death attributable to individual surgeons
The problems of confounding discussed above make it difficult to interpret the operative risks of
individual surgeons. However, the ECST represents a cohort of surgeons operating on a
relatively standard population of patients, with standardised data collection and independent
assessment of outcome by neurologists. As described in Chapter 11, publication bias makes it is
very difficult to conclude much from comparisons of published case series operated by different
sugeons. It seems sensible, therefore, to take advantage of the relative standardisation of the
ECST cohort. In fact, figure 13.7 suggests that there was remarkably little heterogeneity of
operative risk. Although it is still theoretically possible that this is due to confounding, it is
intuitively unlikely that variations between surgeons in case-mix or operative technique would
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reduce the apparent heterogeneity. The only outlier was Surgeon X, and it is possible that the
poor results obtained by Surgeon X were due, at least in part, to case-mix. It is, however,
impossible to be certain.
Conclusion
In conclusion, the operative risks of stroke and death in the ECST were comparable with those in
NASCET and in other similar published studies. The risk appeared to be related to a number of
baseline clinical and angiographic characteristics of the patients but, for the most part, appeared to
be unrelated to surgical techniques or the identity of the individual surgeons.
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13.7 Legends to figures
Figure 13.1. The number of strokes and deaths which occurred within 30 days of carotid
endarterectomy in the 1729 ECST patients studied in this chapter according to the time from
surgery to symptom onset.
Figure 13.2 The risk of stroke and death within 30 days of endarterectomy in the ECST
stratified according to the degree of stenosis of the symptomatic carotid artery.
Figure 13.3. The number of ECST surgeons who used local anaesthetic and anticoagulation
during endarterectomy according to the proportion of their patients in whom they used the
techniques.
Figure 13.4. The number of ECST surgeons who used intraoperative carotid artery shunting,
carotid patching or EEG monitoring during endarterectomy according to the proportion of their
patients in whom they used the techniques.
Figure 13.5 The upper 95% confidence interval of an operative risk of stroke and death of 0%
according to the number of cases on which the estimate is based. The dotted line represents the
7.1% risk observed in the ECST.
Figure 13.6 The number of operations performed in the ECST by those surgeons who did not
have any operative strokes and deaths within the trial.
Figure 13.7 The operative risks of stroke and death within the ECST for those surgeons who
had operative risk greater than zero according to the number of operations which they



































































































A systematic review of clinical and angiographic predictors of stroke










Background and purpose: To identify risk factors for operative stroke and death due to carotid
endarterectomy.
Methods'. A systematic review of all studies published between 1980 and 1995 which related the
risk of stroke and death due to carotid endarterectomy to various pre-operative clinical and
angiographic characteristics. Data on the 1729 patients, described in Chapter 13, who underwent
carotid endarterectomy in the ECST were also included in the review.
Results'. Thirty six published studies fulfilled the inclusion criteria and, in conjunction with the
ECST data, allowed the effect of 14 potential risk factors to be examined. The odds of stroke and
death were decreased in patients with ocular ischaemia alone (amaurosis fugax or retinal artery
occlusion) compared with those with cerebral TIA or stroke (7 studies; odds ratio = 0.49, 95% CI
= 0.37-0.66, P<0.00001). The odds of stroke and death were increased in women (7 studies; OR =
1.44, 1.14-1.83, P<0.005), at age over 75 years (10 studies; OR = 1.36, 1.09-1.71, P<0.01), with
systolic blood pressure> 180mmHg (4 studies; OR= 1.82, 1.37 - 2.41, P<0.0001), with peripheral
vascular disease (1 study; OR = 2.19, 1.40- 3.60, P<0.0005), with occlusion of the contralateral
internal carotid artery (14 studies; OR = 1.91, 1.35- 2.69, P0.0001), with stenosis of the ipsilateral
internal carotid siphon (5 studies; OR = 1.56, 1.03 - 2.36, P=0.02), and with stenosis of the
ipsilateral external carotid artery (1 study; OR = 1.61, 1.05 - 2.47, P=0.03). Operative risk was not
significantly related to presentation with cerebral TIA versus stroke, diabetes, angina, recent
myocardial infarction, current cigarette smoking, or plaque surface irregularity at angiography.
Conclusions'. The risk of stroke and death due to carotid endarterectomy is related to several
clinical and angiographic characteristics. These observations may help clinicians to estimate the
likely operative risks for individual patients, and will also facilitate more meaningful comparison of
the operative risks of different surgeons or different institutions by allowing some adjustment for
differences in case mix.
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14.2 Introduction
The absolute benefit derived from carotid endarterectomy is limited by the morbidity and mortality
of the operation itself. The balance of risk and benefit is particularly fine in patients in whom the
risk of stroke on medical treatment is very low to begin with, such as those with asymptomatic
stenosis or amaurosis fugax.1"6 In order to maximise the cost-effectiveness of endarterectomy, we
must identify subgroups of patients who are at high risk of stroke without surgery, but who have a
relatively low operative risk of stroke and death. Much work has gone into prediction of the risk of
major stroke on medical treatment alone,6'7 but there has been less research into the factors which
predict operative risk. Although, as detailed in Chapter 11, there have been at least 126 reports of
the morbidity and mortality of carotid endarterectomy published over the last 15 years, many of
which have made some attempt to identify possible risk factors, there has been no systematic
review of risk factors for operative stroke and death. Such a review is required both in order to
target endarterectomy more effectively and in order to help correct for case-mix in clinical research
and audit. I therefore performed a systematic review of all studies published between 1980 and
1995 which related the risk of stroke and death due to carotid endarterectomy to pre-operative
clinical and angiographic characteristics. The review also includes unpublished data from the
European Carotid Surgery Trial.8'9
14.3 Methods
The methods of the systematic review were detailed in Chapter 14. Briefly, studies were identified
by a single observer from CD-ROM (Cambridge Medline, 1980 - 1986) using the search strategies:
carotid endarterectomy; carotid surgery. The Cochrane Collaboration Stroke Database10 was also
searched, but there was no systematic hand searching of journals. The reference lists of all papers
identified electronically were searched.
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Articles were included in this review if they fulfilled the following criteria: 1) prospective or
retrospective (case note review) study; 2) reported the numbers of strokes and deaths occurring
within 30 days of carotid endarterectomy (or similar time period); 3) endarterectomy performed for
symptomatic stenosis, asymptomatic stenosis or a combination of the two, but not explicitly for
acute stroke; 4) operative risks defined per operation rather than per patient in studies in which
some patients underwent bilateral endarterectomy; 5) operative risk stratified according to one or
more clinical or angiographic characteristics assessed prior to surgeiy; 6) no evidence of a
systematic policy for patients with different characteristics to be operated on by different surgeons
or at different institutions. Unpublished data on the 1729 patients who underwent carotid
endarterectomy as part of the ECST 8'9 were included. Data on the case fatality and surgical
morbidity from the North American Symptomatic Carotid Endarterectomy Trial 11 were available
at the time when this review was done.
The risk of stroke and death was defined per operation. The overall relative odds of stroke and
death for one pre-operative characteristic versus another were calculated using the Mantel-
Haenszel method.12 Differences between studies in the relationship between each clinical
characteristic and operative risk was assessed using the chi squared test for heterogeneity.
14.4 Results
A total of 126 studies reporting the risk of stroke and death associated with carotid endarterectomy
were identified from our literature search. Six studies contained no useful data and 84 did not
stratify operative risk of stroke and death by baseline characteristics. In addition to the unpublished
data from ECST, a total of 36 studies fulfilled the inclusion criteria.3,13"47 One study 47 was
excluded because the data reported overlapped with that of a subsequent study.23 As detailed in
305
Chapter 13, there were 122 major strokes or deaths within 30 days of endarterectomy in the 1729
ECST surgery patients.
The clinical and angiographic characteristics for which the relationship with operative risk was
reported are summarised in table 14.1. Five clinical characteristics were associated with a
statistically significantly increased operative risk of stroke and death: surgery for cerebral
symptoms (stroke or transient ischaemic attack) compared with monocular ischaemia (amaurosis
fugax or retinal artery occlusion) (figure 14.1); female versus male sex (figure 14.2); age above or
below 75 years (figure 14.3); systolic blood pressure > 180 mmHg (figure 14.4); peripheral
vascular disease (figure 14.4). There was no significant heterogeneity between studies in the odds
of stroke or death for any of these risk factors (table 14.1).
Three angiographic characteristics were associated with an increased risk of operative stroke or
death: contralateral internal carotid artery occlusion (figure 14.5); stenosis of the intracranial
portion of the ipsilateral internal carotid artery (figure 14.6); and stenosis of the ipsilateral external
carotid artery (figure 14.6). None of these analyses showed statistically significant heterogeneity
between studies (table 14.1). There was no significant relationship between operative risk and the
presence of diabetes, angina, recent myocardial infarction, plaque surface irregularity or a history
current smoking (table 14.1). There was no difference between the operative risk associated with
cerebral TIA vs stroke (figure 14.7), although there was significant heterogeneity (X2= 14.0, df=6,
p=0.04).
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Meta-analysis of the six published studies suggested that prior stroke was associated with an
increased risk (odds ratio = 1.46, 95% CI = 1.04 - 2.04), whereas the ECST data suggested a
significantly lower risk (odds ratio = 0.62, 95% CI = 0.42 - 0.91).
14.5 Discussion
This is the first systematic review of the clinical and angiographic factors associated with an
increased risk of stroke and death due to carotid endarterectomy. The analysis was restricted to
defining the overall relative odds of stroke and death according to the presence or absence of each
potential risk factor in those studies where the information was available. In view of the marked
variation between different studies in the reported risks of stroke and death due to carotid
endarterectomy demonstrated in Chapter 11, absolute risks were not determined. Restriction of the
analysis to relative odds allowed the inclusion, where appropriate, of data from reports of surgery
for asymptomatic stenosis as well as symptomatic stenosis. Even though, as demonstrated in
Chapter 12, the reported absolute risks of surgery for asymptomatic stenosis are consistently lower
than in patients with symptomatic stenosis, there is no evidence that the relative effect of clinical
characteristics such as age or sex on the operative risk of stroke and death will differ. This is
supported by the lack of statistically significant heterogeneity between studies for any of the risk
factors for which data from studies performed in symptomatic patients were combined with studies
performed in asymptomatic patients.
Clinicalpresentation and operative risk
These data suggest that the risk of stroke and death due to carotid endarterectomy depends on the
type of presenting symptoms. The odds of stroke and death in patients with only ocular symptoms
(amaurosis fugax or retinal artery occlusion) are less than half those in patients with cerebral TIAs.
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Although not strictly comparable, the 2.5% (95% CI= 1.8-3.5) risk of stroke and death in the 8
reports of endarterectomy for ocular symptoms alone is non-significantly lower than the 3.4% (95%
CI = 2.4-4.3) overall risk derived from the 25 studies of endarterectomy for asymptomatic stenosis
detailed in Chapter 12. It is interesting to note that the risk of stroke on medical treatment is also
lower in patients with amaurosis fugax than patients with cerebral TIA.5'6
Contrary to expert guidelines on carotid endarterectomy,48'49 there was no overall difference in the
operative risk of stroke and death in patients operated for stroke compared with those operated for
transient cerebral ischaemia, although there was statistically significant heterogeneity between
studies. The increased risk in patients operated for stroke in the published studies may well have
been due to the inclusion of patients with stroke-in-evolution or very recently completed stroke in
some of these studies. In the ECST, in which patients operated for stroke had a significantly lower
operative risk than patients operated for transient cerebral ischaemia, surgeons were advised not to
operate until at least one month after the occurrence of a stroke. The suggestion that surgery for
TIAs has a lower operative risk than surgery for stroke may also be due to a failure to distinguish
between ocular and cerebral TIAs. The real dichotomy is not between TIA and stroke, but between
ocular ischaemia and cerebral ischaemia. This should be reflected in future guidelines. The
expected operative risks for endarterectomy for asymptomatic stenosis and ocular ischaemia are in
the region of 2-4%, whereas the risk of endarterectomy for cerebral ischaemia is approximately
double this.
Sex and operative risk
Operative morbidity and mortality of coronary artery surgery are higher in women than in men.50
The relationship between sex and the risk of stroke and death due to carotid endarterectomy was
therefore examined. In the seven studies which reported data, the overall odds of stroke and death
were increased by 44% in women. A statistically significantly increased operative risk in women
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was mentioned in two further studies, but insufficient data were given to allow inclusion in the
review 51'52 The increased risk reported in women might be due to publication bias, authors only
reporting data if there is an interesting trend. However, no studies reported a statistically
significantly increased operative risk in men. The higher operative risk observed in women
compared with men might be accounted for by differences in other factors, such as age, presenting
symptoms or coexisting illness. However, the multiple regression analysis of the ECST data
detailed in Chapter 13 corrected for the effect of the other variables listed in table 14.1 and failed
to reduce the association between female sex and and operative risk. It is unclear why women
should be at greater operative risk than men. It is possible that the fact that the carotid arteries in
women are, on average, approximately 40% smaller than in men, makes the operation technically
more difficult.
Other clinical and angiographic characteristics and operative risk
The risk of stroke and death due to endarterectomy was increased in patients aged 75 and over,
those with systolic hypertension, and those with peripheral vascular disease. The association of
peripheral vascular disease with increased operative risk was reported in another study,53 but no
data were given. With regard to hypertension, it is unclear whether treatment prior to surgery would
be beneficial. The increased risk of surgery in patients aged 75 years and over is not large, and age
should not be regarded as a contra-indication to surgery. There was no evidence that angina, recent
myocardial infarction, diabetes or smoking are associated with an increased risk of stroke or death
due to endarterectomy, although more data are required before any useful conclusions can be
drawn. They may, of course, be associated with other post-operative morbidity, such as myocardial
infarction or chest infection.
Given the observation in Chapter 8, and that by the NASCET trialists,54 that patients with irregular
stenoses are at increased risk of ipsilateral ischaemic stroke on medical treatment, the observation
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that angiographic irregularity of the plaque surface is not clearly associated with an increased risk
of stroke with surgical treatment is important. Patients with irregular or ulcerated plaques are
probably, therefore, particularly likely to benefit from endarterectomy, although more data on the
relationship between plaque surface morphology and operative risk are required.
There was a trend towards an increased operative risk with occlusion of the contralateral internal
carotid artery in 12 of the 14 studies identified. However, because of the relatively low prevalence
of contralateral occlusion in the studies reviewed (407/8626, 4.7%), this only reached statistical
significance in two. This is also likely to account for the lack of a significant association between
contralateral occlusion and operative risk in the multiple regression analysis of the ECST data
detailed in Chapter 13.
Limitations of this study
The studies included in the systematic review were of varying methodological quality. Some were
retrospective and only a minority of the remainder had independent assessment of outcome by a
neurologist. However, although this may have led to an underestimation of the absolute operative
risk in some studies, it is assumed that this will not bias the relative odds of stroke and death due
to surgery with respect to particular risk factors. It is also assumed that the "effect" of the risk
factor on operative risk is relatively independent of other treatments, such as anticoagulation,
patching or shunting, the use of which may have varied between studies. Previous experience of
similar analyses suggests that these assumptions are reasonable. In the systematic comparison of
the operative risk of carotid endarterectomy for asymptomatic stenosis compared with symptomatic
stenosis in Chapter 12, there were major differences between the studies in terms of methodology
and other treatments given but a trend towards a reduced operative risk associated with
asymptomatic stenosis was found in 24 (96%) of the 25 studies, and there was virtually no
quantitative heterogeneity of effect between studies (X=13.6, df=24, P=0.96). In the present
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study, one of the meta-analyses showed borderline statistically significant heterogeneity (table
14.1). However, given that the study includes 12 meta-analyses, one significantly heterogeneous
result would be reasonably expected by chance. The remainder of the analyses showed relatively
little heterogeneity suggesting that the assumptions described above were reasonable.
As discussed above with reference to the increased operative risk reported in women, publication
bias is a further potential problem with the study. It is quite possible that some of the studies
included in the analyses looked at the interaction of several risk factors with operative risk, but
only published those which were "interesting" or statistically significant. However, this should
introduce bias in both directions i.e. analyses are probably equally likely to be published whether
or not a particular risk factor indicates an abnormally high or an abnormally low operative risk.
Funnel plots of the analyses do not show any obvious skewing suggestive of publication bias (data
not shown).
The associations between clinical and angiographic characteristics and the risk of stroke and death
due to endarterectomy in the systematic review cannot, of course, be corrected for the possible
confounding effect of other variables. However, the risk factors identified in the multiple
regression analysis of ECST data detailed in Chapter 13 are independent to the extent that the
association with operative risk has been corrected for the other potential risk factors in table 14.1.
This does not, of course, mean that the associations are necessarily causal. For example, the
association between peripheral vascular disease and an increased operative risk is likely to be due
to some confounding factor which has not been measured in this study. However, in terms of
identifying patients at high risk of operative stroke and death, it is association rather than causation
which is important.
In order to improve the cost effectiveness of carotid endarterectomy, patients should be selected on
the basis of their likely risk of stroke without surgery as well as their risk of stroke and death due to
endarterectomy. However, although risk factors for an increased surgical risk have been identified,
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it does not follow that the presence of these risk factors will necessarily reduce the likely absolute
benefit of endarterectomy. Certain characteristics may be associated with an increased risk of
stroke on medical treatment as well as surgical treatment, and will not, therefore, be associated with
reduced absolute benefit from surgery. Other characteristics, such as female sex, appear to indicate
an increased surgical risk but are not related to the risk of stroke on medical treatment alone, and
may therefore be useful in identifying patients with less to gain from endarterectomy. The overall
effects of particular risk factors on the efficacy of endarterectomy are detailed in Section 5.
Conclusions
This study has defined several clinical and angiographic characteristics which are associated with
an increased risk of stroke and death due to carotid endarterectomy. These observations may help
clinicians to estimate the likely operative risks for individual patients, and will also facilitate more
meaningful comparison of the operative risks of different surgeons or different institutions by
allowing some adjustment for differences in case mix. However, the risk factors derived from the
systematic review and those derived from analysis of the ECST data need to be validated on a large
independent dataset before they can be used routinely in clinical practice.
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14.7 Legends and figures
Figure 14.1. The odds of stroke and death due to endarterectomy for monocular ischaemia
(amuarosis fugax and retinal artery occlusion) compared with cerebral ischaemia (TIA or
completed stroke). The odds ratio for each study is represented by a square, the area of which is
proportional to the statistical precision of the estimate. The line represents the 95% confidence
interval of the odds ratio. The diamond represents the overall pooled estimate.
Figure 14.2 The odds of stroke and death due to carotid endarterectomy in women compared with
men.
Figure 14.3. The odds of stroke and death due to endarterectomy in patients aged 75 years and
older compared with patients aged less than 75 years.
Figure 14.4. The odds of stroke and death due to carotid endarterectomy associated with the
presence of each of the following risk factors: hypertension (systolic blood pressure > 180 mmHg),
diabetes mellitus, angina, recent myocardial infarction (within previous year), peripheral vascular
disease, and current cigarette smoking.
Figure 14.5. The odds of stroke and death due to carotid endarterectomy in patients with occlusion
of the contralateral carotid artery compared with those with a patent artery.
Figure 14.6. The odds of stroke and death due to carotid endarterectomy associated with the
presence of each of the following angiographic characteristics: ipsilateral plaque surface
irregularity; stenosis of the ipsilateral carotid syphon; >50% stenosis of the ipsilateral external
carotid artery.




















































































































































REF HYPERTENSION YES NO
33 Morrow et al (1987) 4/ 65 0/ 24
23 Goldstein et al (1994) 21/ 186 38/ 511
25 Riles et al (1994) 44/1183 22/1116
ECST (Unpublished) 41/ 408 81/1321
All studies 110/1842 141/2972
REF DIABETES YES NO
25 Riles et al (1994) 17/ 450 49/1882
ECST (Unpublished) 15/ 197 107/1542
All studies 32/ 647 156/3424
REF ANGINA YES NO
23 Goldstein et al (1994) 22/ 229 37/ 468
ECST (Unpublished) 24/ 305 98/1424
All studies 46/ 534 135/1892
REF RECENT MI YES NO
23 Goldstein et al (1994) 3/ 16 56/ 681
ECST (Unpublished) 5/ 48 117/1681
All studies 8/ 64 173/2362
REF PERIPHERAL VASC DISEASE YES
ECST (Unpublished) 35/ 284
NO
87/1445
All studies 35/ 284 87/1445
REF CURRENT SMOKING YES NO
25 Riles et al (1994) 33/1001 33/1331
ECST (Unpublished) 63/ 817 54/ 737
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Chapter 15
Interpretation of the overall results of clinical trials
15.1 Summary
15.2 Generalising the results of clinical trials to future patients
15.3 An exploratory analysis of the European Carotid Surgery Trial
15.4 An exploratory analysis of the UK-TIA Aspirin Trial
15.5 Implications for the cost-effectiveness of treatment
15.6 Implications for meta-analysis
15.7 How can the application of trial results to individual patients be improved?





This chapter discusses the difficulties of applying the overall results of clinical trials to individual
patients. It describes two simple exploratory analyses of the ECST and the UKTIA Aspirin Trial
which illustrate the potential for heterogeneity of treatment effect within clinical trials. Alternative
approaches to the application of the overall results of trials to clinical practice are discussed.
15.2 Generalising the results of clinical trials to future patients
One ofthe most important things about treatment is that it should be effective
- not merely that it ought to be effective.
Asher19611
It is now widely accepted that, if at all possible, medical interventions should be tested using
randomised controlled trials.2 However, very large trials, or meta-analyses of several smaller
trials, are often necessary to define treatment effects with narrow confidence intervals.3 The results
of such trials or meta-analyses are usually expressed as the overall odds or risk of outcome events
in the treated group compared with controls i.e. the relative treatment effect It is often difficult,
however, given the very heterogeneous population of individuals who tend to be included in
megatrials and meta-analyses, to know whether the overall result can be applied with confidence to
the decision whether or not to treat an individual patient. The absolute benefit a patient will
derive from a treatment will, of course, vaiy depending on their risk of a poor outcome without
treatment: a 50% relative risk reduction might be very worthwhile if the absolute risk of a poor
outcome is reduced from 20% to 10%, but possibly not if it is reduced from 1% to 0.5%. In
contrast, relative treatment effect is assumed to be qualitatively, if not quantitatively, constant, and
the overall relative risk reduction to be generalisable to all future patients who fit the trial entry
criteria.2'3 In other words, it is assumed that all treated patients, and similar future patients, are
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subject to a relative treatment effect which is qualitatively similar to the overall trial result. This is
convenient, but may not be true, and has seldom been tested. It is quite conceivable that a
treatment might be beneficial in some patients and harmful in others, the overall trial result merely
reflecting the balance between these two groups.
Strictly speaking, with the exception of n-of-1 studies, the results of clinical trials cannot be applied
to individuals. A single patient cannot experience a 50% reduction in death or a 20% improvement
in survival. Such risks can only be determined by analysis of groups of similar patients. However,
patients included in a clinical trial are heterogeneous and may, for example, differ in the severity of
their illness and consequently their absolute risk of a poor outcome. Therefore, a treatment which
produces an overall relative risk reduction, but which has a significant morbidity or mortality, may
be ineffective or even harmful in low risk patients. Generalising the overall trial result to all future
patients, similar to those in the whole trial, assumes that high and low risk groups cannot be
identified at the outset. Although on average this strategy will do more good than harm, some low
risk patients may be unnecessarily harmed.
15.3 An exploratory analysis of the European Carotid Surgery Trial
Heterogeneity of relative treatment effect is especially likely with a treatment, such as carotid
endarterectomy, which has an appreciable risk of serious harm. The operation has a 7% operative
risk of stroke or death (Section 4). Despite this risk, when compared with medical treatment alone,
endarterectomy reduces the overall risk of ipsilateral ischaemic stroke in patients with a recently
symptomatic severe stenosis by about 50% in relative terms.4,5 It now widely recommended,
therefore, that all such patients should be considered for surgery.6'7 However, in neither ECST nor
NASCET did more than 25% of patients randomised to medical treatment actually have a stroke
on follow-up. In other words, the remaining 75% of patients who remained stroke free could not
possibly have benefited from surgery had they been randomised to endarterectomy. Indeed, given
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the risk of stroke or death due to the operation, they would, as a group, undoubtedly have been
harmed.
In order to assess the relationship between baseline absolute risk and relative treatment effect, the
results of the ECST were reanalysed. This simple pilot analysis was performed at the beginning of
the period of research on which this thesis is based and includes only patients randomised prior to
1992. It was restricted to patients with a severe carotid stenosis (70-99%) in whom endarterectomy
had been shown to be of overall benefit.
Patients in the surgery and no-surgery groups were stratified according to their absolute risk of
ischaemic stroke in the distribution of the symptomatic carotid artery at trial entry using a simple
risk factor score derived by the NASCET trialists.5 The score was based on clinical data obtained
at randomisation. The no-surgery and surgery groups were then divided into low, moderate and
high risk categories on the basis of their risk factor scores. These risks were then compared with the
observed risk of ipsilateral ischaemic stroke during the trial in the no-surgery group and the risk of
ipsilateral ischaemic stroke and perioperative stroke or death in the surgery group. The relative and
absolute treatment effects were calculated at the three different levels of baseline absolute risk by
comparing the observed risk in surgery patients with the observed risk in the no-surgery patients
within each predicted risk group (table 15.1).
In the no-surgery group, the observed stroke risk fell from 20.2% in patients predicted to be at high
risk at randomisation to 8.4% in those predicted to be at low risk (X2 for linear trend = 6.2,
P<0.01); i.e. the observed risk agreed with the predicted risk. In the surgical group, the observed
risk of stroke tended to fall as the predicted baseline risk of stroke on medical treatment increased.
As a result, the relative treatment effect in the low risk group suggested that surgery might be
harmful, causing 14 additional strokes per 1000 patients treated (table 15.1), whereas surgery
appeared to be particularly beneficial in the high risk cases, preventing 141 strokes per 1000
patients treated (trend in relative risk reduction, PO.01).
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Even assuming a constant relative treatment effect, knowledge of the absolute untreated risk for a
particular patient must still be useful. However, this exploratory analysis suggested that, in the
ECST, the relative treatment effect varied with baseline absolute risk, and that the overall result of
the trial might not be generalisable to all symptomatic patients with severe carotid stenosis. These
results prompted the more detailed analyses described in Chapter 17.
Table 15.1. The observed stroke risk in patients with a 70-99% symptomatic carotid stenosis randomised prior to 1992 in
the no-surgery and surgery groups in the ECST stratified according to predicted baseline risk of ipsilateral ischaemic
stroke using data obtained at randomisation. The relative and absolute reductions in stroke ipsilateral ischaemic stroke risk
following surgery and the number of patients that need to be treated to prevent one stroke are shown for each predicted
risk group.
Predicted risk No-surgery group Surgery group Relative risk Absolute risk NNT
N strokes (risk) N strokes' (risk) (95% CI) reduction
< 10% 119 10 (8.4%) 183 18 (9.8%) 1.16 (0.6-2.4) -1.4% -71
10- 15% 178 25 (14.0%) 273 19 (7.0%) 0.53 (0.3-0.9) 7.0% 14
> 15% 89 18 (20.2%)2 132 8 (6.1%) 0.34 (0.1-0.7)3 14.1% 7
Total 386 53 (13.7%) 588 45 (7.7%) 0.51 (0.3-0.8) 6.0% 17
1 includes all surgery related strokes and deaths as well as all subsequent ipsilateral ischaemic strokes.
2 X2 for linear trend in absolute stroke risk = 6.2, p<0.01
3
test for trend in relative risks, p<0.01
15.4 An exploratory analysis of the UK-TIA aspirin trial
Carotid surgery has a relatively high morbidity and mortality and might therefore be expected to be
liable to heterogeneity of effect. The efficacy of safer treatments should be determined to a lesser
extent by the treatment risk and would not therefore be expected to vary so markedly with absolute
baseline risk. However, apparently safe treatments can still prove harmful in certain groups of
patients. In the CAST study,8 for example, mortality among patients with mild cardiac arrhythmias
was increased by treatment with encainide or flecainide. Furthermore, even with a low risk
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treatment, relative treatment effect may still vary with the severity of disease. For example,
treatment may simply be too late to affect the outcome if a disease is far advanced. In order to
assess this, the results of the UK-TIA aspirin trial9 were reanalysed in the same way as the ECST
trial, again using an independently derived and validated prognostic model.10
Table 15.2. The observed major stroke risks in the UK-TIA Aspirin trial in controls and in both aspirin groups combined
stratified by predicted risk of stroke at randomisation. The relative and absolute reductions in stroke risk with aspirin
treatment and the number of patients that need to be treated to prevent one stroke are shown for each predicted risk group.
Predicted risk Control group Aspirin groups combined Relative risk Absolute risk NNT
N strokes (risk) N strokes (risk) (95% CI) reduction
< 10% 149 10 (6.7%) 273 8 . (2.9%) 0.44 (0.2- 1.1) 3.8% 26
10-15% 234 27 (11.5%) 448 40 (8.9%) 0.77 (0.5-1.2) 2.6% 39
> 15% 428 56 (15.4%)' 890 133 (14.9%) 0.97 (0.7 - 1.3)2 0.5% 200
Total 811 103 (12.7%) 1611 181 (11.2%) 0.88 (0.7-1.1) 1.5% 67
' X2 for linear trend in absolute stroke risk = 7.9, p<0.005
2
test for trend in relative risks, p<0.05.
The UK-TIA aspirin trial examined the effectiveness of two doses of aspirin as prophylaxis against
major stroke in patients with a recent TIA or minor ischaemic stroke. The observed major stroke
risk in the control group fell from 15.4% in patients predicted to be at high risk to 6.7% in patients
predicted to be at low risk (table 15.2, X2 for linear trend = 7.9, P<0.005). Both the relative and
absolute benefit of aspirin increased as predicted absolute stroke risk fell. The confidence intervals
of the relative risk reduction of treatment within each of the absolute risk groups were wide, but the
same trend was found with both high and low dose aspirin. The antiplatelet action of aspirin does
vary between patients" and it is not implausible that the drug might be least effective in patients
with the most severe disease. However, this analysis was a relatively crude exploratory analysis
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and is no more than hypothesis-generating. The possibility that the relative efficacy of aspirin
might vary in relation to baseline risk of stroke must be confirmed in other similar trials before it is
accepted.
15.5 Implications for the cost-effectiveness of treatment
Cost-effectiveness can be expressed as the number of patients it is necessary to treat in order to
prevent one outcome event. In the UK-TIA aspirin Trial, one stroke was prevented per 26 low risk
cases treated compared with 200 high risk cases (table 15.2). Aspirin is not expensive, but
variability of relative and absolute efficacy of more expensive medical interventions might have
important financial implications. In ECST severe stenosis patients, seven endarterectomies were
required in order to prevent one stroke in the high risk cases, 14 in moderate risk cases, whereas
one stroke was caused per 71 operations in low risk cases even though all had "severe" carotid
stenosis (table 15.1).
15.6 Implications for meta-analysis
Meta-analysis is useful in order to define whether the overall effect of a treatment is beneficial, but
may compound the errors of generalising overall relative risk reductions from individual trials. The
average response to treatment is defined with narrower confidence intervals in an even more
heterogeneous population of patients. Given the evidence of possible heterogeneity of relative
treatment effect within individual trials, it could be argued that meta-analysis of the overall results
of several independent trials is, in some ways, a step in the wrong direction.
Meta-analysis of individual patient data is more flexible, and does allow stratification of patients
by baseline risk. Unfortunately, detailed individual patient data are often unavailable. In this
situation, certain authors have attempted to determine whether or not the relative treatment effects
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of trials within meta-analyses correlate with the absolute risk of relevant outcomes in the control
group. However, as is shown in Chapter 16, this produces artifactual results.
15. 7 How can the application of trial results to individual patients be improved?
Subgroup analysis is traditionally based on single variables. However, the efficacy of many
treatments will depend upon a number of inter-dependent variables, the effects of which are
unlikely simply to be additive. For example the efficacy of fibrinolytic therapy in suspected acute
myocardial infarction depends on age, the time elapsed since the onset of symptoms and the
electrocardiographic changes.12 Prognostic models based on multiple regression analysis allow the
nature of the interaction between multiple risk factors to be defined.13 The likely effect of the
particular characteristics of an individual patient can then be determined.
This approach has proved useful in other branches of medicine. It has been used, for example, to
help make sense of trials of bone marrow transplantation versus consolidation chemotherapy in
first remission of acute leukaemia.14,15 Put simply, chemotherapy is a relatively safe treatment but
is associated with a high risk of subsequent relapse, whereas bone marrow transplantation is
associated with an high early mortality but a low risk of subsequent relapse in patients who
survive. Consequently, there is little overall difference in disease free survival when the treatments
are compared in randomised trials.16 However, as one might expect, when prognostic models are
used to stratify patients according to their risk of death without bone marrow transplantation,
transplantation appears to improve survival in poor prognosis patients, but increase case-fatality in
good prognosis patients.14,15 Again the overall trial results are simply reflecting the balance
between benefit in some patients and harm in others. Similar heterogeneity of relative treatment
effect with baseline absolute risk was demonstrated for coronary artery bypass grafting using a
meta-analysis of individual patient data.17
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In the simple exploratory analyses detailed in this chapter, prognostic models have been used to
stratify patients according to their predicted risk of a poor outcome without treatment. However, in
terms of selecting which future patients require treatment this provides only half the necessary
information. Treatment should be targeted at individuals who are at a high risk of a poor outcome
without treatment but who are also at a low risk of a poor outcome with treatment. Since outcome
with and without treatment may depend on different risk factors, two prognostic models may be
required. Knowledge of the predicted absolute risks of a poor outcome with and without treatment
would allow as informed a decision as possible as to whether or not treatment was likely to be
beneficial or harmful. This approach is attempted in Chapter 17 using data from the ECST.
15.8 Limitations of prognostic modelling
Multiple regression modeling has limitations,18'19 particularly if the number of patients or
outcomes are small, or if important prognostic variables are not measured or not known to exist.
The use of models to stratify patients by absolute risk of a poor outcome is a form of post-hoc
subgroup analysis, and as such has the potential to produce misleading results. If this is to be
avoided, certain requirements must be met. The models used should be derived from totally
independent data and should be based only on variables measured at baseline. Internal validation is
not adequate. Multiple analyses of small trials will inevitably give rise to chance findings and
should, therefore, be avoided. Although based on the use of previously validated, independent
prognostic models, important findings should still be confirmed in other trials before being
accepted. Finally, analysis of variation of relative treatment effect with absolute baseline risk
should be be based on relative risks rather than relative odds. Analyses based on relative odds are
difficult to interpret because the relative odds reduction will inevitably vary with the baseline
absolute risk, whereas the relative risk reduction is unaffected unless there is genuine variation in
the relative treatment effect (see Chapter 16).
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15.9 Conclusions
Large simple randomised trials and meta-analyses have proved very effective in assessing
treatments and changing clinical practice. However, the overall results may not always be
generalisable to individual patients. In both trials analysed in this chapter, variability of relative
treatment effect with absolute baseline risk resulted in considerable differences in absolute
treatment effect. The approach to the application of the results of clinical trials to individual
patients which is suggested is most applicable to treatments which are associated with a risk of
serious harm, but should also be considered for low risk but expensive treatments. If clinicians
were able to treat only those patients who actually needed treatment and avoid unnecessary
treatment of patients who were destined to do well without treatment, the financial savings could be
considerable. While multiple subgroup analyses are undesirable and potentially misleading, we
should be cautious about assuming that overall trial results can necessarily be applied to all
patients. If we accept the view of Richard Asher that treatment should actually be effective, then
we should make some attempt determine in whom it is likely to be effective. Other large trials
should be analysed in the same way in order to determine whether heterogeneity of relative
treatment effect is at all common. If it is, then it will need to be taken into account in deciding
which individual patients to treat.
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Chapter 16
Can meta-analysis be used to determine the effect of treatment












This chapter deals with the topic of meta-regression. This is the use of a meta-analysis of overall
trials results to test for heterogeneity of relative treatment effect with baseline risk of a poor
outcome in the control group. It has been used by some investigators as an easier alternative to
meta-analysis of individual patient data. However, this chapter demonstrates a number of artefacts
inherent in the process which invalidate the technique. The work was presented to an international
audience at the Annual Meeting Cochrane Stroke Review Group in Edinburgh in 1996. A similar
critique developed at about the same time by an independent group and was published the
following year.1
16.2 Introduction
As discussed in Chapter 15, the overall results of clinical trials cannot necessarily be applied to all
individual patients.2 The absolute benefit derived by an individual will, of course, depend on their
absolute risk of a poor outcome if untreated, but there is also evidence from some randomised trials
that the relative treatment effect may vary with absolute baseline risk. Analysis of relative
treatment effect at a given absolute baseline risk requires that outcome is compared in treated and
control patients who were at similar risk of that outcome at randomisation. This can be achieved if
both treated and control patients are stratified into similar categories of baseline risk using
prognostic models. However, this requires individual patient data and an independently derived and
previously validated prognostic model. As a much easier alternative, it has been suggested that
treatment effect can be analysed across different baseline risks in meta-analyses of clinical trials.
Several approaches have been adopted including analysis of the relative risk or odds of a poor
outcome in the treated versus control patients with respect to the absolute risk of the study
outcome in the control group in each trial4-9 or analysis of the absolute risk of the study outcome
in the treatment group with respect to the absolute risk in the control group.10'11 This approach is
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illustrated below in three meta-analyses of treatments for myocardial infarction for which the main
study outcome was death and for which information on case-fatality in the control groups of the
trials within each meta-analysis was available over comparable periods of follow-up.
16.3 Examples
Intravenous streptokinase in acute myocardial infarction: Intravenous streptokinase has been
shown in a meta-analysis of small trials,12 and in subsequent megatrials,13'14 to reduce case
fatality after acute myocardial infarction. However, analysis of these trials shows that relative
treatment effect appears to be significantly related to case fatality in control patients (figure 16.1.1,
table 16.1). Case fatality seems to be reduced in patients with an untreated risk of greater than
25%, but is possibly increased in patients with an untreated risk of less than 15%. Although the
length of follow-up on which the risk of death in controls was based was not identical in all
trials in this meta-analysis (table 16.1), when the analysis was restricted to the 14 trials in which
follow-up was 3-6 weeks, the correlation between treatment effect and control group case
fatality was essentially unchanged (r = -0.68, P<0.01).
Prophylactic anti-arrliytlimic drugs after myocardial infarction: Prophylactic treatment with
anti-arrhythmic drugs after myocardial infarction increased case fatality in the CAST study,15
although no overall treatment effect was found in a meta-analysis of all trials.11 A plot of treatment
effect against case fatality in the control group during the first year of each trial (figure 16.1.2)
seems to suggest that anti-arrhythmic medication does increase case fatality in patients with an
untreated risk of less than 5% (as in the CAST study), but may reduce case fatality in patients at
higher baseline risk.
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Intravenous magnesium in acute myocardial infarction: The use of intravenous magnesium in
patients with acute myocardial infarction is controversial.16 An initial large trial,17 and a meta¬
analysis of smaller trials,18 demonstrated a significant reduction in case fatality, but this was not
confirmed in a recent megatrial.19 However, much of the apparent heterogeneity appears to be due
to variation in relative treatment effect with baseline risk (figure 16.1.3, table 16.1).
Table 16.1. The characteristics of three meta-analyses of clinical trials of treatments used for acute myocardial
infarction.
Meta-analysis: Thrombolysis l2"14 Anti-arrhythmics" Magnesium l7"19
Trials 22 14 8
Mean (range) risk in control group (%) 19.6(5.0-36.0)' 14.4 (3.2-41,6)2 9.6 (2.2-17.0)3
Heterogeneity of risk in control group4 P<0.001 P<0.001 P0.001
Treatment effect (risk ratio, 95% CI)
All trials 0.77 (0.72-0.82) 1.18 (0.99-1.40) 1.03 (0.97-1.09)
Trials with control risk below mean 0.78 (0.73-0.84) 1.34 (1.10-1.63) 1.06(1.00- 1.13)
Trials with control risk above mean 0.66 (0.54-0.81) 0.79 (0.56-1.12) 0.64 (0.44-0.99)
Correlation of treatment effect (relative risk)
with absolute risk in:5
Control group -0.71 (-0.5,-0.9) -0.56 (-0.1,-0.8) -0.72 (-0.1,-0.9)
Treatment and control groups combined -0.16 (0.3, -0.5) -0.22(0.3, -0.7) -0.38 (0.4, -0.9)
' risk of death based on mortality at 4 days in 1 trial, 3-8 weeks in 14 trials, and >8 weeks in 7 trials
2 risk of death based on mortality at 1 year
3 risk of death at hospital discharge (5 trials) or 1 month (3 trials). 1 trial with only 24 hours follow-up was excluded.
4 chi square test for heterogeneity
5 both variables log transformed and correlation calculated using the Pearson product moment method.
The relative efficacy of each of the above treatments appears to vary with the baseline risk of a
poor outcome in the control group. Similar analyses have suggested that cholesterol lowering may
also be harmful in low risk patients.4 If genuine, these observations would be of considerable
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clinical importance. However, these analyses are flawed. One of the flaws relates to the
production of artefactual relationships between treatment effect and baseline risk as a consequence
of regression to the mean.1,20 It has been argued that a plot of the absolute risk of a poor outcome
in the treatment group against the absolute risk in the control group overcomes the regression to the
mean artefact, and has been used to show that treatment of hypertension increases case-fatality in
low risk patients.10 However, this approach is flawed. This chapter describes meta-analyses of
computer-generated simulations of randomised controlled trials which illustrate some of these
flaws.
16.4 Methods
Clinical trials were simulated using random integers generated by a computer program (SPSS for
Windows, release 6.0). Each number represented a patient. One set of 100 random numbers
represented the treated patients and another set of 100 represented the control patients. Patients
who suffered a trial outcome event on follow-up were defined as numbers exactly divisible by a
specified whole number e.g. 20 for absolute risks of 5%. The proportion of such numbers in the
treatment set was compared with the that in the control set in order to calculate the relative risk of
the outcome with treatment. The principle is similar to previously reported simulations of trials
using dice.21
Relative treatment effect vs absolute risk in the controlgroup
Within each trial the treatment and control groups had the same number of patients (100 treated vs
100 control) and the same expected risk of the study outcome. Any observed treatment effect was
therefore due to chance. Meta-analyses were simulated using series of 50 consecutively simulated
trials each with the same expected risk of study outcomes. Any heterogeneity in absolute risk
among the control groups of different trials was therefore due to chance. Three meta-analyses were
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produced, each differing in the expected absolute risks of outcome events in the 50 simulated
trials: 5%, 20% and 50%. Relative treatment effect was assessed using the relative risk of outcome
events in the treatment group compared with the control group.
Absolute risk in the treatment group vs absolute risk in the control group
In order to examine the relationship between absolute risk in the treatment group and absolute risk
in the control group in meta-analyses of trials with low risks of outcome events, two further meta¬
analyses were created: 50 simulated trials (100 treated patients vs 100 controls) with an expected
risk of outcome events in the control group of 2% and no true treatment effect; 250 simulated
trials (100 treated patients vs 100 controls) in which the expected relative risk reduction was 50%
and in which the risk of outcome events in the control groups were 2%, 4%, 10%, and 20% (50
trials with each risk). Correlation between treatment effect and baseline risk was calculated using
the Pearson product moment method in all simulated meta-analyses unless stated otherwise.
16.5 Results
Relative treatment effect vs absolute risk in the control group
As expected there was no overall treatment effect in the simulated meta-analyses (table 16.2).
However, when trials were divided according to whether the observed risk of outcome events in
the control group was greater or less than the mean control risk in the whole meta-analysis,
"treatment" was harmful in trials in low risk patients and effective in trials in high risk patients
(table 16.2). Relative treatment effect correlated significantly with the absolute risk of outcome
events in the control group in all three simulated meta-analyses (figure 16.2, table 16.2). However,
when relative treatment effect was plotted against the mean absolute risk of trial outcome events in
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the treatment and control groups combined no significant correlation was found in any of the
simulated meta-analyses (table 16.2).
Table 16.2. The characteristics of three meta-analyses each containing 50 computer-simulated clinical trials.
Meta-analysis:
Expected absolute risk in control group
5% 20% 50%
Mean (range) risk in control group (%)
Heterogeneity of risk in control group '
Treatment effect (risk ratio, 95% CI)
Overall
Trials with control risk below mean





19.4 (11- 29) 51.3 (39-63)





0.62 (0.48- 0.80) 0.74 (0.65-0.85) 0.83 (0.74-0.92)
Correlation of treatment effect (relative risk) with
absolute risk in:2
Control group
Treatment and control groups combined
-0.85 (-0.7, -0.9) -0.81 (-0.7, -0.9) -0.68 (-0.5, -0.8)
-0.21 (-0.5, 0.1) -0.18 (-0.4, 0.1) 0.05 (-0.2, 0.3)
Correlation of absolute risk in treatment group with
absolute risk in:
Control group
Treatment and control groups combined
-0.27 (-0.5, 0) 0.08 (-0.2, 0.4) 0.22 (-0.1, 0.5)
0.60 (0.4 , 0.8) 0.62 (0.4 , 0.8) 0.71 (0.5, 0.8)
1 Chi square test for heterogeneity
2 both variables log transformed and correlation calculated using the Pearson product moment method
Absolute risk in the treatment group vs absolute risk in the control group
There was no significant correlation between absolute risk of trial outcome events in the treatment
group versus that in the control group in the simulated meta-analyses with expected control group
risks of 20% and 50% (table 16.2), but there was a borderline significant negative correlation in the
simulated analysis with an expected control risk of 5% (table 16.2) and a significant negative
correlation (r= 0-0.51, P0.001, Spearman rank correlation) was observed in the meta-analysis of
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simulated trials with an expected control risk of 2% (figure 16.3). In the meta-analysis of 250
simulated trials with an expected relative risk reduction of 50%, 216 trials (86%) yielded a relative
risk of less than one, suggesting that treatment was effective. All 34 trials with a relative risk of
greater than one, suggesting possible harm, had absolute risks of the study outcome in the control
group of less than 10% (figure 16.4).
16.6 Discussion
Relative treatment effect v.v absolute risk in the control group
Regression to the mean artefact: Although there was no overall treatment effect in the simulated
trials, treatment appeared to be effective in trials performed in high risk patients and harmful in
trials performed in low risk patients. The variation of relative treatment effect with baseline risk
observed in the simulated meta-analyses was, of course, artefact. The artefactual correlation
produced if one variable is plotted against a second variable which is partly dependent on the first
variable (e.g. Y - X vs X, Y/X vs X) is well recognised by statisticians. Relating either the relative
or the absolute risk reductions with treatment to the baseline risk in the control group will fall foul
of this principle. It is explained by regression to the mean.22 In all randomised trials, no matter
how well conducted, some of the observed treatment effect will be due to chance. In trials in which
chance results in a low risk of the study outcome in the control group, the treated group will tend,
on average, to have a higher risk. In this situation, the treated group will either do worse than the
control group, or if treatment is effective, the true effect will be underestimated. In contrast, if by
chance, the control group has a high risk of the study outcome, the baseline risk in the treated group
will on average be lower, and the efficacy of treatment may be overestimated. The relationship
between treatment effect, either relative or absolute, and the absolute risk of the study outcome in
the control group will always be partly artefact. In the simulated trials in this study, the variances
of the absolute risk in the control groups were the same as those in the treatment groups. In this
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special case, variation in the control group risk will account for 50% of the variation in the
treatment effect. The expected correlation between the two variables will therefore be the
square root of 0.5 (i.e. 0.71). The findings in the simulated meta-analyses were consistent with
this (table 16.2).
Use of meta-analyses to examine variation in treatment effect in patients at different levels of
baseline risk is, therefore, potentially misleading. Effective treatments may appear harmful in low
risk patients and ineffective treatments may appear beneficial in high risk patients. The effect of
regression to the mean can, of course, be eliminated by plotting relative treatment effect against the
average risk of the trial outcome in the treatment and control groups combined; if a relationship
remains some other explanation must be sought. As expected, in the simulated meta-analyses there
was no significant correlation between relative treatment effect and the combined treatment and
control group risk (table 16.2). This approach is consistent with the fixed effects method of meta¬
analysis in which treatment effect is defined as the difference in the event rate in the treatment
group and that in the treatment and control groups combined,23 and is certainly appropriate when
there is no overall evidence of a clear treatment effect. However, if a treatment was genuinely
harmful in low risk patients and beneficial in high risk patients, the relationship between baseline
H
risk and relative treatment effect would be weakened if relative treatment effect was plotted against
the combined treatment and control risk rather than the control risk alone, although a trend should
still be present. In practice, therefore, it is difficult to correct for the effect of regression to the
mean in meta-analyses of real trials. The simulated meta-analyses in this study differ from real
meta-analyses in that there was no statistically significant heterogeneity of absolute risk in the
control groups (table 16.1), and there was definitely no overall treatment effect. However, the
absence of any correlation in the real meta-analyses when relative treatment effect was plotted
against the combined treatment and control risk (table 16.1) suggests that the trends seen in figure
16.1 are probably artefact.
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Recognition of the effect of regression to the mean on the relationship between treatment effect and
baseline risk in controls may actually be of some use in interpreting apparent heterogeneity of
relative treatment effect in meta-analyses of clinical trials. For example, in the meta-analysis of the
effect of anti-arrhythmic medication on case fatality following myocardial infarction (figure 16.1),
the CAST study appears to have had an unusually low control group risk relative to the other trials,
suggesting that the apparent harm caused by treatment with antiarrhythmic medication may have
been due to chance or an imbalance in prognosis between the treatment and control groups at
randomisation. Had the control group risk in the CAST study been similar to that in the other trials,
and the trial had still demonstrated significant harm, the result would have been more convincing.
Odds ratio artefact: A further pitfall in examining variation in relative treatment effect with
baseline risk is to use the relative odds of outcome events in the treatment group compared with
control group rather than the relative risk. If treatment is effective overall, the relative odds
reduction will invariably increase as the observed risk of trial outcome events in the control group,
or the treatment and control group combined, increase (figure 16.5). For example, in a trial of 1000
treated patients and 1000 controls with a relative risk reduction in the trial outcome with treatment
of 50%, the relative odds reduction would be 51.3% (95% CI, 20.6-70) if the control group risk was
5%, 66.7% (59.7-72.4) if the risk was 50%, and 90.9% (88.4-92.9) if the risk was 90%. The use
odds ratios as measures of treatment effect confuses the interpretation of previous reports of
variation in relative treatment effect with baseline risk.4"6
Absolute risk in the treatment group vs absolute risk in the control group
High and low control risk artefact: It has been argued that a plot of absolute risk of the study
outcome in the treatment group against that in the control group avoids regression to the mean
artifact.10,11 However, this is false. No matter how these two variables are plotted they will still
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be subject to regression to the mean. High control group risks will still tend to be associated with
lower risks in the treatment group and vice versa. How the risks are plotted does not change this.
This technique is subject to further artefact. This occurs because risk estimates are limited to
values between 0% and 100%. As the absolute risk of the study outcome in the control group
approaches these limits, the probability that the risk in the treatment group will be more extreme
decreases. This is illustrated for trials with a low risk of study outcomes in figure 16.3 in which
there is an artefactual negative correlation between the absolute risks in the treatment and control
groups, and in figure 16.4 in which "negative" results cluster among trials with low risks of the
study outcome in the control group despite an expected 50% relative reduction at all levels of
control group risk. Obviously in real life, the situation is more complex than in the examples in
figures 16.3 and 16.4 as trial sizes and treatment effects may vary. However, they do show that
effective treatments have a high risk of appearing ineffective at levels of risk which are commonly
encountered in real life. This artefact is independent of the regression to the mean artefact observed
when treatment effect is plotted against control group risk, and may account, at least in part, for
the apparent harm caused by antihypertensive treatment in low risk patients.10 In common with
the regression to the mean artefact, high and low control risk artefact is often corrected by plotting
absolute treatment effect against the mean risk of the trial outcome event in the treatment and
control groups combined. However, this approach can also sometimes be misleading, and more
sophisticated approaches may be required.
16.7 Conclusion
In conclusion, meta-analyses of clinical trials relating relative treatment effect or absolute risk in
the treatment group to the absolute risk of the study outcome in the control group are subject to
artefact and should be interpreted with great caution. There is no easy solution to this problem.
Analysis with respect to the mean absolute risk in the treatment and control groups combined is
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not subject to artefact, but may underestimate or mask real differences in relative treatment effect
at different levels of absolute baseline risk. It is, however, consistent with the fixed effects method
of meta-analysis, and will avoid the potentially false impression that effective treatments are
harmful in low risk patients. The best way in which variation in treatment effect with baseline
risk can be reliably examined is by analysing individual patient data from a large trial, or several
smaller trials combined, stratified by baseline risk calculated using independently derived and
validated prognostic models. This is the approach which is used in Chapter 17 to determine which
patients benefits most from carotid endarterectomy.
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16.9 Legends to figures
Figure 16.1 (1-3). A log plot of treatment effect (relative risk, 95% CI) against the absolute risk of
trial outcome events (death) in control patients in clinical trials in meta-analyses of three
treatments for myocardial infarction: 1) intravenous streptokinase;12"14 2) prophylactic anti¬
arrhythmic medication;11 3) intravenous magnesium.17"19
Figure 16.2. A log plot of treatment effect (relative risk) against the absolute risk of trial outcome
events in the control group (log scale) in three meta-analyses of 50 simulated trials (100 treated
patients vs 100 controls) of a treatment which has no true effect in populations with expected risks
of the trial outcome event of 5%, 20% and 50%. Each point may represent more than one trial.
Figure 16.3. A plot of the absolute risk of the trial outcome in the treatment group against the
absolute risk in the control group in a meta-analysis of 50 simulated trials (100 treated patients vs
100 controls) of a treatment which has no true effect in a population with an expected risk of the
trial outcome of 2%. Each point may represent more than one trial. Correlation calculated using the
Spearman rank method.
Figure 16. 4. A plot of the absolute risk of the trial outcome in the treatment group against the
absolute risk in the control group in a meta-analysis of 250 simulated trials (100 treated patients vs
100 controls) with an expected relative reduction in the risk of the study outcome of 50% with
treatment and with control group absolute risks of 2%, 4%, 10% and 20% (50 trials with each
risk). Each point may represent more than one trial. The solid line represents no treatment effect,
the dashed line represents the expected 50% relative risk reduction with treatment, and the dotted
lines represent the 95% confidence limits of the expected relative risk reduction.
Figure 16.5 The variation in relative odds reduction and 95% confidence interval (solid lines)
with baseline absolute untreated risk assuming a constant (50%) relative risk reduction (dashed











































































Prediction of the effect of carotid endarterectomy in individual patients:










Background: The overall results of ECST and NASCET have shown that carotid endarterectomy
reduces the risk of carotid territory ipsilateral ischaemic stroke in patients with a recently
symptomatic 70-99% carotid stenosis. It is widely regarded as the treatment of choice in such
patients. However, the risk of stroke on medical treatment alone is only about 20% over the next
three years. The other 80% of patients, who are destined to remain stroke-free without surgery,
cannot possibly benefit from the operation, and some will be harmed. The effectiveness of
endarterectomy could be improved considerably if we were able to identify, and operate on, only
those patients with a high risk of stroke on medical treatment and a low risk of operative stroke or
death.
Methods: Two prognostic models were developed using data on the 2060 patients with 0-69%
carotid stenosis from the ECST; one for the risk of ipsilateral carotid territory ischaemic stroke on
medical treatment and one for the risk of stroke and death within 30 days of carotid
endarterectomy. A simple scoring system to identify patients with a high risk of stroke on medical
treatment, but a relatively low operative, risk was derived from the two models. The models were
validated, and the scoring system was tested, on the 990 ECST patients with 70-99% stenosis.
Findings: When stratified using the scoring system, based on 7 independent prognostic factors,
endarterectomy was beneficial in only 162 (16%) of the 990 patients with 70-99% carotid stenosis.
The odds of carotid territory ipsilateral ischaemic stroke were decreased considerably by surgery in
this group (OR = 0.12, 95% CI = 0.05-0.29), but not in the other 828 (84%) patients with 70-99%
stenosis (OR=1.00, 95% CI = 0.65-1.54). The reductions in the 5 year actuarial risks of stroke with
surgery were from 40% to 7% (log rank = 20.5, P<0.00001) and 12% to 11% (log rank = 0.8,
P=0.7) respectively.
Interpretation: Contrary to the overall results of recent trials, the majority of patients with recently
symptomatic 70-99% carotid stenosis do not benefit from carotid endarterectomy. The operation is
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only beneficial in a relatively small subgroup of patients. These patients can be identified using a
simple scoring system. These results have implications for the effective use of carotid
endarterectomy and highlight the potential value of risk modelling in the application of the results
of trials to clinical practice.
17.2 Introduction
As shown in Chapter 8, atherothrombotic stenosis at or around the carotid bifurcation is associated
with an increased risk of ipsilateral carotid territory ischaemic stroke. This risk is reduced, in
certain patients, by carotid endarterectomy.1 As discussed in Chapter 1, there have been five
randomised controlled trials of carotid endarterectomy for recently symptomatic carotid stenosis.2"6
The first two were small and did not produce clear results.2'3 The larger VA Cooperative
Symptomatic Carotid Stenosis Trial (VA #309) reported a non-significant trend in favour of
surgery.4 In 1991, the ECST and the NASCET demonstrated a clear reduction in the overall risk
of stroke in operated patients with recently symptomatic severe (70-99%) carotid stenosis.5'6 The
ECST also demonstrated that surgery is harmful in patients with lesser degrees of stenosis.7 The
NASCET trialists have recently confirmed the lack of benefit in patients with 30-49%, but have
demonstrated a small benefit in patients with 50-69% stenosis.8 However, as detailed in Section 2,
comparison of the ECST and NASCET results is complicated by the fact that different methods of
measurement of the degree of stenosis on angiograms were used, the method used in NACSET
underestimating the degree of stenosis compared to the ECST method.9 The 50-69% stenosis group
in which NASCET reported some benefit from surgery is, in fact, equivalent to the 70-80% group
in the ECST.
These trials have, therefore, demonstrated overall benefit from endarterectomy in patients with a
recently symptomatic stenosis of 70-99% by the ECST method. However, this is of relatively little
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help to the clinician who has to decide whether or not an individual patient is likely to benefit from
surgery. Although endarterectomy reduces the overall risk of ischaemic stroke by about 50% in
relative terms over the next three years in patients with 70-99% stenosis, only about 20% of such
patients actually suffer a major stroke on medical treatment alone.5'6 Strictly speaking, therefore,
the operation is of no value in the other 80% of patients who, despite having a severe stenosis, are
destined to remain stroke-free without surgery. Indeed, as a group, these patients will be harmed by
surgery because of the not insignificant operative morbidity and mortality i.e. the operation would
cause some strokes and deaths in patients who would have been fine on medical treatment alone.
Whether or not the operation is beneficial for a given individual will be determined by the balance
between the risk of stroke and death due to the operation itself and the risk of ipsilateral ischaemic
stroke (i.e those strokes which are prevented by endarterectomy) without surgery for that particular
patient. At present the extrapolation of the overall results of the large RCTs of endarterectomy
directly to clinical practice assumes that we cannot identify high and low risk severe stenosis
patients at the outset. However, as demonstrated in Chapter 15, this may not necessarily be the
case. Although the analyses of the recent trials of endarterectomy were stratified by the degree of
carotid stenosis (probably the most powerful predictor of stroke risk), there are several other
clinical and angiographic characteristics which also identify patients at high risk of stroke and other
vascular outcomes on medical treatment alone.12"14 For example, as shown in NASCET,13
patients with recent cerebral TIA or minor stroke are at greater risk of stroke than patients with
amaurosis fugax. Similarly, as shown in Chapter 8, and again by the NASCET,14 patients with an
irregular carotid plaque are at higher risk than patients with smooth plaques. Moreover, as shown in
Chapters 13 and 14, there are several important risk factors for the operative risk of stoke and death
due to endarterectomy. A clinician needs to be able to take all the characteristics of the individual
patient into account in order to operate only on those patients at high risk of stroke on medical
treatment and a low operative risk, and to avoid surgery in those patients who have a low risk of
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stroke on medical treatment or a high operative risk. This is best achieved by using two separate
formal prognostic models, the first for the risk of ipsilateral carotid territory ischaemic stroke on
medical treatment and the second for the risk of stroke and death within 30 days of carotid
endarterectomy.
In order to test the utility of such an approach in the ECST patients with a severe stenosis,
independently derived prognostic models were required. No such models were available, either in
the published literature or from other similar datasets. It was therefore necessary to split the ECST
dataset, and derive the models on ECST patients with 0-69% stenosis. Using these models a
simplified prognostic score was developed to identify patients with a high risk of stroke on
medical treatment, but a relatively low operative risk. The models were then tested on the patients
with 70-99% stenosis and the increase in clinical effectiveness of endarterectomy which would be
gained by the routine use of these models in order to select those patients most likely to benefit
from surgery was determined.
17.3 Methods
Development ofprognostic models
Models were developed using the routinely collected baseline clinical and angiographic data which
had been collected in the trial. These have been detailed in previous chapters. All analyses were
performed using SPSS for Windows version 7.0 (SPSS, Chicago, USA) and used the treatment
group defined at randomisation (intention-to-treat analysis) rather than groups defined on the basis
of treatment actually received. The following models were developed.
Medical model: A model predicting the risk of ipsilateral carotid territory ischaemic stroke on
medical treatment was derived on data from patients with 0-69% stenosis who had been
randomised to no-surgery in the ECST. The outcome used was the first major ischaemic stroke
(fatal or lasting longer than seven days) on follow-up. Where no CT brain scan was available or
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where the scan was performed more than 30 days after the stroke, the stroke was categorised as
ischaemic. The occurrence of stroke in patients randomised to medical treatment was consistent
with requirements for a Cox's proportional hazards model. A forward conditional stepwise Cox's
regression analysis was therefore used. Variables were entered into the model at a significance
level of 0.05 and discarded at a level of 0.1.
Surgical model: A model predicting the risk of any major stroke (fatal or lasting longer than seven
days), or death from any other cause, within 30 days of endarterectomy was derived on patients
with 0-69% stenosis who had been randomised to surgery in the ECST. A forward conditional
stepwise logistic regression analysis was used. Variables were entered into the model at a
significance level of 0.05 and discarded at a level of 0.1.
Validation of the models
In order to facilitate the use of the models in clinical practice, and to counteract "over-fitting" of
the model to the derivation cohort, they were simplified prior to validation. Patients were simply
stratified by the number of statistically significant prognostic variables which they possessed
rather than by the linear predictor derived from the regression model. The hazard ratios relating to
each of the significant variables were rounded to the nearest whole number. Each variable was then
allotted an integer score based on its hazard ratio. The outcome prediction for an individual patient
was simply taken as the sum of the scores derived from the prognostic variables which the patient
possessed.
The simplified models were tested on the appropriate treatment group using the ECST data on
patients with 70-99% stenosis. For the surgical model the observed risk of major stroke and death
within 30 days of endarterectomy was stratified according to the integer score of individual
patients. For the medical model the five year actuarial risk of ipsilateral carotid territory major
ischaemic stroke, censoring for non-stroke death, was used.
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In order to identify those patients most likely to benefit from endarterectomy, a predictive score
must add points for the possession of prognostic variables associated with a high risk of stroke on
medical treatment alone and remove points for the possession of variables associated with a high
risk of operative stroke or death. Given that the risk of ipsilateral carotid territory ischaemic
stroke on medical treatment in patients with 70-99% stenosis in ECST and NASCET was
approximately double the risk of stroke or operative death in the surgical patients (figure 17.1), the
reduction in score resultant upon the possession of variables associated with an increased surgical
risk was reduced to half that derived from the hazard ratios in the surgical model.
Stratification ofthe trial result using thepredictive score
The predictive score described above was calculated for each of the patients with 70-99% stenosis
in the ECST. The effect of carotid endarterectomy on the five year Kaplan Meier estimate of risk
of ipsilateral carotid territory major ischaemic stroke or surgical major stroke or death, censoring
for non-stroke death, was calculated for each score. The statistical significance of the effect of
surgery was tested at each score using the log rank test.
Non-validatedmodels
The models described above were a compromise. Derivation was limited to patients with 0-69%
stenosis so that the models could be used to stratify patients with 70-99% stenosis i.e. those
patients in whom the trials have demonstrated overall benefit. In order to assess the stability and
completeness of the validated models, derived on the 0-69% stenosis group, more definitive models
were derived on the whole 0-99% stenosis groups. The derivation of these models was as detailed
above except that a stepwise approach was not used and all variables were entered into the models.
These models require external validation.
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17.4 Results
Development and validation ofmodels
There were 2060 patients with 0-69% stenosis in the ECST: 1203 randomised to surgery and 857 to
no-surgery. There were 78 first ipsilateral carotid territory major ischaemic strokes on follow-up in
the no-surgery group and 84 major strokes or deaths within 30 days of endarterectomy in the
surgery group. Four baseline clinical and angiographic variables were predictive of ipsilateral
carotid territory major ischaemic stroke in the no-surgery group (table 17.1). On the basis of this
model the following simplified risk factor score was derived: cerebral vs ocular events (1 point),
plaque surface irregularity (1 point), events within the last two months (1 point), carotid stenosis:
70-79% (0 points); 80-89% (1 -point), 90-99% (2 points). The allocation of points for stenosis in
the 70-99% range was based on the increase in stroke risk seen in this range in those patients
randomised to medical treatment in the NASCET trial (unpublished data, personal communication,
Professor Henry Barnett).
Table 17.1. A Cox's proportional hazards model for ipsilateral carotid territory major ischaemic
stroke (i.e. fatal or lasting longer than seven days) on medical treatment derived from the 857
patients with 0-69% stenosis who were randomised to no-surgery in the ECST.
Prognostic variable Hazard ratio (95% CI) Significance
Cerebral vs ocular events 2.45 (1.09-3.71) 0.02
Plaque surface irregularity 2.09 (1.21-3.62) 0.008
Events within the last two months 1.82 (1.02-3.18) 0.04
Carotid stenosis( / % stenosis) 1.03 (1.01 - 1.04) 0.001
Non-significant variables: age, sex, stroke vs TIA, residual neurological signs, diabetes, diastolic blood
pressure, systolic blood pressure, systolic blood pressure >180mmHg, angina, previous myocardial
infarction, atrial fibrillation, left ventricular hypertrophy, cardiac failure, cerebral infarction on CT brain scan,
peripheral vascular disease.
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Three baseline clinical variables were predictive of major stroke or death within 30 days of
endarterectomy (table 17.2). On the basis of this model the following simplified risk factor score
was derived: female sex (1 point); peripheral vascular disease (1 point); systolic blood pressure >
180mmHg (1 point).
Table 17.2. A multiple logistic regression model for any major stroke (i.e. fatal or lasting longer
than seven days) or death from other causes within 30 days of carotid endarterectomy derived from
1203 patients with 0-69% stenosis who were randomised to surgery in the ECST.
Prognostic variable Hazard ratio (95% CI) Significance
Female sex 2.05 (1.29-3.24) 0.002
Peripheral vascular disease 1 2.48 (1.51-4.13) 0.0004
Systolic blood pressure > 180mmHg 2.21 (1.29-3.79) 0.004
Non-significant variables: age, stroke vs TIA, cerebral vs ocular events, number of events within last two
months, residual neurological signs, diabetes, diastolic blood pressure, angina, previous myocardial
infarction, atrial fibrillation, left ventricular hypertrophy, cardiac failure, degree of carotid stenosis, plaque
surface irregularity, cerebral infarction on CT brain scan.
Application of the no-surgery model to the 70-99% no-surgery group produced a highly significant
trend in the five year actuarial risk of ipsilateral carotid territory major ischaemic stroke on medical
treatment (P0.00001, table 17.3).
Application of the surgery model to the 70-99% surgery group also produced statistically
significant heterogeneity of risk of major stroke or death within 30 days of endarterectomy (table
17.4).
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Table 17.3. The five year actuarial risk (95% CI) of ipsilateral carotid territory major ischaemic
stroke in 394 patients with 70-99% stenosis who were randomised to no-surgery stratified by the
number of risk factors possessed by each patient.
Number of risk factors Cases Strokes Five year actuarial % risk 1 (95% CI)
0 7 0 0 n/a
1 48 2 6.0 0 - 14
2 141 14 13.1 7 - 20
3 133 22 21.0 13 -29
4 53 21 45.2 31 -60
5 12 4 38.1 9 -68
1
Log rank statistic = 31.5, P<0.00001
Table 17.4. The 30 day risk (95% CI) of any major stroke or death following carotid
endarterectomy in 596 patients with 70-99% stenosis who were randomised to "surgery" stratified
by the number of risk factors possessed by each patient.
Number of risk factors Cases Strokes or deaths 30 day % risk1 (95% CI)
0 298 14 4.7 3 - 8
1 234 17 7.3 4 - 11
2 58 7 12.1 5 - 23
3 6 1 16.7 4 - 64
1 Chi squared test for linear trend (risk factor groups 2 and 3 collapsed to avoid small numbers) = 5.3, P=0.02
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Stratification of the trial result using the predictive score
The score predicting likely overall benefit from endarterectomy (i.e. high medical risk and low
surgical risk), derived from the medical and surgical models in the manner described in the
methods, is shown in table 17.5. The scores for patients in the 70-99% stenosis group in the ECST
ranged from 0 to 5.0. Figure 17.1 shows the overall effect of endarterectomy on the five year risk
of ipsilateral carotid territory major ischaemic stroke or surgical stroke or death in patients with 70-
99% stenosis in the ECST. Figure 17.2 shows the reduction in the five year actuarial risk of
ipsilateral carotid territory major ischaemic stroke or surgical major stroke or death in the surgery
group compared with the medical group at each score. The operation was possibly harmful in
patients with scores of one or less and was only significantly beneficial in patients with scores of
four or more.
Table 17.5. The simplified risk score model predicting the overall efficacy of endarterectomy
derived from patients with 0-69% stenosis in the ECST
Prognostic variable Points
Cerebral vs ocular events 1
Plaque surface irregularity 1






Peripheral vascular disease -0.5
Systolic blood pressure > 180mmHg -0.5
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The effect of surgery on the risk of ipsilateral carotid territory major ischaemic stroke lasting
longer than seven days or surgical major stroke and death is shown for ECST 70-99% stenosis
patients with risk scores of less than four and patients with risk scores of four or more in figures
17.3 and 17.4 respectively. In the 828 patients with scores of less than four, there was no
significant benefit from surgery (OR = 1.00, 95% CI = 0.65 - 1.54, log rank = 0.8, P=0.7, figure
17.3), whereas there was a highly statistically significant 33% absolute risk reduction in the five
year actuarial risk in the 162 patients with risk scores of four or more (OR = 0.12, 95% CI = 0.05-
0.29, log rank = 20.5, P0.00001, figure 17.4). The effectiveness of surgery in the two groups is
compared in table 17.6. Only three operations are required to prevent one major stroke at five years
in patients with a score of four or more, whereas 14 operations are required in the 70-99% stenosis
group as a whole. Although patients with a score of four or more comprise only 16% of the group,
operating only on these patients would prevent almost as many adverse events overall as operating
on all patients with 70-99% stenosis (33 events prevented by 101 operations vs 30 events prevented
by 596 operations).
Non-validated models
Tables 17.7 and 17.8 show the results of the non-validated models which were derived from the
whole of the surgery and no-surgery groups (i.e. patients with 0-99% stenosis). Both of these
models require external validation. The medical model contained nine variables which were
independent predictors of the risk of ipsilateral carotid territory ishcaemic stroke. Each of the five
variables in the validated model (based on the 0-69% stenosis group) remained significant
independent predictors in the more detailed model. The degree of stenosis was best represented as a
cubic term. Three of the four significant terms in the non-validated surgical model were present in
the validated model.
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Table 17.7. The non-validated Cox's proportional hazards model for ipsilateral carotid territory major
ischaemic stroke (i.e. fatal or lasting longer than seven days) on medical treatment derived on all the 1208
patients with 0-99% stenosis in the medical group.
Wald statistic' P Hazard ratio 95% CI
Significant terms
Cerebral events vs ocular events * 7.1 .008 2.45 1.27-4.75
Residual neurological signs after seven days 7.4 .006 1.30 1.08 - 1.57
Diabetes 7.5 .007 1.82 1.18-2.80
Any ischaemic event within last two months * 9.0 .003 1.71 1.20-2.44
Number of events within last three months (per event) 6.6 .01 1.02 1.01 - 1.03
Previous myocardial infarction 5.1 .02 1.31 1.04- 1.65
Degree of carotid stenosis:2
Cubic term 28.9 .0000 1.34
(Square term 28.4 .0000 1.30)
(Linear term * 26.4 .0000 1.25)
Plaque surface irregularity * 6.5 .01 1.80 1.14-2.83
Post-stenotic collapse of the internal carotid artery 4.5 .03 0.40 0.17-0.94
Non-significant terms
Age (per year) 0.3 .62 1.01 0.98-1.03
Male sex 1.0 .31 1.23 0.83 - 1.82
Systolic blood pressure (per 10 mmHg) 0.1 .82 1.05 0.90-1.15
Diastolic blood pressure (per 10 mmHg) 0.3 .61 1.10 0.80-1.30
Peripheral vascular disease 0.0 .90 1.03 0.65 - 1.63
Angina without previous myocardial infarction 0.1 .77 0.96 0.71 - 1.29
ECG signs of left ventricular hypertrophy 0.0 .90 1.07 0.40-2.10
Cerebral infarction on symptomatic side on CT brain scan3 1.8 .18 1.32 0.88-1.96
Occlusion of the contralateral internal carotid artery 0.0 .96 1.00 0.72-1.63
1
Degrees of freedom for all variables =1
2 Cubic term used in the model shown. Parameters given for squared and linear terms are those obtained
when the term was substituted for the cubic term. For the purpose of illustration the hazard ratios and
confidence intervals given in the table refer to the increase in risk for 80% stenosis vs 70% stenosis.
3 This term is a significant predictor if residual neurological signs after seven days is omitted from the
model: Wald statistic = 5.9, P = 0.03, hazard ratio = 1.54, 95% CI = 1.03 -2.12
* Significant predictor of outcome in the validated model derived on the 0-69% stenosis group (table 17.1)
All the significant terms in this model remained statistically significant when the model was re-derived
excluding the non-significant terms listed above. This model is available from the authors.
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Table 17.8. The non-validated logistic regression model for any major stroke (i.e. fatal or lasting longer than
seven days) or death from other causes within 30 days of carotid endarterectomy derived from all 1799
patients with 0-99% stenosis who were randomised to surgery in the ECST.
Wald statistic1 P Hazard ratio 95% CI
Significant variables
Female sex * 9.3 .002 1.86 1.25-2.78
Peripheral vascular disease * 6.9 .009 1.84 1.17-2.89
Systolic blood pressure (per 10 mmHg) * 7.8 .005 1.15 1.04- 1.25
Cerebral events vs ocular events 5.1 .024 2.23 1.11 -4.48
Non-significant variables -
Age (per year) 0.1 .74 1.004 0.98-1.03
Residual neurological signs after 7 days 0.01 .89 1.02 0.82-1.25
Diabetes 0.02 .88 0.95 0.52- 1.75
Any ischaemic event within last two months 0.04 .84 1.04 0.68- 1.60
Number of events within last three months (per event) 0.15 .69 1.004 0.98-1.02
Diastolic blood pressure (per 1 OmmHg) 1.97 .16 0.85 0.65-1.06
Previous myocardial infarction 1.00 .32 1.15 0.87-1.51
Angina without previous myocardial infarction 0.74 .39 0.88 0.67-1.17
ECG signs of left ventricular hypertrophy 0.17 .68 0.98 0.76-1.29
Degree of carotid stenosis (linear term, per 10% stenosis) 1.1 .29 1.06 0.95 - 1.17
Plaque surface irregularity 2.27 .13 1.39 0.91-2.12
Post-stenotic collapse of the internal carotid artery 3.58 .06 0.25 0.06-1.05
Occlusion of the contralateral internal carotid artery 0.12 .73 1.11 0.60-2.05
Cerebral infarciton on symptomatic side on CT brain scan 0.40 .53 1.13 0.80- 1.56
Side of operated carotid artery (left vs right) 0.01 .92 1.14 0.77-1.66
1
Degrees of freedom for all variables =1
* Significant predictor of outcome in the validated model derived on the 0-69% stenosis group (table 17.2)
All the significant terms in this model remained statistically significant when the model was re-derived
excluding the non-significant terms listed above. This model is available from the authors.
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17.5 Discussion
Although carotid endarterectomy reduces the risk of stroke in patients with a recently symptomatic
70-99% carotid stenosis, the clinical usefulness of the procedure is still questioned.15 It is
necessary to operate on about 14 patients to prevent one patient having an ipsilateral carotid
territory ischaemic stroke lasting longer than seven days over the next five years (figure 17.1).
These results suggest that the number of operations required to prevent one stroke can be reduced
considerably by the use of prognostic models to identify those patients who are most likely to
benefit from surgery. Rather than operating on all patients with 70-99% stenosis, as is the current
practice, a similar number of strokes might be prevented by operating on a small identifiable
subgroup of patients with a high risk of stroke without surgery and a relatively low operative risk.
Carotid endarterectomy seems highly effective in this subgroup, but is of little or no value in the
majority of patients with recently symptomatic 70-99% stenosis.
Risk Factor modeling
High and low risk patients can be identified in cohort studies and clinical trials using single
variable subgroup analysis or more detailed prognostic models. Prognostic models have two main
advantages. Firstly, they allow clinicians to take the effect of several different baseline
characteristics into account, whereas traditional subgroup analysis is limited to one or two
characteristics at a time. Individual patients may have several important risk factors each of which
interact in a way which cannot be described using univariate subgroup analysis. Secondly, single
variable subgroup analyses are subject to the play of chance and the problems of multiple post-hoc
comparisons, whereas stratification of trial results using an independently derived prognostic score
is a single analysis based on the reasonable a priori hypothesis that treatment effect is likely to vary
with the risk of a poor outcome in the different treatment groups.
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Previous prognostic models for the risk of stroke on medical treatment in patients with TIA or
minor stroke have either been based on relatively small cohorts of patients, or not included the
degree of stenosis of the symptomatic carotid artery, 1012 which is now recognised to be a very
powerful prognostic variable. No prognostic model has been validated in an independent group of
patients and used routinely in clinical practice.
Shortcomings of this analysis
There are many potential pitfalls in the development and validation of prognostic models.16'17
Where possible these have been avoided, but the analyses presented above still have a number of
shortcomings. In the absence of independently derived and validated prognostic models, the
medical and surgical groups were split in order to derive and validate ECST models. Since, it was
intended that a predictive score should be developed to stratify patients in the 70-99% stenosis
group (i.e. those patients in whom surgery was of overall benefit), models were derived on the 0-
69% stenosis group (a random 50:50 split of the dataset would have left too few 70-99% stenosis
patients in the validation set). However, this did have certain disadvantages. The 0-69% stenosis
groups were relatively small; neither contained the recommended 10-20 outcome events per risk
factor entered into the models.18 More robust and powerful models might be developed from larger
cohorts with more outcome events, and from cohorts of patients with 70-99% stenosis i.e. the
group of patients in whom they were intended to be used. For example, important prognostic
variables in patients with severe stenosis, such as post-stenotic collapse of the internal carotid
artery (table 17.7),19 are not important in patients with 0-69% stenosis. Nevertheless, the models
still performed well in the 70-99% stenosis group despite these potential shortcomings. It was also
reassuring that all the risk factors which were significant predictors of outcome in the models
derived on the 0-69% groups remained significant in the more detailed models derived on the
whole 0-99% stenosis groups. The independent risk factors for stroke and death within 30 days of
377
carotid endarterectomy were all found to be significantly associated with a poor operative outcome
in the systematic review of previous studies described in Chapter 14.
The mathematical models derived from the regression analyses were reduced to scores based on the
presence or absence of the statistically significant independent prognostic factors. It was felt that a
simple risk factor score was more likely to be used by clinicians in routine clinical practice. There
are numerous complex prognostic models in the literature, but very few ever reach clinical practice.
This approach is likely to have reduced rather than inflated the power of the models, and should
counteract the tendency of prognostic models to be "over-fitted" to the derivation cohort.17 The
combination of the medical and surgical models into a single predictive score could also have been
more sophisticated. The weighting of surgical risk factors as half that of medical risk factors simply
reflected the ratio of the absolute risk of operative stroke and death to the absolute risk of stroke on
medical treatment in patients with 70-99% stenosis in the ECST. The weighting could be varied
depending on the operative risk of the population to which the model was being applied and the
length of follow-up on which the decision whether or not to operate was based; the absolute risks in
the medical and surgical groups vary independently with time. The simplicity of the risk score may
have underestimated the power of the risk modelling approach, but the analyses suggest that it still
has considerable potential. The models will be further validated and refined in future. Finally, the
dichotomy of the 70-99% stenosis group into those with a risk score of less than four and those
with a score of four or more was data-dependent. Given that the pre-hoc hypothesis was that
likely benefit from endarterectomy would increase with the risk score this was not entirely
unreasonable. However, further refinement of the models and more sophisticated modeling of the
relationship between the risk score and likely benefit from surgery will be necessary in future. It is
intended that this should be done in collaboration with the NASCET trialists. Although the models
appear to work well in our 70-99% stenosis group, virtually all models tend to work less well when
applied to truly independent datasets.17
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Wider implications of the results
Overall results of clinical trials can cover up considerable heterogeneity of treatment effect across
groups of patients at different baseline risks of a poor outcome. As described in Chapter 16, it has
been suggested that this could be investigated by analysis of trends in overall results of clinical
trials included in meta-analyses (meta-regression). However, such analyses produce artefactual
results and are very difficult to interpret. In practice, risk factor modeling using individual patient
data is the most reliable way in which to test for heterogeneity of relative treatment effect with
baseline risk. Any treatment which has a finite risk of serious complications is likely to be
ineffective or harmful in patients in whom the risk of a poor outcome without treatment is
sufficiently low. For example, stratification of patients in randomised controlled trials of coronary
artery bypass grafting by their predicted risk of cardiac death on medical treatment using an
independently derived prognostic model showed that surgery was harmful in patients at low risk of
cardiac death without surgery and highly beneficial in high risk patients.20 Preliminary results
suggest that a similar approach may be helpful in the decision as to which individuals with
hypertension should be given drug treatment.21 The analyses presented here have shown that risk
factor modelling is likely to help to clinicians to predict which individual patients are likely to
benefit from carotid endarterectomy.
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17.7 Legends to figures
Figure 17.1. The effect of carotid endarterectomy on the risk of ipsilateral carotid territory major
ischaemic stroke (i.e. fatal or lasting longer than seven days) and operative major stroke or death in
ECST patients with 70-99% carotid stenosis.
Figure 17.2. The reduction in the five year actuarial absolute risk of ipsilateral carotid territory
major ischaemic stroke or surgical major stroke or death in the surgery group compared with the
medical group at each score. Statistical significance is tested at each score using the log rank test
and the number of cases on which the estimate is based is given for each score.
Figure 17.3. The effect of carotid endarterectomy on the risk of ipsilateral carotid territory
ischaemic stroke lasting longer than seven days and operative stroke lasting longer than seven days
or death in ECST patients with 70-99% carotid stenosis and a risk score of less than four.
Figure 17.4. The effect of carotid endarterectomy on the risk of ipsilateral carotid territory
ischaemic stroke lasting longer than seven days and operative stroke lasting longer than seven days
or death in ECST patients with 70-99% carotid stenosis and a risk score four or more.
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The aim of this thesis was to provide information, additional to the overall results of the ECST,
which would improve the effectiveness of carotid endarterectomy in the prevention of stroke in
clinical practice. Although, it is difficult to draw all the different strands of the thesis together
to form a single conclusion, perhaps the overall conclusion should be that we still have some
way to go before we can say that we have developed optimal strategies for the imaging of
atherothrombotic stenosis of the carotid artery, and the selection of patients for endarterectomy.
The work presented in this thesis has, however, shed light on some clinically important
questions. There were also numerous minor observations, but only the clinically important
questions will be discussed below:
1) What is the optimal strategy for the imaging andmeasurement ofcarotid stenosis?
The main conclusion of the systematic review of published studies of imaging and
measurement of carotid stenosis, detailed in Chapters 3 and 4, is that the quality of the existing
literature is poor. Although there are several hundred published papers, very few of them are of
a sufficient standard to inform clinical decision making. Quality standards have been
developed on the basis of these reviews, and are being published.
The data presented in Chapters 5 and 6 suggest that the common carotid method is probably the
best of the three commonly used methods of measurement of the degree of linear carotid
stenosis on angiograms. However, it seems unlikely that many clinicians will adopt this
method in preference to the ECST or NASCET methods.
2) Which angiographic characteristics of a carotid stenosis predict the risk of stroke on
medical treatment?
The data presented in Chapters 7, 8, and 9 show that there are several angiographic
characteristics, in addition to the degree of carotid stenosis, which are useful in predicting the
risk of ipsilateral carotid territory ischaemic stroke on medical treatment. For example,
angiographic plaque surface morphology can be measured with moderate to good
reproducibility and appears to have pathological validity. Patients with irregular plaques have a
higher risk of stroke on medical treatment than patients with smooth plaques at all degrees of
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stenosis. By contrast, patients with post-stenotic collapse of the distal internal carotid artery
have a paradoxically low risk of stroke on medical treatment.
3) Is treatment ofhypertension likely to increase or reduce the risk ofstroke on medical
treatment in patients with significant carotid stenosis?
This question cannot be answered with confidence without a randomised controlled trial.
However, whether or not a trial is necessary is likely to depend on observational studies. If the
relationship between blood pressure and stroke risk was the same as it is in primary prevention
or TIA and stroke patients in general, then a trial would probably not be necessary. It would be
reasonable to generalise the results of the ongoing secondary prevention trials to patients with
significant carotid disease. However, the data presented in Chapter 9 do not show the usual
relationship. Although the numbers are small, they suggest that the relationship may be flat or
even reversed. As a consequence of this observation, I am now organising a large collaborative
study of individual patient data from several cohorts of patients with symptomatic and
asymptomatic carotid stenosis in order to define the relationship between blood pressure and
stroke risk more precisely in patients with different levels of stenosis.
4) Should endarterectomy be performed on the asymptomatic contralateral carotid artery?
Many patients with a recently symptomatic severe carotid stenosis also have a significant
stenosis of the contralateral carotid artery. This is usually asymptomatic. In fact, this is one of
the most common modes of "presentation" of asymptomatic carotid stenosis. It is uncertain
to what extent such patients would benefit from staged bilateral endarterectomy. However, the
data presented in Chapter 12 suggest that the risk of ischaemic stroke in the distribution of the
contralateral asymptomatic carotid artery is relatively low. Although, the power of the analysis
was not great, there was no evidence that the risk of stroke was any higher than that reported
distal to truly asymptomatic stenoses. Although the risk of endarterectomy is likely to be
relatively low, as shown in Chapter 12, the potential benefit from endarterectomy would be
small.
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5) What is the real risk ofstroke and death due to carotid endarterectomy?
It has been argued that the operative risks reported in ECST and NASCET were high, and were
not representative of good surgical practice. It has been suggested that the results of the trials
are therefore invalid: if a surgeon has a low complication rate, then he or she should be able to
operate on a broader range of stenosis than was suggested in the trials. The systematic review
of published risks which was presented in Chapter 11 revealed very considerable heterogeneity
of operative risk of stroke and death. However, most of this heterogeneity appeared to be
related to the methodology of the studies and the affiliations of the authors. Studies in which
single surgeons reported their own data gave very low risks, whereas studies which included
neurologists among the authors gave relatively high risks, particularly when the neurologist had
examined the patients post-operatively. The later studies reported risks of stroke and death
which were very similar to those in ECST and NASCET. It is likely that these represent the
real risk of stroke and death due to endarterectomy - at least, the average risk across a
population of good surgeons..
6) What are the riskfactorsfor stroke and death due to endarterectomy?
This question was addressed in Chapters 13 and 14. Several clinical and angiographic
characteristics appear to be independent predictors of the risk of stroke and death due to
endarterectomy. Further work is necessary in order to produce good validated models, but the
evidence suggests that this will be possible. The simple risk score derived from ECST patients
with 0-69% stenosis was consistent with the risk factors derived from the literature (Chapter
14), and revealed significant heterogeneity of operative risk when it was used to stratify the
ECST patients with 70-99% stenosis (Chapter 17).
7) What are the risk factors for ipsilateral carotid territory ischaemic stroke on medical
treatment?
This question was addressed in Chapters 8, 9 and 17. Several clinical and angiographic
characteristics appear to be independent predictors of the risk of ipsilateral carotid territory
ischaemic stroke over and above the degree of stenosis. Further work is necessary in order to
produce good validated models, but it seems likely that the models presented in Chapter 17 will
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be useful. It is intended that all the models, and other important observations, derived from the
ECST data will be tested on the NASCET data later this year.
8) Can we identify which individual patients with recently symptomatic carotid stenosis are
most likely to benefitfrom endarterectomy?
As detailed in Chapter 15, there are theoretical reasons for doubting the wisdom of simply
applying the overall results of clinical trials to all future patients similar to those included in a
particular trial. Although Chapter 16 highlighted some of the potential pitfalls of analysis of
the relationship between relative treatment effect and baseline risk, the data presented in
Chapter 17 suggested that there are major potential gains in the cost-effectiveness of
endarterectomy to be had if patients are selected more critically. Using data on the ECST
patients with 0-69% carotid stenosis, a simple prognostic score was developed to identify
patients which a high risk of stroke on medical treatment and a low risk of stroke and death due
to endarterectomy. Stratification of the ECST patients with 70-99% stenosis using the score,
suggested that endarterectomy is only beneficial in a relatively small proportion of patients




Summary of ECST protocol (April 1992):
abridged for this thesis
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Objectives
This is a multicentre, randomised trial of carotid endarterectomy in various categories of symptomatic
patients with carotid territory ischaemia (transient ischaemic attack, amaurosis fugax, retinal artery
occlusion, minor ischaemic stroke, and non-disabling major ischaemic stroke) with stenosis and/or
ulceration at the origin of the symptomatic internal carotid artery in the neck. It will determine: (1) the
reduction in long-term risk of ipsilateral ischaemic stroke conferred by technically successful surgery when
added to the best available medical treatment; (2) the likelihood of stroke, death or other complications as a
direct result of surgery; (3) the extent to which ipsilateral ischaemic stroke normally contributes to the
overall long-term prognosis with respect to stroke at all sites.
Methods and analysis
Three-fifths of the patients will be randomly allocated to a policy of carotid endarterectomy as soon as
possible and two-fifths to a policy of avoid carotid endarterectomy for as long as possible. The patients will
be stratified by centre. All patients will receive the best medical treatment which, in each centre, will be
similar for the "surgery" and "no surgery" patients. The trial will not be "blind" but the outcome events of
main concern (major stroke and all deaths) will be reviewed by a clinical audit committee using a precis of
the patient's history (prepared by collaborating neurologist and Professor Warlow, on the basis of the
available medical records) which will not state whether surgery was undertaken.
Eligibility (for randomisation)
1) Any patient with transient ischaemic attack, amaurosis fugax, retinal infarction, minor ischaemic
stroke (symptoms less than a week), or nondisabling major ischaemic stroke (return to normal activities)
within the distribution of one or both carotid arteries.
2) The qualifying cerebrovascular event must have been less than six months before randomisation.
3) For patients with stroke the onset must have been four weeks or more before any surgery.
4) There must be atheromatous carotid stenosis and/or ulceration of the symptomatic internal carotid
artery(s) at its origin, with no other definite and more likely source of embolism to the brain or eye.
5) The patient must be willing to take part in the trial.
6) No contra-indication to surgery.
7) An endarterectomy is not thought to be definitely necessary or definitely unnecessary. In other words,
patients will be randomised in the "grey area of uncertainty."
8) Follow-up is practicable.
Surgery
The surgeons must be designated collaborators in the trial. The operative and anaesthetic techniques will be
those with which a particular surgeon has confidence. If the symptoms have been referable to both carotid
arteries then a bilateral endarterectomy, as a staged procedure, may be undertaken in the "surgery" group.
Ideally, asymptomatic lesions should not be operated on.
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Investigations required before randomisation
1) Haemoglobin, haematocrit, ESR, platelet count, fasting (or random) blood sugar and cholesterol,
syphilis serology.
2) Chest X-ray, ECG.
3) CT scan is strongly recommended if cerebral symptoms have occurred.
4) Carotid angiography, or high quality arch angiography, to show the symptomatic carotid bifurcation
and any other relevant areas.
Medical treatment
All patients will receive the best available medical treatment and the policy of each centre will be monitored
during follow-up to ensure that the "surgery" and "no surgery" group receive similar medical treatment in
each centre.
Entry
1) If a patient is eligible and could soon be operated on, telephone the Clinical Trials Service Unit (CTSU)
44-(0)865-240972 (Monday to Friday 09.00-1 7.00 British time) with patient's full name, exact date of
birth, name of randomising neurologist and surgeon, and clinical details. A random allocation will be made
to surgery as soon as possible or avoid surgery for as long as possible.
1) Post surgical details if randomised to surgery, angiogram report, and copies of angiograms to the
Trials Unit within six weeks of randomisation (use left and right stickies on angiogram films).
3) Arrange appointment for four months or so after randomisation.
4) Inform family doctor by letter.
5) Use European Carotid Surgery Trial stickies on the notes and correspondence.
Follow-up
Visits at four months, 12 months, and annually thereafter. At each visit complete follow-up form and post
or fax to the Neurosciences Trials Unit. EVERY ATTEMPT MUST BE MADE TO KEEP ALL
PATIENTS ON FOLLOW-UP THROUGHOUT THE TRIAL.
Persistent Attacks
Ifmedical treatment is ineffective patients in the "no surgery" group may eventually be thought to require
elective surgery. They will still by analysed in the group to which they were originally randomised, as will
any patient in the "surgery" group who, for some reason, does not get operated on.
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Background to the ECST
In April 1978 a group of British neurologists and methodologists met in Oxford to discuss the management
of patients with transient ischaemic attacks (TIA). As a result the UK-TIA Aspirin Trial was established
and in August 1979 patient recruitment started. Even at that time concern had been expressed about the
value of carotid endarterectomy and it soon became clear that very different surgical policies were being
pursued in the various neurological centres involved in the Aspirin Trial. By early 1980 the accession rate
for the Aspirin Trial was going well at about nine patients per week and the organisation to run the trial had
become established in the University of Oxford Department of Clinical Neurology and Clinical Trials
Service Unit (CTSU). It was therefore felt that this would be a good time to initiate a trial of carotid
endarterectomy since the value of the operation was uncertain, most of the neurologists involved in the
Aspirin Trial supported the idea of a surgery trial, TIA patients were already being intensively followed up
in the Aspirin Trial, and an organisation to run the surgery trial could easily be grafted on to the
organisation already running the Aspirin Trial. On March 15th, 1980 some of the neurologists collaborating
in the Aspirin Trial and a group of interested vascular surgeons met at St Mary's Hospital, London (where
the first successful reconstruction of a carotid artery had been performed some 27 years previously). As a
result of this meeting, and a subsequent one on May 22nd, 1980 a protocol was drawn up and application
made to the Medical Research Council (MRC) in September 1980 for additional funding for a UK trial of
carotid surgery.
The Neurosciences Board of the MRC turned down the application in March 1981 but, as a result of some
changes in the protocol and a tightening up of some aspects of the trial design, the Board later became
prepared to fund the trial. Detailed arrangements for organising the trial were made in the summer of 1981
and by September/October patients were being recruited.
It soon became clear that while the trial was eminently feasible, enough patients would never be found in
the UK within a reasonable period of time. Therefore, we decided to seek wider collaboration and in 1982
included three centres from France and in 1983 centres in Holland joined as well. By 1984 we had included
one centre in Germany and others in Italy. Additional centres in the UK also joined us. In 1985 a centre in
Zagreb joined (but then dropped out again) and by then there were 33 centres altogether. The increasing
number of centres was a response to shared uncertainty about the value of the operation and, as a result, we
are likely to have a much large sample size than originally predicted. This means that we will have a more
accurate estimate of the effect of carotid endarterectomy and also be more able to examine sub-groups of
patients.
At the March 1984 collaborators' meeting in Oxford we decided to call our effort "The European Carotid
Surgery Trial" (ECST) The initial three year grant from the MRC ended in August 1984. We applied for
five more years funding but, largely because of central government cuts in the grant to the MRC, we
received funding for only another two years. Fortunately, however, we were refunded again, this time for
five years from March 1987. In 1987 there were far more people and centres collaborating; about 300
collaborators, in 63 centres, in 12 Western European Countries. Indeed, the only Western European
Countries not collaborating were Austria, Switzerland, Ireland and Luxembourg. By then the trial office
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had moved from Oxford to Edinburgh (as a result of Professor Warlow's move) and completely new staff
were recruited. The MRC refunded the trial again for another five years from 1992.
In 1988 the Canadians and Americans started their own randomised trial of carotid endarterectomy and
Professor Henry Barnett left our Data Monitoring Committee to lead it. Naturally there was enough
collaboration between the organisers of the two trials to ensure the protocols were very similar, certainly
similar enough for later overview (meta) analysis.
In February 1991 the Data Monitoring Committee of the ECST, and of the North American Symptomatic
Carotid Endarterectomy Trial (NASCET), came to an almost simultaneous, but independent, decision to
recommend that the results for "tight" stenosis patients (70-99%) and, in the case of the ECST which
included a wider range of patients for "mild" stenosis patients (0-29%), should be revealed to the
collaborators. For the ECST these results were communicated by a conference telephone call on 22nd
February 1991 and, on the same day, the NASCET results were revealed in North America by the wide
distribution of an NIH Medical Alert. The results were published in the Lancet for the ECST (European
Carotid Surgery Trialists' Collaborative Group 1991) and in the New England Journal of Medicine for the
NASCET (North American Symptomatic Carotid Endarterectomy Trial Collaborators 1991). This provided
a major impetus to the ECST and by April 1992 there were 97 collaborating centres in 12 European
countries. For both trials, the intention is now to continue follow-up of all randomised patients and to
continue recruitment of patients with "moderate" carotid stenosis (30-69%) for whom the balance of risk
and benefit of carotid endarterectomy is still unclear.
Objectives
The European Carotid Surgery Trial is an international, randomised, multi-centre trial in various categories
of symptomatic patients with carotid territory ischaemia (TIA, amaurosis fugax, retinal infarction, minor
stroke, and non-disabling major stroke) with stenosis and/or ulceration at the origin of the symptomatic
internal carotid artery (ICA) in the neck. The advisability of carotid endarterectomy in such patients chiefly
depends on:
1) The magnitude of the risk of stroke and/or death as a direct result of surgery.
2) The magnitude of any longterm reduction in the risk of ipsilateral ischaemic stroke conferred by
successful surgery.
3) The length of future life (without stroke in sites other than the ipsilateral cerebral hemisphere) during
which any longterm reduction in the risk of ipsilateral ischaemic stroke can be expected to be enjoyed.
Because each of these quantities will differ from patient to patient (depending on such variables as age,
extent of carotid disease, and extent of vascular disease at other sites) we will subdivide the patients into
broad categories and, within each category, assess what the risks and benefits of surgery appear to be. The
spectrum of patients who are randomised will be carefully described in terms of these prognostic variables,
particularly the extent of disease in the symptomatic carotid artery(s) expressed as the percentage diameter
reduction at the origin of the ICA (or distal common carotid artery, ifmore stenosed). To begin with three
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categories will be defined: "mild" (0-29%), "moderate" (30-69%) and "severe" (70-99%) stenosis. We will
therefore determine:
1) The magnitude of any reduction in the longterm risk of ipsilateral ischaemic stroke conferred by
technically successful surgery (see below) when added to the best available medical treatment (and thus be
able to infer whether, among a roughly although not necessarily exactly similar spectrum of future patients,
technically successful surgery will be of substantial benefit).
2) The likelihood of technical failure of surgery for each category of patients, since we will observe the
frequency of stroke or death, and other complications, as a short-term result of current surgical practice (this
likelihood not being generalisable to other surgeons). A major (or other) event occurring within 30 days of
operation (or arising out of some other relevant antecedent event in the same period) will be deemed a
surgical complication. These are the technical failures of surgery. Technically successful surgery is a term
used to indicate that 30 days after carotid endarterectomy the patient is alive and has experienced no stroke
(it does not imply anything about the patency of the operated artery which normally we do not know
because non-invasive follow-up imaging is not required).
3) The extent to which the risk of ipsilateral ischaemic stroke normally contributes to the overall
longterm prognosis with respect to stroke of all causes and at all sites.
Method
The trial is multi-centre, randomised and stratified by centre. All patients will receive the "best available
medical treatment"; in three-fifths a policy of undertaking a carotid endarterectomy of the symptomatic ICA
(or arteries) as soon as possible will be pursued, and in the other two-fifths a policy of avoiding surgery for
as long as possible will be pursued. In each centre there must be at least one neurologist and surgeon
working together; the former to categorise the patients accurately before randomisation and to organise the
follow-up with particular attention to any major outcome events from the moment of randomisation, and the
latter to do the best possible and safest carotid endarterectomy.
Each centre will define their medical policy which must be applied to all patients. The medical policy, and
its uniformity between the "surgery" and "no surgery" patients, will be monitored in the trial office by
information gained at follow-up and any major departures from the policy will be discussed with the
relevant centre. The medical policy preferred by one centre may differ somewhat from that preferred by
another and although we would encourage discussion between centres in the hope of reducing the more
extreme differences, some differences will inevitably remain. Moreover, as information accumulates from
other sources (eg the Antiplatelet Trialists' Collaborative Overview) some centres may wish to alter their
policy of medical management. This is acceptable as long as they apply it equally to their '.surgery" and
"no surgery" groups. Because the patients will be stratified by centre, differences in medical management
between centres will not bias the "surgery" versus "no surgery" comparison. It would be unrealistic to
expect every centre to agree on a common medical policy (or that medical management will not evolve)
because there is debate as to exactly what level of blood pressure is appropriate in patients of a particular
age and sex, let alone what should be recommended in the way of antithrombotic drug treatment.
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The results will be continuously monitored in the trial office and patients will always be analysed in the
groups to which they were originally randomised (ie on an "intention-to-treat" basis). No patient will be
lost to follow-up if at all possible and no randomised patient will be excluded from the analysis. The interim
results of the trial will not be communicated directly to the collaborators but will be considered by a data
monitoring committee whose members are quite independent from the trial itself. At the end of the trial
any collaborator may analyse the data for themselves if they wish to.
If the major ischaemic stroke rate (disabling and non-disabling) in the cerebral hemisphere ipsilateral to the
relevant carotid artery differs by more than three standard deviations from the expected (on the null
hypothesis that the outcome in the two groups is the same) using a standard life-table analysis, the data
monitoring committee may wish to inform the collaborators. All ipsilateral major strokes will be included
in this analysis irrespective of whether they occur immediately or long after surgery, and also the very few
strokes that might occur between randomisation and surgery will be counted. Independent of the ongoing
data analysis, a decision was made in 1985 to consider the "mild", "moderate" and "severe" stenosis groups
separately on the assumption that any advantage to surgery would appear first in the "severe" stenosis
subgroup.
In addition, all major strokes at any site, death due to stroke and all other causes, minor stroke, TIA, retinal
infarction and myocardial infarction will be monitored and analysed. If possible, the distinction between
stroke due to cerebral infarction or cerebral haemorrhage will be established by early CT scanning, or by
post-mortem.
Relationship with trials of medical treatment
Some patients may be in trials of medical treatment but this will not affect the analysis of any of the trials
since randomisation should result in a more or less equal percentage of "active drug" or "control drug"
patients in the "surgery" and "no surgery" groups. Likewise, there should be a more or less equal number of
operated patients in each of the arms of any medical treatment trial.
Numbers required
The numbers required depend on the effectiveness of surgery (which of course we do not know), the major
stroke rate and the duration of follow-up. By 1991, with over 2,500 patients randomised, it became clear
that surgery was ineffective for "mild" and effective for "severe" stenosis patients, but that a larger sample
size (and longer follow-up) would be required for the "moderate" stenosis patients. Also follow-up for all
randomised patients would need to be continued to assess the durability of the effects of surgery in the
"mild" and "severe" stenosis groups.
Entry criteria
Patients of both sexes, any race, and of any age who, within the six months before randomisation, have
experienced any combination of TIA, amaurosis fugax, retinal infarction, minor ischaemic stroke or non-
disabling major ischaemic stroke within the distribution of one or both internal carotid arteries, and who
have a stenosing and/or ulcerating lesion of the symptomatic artery(s) at its origin in the neck.
397
Exclusions from randomisation and trial entry
1) Patients who are felt to be in definite need of surgery for reasons of patient preference, medical need, or
because they have been referred specifically for surgery by a physician not involved in the trial (for further
discussion, see below).
2) Patients for whom surgery is felt to be definitely inappropriate because of
( a) patient preference
( b ) poor general health
( c ) little if any carotid stenosis (for further discussion, see below)
( d ) ICA occlusion, or stenosis distal to the bifurcation more severe than at the bifurcation
( e ) a lesion thought to be technically inoperable (eg too distal)
( f) other likely sources of embolism (eg recent myocardial infarction, mitral stenosis, atrial fibrillation)
( g) vertebrobasilar events only.
3) Patients for whom follow-up is impractical due to distance or any other reason.
4) Patients whose TIA's are not thought to be due to atherothromboembolism.
5) Previous carotid endarterectomy of the symptomatic artery.
Note: (i) Previous or projected vascular operations on the legs, abdomen or heart are not exclusions to trial
entry; (ii) Previous carotid endarterectomy on the contralateral side is not an exclusion to trial entry; (iii)
A record of eligible but excluded patients who have elective carotid surgery will be kept and the reasons for
exclusion stated.
Definitions
Note: Symptoms are what the patient notices wrong (eg pins and needles, weakness) whereas signs are
what the doctor finds (eg sensory loss, weakness, abnormal reflexes).
Amaurosis Fugax (AFx) or Transient Monocular Blindness (due to ischaemia): acute total or partial loss
of vision in one eye with symptomatic recovery within 24 hours and, after adequate investigation, assumed
to be due to arterial thromboembolism in the retinal circulation. Emboli may or may not be seen and there
must be no retinal or ocular pathology (particularly glaucoma) to account for the symptoms. Most attacks
last only a few minutes and if attacks last longer than about 30 minutes the patient should be seen by an
ophthalmologist for confirmation of the diagnosis. Note: AFx is one category ofTIA (see below).
Angina Pectoris: central chest/arm pain related to physical exertion or emotion and relieved by rest.
Blood Pressure: to be measured with the patient rested for at least a minute and lying flat. Diastolic
pressure to be recorded as phase V (disappearance of sounds). If there is a substantial pressure difference
between the two arms then the highest is to be recorded and subsequent recordings taken in that arm.
Left Ventricular Hypertrophy: this will be assessed on the baseline ECG and defined as ST segment
depression and T wave inversion in leads 1,11, AVL, V4-V6 and/or the voltage sum of the tallest R wave
and the deepest S wave >- 40 mm in the precordial leads, provided the QRS duration <0.10 seconds.
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Minor Stroke: an acute disturbance of focal neurological function with symptoms lasting more than 24
hours but less than a week. Neurological signs of no functional significance (see below) are allowable
thereafter. CT scanning must be done as early after the event as possible (preferably within two weeks) to
exclude as far as possible patients with intracerebral bleeding and the cause of the event will then be
assumed to be infarction due to thromboembolism, required. Lumbar puncture is not required.
Major Stroke', an acute disturbance of focal neurological function with symptoms lasting more than one
week and thought to be due to an intracranial vascular disturbance. CT scanning must be done as soon as
possible, preferably within two weeks, to exclude intracerebral haemorrhage. Every effort must be made to
establish whether the cause is infarction or haemorrhage (primary intracerebral or subarachnoid) and to
localise the lesion accurately. For any stroke during follow up, we will record residual stroke-related
disability at about six months on the very simple Rankin Scale: Asymptomatic; Non-disabling symptoms
which do not interfere with lifestyle; Minor disability - symptoms which lead to some restriction of lifestyle,
but do not interfere with the patients' capacity to look after themselves; Moderate disability - symptoms
which significantly interfere with lifestyle or prevent totally independent existence; Moderately severe
disability - symptoms which clearly prevent independent existence, although patient does not need constant
attention day and night; Severely disabled - totally dependent, requiring constant attention day and night;
Death.
A non-disabling Major Stroke (NDMS) (This is a special category for the purposes of trial eligibility.)
Minor strokes are, by definition, not disabling after one week from the onset (see above) but major strokes
may not necessarily be disabling even though symptoms persist for longer than one week. A NDMS is
defined as a major stroke which has left the patient with only trivial symptoms and/or signs so that their life
is not substantially affected and they have everything, or more or less everything, to lose from a further
stroke in the same vascular territory causing significant disability (ie the stroke disability will be Rankin
grade 1 or possibly 2). The patient with a NDMS would be able to continue their normal work or, if not
working, their normal domestic life to an extent compatible with their age.
Myocardial Infarction: this is to be regarded as a definite event in the past if one or more of the following
criteria are met on entry to the trial:
( 1 ) The patient has been told by a doctor that he has had a heart attack.
(2 ) Unequivocal ECG evidence of old MI is still present.
( 3 ) A past history of severe central chest pain lasting more than 30 minutes with ECG
recording showing evolutionary ST and T wave changes.
During follow-up fatal (but not non-fatal) MI will be defined more carefully, using the usual WHO criteria
which depend on ECG and/or cardiac enzyme changes along with the appropriate clinical history and, if
available, post-mortem examination. Patients who die suddenly (within hours) of the onset of symptoms
which sound ..cardiac" (mainly chest pain), or who are found dead having been well a few hours earlier, will
be deemed to have died from presumed cardiovascular disease. If a post-mortem is done then at least
intracranial haemorrhage or a ruptured aortic aneurysm can be excluded and - in most cases - coronary
atheroma is what is found. However, unless there is clear evidence ofmyocardial infarction or definite and
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recent coronary thrombosis the patient will not be classified as fatal MI. but as a sudden cardiovascular
death.
NOTE: PROTOCOL CHANGE 1991: non-fatal Mis occurring after September 14 1991 will no longer
be regarded as major outcome events because a) surgery is most unlikely to influence the occurrence ofM]
and b) that was actually the result in the 1991 interim analysis.
Peripheral Vascular Disease: intermittent claudication in one or both lower limbs, ischaemic rest pain,
gangrene in the feet or toes, or absent pulses in one or both feet.
Retinal Infarction: acute total or partial monocular loss of vision with symptoms persisting more than 24
hours and with the fundal appearance of central retinal or branch artery occlusion. Diagnosis to be
confirmed by an ophthalmologist.
Transient Ischaemic Attack: an acute disturbance of focal neurological or monocular function with
symptoms lasting less than 24 hours and (after adequate investigation) assumed to be due to vascular
disease of an arterial embolic or thrombotic kind. Neurological signs of no functional significance (see
below) may be found subsequently and these residual signs will be recorded at baseline. Some patients may
have hypodense areas on CT or lesions on MRI but must still be classified as T1A on the basis of the
symptoms being less than 24 hours. Non-focal symptoms are allowable only if accompanied by focal
symptoms.
Focal Neurological Symptoms: Amaurosis fugax; Language disorder; dysphasia; dyslexia; dysgraphia;
Dyscalculia; Homonymous visual field loss starting suddenly, with no spread or intensification, and no
positive features (this excludes migraine without headache); Sudden visual loss in both eyes simultaneously;
Diplopia; Dysarthria; Dysphagia; Unilateral weakness or clumsiness of upper limb or lower limb or face
Unilateral sensory disturbance of face or limbs (excluding pain alone and the kind of disturbance associated
with functional overbreathing, pressure on peripheral nerves, focal seizures, etc)
Non-Focal Neurological Symptoms (ie those which, if present without focal symptoms, exclude patients
from entry since they are often due to causes other than cerebral ischaemia): Loss of consciousness;
Faintness; Generalised weakness and/or ataxia and/or sensory disturbance; Vertigo, imbalance, dizziness,
tinnitus; Drop attacks; Confusional and/or amnesic episodes; Hearing loss.
Neurological Signs of no Functional Significance
After symptomatic recovery from TIA, minor stroke, or NDMS some patients may still have trivial residual
signs which are often variable, disputed by experienced neurologists, and totally missed by less well-trained
observers. These "residual signs" do not exclude patients but are noted at trial entry as present or absent. It
is emphasised that this is a realistic way of defining patients who are often not seen by neurologically
trained observers soon after the event, and thus trivial signs of no functional significance are not noticed or
are recorded when they are not actually present: Mild disturbance ofmemory and/or intellect; Slight speech
and/or language disorder; Anosmia; Horner's syndrome; Unequal pupils; Ptosis; Nystagmus; Subjective
cutaneous sensory disturbance of face or limbs; Depressed corneal reflex; Deafness; Minor degree of palatal
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weakness; Slightly slow tongue movements; Asymmetric reflexes; Extensor plantar response; Minor
clumsiness or arms, hands, legs or gait.
Old neurological signs as a result of nun-vascular disease do not exclude patients and such signs should not
be included under the heading "residual neurological signs" at baseline (eg from old polio, injury, cervical
spondylosis, etc). Monocular blindness due to retinal infarction shouid not be included under the heading
of "residual neurological signs" at baseline.
Carotid Versus Vertebrobasilar Distribution Events
The literature is confused and contradictory in defining the exact clinical difference between carotid and
vertebrobasilar distribution vascular events and there seems to be little acknowledgement of the fact that a
large proportion of patients cannot be reliably assigned to one arterial distribution or the other. Also, there
is individual variation in the territories supplied by the major cerebral arteries which makes exact rules
impossible to formulate. This is perhaps part of the explanation why the prognosis is different in various
series although it is common but incorrect teaching that carotid distribution events have a worse prognosis
for stroke than vertebrobasilar events. Only patients thought to have carotid distribution attacks will be
randomised although some may well have vertebrobasilar attacks in addition.
Definite Carotid Distribution Symptoms and Signs: Amaurosis fugax; Language disorder
Definite Vertebrobasilar Distribution Symptoms and Signs: Dysphagia; Dysarthria; Diplopia; ""Bilateral
simultaneous sensory disturbance; ""Bilateral simultaneous weakness of face or limbs; ""Bilateral or
homonymous visual disturbance; ""Vertigo
*But not if in isolation because non-vascular diagnoses are likely (eg overbreathing, labyrinthine disorders,
syncope etc.).
Hemiphenomena: Until 1991 we used this term for cases in which it was uncertain whether the carotid or
vertebrobasilar circulation was involved. In actual practice this was when a patient experienced weakness
or numbness down one side of the body without any other symptoms to put the event definitely into one
circulation or the other. Of course, if the unilateral symptoms were accompanied by a symptom of definite
carotid (eg dysphasia) or definite vertebrobasilar (eg rotational vertigo, diplopia) disturbance then the
patient was categorised appropriately. If the unilateral symptoms were accompanied by either dysarthria or
homonymous visual disturbance (which could in this context be due to either carotid or vertebrobasilar
ischaemia) then the patient was still categorised as having had a "hemiphenomena" event. Therefore
hemiphenomena included: Unilateral weakness of face or limbs or Unilateral sensory disturbance of face
or limbs - plus/minus : Homonymous visual disturbance or Dysarthria
Note: A carotid bruit is not definite evidence for a carotid distribution event.
Note: A CT scan or an MRI showing hypodensity in a part of the brain compatible with the ischaemic
symptoms, and of the right age, may sometimes allow more accurate categorisation to "carotid" or
"vertebrobasilar".
Note: Protocol change from 6 January 1992: In accordance with usual clinical practice, and because in our
interim analysis there was no difference in prognosis and response to surgery between hemiphenomena and
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carotid events, hemiphenomena events are now regarded as carotid distribution unless there is some very
good reason to suggest vertebrobasilar ischaemia.
Who will be randomised: the "grey area of uncertainty"
Any eligible patient whom a collaborator thinks must be operated on and any that he thinks must not be
operated on cannot justifiably be randomised in the trial. All would agree that patients with normal,
minimally diseased or occluded symptomatic carotid arteries should definitely not be operated on and most
now believe that those with severe symptomatic carotid stenosis definitely must be operated on. There is,
however, an intermediate "grey area of uncertainty" in which it is uncertain whether it is better to operate or
not and it is within this area that patients will be randomised. It is only those patients who are randomised
who will contribute to the "surgery" versus "no surgery" analysis. These opinions have been much affected
by the interim results of the ECST and NASCET. It is now most unlikely, but not impossible or forbidden,
that "mild" and "severe" stenosis patients will be randomised.
All carotid distribution TIA, amaurosis fugax, retinal infarction, minor stroke and NDMS patients fit
enough for and willing to undergo surgery will have had angiography to show at least the symptomatic
artery in the neck. Some patients will definitely be operated upon because the responsible clinician is
certain that it is advisable to do so. Some will definitely not be operated on, because the responsible
clinician is certain that it would be unwise to do so. Finally, for some there will be uncertainty whether to
operate or not and in this "grey area of uncertainty" patients will be randomised. The size of the "grey area"
will vary depending on the whims, prejudices and experience of the collaborating neurologists and vascular
surgeons. Naturally it is assumed that collaborators in the trial will have reasonably large "grey areas" since
if this was not the case they would presumably not be collaborating in the trial at all.
It is essential to understand that only patients within the "grey area of uncertainty" will be randomised, and
that only the randomised patients will be analysed to estimate the benefits conferred by technically
successful surgery on various categories of patient (particularly with respect to the extent of carotid
disease). The statistical analysis will, of course, compare like with like and will not inadvertently compare
tightly stenosed patients with patients whose degree of stenosis is much milder.
A note on selection. One might think that the strategy of randomising in "grey areas" which vary between
collaborators introduces bias into the trial. This is not the case since only the randomised patients are
analysed. Even in an ideal world where the white, grey and black areas are the same for all surgeons and
neurologists, a trial of carotid endarterectomy would still include only a very small sample of all patients
with carotid distribution events who were fit for surgery. Patients who actually end up in a randomised (or
non-randomised) trial are those who present to a doctor, who are then referred to hospital, who happen to go
to a hospital where there is an adequate vascular surgery service, and who are then actually randomised.
For many reasons, therefore, no trial will include all eligible patients in the world and can only hope to
include a small and selected sample of them. Randomised trials do not rely on a random sample of the
population. Far from it, they contain highly selected patients and it is from the results in the randomised
patients that inferences for future practice must be drawn.
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Consent
The collaborators will be guided by their judgement about individual patients and by their local ethics
committees in determining the degree of consent that is required and this may vary with the interest,
intelligence and anxiety of individual patients. We propose to seek consent in one of two ways depending
on individual circumstances at the time. Consent before randomisation: the possible advantages and
possible disadvantages of the operation will be explained to the patient along with some idea of the purpose
of a randomised trial and the fact that many neurologists and surgeons are collaborating in an attempt to
establish the best treatment for patients in general. The patient will be told the operation is an established
and not an experimental procedure but that it is uncertain whether it will reduce the risk of stroke in their
case. It should be stressed that all patients will be regularly followed up and will receive the very best
available medical treatment. Consent after randomisation: when an eligible patient is found the clinician
randomises the patient and then if the allocation is to "surgery" tells the patient the operation may reduce
the risk of stroke in the same kind of way that he would if there was no trial and he was seeking consent for
a normal operative procedure. The physician may or may not explain that this is part of a trial and how the
patient had come to be selected for surgery depending on his view of what degree of information is
appropriate for the individual patient involved and also on the advice of his local ethics committee. If the
allocation is to "no surgery" the physician will give the patient as much information as he would normally
give to a patient not being referred for surgery and he may or may not explain the trial and how the patient
had been selected.
An explanation of the principles and technique of randomisation, emphasis on the risks of stroke without the
operation, or emphasis on the risks of stroke as a result of the operation may not always be advisable. In
some patients the fears that any very exact explanation would arouse might be better avoided for the sake of
the patient, just as is normally done in routine clinical practice. In general we do not consider formal
written consent to be essential (unless the local ethics committee deems it to be so) but in cases of doubt as
the the degree of consent to be solicited collaborators should be prepared to err on the side of more
complete information than to risk giving less information than appropriate for a particular patient. There is
an ethical need to enter a sufficient number of patients into the trial to discover how future patients should
be treated but this must not over-ride the ethical imperative that each patient has a right to accurate and
detailed information if requested. Before entering patients into the trial each collaborating centre will seek
approval from their local ethics committee or in any other way which, in the local circumstances, is thought
to be more appropriate.
Investigations before randomisation
The collaborators must be convinced that there is no cause for the neurological symptoms other than
thromboembolism in association with atheromatous carotid stenosis and/or ulceration and that there is no
material contraindication to surgery. The following investigations are recommended: haemoglobin,
haematocrit and erythrocyte sedimentation rate, platelet count, blood urea, fasting or random blood sugar,
fasting or random blood cholesterol, syphilis serology, chest x-ray, MSU, echocardiogram if indicated, and
CT-scanning (or MRI) - this is strongly encouraged in all patients but is less necessary in those with only
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ocular ischaemia. It will establish a baseline from which any subsequent infarction or haemorrhage can be
assessed, and any preexisting infarct can be accounted for as one of the possible prognostic variables (both
with respect to longterm outcome and the immediate outcome of surgery). If possible, CT should be done
within two weeks of any stroke to have the best possible chance of excluding a primary intracerebral
haemorrhage.
Angiography - This is essential before randomisation so that:
1) Other causes of transient focal neurological episodes can be excluded (eg aneurysm, angioma)
2) Patients in a collaborator's "black area" can be operated on (see discussion above)
3) Patients in a collaborator's "white area" can avoid operation (see discussion above)
4) Patients can be stratified retrospectively for various degrees of arterial disease.
5) The surgeon can be sure the stenotic lesion is operable,
Note: By the 1990s, in most centres non-invasive ultrasound techniques were being used to select
patients with carotid stenosis for angiography and so that patients with little carotid disease could be spared
the hazards of angiography. Since new angiographic technologies are coming into centres at different times
we have agreed that: The absolute minimum is an adequate view to show the anatomy of the origin of the
symptomatic internal carotid artery(s) with biplanar views if possible, plus as good a view as possible of the
intracranial circulation on that side. We would like - if possible - views of the contralateral internal carotid
artery in the neck, but this is not mandatory. These "adequate views" may be obtained by selective
conventional angiography, selective digital intra-arterial angiography of the carotid system, arch
angiography and - at absolute rock bottom - by digital intravenous angiography.
Categorisation of the extent ofarterial disease
There is no generally agreed method for measuring and describing the extent of arterial disease revealed by
an angiogram (or by any other test) and the meaning of a "surgically significant lesion" has not been
clarified. In this trial there will be retrospective stratification and categorisation (Peto et al, 1 976) of the
extent of disease of the symptomatic (and asymptomatic) ICA using whatever measurement is thought to be
the most accurate and acceptable at the time of analysis. Thus, during the trial we shall collect all data
which might be useful including: (1) Copies of all appropriate x-ray films (ie views of the symptomatic
artery(s) in the neck, plus any other x-rays showing an abnormality) which can be evaluated "blind" to the
patient's treatment or outcome by a review committee during, or at the end of the trial; (2) The angiogram
reports; (3) An estimate, in the operated patients, by the surgeon as to whether the stenosis is "mild",
"moderate", or "severe" and whether thrombosis or ulceration is present; (4) As from 6 January 1992, an
estimate at baseline by the collaborating neurologist / surgeon of the % diameter reduction of the
symptomatic ICA origin.
Note: If the distal common carotid artery is more stenosed than the proximal ICA, then the greater
stenosis will be recorded in the ECST.
Note: If both ICAs are symptomatic then, for the analysis, the "symptomatic" artery will be taken as the
most stenosed artery, provided it is not occluded.
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All methods of categorisation will be compared so that agreement can then be reached as to which the most
appropriate method should be, particularly when it comes to reporting the trial results in such a way that
they can be applied to subsequent patients in normal clinical practice. Also, studies of inter and intra-
observer variability will be carried out.
Surgery
Surgeons must be designated collaborators in the trial and should not delegate surgery to a junior colleague.
Not only should they be experienced in carotid endarterectomy but they should have a good "track record"
although it is recognised that a good surgeon can be a good surgeon without having done a large number of
operations. The operative technique and type of anaesthesia should be those in which the collaborating
surgeon has confidence. It will not be possible to compare formally the surgical techniques between centres
but the following will be noted: Duration of operation (skin incision to skin closure time); Type of
anaesthesia (general or local); EEG monitoring during surgery; Transcranial Doppler monitoring during
surgery (data collected from 6 January 1992); Stump pressure if measured; Occlusion time; Shunt or no
shunt; Thrombus present or not; Ulceration present or not; Degree of stenosis (mild, moderate or severe);
Anticoagulation during surgery; Distal intimal flap secured (data collected from 6 January 1992); Patch or
no patch, and type; Ease of operation (difficult, average, easy); Post-operative hypertension (requiring
treatment); Post-operative hypotension (requiring treatment); Whether nerve to carotid sinus is cut
(abandoned in 1992); Surgical complications (TIA, stroke, death, MI, peripheral nerve injury; venous
thromboembolism, neck haematoma etc.)
Surgery should be undertaken as soon as possible after randomisation, but in patients with minor stroke or
non-disabling major stroke there is evidence to suggest that surgery should be delayed. This is because the
risk of postoperative stroke, due to haemorrhage into an ischaemic or infarcted area of brain which is
revascularised by the endarterectomy, is particularly high. Therefore, patients with major stroke should not
be operated on until something like four or more weeks after onset.
Randomisation must not be carried out until the patient is ready for surgery and the surgeon can operate
soon. In other words, there should be a very short time interval (days rather than weeks) between
randomisation and any surgery so that few, if any, strokes occur between randomisation and surgery. If they
do, they will still be counted in the "surgery" group from the point of view of the analysis.
NOTE. No other operation in the neck or elsewhere (eg repair of aortic aneurysm) is allowed under the
same anaesthetic unless this becomes unexpectedly necessary once the patient is under the anaesthetic.
Bilateral carotid endarterectomies should normally be "staged" and not done under the same anaesthetic
(see below).
What to do about persistent attacks
It is quite likely that some patients will have persistent and unacceptably frequent TIA's or AFx and, if
medical treatment is ineffective, a few patients in the "no surgery" group may eventually be thought to
require a carotid endarterectomy in an attempt to reduce the frequency of the attacks rather than necessarily
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to reduce the risk of ipsilateral ischaemic stroke. The analysis, however, will be of the patients in their
original two randomised groups and will, therefore, be in essence a comparison of undertaking "surgery as
soon as possible" versus "avoiding surgery for as long as possible". This "intention-to-treat" method of
analysis is an accurate reflection of real clinical management and is, therefore, reasonable and justifiable
(Peto et al, 1976). Some collaborators may wish to anticoagulate patients with frequent attacks and this is
allowable but should be recorded on the follow-up forms.
What to do about bilateral carotid disease
(a) For patients with bilateral carotid symptomatic disease (at presentation or later) randomisation occurs
only once; if to "no surgery" then no operation at all, if to "surgery" then carotid endarterectomy on one or
both sides according to the clinician's wishes. All operations must be recorded with the full details.
(b) For patients with contralateral asymptomatic carotid stenosis, if randomised to "no surgery" for the
symptomatic side then no surgery to the asymptomatic side either. If randomised to "surgery" for the
symptomatic side then endarterectomy on the asymptomatic side can be done if the clinician so wishes but it
is not encouraged. In short, it is the patient who is randomised, not the artery.
Randomisation
Randomisation will take place over the telephone to the Clinical Trials Service Unit (CTSU), Oxford. The
neurologist should complete the Randomisation Notepad for patients who meet the entry criteria and none
of the exclusion criteria. The collaborator will be asked by the telephone operator to answer each question
on the Randomisation Notepad in the same order. Once all the questions have been answered, the operator
will state the allocated treatment: EITHER, a policy of undertaking carotid endarterectomy as soon as
possible OR, a policy of avoiding carotid endarterectomy for as long as possible.
After randomisation, the Randomisation Notepad can be kept for collaborators' own records. It should not
be sent to the NTU. However, the following documents should be sent to the NTU. Edinburgh:
1) The radiologist's report on the angiography, translation if the language is other than English or French.
2) Copies of the angiograms showing the symptomatic carotid artery and any other abnormalities.
3) Surgery Details form for those patients allocated to surgery.
Each month collaborators will receive a computerised print-out indicating: 1) Patients entered from each
centre; 2) Patients entered in the trial as a whole; 3) Requests for any incomplete or unclear data.
Medical Treatment
This will be initiated at the time when any such treatment is normally started, very often as soon as a patient
is seen. A similar policy should be adopted for all patients, operated and unoperated. in each centre.
Follow-up
All patients should be seen at four months and one year after randomisation, and annually thereafter until
the end of the trial. At each of these specified follow-up times the follow-up form should be completed and
returned to the NTU, Edinburgh. Each month the collaborators will be sent a computerised print-out of
forms overdue by more than four weeks. It is anticipated that the follow-up will be done by neurologists
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rather than surgeons since the former are more likely to be responsible for the patients' continuing medical
treatment. Intermediate follow-ups may be done if there is a medical need (for example, for the supervision
of blood pressure therapy), if the patient is also in other trials, or it post-stroke disability has to be assessed
about six months after a post-randomisation stroke. If the patients cannot get to the hospital, then follow-up
can be done by telephone, or through the family doctor, or in any other suitable way depending on the local
circumstances. If the patient dies or has a stroke, in addition to completing the follow-up form, a major
event form should also be completed.
Notified events ofmajor stroke (with CT-scanning if at all possible) and death will be audited by a clinical
audit committee on the basis of a case summary written by the collaborating neurologist on the major event
form and edited by Professor Charles Warlow to omit the treatment allocation, on the basis of all available
medical and post-mortem records. Perioperative strokes and deaths will be particularly carefully
documented to try and determine their nature and cause. Continuing TIA, amaurosis fugax, minor stroke,
non-fatal MI, retinal infarction, angina and claudication will also be recorded.
Follow-up should continue even if a major event (apart obviously from death) has occurred so that it will
still be possible to analyse death rate if a non-fatal stroke has occurred earlier.
Original introduction (January 1981 and June 1985)
This introduction has been left in the Protocol for historical interest. Clearly much of it has been outdated
by recent information concerning the prognosis of TIA patients, the availability of antiplatelet drugs, and
the interim results of the European Carotid Surgery Trial (ECST) and the North American Symptomatic
Carotid Endarterectomy Trial (NASCET).
Transient ischaemic attacks (TIA) are followed by stroke at the rate of approximately 5% per annum (Baker
et al, 1968) and by stroke and/or death at the rate of approximately 10% per annum (Baker et a], 1968;
Canadian Cooperative Study Group, 1978). The age-standardised mortality ratio for TIA patients compared
with a TIA-free population is about three (Heyden et a], 1980) and death is more usually cardiac than stroke
related (Cartlidge et al, 1977). The frequency ofTIA preceding cerebral infarction is uncertain but has been
reported to be as low as 5% and as high as 39% (David & Heyman, 1960; Friedman et al, 1969; Royden
Jones & Millikan, 1976; Whisnant et al, 1973; Marti-Vilaita et al, 1979), this variation being a reflection of
how difficult it is to assess the frequency of an easily forgotten transient neurological symptom in a patient
who has, at the time of questioning, sustained a stroke. If, however, even only 10-20% of all strokes are
preceded by TIA, and if the TIA themselves are reported and recognised by doctors, and if treatment to
prevent subsequent stroke is effective, then recognising and treating TIA patients should have a useful
impact on stroke mortality and morbidity.
The only reasonably certain treatment in TIA patients is the control of hypertension because such treatment
is effective in asymptomatic individuals, and in those who have survived a stroke (Warlow, 1982). It is
unlikely that the effect in TIA patients is substantially different since it 'is now agreed that TIA are very
seldom caused by hypotension, and indeed hypertension is considerably more frequent in TIA patients than
in controls (de Bono and Warlow, 1981). Minimising other vascular risk factors such as smoking, obesity,
diabetes mellitus, high haematocrit, and lack of exercise may be useful although such policies have not been
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tested in formal clinical trials. The use of antithrombotic drugs is controversial. Conventional anti¬
coagulants were once fashionable but the only available data are to fragmentary to allow any sensible
conclusions to be drawn (Warlow, 1982) and on the whole this treatment is impractical in the long term,
particularly as T1A patients tend to be elderly. The use of regular aspirin as an antiplatelet agent is also
controversial (Warlow, 1982) but is currently being tested in the UK-TIA Aspirin Trial (UK-TIA Study
Group, 1979).
TIA in the distribution of the internal carotid artery (ICA) are associated with atherothrombotic stenosis
and/or ulceration at its origin in the neck in about 40% of cases, and occlusion in about 10% (Warlow,
1981). Stenotic or ulcerating lesions may be removed by endarterectomy and the important questions are
whether these lesions really are the cause of TIA and, more importantly, are likely to be the cause of
subsequent stroke; whether the long term risk of ipsilateral cerebral infarction is reduced by surgery; and
whether any such risk reduction is greater than or less than the short term risk of surgery itself. The
association between carotid disease and TIA (Harrison & Marshall, 1976) does not necessarily imply that
the relationship is causal. However, embolism of atheromatous cholesterol-containing or thrombotic
material from such lesions is a likely explanation since emboli can be observed occluding or passing
through the retinal arterioles and the chance of finding loose thrombotic material at operation is highest in
patients operated soon after a TIA (Harrison & Marshall, 1976). There is, therefore, not much doubt that
some, and possibly a large proportion of carotid TIA's are due to embolism from thrombosis complicating
atheroma at the origin of the ICA. It is assumed, but not proved, that subsequent stroke is very often due to
further thromboembolism in the same artery, or possibly thrombotic occlusion at the origin of the ICA itself.
It is, therefore, logical to remove stenosing or ulcerating lesions at the easily accessible origin of the ]CA in
the neck, but it is very uncertain how extensive the lesion has to be to be 'significant' (ie worth removing).
Similar arguments apply to patients with retinal artery occlusion, minor ischaemic stroke, or non-disabling
major ischaemic stroke since they all have much to lose by subsequent cerebral infarction in the ipsilateral
hemisphere.
Carotid endarterectomy is now said to be the commonest vascular procedure in the USA (Thompson &
Garrett, 1980) and many series with a combined total of several thousands of patients have been reported in
the literature. Very regrettably only two were randomised clinical trials (Fields et al, 1970; Shaw et al,
1984). These trials did not show an overall benefit for surgery compared with the best available medical
treatment.
In the first trial 24 medical centres recruited 316 patients with carotid stenosis who had experienced TIA or
minor stroke, but only about half the patients had experienced carotid distribution events and the surgical
mortality ranged from 236% depending on the centre. The mean follow-up period was 42 months and the
.soft' outcome event of continuing carotid TIA was reduced (but not statistically significantly) by surgery.
This outcome was 'soft' since naturally the trial could not be blind and there might have been bias by both
the patients and the observers. In any case, continuing TIA is not a particularly relevant problem since most
patients do not have very frequent or very many TIA and, by definition, they are trivial and cause no
permanent neurological disability. In the vast majority of patients any risk whatsoever from surgery is not
worthwhile just to prevent such infrequent and trivial symptoms. The most important finding from the trial
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was the fact that there were 20 strokes in 169 surgically treated patients (12%) and 19 in the 147 medically
treated patients (13%).
It was, therefore, clear that in the long term surgery conferred no benefit and only if the strokes as an
immediate result of surgery are removed from the analysis does the frequency in the surgical group (4%)
become significantly less than in the medical group (12%) (X2 = 5.9 p < 0.05). Subgroup analysis
suggested that patients with isolated carotid stenosis fared best but the numbers were small and examination
of subgroups is fraught with methodological difficulties (Lee et al, 1980). This trial demonstrated that if a
patient survived surgery without stroke then the risk of subsequent stroke was reduced, but the 95%
confidence limits of this result included a zero risk reduction. In practical terms, assuming the surgical
complication rate in the trial is applicable to routine surgical practice at the present time, it is not worth
recommending surgery since the risk of operative stroke seems to be as great as the risk of stroke without
surgery over the next 42 months or so. If, however, the follow-up had been longer then possibly the
difference between the two groups would have become greater.
The trial has been widely ignored probably because the surgical complication rate may have been higher in
the 1960s than it is now, because the trial was rather small, because there were several faults in its design,
and because of the publication of numerous non-randomised surgical series most ofwhich suggested (on the
basis of unacceptable evidence) that surgery was an effective therapeutic procedure. In fact it is usually the
surgical series from highly specialised centres with a low surgical complication rate (Thompson et al, 1970)
which tend to be quoted in the literature although in routine practice the perioperative risk of stroke and/or
death may be much higher. In one particularly honest account it was 21% (Easton and Sherman, 1977). In
the UK it is not known what the average risk of carotid endarterectomy is likely to be but it has been
calculated that if surgery is to reduce the overall risk of stroke then the stroke and/or death rate due to the
operation itselfmust be something less than 3-4% (Harrison, 1980). Another difficulty with the American
trial is that it appeared to compare surgery with "the best available medical treatments when in actual
practice the comparison should be *the best available medical treatment" versus *the best available medical
treatment plus surgery" and medical management now, particularly the control of hypertension, may very
well be more effective than it was in the 1960s.
The Newcastle trial of carotid endarterectomy was much smaller but the results were consistent with the
American Joint Study. Overall, the immediate risk of surgery was about the same as the long-term risk
without surgery but TIA were reduced in frequency; however, TIA would have to be very alarming and
frequent to take the not inconsiderable risk of the operation. Of course, it may have been that there were so
many operative strokes that further TIA were either impossible or undetectable.
There is, therefore, a very real need for a further randomised trial of sufficient size to determine whether
carotid endarterectomy, using modern surgical and anaesthetic techniques, confers any long term benefit
(and if so, of what degree) in patients with carotid stenosis who have experienced a TIA, minor or non-
disabling major ischaemic stroke, or retinal infarction in the distribution of the operated artery. There is no
ethical objection to another trial since the only previously published trials failed to show clear benefit for
surgery. There is enormous variation in surgical referral rates between British neurologists (UK-TIA Study
Group, 1983) and, in a questionnaire sent to the 47 neurologists involved in the UK-TIA Aspirin Trial in
1980, 21 of 32 respondents (66%) thought that a trial should be attempted and it is largely these
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neurologists and their surgical colleagues who started the present study. We are perfectly well
aware that in some centres carotid endarterectomy is regarded as a standard procedure but on the basis of
the published evidence and our own experience we would disagree that the operation is a procedure of
proven value. We believe that only a properly conducted randomised trial can establish its value. It is of
interest that the Oxford Ethical Committee wrote, after considering our protocol, written consent is
unnecessary, and the Trial completely ethical." and "in fact, some members have come round to the
opinion that as the comparison is between two accepted methods of treatment, it perhaps might not have
needed referral to the Ethics Committee in the first place!" Referral to the Ethics Committee was in fact a
requirement of obtaining financial support from the Medical Research Council.
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Appendix 2
The data collection forms used in the ECST
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EUROPEAN CAROTID SURGERY TRIAL: RANDOMISATION NOTEPAD
To make telephone randomisation quick and easy for you, prepare answers to these questions before
telephoning the randomisation service on:
Depends on Country







Date of B irth / /
Sex Male 0 Female 0
Cerebrovascular Events at any previous time (tick 0 1 box on each line)
Yes No
0 o Transient cerebral ischaemic attack(s) (<24 hours)
0 0 Amaurosis fugax (transient monocular blindness) (<24 hours)
0 □ Minor ischaemic stroke (24 hours-7 days)
0 0 Non-disabling major stroke (>7 days)
0 0 Retinal infarction (>24 hours)
0 0 Any residual neurological siens now? (exclude monocular blindness)
O 0 Right carotid artery symptomatic?
0 0 Left carotid artery symptomatic?
0 0 Right cerebral hemisphere infarct (visible on CT or MRI)
0 0 Left cerebral hemisphere infarct (visible on CT or MRI)
Number of cerebrovascular events in the last 3 months 1 I I
Date ofmost recent qualifying cerebrovascular event involving the symptomatic artery
Estimate of % diameter stenosis of the symptomatic carotid artery | 1 |
(if both carotids are symptomatic, state stenosis of the worst side unless it is occluded)








Myocardial infarction in the past
Angina now, or in the past
Left ventricular hypertrophy (on ECG)
Claudication or rest pain in legs now, or in the past
Treated diabetes and/or blood sugar > 10mmol/l (180mg%)
Blood Pressure systolic Mil diastolic
Drugs being regularly taken now (tick 0 1 box on each line)
Yes No
□ □ Aspirin
□ □ Other antiplatelet (eg ticlopidine)
□ □ Anticoagulants (eg warfarin, heparin)
0 0 Lipid lowering drugs
Date of randomisation / /
Treatment Allocation from Clinical Trial Service Unit, Randomisation Service, Oxford.
Immediate Surgery 0 Medical Care only O
Angiography
Please now send to the trial office:
1. Radiologist's full report
2. Angiogram films: at least 2 views of the symptomatic artery in the neck, plus views of any other
abnormalities either intracranially, or in the neck. If no angiogram of asymptomatic carotid
bifurcation please estimate % diameter stenosis from any ultrasound examination
E.C.S.T. SURGERY DETAILS








Operation Details Right Left
Date of surgery (dd/mm/yy)
Duration of surgery (skin to skin) (minutes)
Anaesthesia (local or general)
EEG monitoring during surgery (yes/no)
Transcranial Dopplcr monitoring (yes/no)
Stump pressure (raras Hg)
Occlusion time (minutes)
Shunt (yes/no)
Thrombus at endarterectomy site (yes/no)
Ulceration at endarterectomy site (yes/no)
Degree of stenosis (mild, moderate, severe)
Anticoagulation during surgery (yes/no)
Distal intimal flap secured (yes/no)
Patch (yes and type/no)
Operation was (easy, average, difficult)
Complications during and after surgery
Yes No
□ □ Death: Cause
□ □ Stroke: which side of brain I I
□ □ TIA/amaurosis fugax: which side of brain/eye f |
□ □ Peripheral nerve palsv: give details
□ □ Post-operative hypertension requiring treatment
□ □ Post-operative hypotension requiring treatment
□ □ Neck haematoma requiring re-operation
□ □ Deep vein thrombosis
□ □ Pulmonary embolism
□ □ Other: please describe
Post this form to: Neurosciences Trials Unit, Department of Clinical Neurosciences,
Western General Hospital, Crewe Road, Edinburgh EH4 2XU or fax (44)(0)31-332-5150.
E.C.S.T. FOLLOW-UP FORM







EVENTS SINCE PATIENT WAS LAST SEEN: (tick □ 1 box on each line)
Yes No Date
□ □ / Death












Duration of symptoms (days) I I I (enter 99 if still persisting)
Haemorrhage | 1 Infarct [ | Not known i J
L Carotid (^] R Carotid j 1 Vertebrobasilar j
Anticipated Rankin Score at 6 months post stroke I 1
Amaurosis fugax left eye
Amaurosis fugax right eye
TIA brain Left carotid
TIA brain Right carotid
TIA Vertebrobasilar
Retinal infarct left eye




_ Other Please describe.
CURRENT DRUGS: (tick 0 1 box on each line)
Yes No
[H D Aspirin
□ □ Other Antiplatelet (eg ticlopidine)
□ □ Anticoagulant (eg warfarin)




Post this form to: Neurosciences Trials Unit, Department of Clinical Neurosciences,
Western General Hospital, Crewe Road, Edinburgh EH4 2XU or, fax:
(44)(0)31-332-5150.
EUROPEAN CAROTID SURGERY TRIAL
MAJOR EVENT
Complete this form for any patient having a stroke and/or death.
Identifiers
Patient's name




Section I: Presenting symptoms
Give short account of presen'ing symptoms at the time of randomisation particularly
with respect to type of attack(s) and side of brain or eye.
Section 2: Follow-up
Give very short account of follow-up.
Section 3: Description of the event
Stroke: give date, neurological details, and CT scan results (and date).
Death - send all relevant details to define the cause, and results of post-mortem (if any).
Post-operative event (within 30 days of surgery), please provide the following information.
1. General description of the operation and whether anything unusual noted (blood pressure,
heart rate, monitoring etc.) Please enclose a copy of the anaesthetic chart.
2. Monitoring undertaken during surgery (eg. EEG, Doppleretc.)
3. Full description of symptoms and signs of the stroke
4. Exactly when the stroke happened in relation to the stage of surgery or perioperative period
5. Result and copy of early CT scan (to exclude primary intracerebral haemorrhage) and
result and copy of a later CT if first was normal (to demonstrate size and site of infarct).
Continue overleaf if necessary
Post to: Neurosciences Trials Unit, Department of Clinical Neurosciences, Western General
ARTICLES
Randomised trial of endarterectomy for recently symptomatic
carotid stenosis: final results of the MRC European Carotid Surgery
Trial (ECST)
Articles
European Carotid Surgery Trialists' Collaborative Group*
Summary
Background Our objective was to assess the risks and
benefits of carotid endarterectomy, primarily in terms of
stroke prevention, in patients with recently symptomatic
carotid stenosis.
Methods This multicentre, randomised controlled trial
enrolled 3024 patients. We enrolled men and women of any
age, with some degree of carotid stenosis, who within the
previous 6 months had had at least one transient or mild
symptomatic ischaemic vascular event in the distribution of
one or both carotid arteries. Between 1981 and 1994, we
allocated 1811 (60%) patients to surgery and .1213 (40%)
to control (surgery to be avoided for as long as possible).
Follow-up was until the end of 1995 (mean 6-1 years), and
the main analyses were by intention to treat.
Findings The overall outcome (major stroke or death)
occurred in 669 (37-0%) surgery-group patients and 442
(36-5%) control-group patients. The risk of major stroke or
death complicating surgery (7-0%) did not vary substantially
with severity of stenosis. On the other hand, the risk of
major ischaemic stroke ipsilateral to the unoperated
symptomatic carotid artery increased with severity of
stenosis, particularly above about 70-80% of the original
luminal diameter, but only for 2-3 years after randomisation.
On average, the immediate risk of surgery was worth trading
off against the long-term risk of stroke without surgery when
the stenosis was greater than about 80% diameter; the
Kaplan-Meier estimate of the frequency of a major stroke or
death at 3 years was 26-5% for the control group and 14-9%
for the surgery group, an absolute benefit from surgery of
11-6%. Flowever, consideration of variations in risk with age
and sex modified this simple rule based on stenosis severity.
We present a graphical procedure that should improve the
selection of patients for surgery.
Interpretation Carotid endarterectomy is indicated for most
patients with a recent non-disabling carotid-territory
ischaemic event when the symptomatic stenosis is greater
than about 80%. Age and sex should also be taken into
account in decisions on whether to operate.
Lancet 1998; 351; 1379-87
See Commentary page 1372
♦Writing committee, study organisation, and participants given at
end of paper
Correspondence to: Prof Charles Warlow, Department of Clinical
Neurosciences, Western General Hospital, Edinburgh EH4 2XU, UK
(e-mail: cpw@skull.dcn.ed.ac.uk)
Introduction
We designed the European Carotid Surgery Trial
(ECST) as a randomised comparison of "carotid
endarterectomy as soon as possible" with "avoid surgery
if at all possible, for as long as possible" (ie, surgery
versus control) in patients with one or more carotid-
territory ischaemic episodes within the previous 6 months
and with some degree of stenosis near the origin of the
symptomatic internal carotid artery (ICA). From the
outset we expected that the balance of surgical risk and
benefit, in terms of the prevention of stroke, would vary
among categories of patients, and in particular with
severity of stenosis. This expectation was borne out by
the interim results.1,2 Now that trial recruitment and
follow-up are complete, we can report in detail on the
balance of surgical risk and benefit.
Methods
We carried out the trial in 97 centres in 12 European countries
and one centre in Australia and described much of the
methodology in our first report.1 Ethical approval was obtained
in all centres. Informed consent was obtained from each patient
in accordance with the requirements of the local ethics
committee.
Eligibility
Eligible patients had experienced, in the previous 6 months, one
or more carotid-territory ischaemic events in the brain or eye,
which were either transient (symptoms lasting minutes, hours, or
days) or permanent but did not cause any serious disability. We
excluded patients who were likely to have had embolism from
the heart to the brain or eye, and patients who had more severe
disease of the distal than of the proximal ICA.
After contrast angiography of the symptomatic artery, with
whatever technique was in use at the time in the local centre, the
physicians and surgeons enrolled patients for randomisation
when they were "substantially uncertain" whether or not to
recommend endarterectomy of the affected artery. The
anatomical extent, technique, and quality of angiography varied
widely between centres but at the very least we required
visualisation of the symptomatic carotid bifurcation. A few
patients with occlusion of the symptomatic carotid artery,
although not eligible, were assigned randomised treatment in
error. This error usually came to light at central review of the
angiograms, but these ineligible patients were included in trial
follow-up and analysis.
Measurement of carotid stenosis and definition of the
symptomatic side
We collected the angiograms in the trials office, and a single
observer measured the percentage diameter stenosis on the best
angiographic view of the point of maximum narrowing, using as
the denominator an estimate of the original width of the artery at
this narrowest point and bearing in mind the slight widening of




1213 allocated control (to avoid surgery)
1169 no surgery within 1 year




1745 operated within 1 year
62 no surgery within 1 year
4 not known
• ' r
1211 with any follow-up
1198 follow-up to death or 1995
13 partial follow-up
1807 with any follow-up
1801 follow-up to death or 1995
6 partial follow-up
1
442 deaths or major strokes
Figure 1: Trial profile
the normal ICA origin which is where most of die stenoses were
found.' If only one artery had been symptomatic, this was,
naturally, defined as the symptomatic artery, and it defined the
side for classification of any cerebral or ocular ischaemic
outcome events as ipsilateral or contralateral to that artery. If
both carotid arteries had been symptomatic, we defined die
symptomatic artery, and side, as that with the most recent
symptoms. If the symptoms had occurred at more or less the
same time on each side, die most stenosed artery defined the
symptomatic artery, and side, unless it was clear that the ICA on
this side was occluded or had been operated on electively before
randomisation.
Randomisation and follow-up
We randomised the first patient on Oct 14, 1981, and the last on
March 31, 1994, by telephone to the Clinical Trial Service Unit
in Oxford. A computer program generated the randomisation
schedule, stratified by centre, making it impossible for the local
investigators to know whether the next allocation was going to be
to surgery (60% of the patients) or control (40% of the patients).
Irrespective of trial treatment allocation, all patients received
what was judged to be the best medical treatment. Although this
treatment varied somewhat between centres and over the years,
it usually consisted of advice against smoking, treatment of
raised blood pressure, and antiplatelet drugs. From the moment
of randomisation, we expected follow-up information for every
randomised patient at 4 months, at 12 months, and then
annually until the end of 1995. We planned to follow-up every
patient for at least a year, mostly in neurology clinics, but if
necessary via the patient's family doctor.
Trial treatment
When we allocated a patient to surgery we expected the
operation to be carried out within a reasonable time. For the
purpose of analysis, we defined trial treatment as the first carotid
endarterectomy within a year of randomisation and any
subsequent endarterectomy on the same artery, also within a
year. We designated as cross-overs to the control group any
patients allocated surgery who were not operated on within a
year of randomisation. Likewise, we classified as cross-overs to
the surgery group any control patients who were operated on
within a year of randomisation. The side on which the operation
was to be done was left to the judgment of the surgeon; in just
26 (1-5%) of 1745 cases this was different from what we had
designated as the trial symptomatic side. The protocol allowed
an endarterectomy before randomisation but only if the intent
was then to assign randomised treatment for the other carotid
artery, which must have been symptomatic within the previous
6 months. Patients assigned to surgery could have a bilateral
carotid endarterectomy if clinically appropriate, but we expected
that surgery on either side would be avoided for patients
assigned to control.
Recording of outcome events
We collected the clinical details of all
deaths and of any possible non-fatal strokes
after randomisation, prepared a summary
for agreement by the collaborating
physician, and then sent the summary, with
treatment allocation concealed, to the
clinical audit committee for their final
approval. We resolved any disagreements
by discussion. We classified the outcome
events in various ways, with emphasis on
major strokes, and whether any death was
due to stroke, some non-stroke vascular
cause, or a clearly non-vascular cause.
Stroke was defined as a clinical syndrome
characterised by rapidly developing
symptoms and/or signs of focal and at
times global (applied to patients in deep
coma and those with subarachnoid
haemorrhage), loss of cerebral function lasting longer than 24 h
or leading to death, with no apparent cause other than that of
vascular origin.
Major stroke was a stroke, as defined above, with symptoms
lasting longer than 7 days.
Disabling stroke was a stroke that after 6 months was associated
with disability as recorded on the modified Rankin scale of 3,4,
or 5.' If the patient died of a cause other than stroke within the 6
months after the stroke, or if there had been a further stroke in
that period, we used an intelligent clinical estimate of the likely
future disability from the original stroke. After a disabling stroke,
a patient was classified as permanently disabled, hence only one
such event was possible in each patient.
Fatal stroke was that deemed by the clinical audit committee to
have caused the death of the patient, either directly by the brain
damage or indirectly by some non-neurological complication, at
any stage after the stroke.
Surgical events were all strokes lasting longer than 7 days and
all deaths occurring within 30 days of trial surgery (in surgery or
control patients).
Ipsilateral major ischaemic stroke was any major stroke in the
distribution of the symptomatic (at the time of randomisation)
carotid artery, or of uncertain vascular distribution, and which
was not definitely haemorrhagic in origin, and which was not a
surgical event.
Haemorrhagic major stroke was any major stroke classified by
computed tomography, magnetic resonance imaging, lumbar
puncture, or necropsy as definitely due to primary intracerebral
or subarachnoid haemorrhage.
Other major stroke was any major stroke that was not a surgical
event or an ipsilateral major ischaemic stroke (ie, strokes that
were haemorrhagic, in the vertebrobasilar distribution, or in the
distribution of the contralateral carotid artery).
Non-stroke vascular death was any death that was due to
vascular disease but not stroke, and which did not occur within
30 days of trial surgery. This category included sudden deaths
and those due to the complications of cardiac disease and
ruptured aortic aneurysm.
Non-vascular death was any death definitely due to non-vascular
causes such as cancer.
Unknown cause of death was all deaths not otherwise classified.
Trial outcomes
Each patient could experience several adverse outcomes during
follow-up, which might differ in severity and in likely relevance
to the surgical treatment. It was difficult to choose a main trial
outcome that summarised all the important outcome information
but did not reflect too narrow a prejudice about the likely effect
of carotid endarterectomy. For this reason we focused the main
669 deaths or major strokes
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Surgery (n=1807) Control (n=12±l)
Demography
Male/female 1299 (72%)/508 (28%) 869 (72%)/342 (28%)
Mean (SD) age in years 62-5 (8-1) 62-3(8-0)
Ischaemic events
Any cerebral transient ischaemic 895(50%) 595(49%)
attack
Any amaurosis fugax 452 (25%) 318(26%)
Any minor stroke (symptoms 408(23%) 253(21%)
<7 days)
Any major stroke 491(27%) 340 (28%)
Any retinal infarction 113(6%) 73(6%)
Infarct visible on CT scan on 456(25%) 295(24%)
symptomatic side
Residual neurological signs 535(30%) 346(29%)
Mean (SD) days from last symptoms 62-3 (53-4) 62-3(52-7)
History
Hypertension* 839/1614 (52%) 504/1078(47%)
Mean (SD) systolic blood 151 (22-3) 150-2(21-3)
pressure (mm Hg)
Mean (SD) diastolic blood 86 2(11-4) 86 3(10-8)
pressure (mm Hg)
Ischaemic heart disease 443(24%) 258(21%)
Peripheral vascular disease 292(16%) 203(17%)
Diabetes 208(12%) 145(12%)
Current cigarette smoking* 844/1604 (53%) 557/1077(52%)
Previous carotid endarterectomy" 29/1614(2%) 23/1081(2%)
Laboratory data
Mean blood cholesterol (mmol/L)* 6-4 (13-5) 6-4(13-8)
Mean (SD) packed-cell volume 43-3(6-6) 43-8 (6-9)
(%)"
Stenosis of symptomatic carotid artery
0-29% 240(13%) 179(15%)
30-49% 390(22%) 261(22%)
50-69% 582 (32%) 377(31%)
70-99% 586(32%) 389(32%)
Occluded 9 (0-5%) 5 (0-4%)
Stenosis of contralateral carotid artery
0-29% 894 (53%) 569(51%)
30-49% 379 (22%) 261 (23%)
50-69% 264(16%) 176(16%)
70-99% 107(6%) 67 (6%)
Occluded 49(3%) 49 (4%)
Missing (no views available) 114(6%) 89(7%)
"Variables not collected beyond January, 1992: for cholesterol n=1573 surgery, 1059
control: for packed-cell volume n=1614,1081.
Table 1: Baseline characteristics of all analysed patients
analysis on the most important clinical question—the effect of
surgery on stroke. Because carotid endarterectomy may cause
stroke within a matter of days, but generally not later, the
relative risk of stroke changes with the length of follow-up and so
analysis at a single time point would not fully describe the
balance of risk and benefit from surgery. To overcome this
difficulty, we not only looked at the treatment effect at 3 years, a
data-derived cut-off point when the excess risk of ipsilateral
ischaemic stroke seemed to have disappeared in the control
patients, but also estimated the gain in stroke-free life
expectancy.
To restrict attention to the compound outcome of stroke or
death might suggest that all strokes are comparable to death.
Therefore, we have shown several ways of viewing trial outcomes
disaggregated into several clinically sensible parts: death; major
stroke or death within 30 days of trial treatment (ie, surgical
events, the vast majority of which occurred within 5 days of
surgery and were, therefore, in some way almost certainly caused
by surgery); and major stroke not associated with trial surgery.
We further split this last category into stroke ipsilateral to the
symptomatic artery and not identified as definitely haemorrhagic
(ie, ipsilateral major ischaemic strokes) and all other strokes (ie,
all known haemorrhages, vertebrobasilar or contralateral carotid
ischaemic strokes). These outcomes were not mutually exclusive,
so some tables include some patients twice. However, the
survival curves of compound events were based on only the first
major stroke or death for each patient. All analyses, unless
otherwise stated, were of all outcome events occurring between
the moment of randomisation and the final follow-up for each
patient and by allocated treatment (ie, intention to treat). Even if
some patients allocated surgery never underwent endarterectomy,
they were analysed in the surgery group. Similarly, patients
allocated control who underwent endarterectomy within the 12-
month time limit for trial surgery or later were analysed in the
control group. Thus, some patients in the group allocated
control treatment could have a surgical event after trial surgery.
Statistical methods
The primary objective of our analysis was to estimate the range
of stenosis within which carotid endarterectomy confers
statistically proven benefit. For this purpose we had to estimate
treatment effect as a function of stenosis, which required a
regression model. Since our primary outcome was time to
recurrent major stroke or death, a survival model is appropriate.
We used the Cox proportional-hazards technique. As might be
expected with a surgical intervention, the model had to take into
account a short period of excess risk immediately after surgery
and a diminution of treatment effect after some years. We found
that these effects were adequately modelled by a 5-day
postoperative period of high risk and a constant long-term
treatment effect falling to zero at 3 years. Thus, these terms were
included as time-dependent covariates.
We chose stroke-free life expectancy as the main trial outcome
because the immediate hazard of surgery means that treatment
failures occur sooner, on average, with surgery than without.
Examination of the surviving proportions at a chosen point in
time would not have reflected this early penalty. As with simple
life expectancy, this outcome is strongly affected by age and sex.
We therefore included age and sex in the regression model to
ensure that their true effect was assessed at each stage in the
calculation. Other factors that may affect surgical risk,5 or risk
without surgery,' were not included. Since no treatment effect
was found beyond 3 years, life expectancies were assumed to be
equal in stroke-free survivors in each treatment group beyond
this time and estimated from another study (unpublished).
Further details of this calculation and other features such as
implementation of the intention-to-treat principle with time-
dependent treatment risk, development of the model, steps to
minimise bias due to data-dependent model selection,
justification of duration of time-dependent model terms, and
estimation of baseline hazards are available from the
investigators. The Cox model was estimated with the programme
TDA (version 5.5) and simulations used Minitab (version 9.2).
Results
3024 patients received randomised treatment allocation—
1811 surgery and 1213 control (figure 1). The mean
follow-up was 61 years (mean 61 years in the control
group, 6-0 years in the surgery group; maximum 13-8
years). We lost only 25 patients (0-83%) to follow-up, six
because of emigration. Because 19 of these 25 had at
least some follow-up (mean 3-0 years for controls; 3-2
years for surgery group) we were able to include them in
the analysis up until the time we lost them. Therefore,
3018 (99-8%) patients were included in the trial analysis,
1807 in the surgery group and 1211 in the control group.
There were some small baseline differences between the
groups, particularly in the prevalence of hypertension and
ischaemic heart disease (table 1), but these were unlikely
to have been clinically relevant.
62 (3-4%) of the 1807 patients allocated surgery did
not undergo carotid endarterectomy within a year of
randomisation. Of the 1745 patients who received surgery
as allocated, 50% were operated on within 14 days of
randomisation and 95% within 70 days. Five patients had
a major stroke while awaiting surgeiy. Not surprisingly, a
higher proportion (143 [11-8%]) of the 1211 patients
allocated control did not adhere to the allocation and
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S(n=78) C (n=62) S(n=162) C (n=117) S(n=200) C (n=139) S(n=190) C (n=122) S(n=350) C (n=240)
Major-stroke/surglcal death
Within 30 days of trial surgery 5 (6-4%) 0 3(1-9%) 0 14(7-0%) 0 18 (9-5%) 0 22 (6-3%) 0
Ipsilateral major ischaemic stroke not 6(7-7%) 4 (6-5%) 13 (8-0%) 6 (5-1%) 16 (8-0%) 9 (6-5%) 11 (5-8%) 8 (6-6%) 18 (5-1%) 26(10-8%)
within 30 days
Other major stroke not within 30 days 3(3-8%) 5 (8-1%) 16 (9-9%) 9(7-7%) 13 (6-5%) 6(4-3%) 11 (5-8%) 11 (9-0%) 24 (6-9%) 12 (5 0%)
All major stroke or surgical death 12(15-4%) 9(14-5%) 29(17-9%) 14 (12-0%) 38(19 0%) 14(10-1%) 38 (20 0%) 16(13-1%) 59 (16-9%) 36 (15-0%)
Any major stroke 12 (15-4%) 9(14-5%) 29(17-9%) 14 (12-0%) 37(18-5%) 14(10-1%) 38 (20 0%) 16(13-1%) 57 (16-3%) '36 (15-0%)
Death from any cause 21 (26-9%) 12(19-4%) 47 (29 0%) 30 (25-6%) 56 (28-0%) 40 (28-8%) 46 (24-2%) 24(19-7%) 94 (26-9%) 66 (27-5%)
Any major stroke or death 28 (35-9%) 16 (25-8%) 60 (37-0%) 39 (33-3%) 78(39-0%) 46 (33-1%) 65 (34-2%) 32 (26-2%) 126 (36-0%) 86 (35-8%)
Disabling/fatal stroke or surgical death
Disabling stroke or death within 30 days 2 (2-6%) 0 2(1-2%) 0 5 (2-5%) 0 8(4-2%) 0 11(3-1%) 0
Fatal/disabling ipsilateral ischaemic 2 (2-6%) 3 (4-8%) 4 (2-5%) 1 (0-9%) 8(4-0%) 4 (2-9%) 6 (3-2%) 6(4-9%) 8 (2-3%) 13 (5-4%)
stroke not within 30 days
Other fatal/disabling stroke not within 2(2-6%) 2 (3-2%) 9 (5-6%) 4(3-4%) 8 (4-0%) 4 (2-9%) 7 (3-7%) 3 (2-5%) 15(4-3%) 6 (2-5%)
30 days
All disabling/fatal stroke or surgical 6(7-7%) 5(8-1%) 15 (9-3%) 5(4-3%) 21(10-5%) 8(5-8%) 21(11-1%) 9 (7-4%) 34 (9-7%) 19 (7 -9%)
death
Fatal stroke or surgical death
Fatal stroke/other death within 30 1(1-3%) 0 1 (0-6%) 0 2(1-0%) 0 2(1-1%) 0 4 (1-1%) 0
days of trial surgery
Fatal ipsilateral ischaemic stroke not 1(1-3%) 1(1-6%) 2(1-2%) 0 2(1-0%) 1 (0-7%) 2(1-1%) 2 (1-6%) 2 (0-6%) 5 (2-1%)
within 30 days
Other fatal stroke not within 30 days 0 1(1-6%) 5(3-1%) 1 (0-9%) 3(1-5%) 2(1-4%) 2(1-1%) 3 (2 5%) 6(1-7%) 3(1-2%))
All fatal stroke or surgical death 2 (2-6%) 2(3-2%) 8(4-9%) 1 (0-9%) 7 (35%) 3(2-2%) 6 (3-2%) 5(4-1%) 12 (3-4%) 8 (3-3%)
S=surgery. C=control.
Table 2: Number of patients with each important outcome by degree of stenosis and treatment allocation
underwent carotid endarterectomy at .some stage during
the trial, mostly because of recurrent symptoms; 42
(3-5%) were operated on within a year of randomisation
and thus were classified as cross-overs. As expected, the
severity of symptomatic stenosis varied widely (tables 1
and 2).
Non-trial treatments likely to influence prognosis
A greater proportion of patients allocated control than of
those allocated surgery were recorded as taking aspirin at
randomisation (58-7 vs 54-7%, p<0 05). The use of other
antiplatelet drugs, anticoagulants, and lipid-lowering
drugs was similar in the two groups. During follow-up
there was a tendency for control patients to be treated
somewhat more aggressively. The proportions of control
and surgery patients recorded as receiving treatment on
50% or more of their follow-up forms were: aspirin (79%
vs 77%, p=0-25), other antiplatelet drugs (18% vs 16%,
p=0-38), anticoagulants (8% vs 6%, p=0-09), lipid-
lowering drugs (8% vs 6%, p=0-09), and any of these
preceding drugs (86% vs 82%, p=0 003). These
differences might have reduced any apparent benefit of
surgery.
Important outcome events by severity of symptomatic
carotid stenosis
Table 2 shows the numbers of patients with various
events within categories of stenosis severity for various
Surgery Control
(n=1807) (n=1211)
Fatal stroke or surgical death
Death within 30 days of trial surgery 17 (n=1745) 0 (n=42)
Other ipsilateral ischaemic stroke 21 18
Other stroke 30 30
All fatal stroke or surgical death 68(3-8%) 48 (4-0%)
Other deaths*
Non-stroke vascular or unknown 286(15-8%) 186(15-4%)
Non-vascular 144 (8-0%) 88(7-3%)
Total deaths 498 (27-6%) 322 (26-6%)
•Not within 30 days of trial surgery.
Table 3: Causes of death
important outcomes. The major ischaemic strokes
involved those regions of the brain most likely to be
supplied by the symptomatic artery (ipsilateral major
ischaemic strokes), and those in other regions. All strokes
known to be haemorrhagic were counted with the other
major strokes. Causes of deaths are shown in table 3;
there were no signiScant differences between the groups.
Stroke and death within 30 days of surgery
Among the 1745 patients who were allocated and
received surgery, there were 122 non-fatal major strokes
or deaths (table 4). The overall risk of non-fatal major
stroke or death was 7-0% (95% CI 5-8-8-3). The risk was
slighdy greater in the middle than in the outer ranges of
stenosis (x2 test for heterogeneity p=0-05, figure 2A). Of
the 122 patients, 61 had non-disabling major strokes, 40
non-fatal disabling major strokes, 15 fatal strokes (ten of
whom died within 30 days of trial surgery and so were
counted as surgical deaths), and seven non-stroke deaths
(one after a disabling stroke; table 4). The overall surgical
risk among the patients allocated control treatment who
crossed over and underwent carotid endarterectomy was
4-8% (95% CI 0-6-16-2; 2 of 42 patients).
The risk of major stroke or death associated with non-
trial operations (with the exclusion of operations within
30 days of trial surgery, because any adverse events
during this period were attributed to that trial treatment)
was slightly higher than that associated with trial
operations (5/61, 8-2% [2-7-18-1]) in patients allocated
surgery and 9/101, 8-9% [4-2-16-2] in control patients).
Risk of ipsilateral ischaemic stroke after successful
surgery
In the control group the risk of major stroke was clearly
related to the severity of carotid stenosis, but only within
the first 2-3 years after randomisation. Thereafter, there
was no relation between stroke risk and severity of
stenosis (figure 3). A qualitatively similar picture was
obtained when we restricted the analysis to patients who
survived 5 years; thus the reduction in stroke risk with
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60-69% 70-79% 80-89% 90-99% 100% All
S (n=232) C(n=137) S (n=231) C(n=170) S (n=251) C (n=159) S (n=104) C(n=60) S(n=9) C (n=5) S (n=1807) C(n=1211)
22 (9-5%) 1 (0-7%) 21 (9-1%) 1 (0-6%) 12(4-8%) 0 4 (3-8%) 0 1(11%) 0 122 (6-8%) 2 (0-2%)
14 (6-0%) 14 (10-2%) 13 (5-6%) 15 (8-8%) 13 (5-2%) 34 (21-4%) 5 (4-8%) 19(31-7%) 0 1(20%) 109 (6-0%) 136(11-2%)
16 (6-9%) 11 (8-0%) 16 (6-9%) 21(12-4%) 15 (6-0%) 12 (7-5%) 6(5-8%) 7(11-7%) 1(11%) 2(40%) 121 (6-7%) 96(7-9%)
48(20-7%) 23(16-8%) 46(19-9%) 33 (19-4%) 39(15-1%) 44 (27-7%) 11(10-6%) 24 (40-0%) 2(22%) 3(60%) 321(17-8%) 216(17-8%)
47 (20-3%) 23(16-8%) 44 (19-0%) 33(19-4%) 38(15-1%) 44 (27-7%) 11 (10-6%) 24 (40-0%) 2 (22%) 3(60%) 315(17-4%) 216(17-8%)
58 (25-0%) 32 (23-4%) 63(27-3%) 51(30-0%) 76(30-2%) 48 (30-2%) 34 (32-7%) 17 (28-3%) 3(33%) 2(40%) 498 (27-6%) 322(26-6%)
82 (35-3%) 48 (35-0%) 89 (38-5%) 69 (40 6%) 98 (39-0%) 71 (44-7%) 39 (37-5%) 31(51-7%) 4 (44%) 4(80%) 669 (37-0%) 442 (36-5%)
11 (4-7%) 0 11(4-8%) 1 (0-6%) 6 (2-4%) 0 4 (3-8%) 0 1(11%) 0 61 (3-4%) 1 (0-1%)
4 (17%) 8 (5-8%) 4(1-7%) 7 (4-1%) 7 (2-8%) 18(11-3%) 3(2-9%) 10(16-7%) 0 0 46 (2-5%) 70 (5-8%)
9(3-9%) 5(3 6%) 5(2-2%) 13(7-6%) 9 (3-6%) 6 (3-8%) 3(2-9%) 3(5 0%) 0 1 (20%) 67 (3 7%) 47 (3-9%)
24 (10-3%) 13 (9-5%) 20 (8-7%) 21(12-4%) 22 (8-8%) 24 (15-1%) 10 (9 6%) 13(21-7%) 1(11%) 1(20%) 174 (9-6%) 118(9-7%)
5(2-2%) 0 4(1-7%) 0 1 (0-4%) 0 1(1-0%) 0 1(11%) 0 22(1-2%) 0
3(1-3%) 0 1 (0 4%) 2(1-2%) 4(1-6%) 3(1-9%) 2(1-9%) 4 (6-7%) 0 0 19(1-1%) 18(1-5%)
5 (2-2%) 5 (3-6%) 2 (0-9%) 7(4-1%) 1(0-4%) 6(3-8%) 3(2-9%) 2 (3 3%) 0 0 27 (1-5%) 30(2-5%)
13 (5-6%) 5(3-6%) 7(3-0%) 9(5-3%) 6 (2-4%) 9 (5-7%) 6 (5-8%) 6(10 0%) 1(11%) 0 68(3-8%) 48 (4-0%)
Table 2: Continued
time in patients with severe stenosis could not be
attributed to early mortality in high-risk patients. This
finding led us to compare the balance of risk and benefit
of surgery at 3 years. The effect of successful trial surgery
(ie, not counting any surgical strokes or deaths) on the 3-
year risk of ipsilateral major ischaemic stroke in deciles of
stenosis severity (with the first two deciles combined
because very few patients had 0-10% stenosis), showed a
clear advantage above about 80% stenosis (test of trend
in treatment effect p<0-001, figure 2B).
Effect of surgery on other major strokes
As expected, surgery had less effect on other types of
stroke (ie, haemorrhagic, vertebrobasilar, and
contralateral carotid ischaemic strokes) than on ischaemic
stroke (test of trend in treatment effect p=0-071, figure
2C). Because it was difficult to differentiate some stroke
types, and we were not completely unaware of treatment
allocation, the overall analysis that follows minimised
observer bias by combining all the strokes.
Overall results
For the combined outcome of surgical events, ipsilateral
major ischaemic strokes, and other major strokes, there
was no overall effect below about 70-80% stenosis (figure
2D). The clear downward trend in the benefit of surgery
(p<0-001) from the 90-100% to 80-89% categories of
stenosis is likely to be continued into the 70-79%
category, which suggests that the value of stenosis above
which the surgical effect is beneficial, on average, lies
somewhere in this range of 70-79% stenosis. As an
illustration of the survival curves, we calculated Kaplan-
Meier estimates within the subgroup with 80-99%
stenosis; the early risk of surgery, the benefit over the next
2-3 years, and the lack of any definite benefit thereafter
were clear (figure 4). The absolute difference at 3 years
was 139 events avoided per 1000 patients treated by
surgery.
The predicted proportion of patients with each of the
various outcomes at 3 years is shown in table 5. The
absolute benefit in terms of major strokes and all deaths
was 11-6%—that is, 116 major strokes or deaths from any
cause might be avoided per 1000 patients treated by
surgery. Thus about nine patients must be treated by
surgery for one more patient to be alive and free of major
stroke at 3 years. If the analysis is restricted to disabling
strokes, the number needed to treat is 18.
Estimation ofmajor-stroke-free survival
We have shown how treatment effect at 3 years varies
with stenosis, the contribution from the short-term risk of
surgery and the long-term prevention of stroke after
surgery, and also the size of benefit that might be
achieved if the treatment decision was based on a stenosis
of 80% or above. However, these 3-year risks obscure the
fact that patients allocated surgery tended to have strokes
earlier than those allocated control. This disadvantage of
surgery is directly reflected in stroke-free life expectancy,
which thus seems a more appropriate measure of benefit.
In our Cox proportional-hazards model on which our




Patients receiving trial surgery 1745(97%) 42(3%)
Patients receiving first* surgery more 3 101
than 1 year after randomisation
Patients with operations to both 68 11
ICAs during trial
Patients with repeat surgery to one ICA 9 0
during trial
Surgical events within 30 days of trial surgery
Total major stroke 116 (6-6%) 2(4-8%)
Non-disabling major stroke 61 1
Non-fatal disabling stroke 40 1
Fatal strokef 15 0
Total non-stroke death 7 0
Non-stroke vascular death 5 0
Non-vascular death 2 0
All major stroke or death 122 (7-0%)t 2 (4-8%)
•First beyond date of trial entry.
f 10 of these resulted in death within 30 days of trial surgery.
$ 1 non-vascular death followed a major stroke, hence total is not sum of categories.
Table 4: Surgical operations and adverse events from trial
surgery
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A Actual risk of surgical events (major
stroke or death within 30 days
B Predicted risk of ipsilateral major




D Predicted risk of any major stroke at
3 years and actual risk of a surgical event
% stenosis (ECST method)
Figure 2: Risks of outcome events by treatment group and
severity of symptomatic carotid stenosis
For surgical events, the actual risk is plotted. For ipsilateral major
ischaemic stroke and other major strokes, the predicted risk at 3 years
is plotted. The combined outcome is predicted risk of any major stroke
at 3 years and actual risk of a surgical event.
Numbers above curves=numbers of patients with event.
Vertical bars=95% CI.
Year in trial
Figure 3: Risk of any major stroke (first or subsequent) in
control patients by severity of stenosis and in each of the 8
years after randomisation
analysed time to death or major stroke using not only
treatment allocation and stenosis severity, but also age
and sex. We included these variables partly because
increasing age is associated with an increased risk of
stroke after transient ischaemic attacks,' and female sex
with an increased risk of stroke complicating carotid
endartercctomy,' and also because it makes clinical sense
that life expectancy will actually depend on these
additional variables (table 6). Age and sex had a highly
significant effect on this combined outcome of major
stroke or deadt, similar for control patients and surgery
patients beyond the 5-day high-surgical-risk period; for
example, women were 29% less likely than men to have a
major stroke or die. Risk soon after surgery was greatly
increased in a manner dependent on a complex function
of stenosis and was also higher in women than in men.
However, the age effect soon after surgery exactly
cancelled the age effect applying to all other patients in
the model, which suggests that immediate surgical risk
was not related to age. Surgery patients beyond the end
of the 5-day high-risk period and up to 3 years were at
significantly lower risk than control patients, but this
effect did not vary with age, sex, or severity of stenosis.
This observation fits well with the hypothesis that stenosis
severity is the major determinant of risk and that its
removal leaves all patients in a similar state. Risk in the
Time since randomisation (years)
Number at risk
Surgery 364 335 326 306 286 249 195 143 100
Control 224 189 172 165 158 128 92 63 43
Figure 4: Kaplan-Meier survival curves to show survival free of
major stroke (with non-stroke deaths occurring more than 30
days after surgery censored) in surgery and control patients
with 80-99% stenosis of symptomatic carotid artery





Ipsilateral major stroke 2 0
excluding surgical events
Ipsilateral major stroke 6-8
including surgical events
Other major strokes 2 9
Any major stroke or surgical 8-5
death
Death 8-8
Any major stroke or death 14-9
Kaplan-Meier estimates at 3 years.
Table 5: Frequency (%) of major outcome events among
patients with 80-100% symptomatic carotid stenosis
control group was described by a linear term in stenosis
(ie, an exponential effect in the Cox model). This model
predicted well the Kaplan-Meier estimates of risk at
3 years for the surgery and control groups within deciles
of stenosis and the observed risks of death or stroke in die
5-day high-surgical-risk period (data available from the
investigators).
The model's predictions of the difference in total
major-stroke-free life expectancy between surgery and
control groups are presented as a function of age and of
stenosis, and by sex in figure 5. These graphs can be used
in decisions on whether to offer surgery to a particular
patient, by plotting his or her age and severity of stenosis
on the appropriate graph. Men derived rather more
benefit from surgery than did women, there was more
benefit with increasing severity of stenosis, and younger
patients showed definite benefit over a narrower range of
severe stenosis than did older patients. For example, a
man aged 70, with 80% stenosis, might gain about 8
months of major-stroke-free survival from surgery but
there would be less certainty for a woman with the same
characteristics.
54% of the major strokes were disabling. Although this
proportion did not vary between treatment groups, with
severity of stenosis, or by sex, more strokes in older
patients were disabling: under 60 the proportion was
47%; for those of 60-69, 54%; and for those of 70 and
over, 64%. There were too few disabling strokes for
precise inferences of treatment effects to be made but
Hazard p for difference
ratio in hazard ratio
from 1
Hazards for all patients at all times
Age in years at randomisation 1-042* <0-0001
Female sex 0-71 <0-0001
Patients from 0-5 days after trial surgery
Treatment effect 735 <0-0001
Female sex 2-39 <0-0001
Age in years at randomisation 0-959* 0-0007
Linear term in normalised stenosis (ie l-28f 0-012
(Stenosis%—50J/50)
Square term in normalised stenosis 0-952+ 0-024
Cubic term in normalised stenosis 0-982$ 0-038
Occluded symptomatic carotid artery at 12-77 0-042
randomisation
Patients from 5 days to 3 years after trial surgery
Treatment effect 0-78 0-01
Control patients and surgery patients before trial surgery
Linear term in normalised stenosis 1-104$ <0-0001
•Per year of age.
fPer 10% stenosis.
♦Calculated for a change of stenosis from 50% to 60%.
Table 6: Results from Cox proportional-hazards model of major
stroke or death from any cause
Men
Stenosis (%)
Figure 5: Estimated change in total major-stroke-free life
expectancy in months for men and women depending on their
age and severity of symptomatic carotid stenosis
Curved lines connect points of equal months of major-stroke-free life
expectancy: numbers adjacent to these lines represent number of such
months, either positive favouring surgery or negative against surgery.
Hatched areas represent uncertainty. To the left of these areas there is
definite hazard from surgery (p<005). and to the right definite benefit
(p<0-05). The hatched vertical bar on the right of each graph excludes
occluded arteries from the region of definite benefit.
rough estimates can be obtained by halving the gain in
major-stroke-free life expectancy obtained from figure 5.
Discussion
The ECST has shown that for patients with recently
symptomatic carotid stenosis, carotid endarterectomy
carries a small but serious risk of stroke or death; that
without surgery there is a substantial risk of stroke
ipsilateral to a severely stenosed carotid artery,
particularly in the first 2-3 years; and that most of the
risk of ipsilateral stroke is abolished by successful surgery,
so most of these strokes must be caused by embolism
from, or low flow distal to, severe carotid stenosis. These
qualitative conclusions are based on extreme risk ratios,
and are supported by the accumulating results of the
parallel North American Symptomatic Carotid
Endarterectomy Trial (NASCET).7 They are most
unlikely, therefore, to have been affected substantially by
any minor biases in our trial; for example, the outcome
assessment of stroke could not be completely masked, the
measurement of stenosis was crude, and the trial was
stopped early for patients with severe and mild carotid
stenosis.'
In clinical practice, surgical risk depends on the type of
patients operated on, the technique used, and the skill of
the operating team. Risk may therefore differ from that
reported in this trial, or in any other trial or case series.
Therefore, our reported risk cannot easily be applied to
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there may be no option but to use this estimate of risk
because local institutional surgical risks are rarely
measured prospectively. Even if surgical risks are assessed
properly, up-to-date and precise estimates of risk are all
but impossible because the numbers of operated patients
in the previous 1-2 years are usually so small, and the
proportion of patients harmed by surgery is so low.
Therefore, when considering the surgical risks in
individual patients, most institutions will probably have
to use the sort of risks that we and the NASCET have
reported.
These risks are at least reasonably representative of
what good European and North American surgeons
achieved in the 1980s and 1990s. No doubt surgical risks
will fall with time, and allowance can be made for this
effect, perhaps by shifting downwards the severity of
carotid stenosis above which surgery is indicated. On the
other hand, the outlook without surgery for these patients
may also improve with time as a result, perhaps, of better
antiplatelet drugs, better control of raised blood pressure,
and more effective cholesterol-lowering drugs. Such
changes will have die effect of shifting upwards the
severity of stenosis below which the risk of surgery is not
worth trading off against die prognosis for stroke without
surgery.
This final report adds to our interim results'-2 and to
what is so far available from the NASCET.7 We can now
refine the treatment decision for individual patients. In
particular, we now know more about the severity of
carotid stenosis at which the immediate risk of surgery is
worth taking for future benefit in terms of long-term
stroke prevention, while taking into account life
expectancy. The balance of risk and benefit is definitely
in favour of surgery with extreme degrees of stenosis, and
definitely against surgery for mild stenosis. On the other
hand, where the cut-off point for stenosis should lie, and
how this might be in pan determined by the life
expectancy of the individual patient being considered for
surgery has not been at all clear until now.
Our initial analysis here suggests that on average this
cut-off point should be at about 80% stenosis (which is
equivalent to about 70% stenosis in the NASCET).3 But
this approach takes no account of the patients' life
expectancy and so for how long they might enjoy the
advantages of surgery—in other words, for how long they
might live without a stroke, particularly ipsilateral to the
symptomatic carotid stenosis. Furthermore, surgery itself
seems to be riskier in women than in men, not just in our
study but also in a systematic review of other series.5 The
decision point for severity of stenosis will therefore be
higher in women. That is why we have tried to model age
and sex, as well as the severity of the stenosis, and to
present the results in terms of months of major-stroke-
free survival. Figure 5 shows that men derive rather more
benefit than women, and that in general it is only
definitely worth operating at above about 90% stenosis in
women and above about 80% in men. An extra year or
two of major-stroke-free survival is achievable in men,
and about an extra year in women.
The success of any decision to operate based on
stenosis severity alone, without taking into account age
and sex, is small when assessed in the ECST population
with stenosis above 70%, the previously recommended
cut-off point for surgery. With our model as the gold
standard, although the sensitivity of stenosis alone as the
deciding factor for surgery was high (97% for men and
100% for women), the specificity was poor (69% for men
and 87% for women) and would have resulted in 131
(33%) of 392 inappropriate operations among the men
and 37 (70%) of 53 among the women. Of course, these
inappropriate operations are all in patients for whom we
still have insufficient evidence to recommend either
surgery or no surgery with confidence (ie, we are not
talking about patients for whom surgery is definitely not
worthwhile). But, even with our better model based on
age and sex as well as stenosis, there are still quite large
areas of uncertainty and there are, conceivably, patients
with moderate stenosis who should receive surgery, if
only we knew who they were (in some sense they will be
those at lowest risk with surgery and highest risk of
ipsilateral stroke without surgery).
Some of our uncertainty is die result of quite small
numbers in some groups of patients—for example,
women aged 55 with more dian 90% stenosis and men
aged 80 widi 30% stenosis. This must not be taken to
imply diat the balance of risk and benefit favours surgery,
or indeed no surgery, but merely that we still do not
know exactly where diat balance really lies in groups such
as these. This uncertainty will be reduced when we have
the final results of the NASCET and can do a pooled
analysis of all die individual patients' data from bodi
trials, and also when we can refine and validate much
better models to estimate baseline risk of ipsilateral
ischaemic stroke in patients not treated by surgery (using
not just stenosis severity, age, and sex but other
prognostic factors that may be important such as eye vs
brain ischaemia)" and also better models of surgical risk.
Another factor that might dp the balance in favour of
surgery in an individual parient is the timing of surgery.
On average, we were able to achieve surgery 2-3 months
after the last cerebrovascular symptoms, but earlier
surgery might have a greater relative benefit because the
risk of stroke without surgery decreases rapidly in patients
with severe carotid stenosis (figure 3). Perhaps this
decreasing risk is due to some kind of healing of an
unstable atheromatous plaque or the development of
better collaterals distal to the stenosis.
It is important not to lose sight of other less serious
complications of surgery that we have not reported on
(particularly damage to motor nerves in the operation
field), as well as of the general fear and discomfort of
surgery, which in some patients may well weigh against
the decision to go for surgery, even at quite high degrees
of stenosis. Furthermore, many centres are still not
satisfied that non-invasive evaluation of the severity of
carotid stenosis is sufficiently accurate to replace catheter
angiography. Therefore, the inevitable but small risk of
an angiographic stroke must be taken into account when
advising patients whose ultrasonographic examination
suggests severe stenosis whether to have an angiogram
with a view to later surgery if severe stenosis is confirmed.
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